0001410578-24-00189410-Q EYENOVIA, INC. 20241112202411121716031716031716031

of $562,711 and $503,914 as of September 30, 2024 and December 31, 2023, respectivelyâ€‹â€‹ 6,168,593â€‹â€‹ 5,329,419Convertible notes payable - current portion, net of debt discount of $72,467 and $0 as of September 30, 2024 and December 31, 2023, respectivelyâ€‹â€‹ 3,260,866â€‹â€‹ â€”Total Current Liabilitiesâ€‹â€‹ 15,782,964â€‹â€‹ 9,530,382â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Accrued expenses and other non-current liabilitiesâ€‹â€‹316,275â€‹â€‹ â€”Operating lease liabilities - non-current portionâ€‹â€‹ 836,434â€‹â€‹ 1,292,667Notes payable - non-current portion, net of debt discount of $0 and $448,367 as of September 30, 2024 and December 31, 2023, respectivelyâ€‹â€‹637,500â€‹â€‹ 4,355,800Convertible notes payable - non-current portion, net of debt discount of $163,051 and $398,569 as of September 30, 2024 and December 31, 2023, respectivelyâ€‹Â 1,503,615â€‹Â 4,601,431Total Liabilitiesâ€‹â€‹ 19,076,788â€‹â€‹ 19,780,280â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commitments and contingencies (NoteÂ 8)â€‹Â Â Â â€‹Â Â Â â€‹â€‹Â Â Â â€‹Â Â Â Stockholdersâ€™ Equity:â€‹Â Â Â â€‹Â Â Â Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023â€‹Â â€”â€‹Â â€”Common stock, $0.0001 par value, 300,000,000 shares authorized; 86,375,958 and 45,553,026 shares issued and outstanding as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, respectivelyâ€‹Â 8,638â€‹Â 4,555Additional paid-in capitalâ€‹Â 179,065,877â€‹Â 154,486,098Accumulated deficitâ€‹Â (175,355,212)â€‹Â (145,491,559)Total Stockholdersâ€™ Equityâ€‹â€‹ 3,719,303â€‹â€‹ 8,999,094Total Liabilities and Stockholdersâ€™ Equityâ€‹$ 22,796,091â€‹$ 28,779,374â€‹The accompanying notes are an integral part of these condensed financial statements.â€‹2 Table of ContentsEYENOVIA,Â INC.Condensed Statements of Operations(unaudited)â€‹For the Three Months Endedâ€‹For the Nine Months Endedâ€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Operating Incomeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â

agreement with Arctic Vision represents a collaborative arrangement and Arctic Vision is not a customer with respect to the clinical supply arrangements. The Companyâ€™s policy is to (a) defer the materials and manufacturing costs in order to properly match them up against the income from the clinical supply arrangements; and (b) report the net income from the clinical supply arrangements as other income. Deferred clinical supply costs were $0.4 million and $4.3 million at September 30, 2024 and December 31, 2023, respectively. See Note 8 â€“ Commitments and Contingencies â€“Defective Clinical Supply for additional information.InventoriesInventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The cost of inventory that is sold commercially to third parties is included within cost of sales. The Company will periodically review for slow-moving, excess or obsolete inventories.Inventory is primarily comprised of drug-device combination products, which are available for commercial sale, as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â September 30,Â Â Â Â Â December 31,â€‹Â 2024â€‹2023Finished goodsâ€‹$ 427,217â€‹$ 30,683Raw materialsâ€‹Â 2,540,039â€‹Â 79,115Total inventoryâ€‹$ 2,967,256â€‹$ 109,798â€‹The Company has evaluated the net realizable value of the commercial inventory. The write-down of commercial inventory to net realizable value for the three months ended September 30, 2024 and 2023 was $0.1 million and $0.0 million, respectively. The write-down of commercial inventory for the nine months ended September 30, 2024 and 2023 was $0.8 million and $0.0 million, respectively. The write - down for the nine months ended September 30, 2024 consisted of $0.2 million of inventory write down adjustments to list price for the first quarter of 2024, $0.5 million for the write-down of short dated inventory to net realizable value for the second quarter of 2024 and $0.1 million for the write - down of inventory to net realizable value for the third quarter of 2024. The Company recorded the write-downs to cost of revenue as it relates to goods that were part of commercial inventory during 2024.9 Table of ContentsEYENOVIA, INC.NOTES TO CONDENSED FINANCIAL STATEMENTS(UNAUDITED)Net Loss Per Share of Common StockBasic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, plus fully vested shares that are subject to issuance for little or no monetary consideration. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following table presents the computation of basic and diluted net loss per common share:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â ForÂ theÂ Three MonthsÂ Endedâ€‹For the Nine Months Endedâ€‹â€‹September 30,â€‹September 30,â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Numerator:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss attributable to common stockholdersâ€‹$ (7,887,853)â€‹$ (7,338,733)â€‹$ (29,863,653)â€‹$ (19,293,959)â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹Denominator (weighted average quantities):â€‹Â â€‹â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Common shares issuedâ€‹Â 69,316,561â€‹Â 39,107,338â€‹â€‹ 56,298,569â€‹â€‹ 38,192,414Add: Prefunded warrantsâ€‹Â â€”â€‹Â 926,225â€‹â€‹ â€”â€‹â€‹ 305,349Add: Undelivered vested restricted sharesâ€‹Â 241,764â€‹Â 106,134â€‹â€‹ 178,307â€‹â€‹ 65,311Denominator for basic and diluted net loss per shareâ€‹Â 69,558,325â€‹Â 40,139,697â€‹â€‹ 56,476,876â€‹â€‹ 38,563,074â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹Basic and diluted net loss per common shareâ€‹$ (0.11)â€‹$ (0.18)â€‹$ (0.53)â€‹$ (0.50)â€‹The following securities are excluded from the calculation of weighted average diluted shares of common stock because their inclusion would have been anti-dilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023WarrantsÂ 28,947,744Â 10,926,554OptionsÂ 6,695,042Â 5,218,686Convertible notesâ€‹ 2,327,747â€‹ 2,327,747Restricted stock unitsÂ 368,886Â 86,205Total potentially dilutive sharesÂ 38,339,419Â 18,559,192â€‹Subsequent EventsThe Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.Recently Issued Accounting StandardsIn November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segments Disclosures (Topic 280), which updates reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis. The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-07.10 Table of ContentsEYENOVIA, INC.NOTES TO CONDENSED FINANCIAL STATEMENTS(UNAUDITED)In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect it to have a material impact on its financial statements.â€‹NoteÂ 3Â â€“ Prepaid Expenses and Other Current AssetsAs of September 30, 2024 and December 31, 2023, prepaid expenses and other current assets consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â 2024Â 2023Prepaid insurance expensesâ€‹$ 356,214â€‹$ 167,338Payroll tax receivableâ€‹â€‹ 288,705â€‹â€‹ 500,684Prepaid general and administrative expensesâ€‹â€‹ 131,606â€‹â€‹ 85,938Prepaid patent expensesâ€‹Â 71,073â€‹Â 48,409Prepaid conference expensesâ€‹Â 54,810â€‹Â 123,556Prepaid research and development expensesâ€‹â€‹ 48,172â€‹â€‹ 421,056Prepaid rent and security depositâ€‹Â 18,750â€‹Â 18,750Otherâ€‹â€‹ 18,424â€‹â€‹ â€”Total prepaid expenses and other current assetsâ€‹$ 987,754â€‹$ 1,365,731â€‹â€‹Note 4 - Intangible AssetsOn August 15, 2023, the Company entered into a license agreement (the â€œFormosa Licenseâ€) with Formosa Pharmaceuticals Inc. (â€œFormosaâ€), whereby the Company acquired the exclusive U.S. rights to commercialize any product related to a novel formulation of clobetasol propionate ophthalmic suspension, 0.05% (the â€œFormosa Licensed Productâ€), which was approved by the FDA for ophthalmic use for inflammation and pain after ocular surgery and supplemental disease indications, if any, associated with the New Drug Application for the Formosa Licensed Product. The Formosa License will remain in effect for ten years from the date of the first commercial sale of a Formosa Licensed Product, unless earlier terminated. The Company paid Formosa the aggregate amount of $2.0 million (the â€œUpfront Paymentâ€), consisting of (a) cash in the amount of $1.0 million and (b) 487,805 shares of common stock, which is included in Intangible Assets on the accompanying balance sheet. The Company also capitalized $122,945 of transaction costs, which were primarily legal expenses. In addition to the Upfront Payment, the Company must pay Formosa up to $4.0 million upon the achievement of certain development milestones and up to $80.0 million upon the achievement of certain sales milestones. The trigger for the initial $2.0 million development milestone payments was FDA approval of the Formosa Licensed Product and the effective date of the acceptance by the Company of the transfer and assignment of the FDA approval. This occurred on March 14, 2024. Under the provisions of the Formosa License, the Company had 45 days from the effective date of acceptance of the transfer and assignment of FDA approval to make the payment half in cash and half in common stock, otherwise the payment due would revert to be fully in cash. The Company paid Formosa the aggregate amount of $2.0 million, consisting of (a) cash in the amount of $1.0 million on April 26, 2024 and (b) 613,496 shares of common stock on April 29, 2024 (calculated pursuant to the Formosa License using a five-day volume-weighted average price on March 14, 2024, but valued at $0.4 million on the April 29, 2024 settlement date, resulting in a $0.6 million change in fair value of the equity consideration payable), which is included in Intangible Assets on the accompanying balance sheet as of September 30, 2024. The second $2.0 million development milestone (to be fully paid in cash) was earned upon FDA approval of the Formosa Licensed Product and payment was triggered on the earlier of twelve months after FDA approval or six months following the first commercial sale of the Formosa Licensed Product. Because the payment became probable and estimable, the Company recorded an additional $2.0 million increase in the intangible asset and the related accrual on March 14, 2024.11 Table of ContentsEYENOVIA, INC.NOTES TO CONDENSED FINANCIAL STATEMENTS(UNAUDITED)NoteÂ 5Â â€“ Accrued CompensationAs of September 30, 2024 and December 31, 2023, accrued compensation consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â 2024Â 2023Accrued bonus expensesâ€‹$ 1,141,884â€‹$ 1,302,997Accrued payroll expensesâ€‹Â 514,948â€‹Â 355,616Total accrued compensationâ€‹$ 1,656,832â€‹$ 1,658,613â€‹â€‹NoteÂ 6Â â€“ Accrued Expenses and Other Current LiabilitiesAs of September 30, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â 2024Â 2023Accrued intangible asset milestone obligationâ€‹$ 2,000,000â€‹$ â€”Accrued defective clinical supply settlement, netâ€‹â€‹ 250,000â€‹â€‹ 100,000Accrued clinical studies costsâ€‹â€‹ 121,588â€‹â€‹ â€”Accrued professional servicesâ€‹â€‹ 79,042â€‹â€‹ 63,028Credit card payableâ€‹â€‹ 29,502â€‹â€‹ 27,193Accrued franchise taxâ€‹â€‹ 15,000â€‹â€‹ â€”Accrued research and development expensesâ€‹â€‹ 13,550â€‹â€‹ 89,872Otherâ€‹â€‹ 9,404â€‹â€‹ 7,835Total accrued expenses and other current liabilitiesâ€‹$ 2,518,086â€‹$ 287,928â€‹â€‹NoteÂ 7Â â€“ Notes Payable and Convertible Notes PayableAs of September 30, 2024 and December 31, 2023, notes payable and convertible notes payable consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

LLC (â€œLeerink Partnersâ€) in an â€at-the-marketâ€ offering.OfferingsSecond Quarter OfferingOn April 8, 2024, the Company entered into a securities purchase agreement (the â€œPurchase Agreementâ€) with a single fundamentals-based healthcare investor (the â€œPurchaserâ€), pursuant to which the Company agreed to sell, in a registered direct offering by the Company directly to the Purchaser (the â€œApril Offeringâ€), 3,223,726 shares of common stock. The price per share in the April Offering was $0.6204. The aggregate gross proceeds to the Company from the April Offering were $2.0 million, and net proceeds after offering costs were approximately $1.9 million.Third Quarter OfferingsA summary of the offerings for the third quarter is presented below:â€‹â€‹â€‹

International and our Redwood City facility for the production of Mydcombi cartridges, and the use of our Reno facility for the production of technical elements such as the base unit for the Optejet device.MicroLine is our investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens, which causes the gradual loss of the eyeâ€™s ability to focus on near objects and impairs near visual acuity. We have completed two Phase III studies using our Optejet device. In these studies, patients reported high satisfaction with using the device, and a strong preference over using an eye dropper bottle. Since completing these studies, the market opportunity has markedly deteriorated, and we have chosen to put this program on hold and reallocate our resources towards larger opportunities. When and if the market improves, we have kept open the option to continue development of MicroLine which would include a meeting with the FDA to review our clinical data to date.Mydcombi is the only FDA-approved fixed combination of the two leading mydriatic agents, tropicamide and phenylephrine in the United States and our first FDA-approved product. As an ophthalmic spray delivered with Optejet technology, Mydcombi may present a number of benefits for ophthalmic surgical centers, optometric and ophthalmic offices and patients. Those benefits may include improved cost-effectiveness in centers that employ single-use bottles for mydriasis, more efficient use of office time and resources, and an overall improved doctor-patient experience. We have begun the commercialization of Mydcombi, with the first commercial sale of the product occurring on August 3, 2023 as part of a targeted launch, expanded our launch with the hiring and onboarding of ten sales representatives through September 30, 2024. We received FDA approval for our primary Mydcombi manufacturing facility in February 2024, which we believe will allow us to expand and continue to build our manufacturing operations. On July 24, 2024, we received written comments from the FDA outlining the design of a clinical bridging study to transition Mydcombi into our new Gen-2 Optejet device, which has a significantly lower cost to manufacture than the currently approved product.We are in active discussions with manufacturers of existing and late-stage ophthalmic medications to explore whether development with the Optejet technology can solve unmet medical and business needs. Some of those business needs could include extension of exclusivity under the Optejet patents, improvement in a drugâ€™s tolerability profile, or potential improvement in treatment compliance.On August 15, 2023, we entered into a license agreement with Formosa, whereby we acquired the exclusive U.S. rights to commercialize any product related to a novel formulation of clobetasol propionate ophthalmic suspension 0.05% (the â€œFormosa Licensed Productâ€), which was approved by the FDA, for post-operative inflammation and pain after ocular surgery, on March 4, 2024. The Formosa License will remain in effect for ten years from the date of the first commercial sale of a Formosa Licensed Product, unless earlier terminated.21 Table of ContentsWe paid Formosa an upfront payment in an aggregate amount of $2.0 million which consisted of (a) cash in the amount of $1.0 million and (b) 487,805 shares of common stock valued pursuant to the Formosa License Agreement at $1.0 million. We also capitalized $122,945 of transaction costs in connection with the Formosa License. In addition, we agreed to pay Formosa up to $4.0 million upon the achievement of certain development milestones and up to $80 million upon the achievement of certain sales milestones. The trigger for the initial $2.0 million development milestone payment was FDA approval of the Formosa Licensed Product and the effective date of the acceptance by the Company of the transfer and assignment of the FDA approval, which occurred on March 14, 2024. Based on the achievement of this milestone, we paid Formosa (a) cash in the amount of $1.0 million on April 26, 2024 and (b) 613,496 shares of common stock (calculated pursuant to the Formosa License Agreement at $1.0 million using a five-day volume-weighted average price on March 14, 2024, but valued at $0.4 million on the April 29, 2024 settlement date). The remaining $2.0 million development milestone (to be fully paid in cash) was earned and accrued upon FDA approval, but payment will be triggered on the earlier of twelve months after FDA approval of the Formosa Licensed Product or six months following the first commercial sale of the Formosa Licensed Product.On July 23, 2024, we entered into a collaboration agreement with Senju, under which the companies intend to work to develop EYEN-520, a combination of Senjuâ€™s corneal epithelial wound healing candidate with our Optejet dispensing technology, as a potential treatment for chronic dry eye disease. The companies plan to request a meeting with the FDA in late 2024, to be followed by execution of a definitive agreement related to the further development of the product and anticipated completion of a Phase 2b study in 2025. If successful, the collaboration agreement could be expanded to bring the product into two Phase 3 studies by 2026.On August 7, 2024, we entered into a collaboration agreement with Formosa under which the companies intend to work to develop EYEN-530, a combination of Formosaâ€™s clobetasol propionate ophthalmic solution with our Optejet dispensing technology, as a potential treatment for acute dry eye flare-ups. The companies plan to request a meeting with the FDA in late 2024, to be followed by execution of a definitive agreement related to further development of the product and anticipated initiation of two Phase 3 studies by 2026.On September 26, 2024, we announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%.On September 18, 2024, we received notice from the Staff of Nasdaq providing notification that the Companyâ€™s bid price had closed below the $1.00 minimum bid price requirement for continued listing on Nasdaq under Listing Rule 5550(a)(2). The notification letter stated that we would be provided 180 calendar days to regain compliance. In order to regain compliance, the closing bid price of our common stock has to be at least $1.00 for a minimum of 10 consecutive business days at any time before March 17, 2025. As of November 11, 2024 the Company has not regained compliance with Listing Rule 5550(a)(2).Historically, we have financed our operations principally through equity offerings. We have also generated cash through licensing arrangements and our credit facilities with Leerink Partners and Avenue. However, based upon our current operating plan, there is substantial doubt about our ability to continue as a going concern for at least one year from the date that our financial statements were issued. Our ability to continue as a going concern depends on our ability to complete additional licensing or business development transactions or raise additional capital through the sale of equity or debt securities to support our future operations. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and/or take additional measures to reduce costs.Our net losses were $7.9 million and $7.3 million for the three months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had a working capital deficit and an accumulated deficit of approximately $4.1 million and $175.4 million, respectively.Financial OverviewRevenue and Cost of RevenueRevenue is earned from the sale of our FDA approved products, primarily Mydcombi through September 30, 2024. The first commercial sale of FDA approved products occurred on August 3, 2023 as part of a targeted launch and we expanded our launch with the onboarding of ten sales representatives through September 30, 2024.Cost of sales consists of the cost of the production of the FDA approved products that were sold and the write-down of inventories to net realizable value.22 Table of ContentsResearch and Development ExpensesResearch and development expenses are incurred in connection with the research and development of our microdose therapeutics and consist primarily of personnel-related expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:â—direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;â—personnel-related expenses, which include salaries and other compensation of employees that is attributable to research and development activities; andâ—facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, Â insurance and other supplies used in research and development activities.We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.Our research and development expenses may increase with the continuation of these initiatives and the expansion of development of our Optejet technology functionality, drug compounds and indications.Selling, General and Administrative ExpensesSelling, general and administrative expenses consist primarily of payroll and related expenses, legal and other professional services, insurance expense, marketing expense, and non-cash stock-based compensation expense. We anticipate that our selling, general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and the commercialization of our approved products and current and future product candidates.Reacquisition of License RightsReacquisition of license rights consists of the expense related to the payments that we are required to pay Bausch + Lomb in connection with the reacquisition of the Bausch Licensed Product.Other Income (Expense), NetOther income (expense), net consists of (a) other income (expense) related to our sales of clinical supply to our licensees; (b)Â changes in fair value of equity consideration (the equity payable for the Bausch + Lomb and Formosa transactions); (c)Â interest income earned on Treasury bills; and (d) interest expense incurred on our indebtedness.Results of OperationsThree Months Ended September 30, 2024 Compared with Three Months Ended September 30, 2023Revenue and Cost of RevenueRevenue for the three months ended September 30, 2024 totaled $1,625, which consisted primarily of revenue from the sale of Mydcombi and was offset by cost of revenues of $132,522. Write-down of inventories to net realizable value for the three months ended September 30, 2024 totaled approximately $0.1 million, compared to $12,218 for the three months ended September 30, 2023. The gross loss was primarily due to write-downs of commercial inventory that were still on the balance sheet at September 30, 2024.Revenue for the three months ended September 30, 2023 totaled $1,198, which was offset by cost of revenues of $13,416. We expect to continue to generate negative gross margins on Gen 1 Mydcombi sales during the early stage of commercialization of this product and may experience negative overall gross margins until the commercialization of other products that may generate positive gross margins.23 Table of ContentsResearch and Development ExpensesResearch and development expenses for the three months ended September 30, 2024 totaled $3.5 million, a decrease of $0.1 million, or 3%, compared to $3.6 million recorded for the three months ended September 30, 2023. Research and development expenses consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ ThreeÂ MonthsÂ EndedÂ SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Personnel-related expensesâ€‹$ 1,765,852â€‹$ 1,716,355Direct clinical and non-clinical expensesâ€‹â€‹ 610,404â€‹â€‹ 269,471Depreciation expenseâ€‹â€‹ 289,003â€‹â€‹ 316,674Facilities expensesâ€‹â€‹ 205,958â€‹â€‹ 333,114Non-cash stock-based compensation expensesâ€‹Â 179,776â€‹Â 235,731Other expensesâ€‹Â 89,594â€‹Â 21,070Supplies and materialsâ€‹Â 331,352â€‹Â 685,698Total research and development expensesâ€‹$ 3,471,939â€‹$ 3,578,113â€‹The decrease in supplies and materials expense was primarily due to a net overall decrease in related requirements due to the timing of Gen 1.0 and Gen 2.0 clinical production scale up and clinical testing. The increase in direct clinical and non-clinical expenses was primarily due to increased costs related to the reacquisition of the CHAPERONE study from Bausch + Lomb, Mydcombi stability testing and clinical regulatory expenses. The decrease in facilities expenses was due to costs incurred in 2023 related to getting the new Reno facility online that were not incurred in 2024. The decrease in non-cash stock-based compensation expenses was primarily due to the ending of the amortization period for older equity grants and terminations during the period. The increase in other expenses was primarily due to increased IT expenses related to CHAPERONE data tracking and cybersecurity.Selling, General and Administrative ExpensesSelling, general and administrative expenses for the three months ended September 30, 2024 totaled $3.7 million, an increase of $0.8 million, or 27%, compared to $2.9 million recorded for the three months ended September 30, 2023. Selling, general and administrative expenses consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ Â Â Â Â For the Three Months Ended SeptemberÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Salaries and benefits â€‹$ 1,610,533â€‹$ 963,634Professional fees â€‹Â 719,239â€‹Â 715,832Non-cash stock based compensation â€‹Â 273,222â€‹Â 377,238Sales and marketing â€‹Â 169,377â€‹Â 190,915Otherâ€‹Â 239,081â€‹Â 89,191Insurance expense â€‹Â 212,783â€‹Â 224,645Travel, lodging and meals â€‹â€‹ 161,659â€‹â€‹ 57,707Facilities expense â€‹â€‹ 127,173â€‹â€‹ 111,388Investor relations â€‹Â 118,524â€‹Â 102,430Director fees and expense â€‹Â 97,500â€‹Â 96,875Total selling, general and administrative expensesâ€‹$ 3,729,091â€‹$ 2,929,855â€‹The increase in personnel-related expenses was mainly due to new staff additions made to support commercialization during 2024. The increase in other expenses is primarily due to commercial regulatory costs for Mydcombi and software licensing fees in connection with new staff additions. The decrease in non-cash stock-based compensation expenses was primarily due to the ending of the amortization period for older equity grants. The increase in travel, lodging and meals was primarily due to increased travel by the sales team to promote our FDA approved products.Total Other ExpenseTotal other expense for the three months ended September 30, 2024 was approximately $0.6 million, a decrease of $0.2 million, compared to $0.8 million for the three months ended September 30, 2023. Total other expense for the three months ended September 30, 2024 primarily consisted of approximately $0.6 million of interest expense related to the Avenue loan.24 Table of ContentsResults of OperationsNine Months Ended September 30, 2024 Compared with Nine Months Ended September 30, 2023Revenue and Cost of RevenueRevenue for the nine months ended September 30, 2024 totaled $29,243, which was offset by cost of revenues of $825,910. Write-down of inventories to net realizable value for the nine months ended September 30, 2024 totaled approximately $0.8 million, compared to $12,218 for the nine months ended September 30, 2023. The $0.8 million was comprised of the adjustment to bring the inventory to list price and an additional write-down of short-dated inventory to net realizable value. The gross loss was primarily due to write-downs of commercial inventory that were still on the balance sheet at September 30, 2024.Revenue for the nine months ended September 30, 2023 totaled $1,198, which was offset by cost of revenues of $13,416. We expect to continue to generate negative gross margins on Gen 1 Mydcombi sales during the early stage of commercialization of this product and may experience negative overall gross margins until the commercialization of other products that may generate positive gross margins.Research and Development ExpensesResearch and development expenses for the nine months ended September 30, 2024 totaled $12.5 million, an increase of $3.6 million, or 40%, compared to $8.9 million recorded for the nine months ended September 30, 2023. Research and development expenses consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ Nine MonthsÂ EndedÂ September 30,â€‹Â Â Â Â 2024Â Â Â Â 2023Personnel-related expensesâ€‹$ 5,523,650â€‹$ 5,078,228Direct clinical and non-clinical expensesâ€‹â€‹ 2,641,136â€‹â€‹ 547,697Supplies and materialsâ€‹Â 1,812,674â€‹Â 1,197,692Depreciation expenseâ€‹Â 914,172â€‹Â 537,528Facilities expensesâ€‹Â 652,531â€‹Â 828,111Non-cash stock-based compensation expensesâ€‹â€‹ 618,516â€‹â€‹ 647,058Other expensesâ€‹Â 338,034â€‹Â 74,810Total research and development expensesâ€‹$ 12,500,713â€‹$ 8,911,124â€‹The increase in direct clinical and non-clinical expenses was primarily due to increased clinical regulatory expenses incurred in connection with the reacquisition of the Bausch + Lomb license and Mydcombi stability testing. The increase in supplies and materials expense was primarily due to the expensing of Gen-1 MicroPine clinical product and materials that will now be used in Eyenovia-led clinical trials rather than being sold to Bausch + Lomb as a result of the reacquisition of the Bausch Licensed Product; drug formulation engineering batches related to Gen 2.0 specific formulations and future Mydcombi production. The increase in personnel-related expenses was primarily due to new staff additions made to support commercialization during the last two quarters of 2023 and the first quarter of 2024. The increase in depreciation expense was primarily due to increased equipment purchases and equipment placed in service during the last two quarters of 2023 and the first and second quarters of 2024. The increase in other expenses was primarily due to increased IT expenses related to CHAPERONE data tracking and cybersecurity. The decrease in facilities expenses was due to costs incurred in 2023 related to getting the new Reno facility online that were not incurred in 2024.25 Table of ContentsSelling, General and Administrative ExpensesSelling, general and administrative expenses for the nine months ended September 30, 2024 totaled $11.1 million, an increase of $2.1 million, or 23%, compared to $9.0 million recorded for the nine months ended September 30, 2023. Selling, general and administrative expenses consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ theÂ NineÂ MonthsÂ EndedÂ September 30,â€‹Â Â Â Â 2024Â Â Â Â 2023Salaries and benefits â€‹$ 4,594,448â€‹$ 2,960,978Professional fees â€‹Â 2,248,900â€‹Â 2,108,656Non-cash stock based compensation â€‹Â 921,770â€‹Â 1,278,607Sales and marketing â€‹Â 618,946â€‹Â 588,051Insurance expense â€‹Â 642,499â€‹Â 708,639Travel, lodging and meals â€‹Â 399,142â€‹Â 179,615Facilities expense â€‹â€‹ 376,127â€‹â€‹ 359,057FDA PDUFA fees â€‹â€‹ 361,091â€‹â€‹ â€”Investor relations â€‹Â 347,148â€‹Â 309,106Director fees and expense â€‹Â 311,250â€‹Â 300,625Other expenses â€‹â€‹ 303,794â€‹â€‹ 223,216Total selling, general and administrative expenses â€‹$ 11,125,115â€‹$ 9,016,550â€‹The increase in personnel-related expenses was mainly due to new staff additions related to commercialization efforts made during the last two quarters of 2023 and throughout fiscal year 2024. The increase in regulatory expenses was primarily due to the FDA Prescription Drug User Fee Act (â€œPDUFAâ€) fees for Mydcombi. The decrease in non-cash stock-based compensation expenses was primarily due to the ending of the amortization period for older equity grants. The increase in travel, lodging and meals was primarily due to increased travel by the sales team to promote Mydcombi. The increase in professional fees was primarily due to the short-term need for temporary staff while in the process of hiring permanent employees. The increase in sales and marketing expenses was primarily due to samples initiatives for the Clobetasol launch in 2024. The increase in other expenses was primarily due to software licensing and public filing fees.Reacquisition of License RightsReacquisition of license rights for the nine months ended September 30, 2024 totaled $4.9 million, compared to no expense for the nine months ended September 30, 2023. The $4.9 million is comprised of the aggregate $5.0 million of payments ($2.0 million of cash and $3.0 million settled in common stock) to Bausch + Lomb in connection with the reacquisition of the Bausch Licensed Product (which we are recording as an operating expense), partially offset by $0.1 million related to the repurchase of equipment.Total Other ExpenseTotal other expense for the nine months ended September 30, 2024 was approximately $0.6 million, a decrease of $0.8 million, compared to $1.4 million for the nine months ended September 30, 2023. Total other expense for the nine months ended September 30, 2024 primarily consisted of approximately $2.0 million of interest expense related to the Avenue loan partially offset by $1.2 million of changes in fair value of equity consideration (the equity payable for the Bausch + Lomb and Formosa transactions) and $0.2 million of interest income, primarily from Treasury bills.26 Table of ContentsLiquidity and Going ConcernWe measure our liquidity in a number of ways, including the

following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash and Cash Equivalentsâ€‹$ 7,188,129â€‹$ 14,849,057â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Working (Deficit) Capitalâ€‹$ (4,093,399)â€‹$ 11,176,336 â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Notes Payable (Gross)â€‹$ 12,368,804â€‹$ 15,637,500â€‹Cash FlowSince inception, we have experienced negative cash flows from operations and our operations have primarily been funded by proceeds from equity and debt financings. Our net losses were $29.9 million and $19.3 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of approximately $175.4 million. As of September 30, 2024, we had a cash and cash equivalents balance of $7.2 million, a working capital deficit of $4.1 million and stockholdersâ€™ equity ofâ‰ˆ$3.7 million. As of September 30, 2024 and December 31, 2023, we had $12.4 million and $15.6 million, respectively, of gross debt outstanding.These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q were issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities to support our future operations and the potential for entering into collaborations with other companies to enhance or complement our product and service offerings, and to enable us to make principal and interest payments on our debt obligations in the near term, which will be necessary to avoid a default on such obligations. Our operating needs also include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to further improve the marketability of our product and service offerings. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce selling, general and administrative costs in order to conserve our cash.During the nine months ended September 30, 2024 and 2023, our sources and uses of cash were as follows:Net cash used in operating activities for the nine months ended September 30, 2024 was approximately $24.0 million, which includes cash used to fund a net loss of $29.9 million, reduced by $5.8 million of net non-cash expenses, plus $0.1 million of net cash generated from changes in the levels of operating assets and liabilities. Net cash used in operating activities for the nine months ended September 30, 2023 was $17.5 million, which includes cash used to fund a net loss of $19.3 million, reduced by $3.7 million of non-cash expenses, plus $2.0 million of cash used to fund changes in operating assets and liabilities.Net cash used in investing activities for the nine months ended September 30, 2024 was approximately $0.2 million, which was primarily related to the purchase of property and equipment. Cash used in investing activities for the nine months ended September 30, 2023 was $3.8 million, which was related to $2.7 million for purchases of property and equipment and a $1.1 million cash investment in an intangible asset.Net cash provided by financing activities for the nine months ended September 30, 2024 totaled approximately $16.5 million, which was primarily attributable to $14.2 million of net proceeds from the sale of common stock and warrants in offerings and, $6.0 million of net proceeds from the sale of common stock in our â€œat-the-marketâ€ offering pursuant to the Sales Agreement with Leerink Partners, partially offset by $3.8 million from the repayment of notes payable. Net cash provided by financing activities for the nine months ended September 30, 2023 totaled $19.2 million, which was attributable to $10.9 million of net proceeds received from a registered direct offering, $4.0 million of net proceeds from an at-the-market offering and $4.9 million of net proceeds from the additional tranche under the Loan and Security Agreement. This was slightly offset by the repayment of $0.6 million of notes payable in connection with the D&O Loan.27 Table of ContentsContractual Obligations and CommitmentsDuring the next twelve months, we have commitments to pay (a) $5.7 million to settle our September 30, 2024 accounts payable, accrued expenses and other current liabilities, (b) $0.6 million relating to our non-cancelable operating lease commitments, and (c) $10.1 million of gross payments due under our notes payable, convertible notes payable (if not previously converted).After the next twelve months we have commitments to pay (a) an additional $0.3 million related to our accrued expenses and other non-current liabilities, (b) $0.8 million relating to our non-cancelable operating lease commitments, and (c) $2.3 million of gross payments due in connection with notes payable and convertible notes payable (if not previously converted).Risks and UncertaintiesThe continuing worldwide implications of the war between Russia and Ukraine and the conflict in the Middle East remain difficult to predict at this time. The imposition of sanctions on Russia by the United States and other countries and counter sanctions by Russia, and the resulting economic impacts on oil prices and other materials and goods, could affect the price of materials used in the manufacture of our product candidates. If the price of materials used in the manufacturing of our product candidates increase, that would adversely affect our business and the results of our operations.Off-Balance Sheet ArrangementsThere are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.Critical Accounting EstimatesAs described in Item 7 â€“ Critical Accounting Estimates in our 2023 Form 10-K, as amended by our 2023 Form 10-K Amendment, we prepare our financial statements in accordance with U.S. GAAP, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statements that require estimation but are not deemed critical, as defined above.ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk.Smaller reporting companies such as Eyenovia are not required to provide the information required by this Item.â€‹ItemÂ 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresAs of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act.28 Table of ContentsIn designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.Based on their evaluation, our principal executive officer and principal financial and accounting officer concluded that, as of September 30, 2024, our disclosure controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures as of September 30, 2024.Changes in Internal Control over Financial ReportingThere has been no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.â€‹29 Table of ContentsPARTÂ IIÂ - OTHER INFORMATIONItemÂ 1. Legal Proceedings.We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.ItemÂ 1A. Risk Factors.There have been no material changes to the risk factors set forth in Part I, Item 1A of our 2023 Form 10-K, as amended by our 2023 Form 10-K Amendment.ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds.Recent Sales of Unregistered SecuritiesNone.Purchases of Equity Securities by the Issuer and Affiliated PurchasersNone.ItemÂ 3. Defaults Upon Senior Securities.Not applicable.ItemÂ 4. Mine Safety Disclosures.Not applicable.ItemÂ 5. Other Information.Securities Trading Plans of Directors and Executive OfficersDuring the nine months ended September 30, 2024, none of our directors or officers, or the Company, adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) promulgated under the Exchange Act or any â€œnon-Rule 10b5-1 trading arrangement.â€â€‹30 Table of ContentsItemÂ 6. Exhibits.â€‹ExhibitIncorporatedÂ byÂ ReferenceÂ fromÂ FilingsÂ asÂ NotedÂ BelowÂ (UnlessOtherwiseÂ Indicated)NumberÂ Â Â Â ExhibitÂ DescriptionÂ Â Â Â FormÂ Â Â Â FileÂ No.Â Â Â Â

Option is being exercised. The Purchase Price may be paid as follows:(a)in cash;(b)by check or money order;(c)by surrender to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned by Grantee free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of surrender or attestation equal to the Purchase Price (provided that Grantee may not exercise the Option by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Companyâ€™s stock);(d)through a formal â€œnet exerciseâ€ arrangement adopted by the Company pursuant to which Grantee may exercise the Option and receive the net number of Shares equal to (i)Â the number of Shares as to which the Option is being exercised, multiplied by (ii)Â a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share;â€‹2(e)through a broker-dealer sale and remittance procedure pursuant to which Grantee (i)Â shall provide written instructions to a Company designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate Exercise Price payable for the purchased Shares and (ii)Â shall provide written directives to the Company to deliver the certificates (or other evidence satisfactory to the Company to the extent that the Shares are uncertificated) for the purchased Shares directly to such brokerage firm in order to complete the sale transaction; or(f)any combination of the foregoing methods of payment.7.Compliance with Applicable Laws.(a)If at any time the Administrator determines that the delivery of Shares pursuant to the exercise of the Option is or may be unlawful under Applicable Laws, the right to exercise the Option shall be suspended until the Administrator determines that such delivery is lawful and shall be further subject to the approval of counsel for the Company with respect to such compliance. No Shares will be issued pursuant to this Agreement unless and until all then applicable requirements imposed by federal and state securities and other laws, rules and regulations and by any regulatory agencies having jurisdiction, and by any exchanges upon which the Shares may be listed, have been fully met. The Company may impose such conditions on any Shares issuable pursuant to this Agreement as it may deem advisable, including, without limitation, restrictions under the Securities Act of 1933, as amended, under the requirements of any exchange upon which shares of the same class are then listed, and under any blue sky or other securities laws applicable to those Shares. The Company shall have no obligation to effect any registration or qualification of the Shares under any Applicable Law.(b)As a condition to the exercise of the Option, the Company may require the person exercising the Option to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws.(c)Subject to the Applicable Laws and any governing rulesÂ or regulations, the Company shall issue or cause to be issued the Shares acquired pursuant to the Option and shall deliver such Shares to or for the benefit of Grantee by means of one or more of the following as determined by the Administrator: (i)Â by delivering to Grantee evidence of book entry Shares credited to the account of Grantee, (ii)Â by depositing such Shares for the benefit of Grantee with any broker with which Grantee has an account relationship, or (iii)Â by delivering such Shares to Grantee in certificate form.8.Withholding Obligations. Grantee may incur Tax Obligations under federal, state, local, and/or foreign law, in connection with the grant, vesting, or exercise of the Option, the ownership of the Shares, and other actions taken pursuant to this Agreement, and the Company may be required to satisfy by withholding from Granteeâ€™s compensation or otherwise collect from Grantee. Grantee agrees that the Company (or a Related Entity) may condition the exercise of the Option upon the satisfaction of such withholding tax obligations, and may satisfy such withholding obligations by any of the following means or by a combination of such means, in theâ€‹3Administratorâ€™s discretion: (i) withholding from any compensation otherwise payable to Grantee by the Company; (ii) causing Grantee to tender a cash payment; or (iii) withholding from the Shares otherwise issuable to Grantee upon exercise of the Option the number of Shares with a Fair Market Value (measured as of the date the tax withholding obligations are to be determined) equal to the amount of such tax withholding; provided, however, that the number of such Shares so withheld will not exceed the amount necessary to satisfy the Companyâ€™s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income (or such lesser amount as may be necessary to avoid classification of the Shares as a liability for financial accounting purposes). Grantee understands that all matters with respect to the total amount of taxes to be withheld in respect of such compensation income will be determined by the Administrator in its reasonable discretion. Grantee further understands that, although the Company will pay withheld amounts to the applicable taxing authorities, Grantee remains responsible for payment of all taxes due as a result of income arising under the Agreement.9.Rights as a Stockholder. Neither Grantee nor anyone claiming through Grantee will have any rights as a stockholder of the Company with respect to any Shares subject to the Option until Grantee has exercised the Option as described herein and the Shares are delivered (as evidenced by delivery of a certificate for such Shares or the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).10.Transferability. The Option may not be sold, pledged, assigned, hypothecated, transferred, except by will or by the laws of descent and distribution and in accordance with the Applicable Laws, and is exercisable during Granteeâ€™s life only by Grantee. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Administrator, Grantee may designate a third party who, in the event of Granteeâ€™s death, will thereafter be entitled to exercise the Option.11.Option Not an Employment Contract. Neither the Option nor this Agreement is an employment or service contract, and nothing in this Agreement or the Grant Notice creates or will be deemed to create in any way whatsoever any right or obligation on Granteeâ€™s part to continue in the employment or service of the Company or a Related Entity, or of the Company or a Related Entity to continue Granteeâ€™s employment or service, or interferes with or limits in any way the right of the Company or a Related Entity to terminate Granteeâ€™s employment or service at any time or for any reason in accordance with the Applicable Laws.12.Adjustments. Subject to any required action by the stockholders of the Company, the number of Shares covered by the Option and the Exercise Price, as well as any other terms that the Administrator determines require adjustment, shall be proportionately adjusted for (i) any increase or decrease in the number of issued and outstanding Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Shares, or similar transaction affecting the Shares, (ii) any other increase or decrease in the number of issued and outstanding Shares effected without receipt of consideration by the Company, or (iii) any other transaction with respect to the Companyâ€™s Common Stock including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar transaction; provided, however that conversion of any convertible securities of theâ€‹4Company shall not be deemed to have been â€œeffected without receipt of consideration.â€ Such adjustment shall be made by the Administrator and its determination shall be final, binding and conclusive. Except as the Administrator determines, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason hereof shall be made with respect to, the number of Shares subject to the Option or the Exercise Price. No adjustments shall be made for dividends paid in cash or in property other than Common Stock of the Company, nor shall cash dividends or dividend equivalents accrue or be paid in respect of the Option.13.Administration of Option. This Agreement and the Option shall be administered by the Board. To the extent permitted by the Applicable Laws, the Board may delegate by resolution any or all of its powers under this Agreement to one or more Committees. All references in this Agreement to the â€œAdministratorâ€ shall mean the Board or a Committee referred to in this paragraph, to the extent that the Boardâ€™s powers or authority under this Agreement have been delegated to such Committee. The Board may retain the authority to concurrently administer this Agreement and the Option with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. The Administrator shall have full discretionary authority to construe and interpret the terms of this Agreement and to determine all facts necessary to administer this Agreement and the Option. All decisions by the Administrator shall be made in the Administratorâ€™s sole discretion and shall be final and binding on all persons having or claiming any interest in this Agreement or the Option.14.No Effect on Retirement and Other Benefit Plans. Except as specifically provided in a retirement or other benefit plan of the Company or a Related Entity, the Option shall not be deemed compensation for purposes of computing benefits or contributions under any retirement plan of the Company or a Related Entity, and shall not affect any benefits under any other benefit plan of the Company or a Related Entity, in each case, whether such plan is now or hereafter existing.15.Electronic Delivery. The Administrator may decide to deliver any documents related to the Option through an online or electronic system established and maintained by the Company or another third party designated by the Company or to request Granteeâ€™s acceptance of the Option by electronic means. By accepting the Option, Grantee consents to receive such documents by electronic delivery and agrees to participate in the Option through an online or electronic system established and maintained by the Company or another third party designated by the Company, and such consent shall remain in effect throughout Granteeâ€™s Continuous Service with the Company and any Related Entity and thereafter until withdrawn in writing by Grantee.16.Data Privacy. The Administrator may decide to collect, use and transfer, in electronic or other form, personal data as described in this Agreement for the exclusive purpose of implementing, administering and managing the Option. By accepting the Option, Grantee acknowledges that the Company holds certain personal information about Grantee, including, but not limited to, name, home address and telephone number, date of birth, social security number or other identification number, salary, nationality, job title, details of all equity awards awarded, cancelled, exercised, vested or unvested, for the purpose of implementing, administering and managing the Option (the â€œDataâ€). Grantee further acknowledges that Data may be transferred to any third parties assisting in the implementation, administration and management of the Optionâ€‹5and that these third parties may be located in jurisdictions that may have different data privacy laws and protections, and Grantee authorizes such third parties to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Option, including any requisite transfer of such Data as may be required to a broker or other third party with whom the recipient or the Company may elect to deposit any Shares acquired pursuant to the Option.17.Application of SectionÂ 409A. The Option and this Agreement shall be interpreted to be exempt from the requirements of Section 409A pursuant to Treas. Reg. Â§ 1.409A-1(b)(5)(i). Notwithstanding anything in this Agreement to the contrary, Grantee will be solely responsible for the tax consequences of the Option, and in no event will the Company have any responsibility or liability if the Option does not meet any applicable requirements of Section 409A. Although the Company intends to administer the Option and this Agreement to prevent taxation under Section 409A, the Company does not represent or warrant that the Option or this Agreement complies with any provision of federal, state, local or other tax law. If, upon Granteeâ€™s separation from service, Grantee is a â€œspecified employeeâ€ within the meaning of Section 409A, any payment that is subject to Section 409A and triggered by a separation from service and would otherwise be paid within six months after Granteeâ€™s separation from service will instead be paid in the seventh month following Granteeâ€™s separation from service (to the extent required by Section 409A(a)(2)(B)(i)).18.Grantee Acknowledgement. Grantee acknowledges and agrees that the Option is granted in full satisfaction of Granteeâ€™s right, if any, to an equity award under any offer letter, employment agreement or similar letter, agreement, or communication from the Company or any Related Entity.19.Definitions.(a)â€œAdministratorâ€ has the meaning set forth in Section 13.(b)â€œAgreementâ€ means this Inducement Stock Option Award Agreement, including any amendments thereto.(c)â€œApplicable Lawsâ€ means the legal requirements relating to the Option under applicable provisions of federal and state securities laws, the corporate laws of Delaware, and, to the extent other than Delaware, the corporate law of the state of the Companyâ€™s incorporation, the Code, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to the Option.(d)â€œBoardâ€ means the Board of Directors of the Company.(e)â€œCauseâ€ means, with respect to the termination by the Company or a Related Entity of Granteeâ€™s Continuous Service:(i) that such termination is for â€œCauseâ€ as such term (or word of like import) is expressly defined in a then-effective written employment agreement, consulting agreement, service agreement or other similar agreement between Grantee and the Company or such Related Entity, provided, however, that with regard to any agreement that defines â€œCauseâ€â€‹6on the occurrence of or in connection with a Corporate Transaction, such definition of â€œCauseâ€ shall not apply until a Corporate Transaction actually occurs; or(ii)in the absence of such then-effective written agreement and definition, is based on, in the determination of the Administrator: (A) Granteeâ€™s performance of any act, or failure to perform any act, in bad faith and to the detriment of the Company or a Related Entity; (B) Granteeâ€™s dishonesty, intentional misconduct or material breach of any agreement with the Company or a Related Entity; (C) Granteeâ€™s material breach of any noncompetition, confidentiality or similar agreement with the Company or a Related Entity, as determined under such agreement; (D) Granteeâ€™s commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person; (E) Granteeâ€™s engaging in acts or omissions constituting gross negligence, misconduct or a willful violation of a Company or a Related Entity policy which is or is reasonably expected to be materially injurious to the Company and/or a Related Entity; or (F) Granteeâ€™s failure to follow the reasonable instructions of the Board or Granteeâ€™s direct supervisor, which failure, if curable, is not cured within 10 days after notice to Grantee or, if cured, recurs within 180 days.(f)â€œCodeâ€ means the Internal Revenue Code of 1986, as amended, or any successor statute.(g)â€œCommitteeâ€ means the Compensation Committee of the Board or another committee appointed by the Board to administer the Option in accordance with Section 14.(h)â€œCommon Stockâ€ means the Companyâ€™s voting common stock, $0.0001 par value per share.(i)â€œCompanyâ€ means Eyenovia, Inc., a Delaware corporation, or any successor entity that assumes the Option in connection with a Corporate Transaction.(j)â€œContinuous Serviceâ€ means that Granteeâ€™s provision of services to the Company or a Related Entity is not interrupted or terminated. In jurisdictions requiring notice in advance of an effective termination as an employee or other service provider, Continuous Service shall be deemed terminated upon the actual cessation of providing services to the Company or a Related Entity notwithstanding any required notice period that must be fulfilled before a termination can be effective under Applicable Laws. Granteeâ€™s Continuous Service shall be deemed to have terminated either upon an actual termination of Continuous Service or upon the entity for which Grantee provides services ceasing to be a Related Entity. Continuous Service shall not be considered interrupted in the case of (i) any approved leave of absence, (ii) transfers among the Company, any Related Entity, or any successor, or (iii) any change in status as an employee or other service provider as long as the individual remains in the service of the Company or a Related Entity.(k)â€œCorporate Transactionâ€ means any of the following transactions, provided, however, that the Administrator shall determine under parts (iv) and (v) whether multiple transactions are related, and its determination shall be final, binding and conclusive:â€‹7(i)a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which the Company is incorporated;(ii)the sale, transfer or other disposition of all or substantially all of the assets of the Company;(iii)the complete liquidation or dissolution of the Company;(iv)any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A) the Shares outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B) in which securities possessing more than 50% of the total combined voting power of the Companyâ€™s outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger; or(v)acquisition in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act of 1934, as amended) of securities possessing more than 50% of the total combined voting power of the Companyâ€™s outstanding securities.(l)â€œDate of Grantâ€ means the Date of Grant shown on the Grant Notice.(m)â€œDisabilityâ€ means a â€œdisabilityâ€ (or word of like import) as defined under the long-term disability policy of the Company or the Related Entity to which Grantee provides services regardless of whether Grantee is covered by such policy. If the Company or the Related Entity to which Grantee provides service does not have a long-term disability plan in place, â€œDisabilityâ€ means that Grantee is unable to carry out the responsibilities and functions of the position held by Grantee by reason of any medically determinable physical or mental impairment for a period of not less than 90 consecutive days. Grantee will not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Administrator.(n)â€œExercise Priceâ€ means the Exercise Price per Share shown on the Grant Notice.(o)â€œExpiration Dateâ€ means the Expiration Date shown on the Grant Notice.(p)â€œFair Market Valueâ€ means, as of any date, the value of the Common Stock determined as follows. (i) If the Common Stock is listed on one or more established stock exchanges or national market systems, including without limitation The Nasdaq Global Select Market, The Nasdaq Global Market, or The Nasdaq Capital Market of The Nasdaq Stock Market LLC, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if noâ€‹8sales were reported) as quoted on the principal exchange or system on which the Common Stock is listed (as determined by the Administrator) on the date of determination (or, if no closing sales price or closing bid was reported on that date, as applicable, on the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable;(ii)If the Common Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such stock as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a Share shall be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no such prices were reported on that date, on

the last date such prices were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or(iii)In the absence of an established market for the Common Stock of the type described in (i) and (ii), above, the Fair Market Value thereof shall be determined by the Administrator in good faith by application of a reasonable valuation method consistently applied and taking into consideration all available information material to the value of the Company in a manner in compliance with Section 409A.(q)â€œGrant Noticeâ€ means the accompanying Notice of Inducement Stock Option Grant, including any amendments thereto.(r)â€œGranteeâ€ has the meaning set forth in the introductory paragraph of this Agreement.(s)â€œNotice of Exerciseâ€ has the meaning set forth in Section 5 of this Agreement.(t)â€œOptionâ€ has the meaning set forth in Section 1 of this Agreement.(u)â€œParentâ€ means a â€œparent corporation,â€ whether now or hereafter existing, as defined in Section 424(e) of the Code.(v)â€œPurchase Priceâ€ has the meaning set forth in Section 6 of this Agreement.(w)â€œRelated Entityâ€ means any Parent or Subsidiary of the Company.(x)â€œSection 409Aâ€ means Section 409A of the Code and the Treasury Regulations and other guidance issued thereunder by the United States Department of the Treasury.(y)â€œShareâ€ means a share of the Common Stock.(z)â€œSubsidiaryâ€ means a â€œsubsidiary corporation,â€ whether now or hereafter existing, as defined in Section 424(f) of the Code.â€‹9(aa)â€œTax Obligationsâ€ means all income tax, social insurance, payroll tax, fringe benefits tax, or other tax-related liabilities related to the Option, as determined under the Applicable Laws.20.Miscellaneous.(a)Notices. Any notice, demand or request required or permitted to be given pursuant to the terms of this Agreement will be in writing and will be deemed given when delivered personally, one day after deposit with a recognized international delivery service (such as FedEx), or three days after deposit in the U.S. mail, first class, certified or registered, return receipt requested, with postage prepaid, in each case addressed to the parties at the addresses of the parties set forth in the Grant Notice or such other address as a party may designate by notifying the other in writing.(b)Successors and Assigns. The provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and upon Grantee, Granteeâ€™s executor, personal representative(s), distributees, administrators, permitted transferees, permitted assignees, beneficiaries, and legatee(s), as applicable, whether or not any such person will have become a party to this Agreement and have agreed in writing to be joined herein and be bound by the terms hereof.(c)Severability. The provisions of this Agreement are severable, and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, then the remaining provisions will nevertheless be binding and enforceable.(d)Amendment. Neither this Agreement nor the Grant Notice may be amended unless the amendment is agreed to in writing by both Grantee and the Company.(e)Choice of Law. This Agreement will be construed and enforced in accordance with and governed by the laws of the State of Delaware, without giving effect to the choice of law rules of any jurisdiction.(f)Entire Agreement. This Agreement, along with the Grant Notice, constitutes the entire agreement between the parties hereto with regard to the subject matter hereof, and supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to such subject matter.(g)Construction. Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of this Agreement. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term â€œorâ€ is not intended to be exclusive, unless the context clearly requires otherwise.â€‹â€‹10EXHIBIT AEYENOVIA, INC.INDUCEMENT STOCK OPTION AWARDNOTICE OF EXERCISEEyenovia, Inc.â€‹â€‹â€‹â€‹â€‹Attention: Chief Executive Officerâ€‹â€‹Date of Exercise:â€‹â€‹1.Exercise of Option. This constitutes notice to Eyenovia, Inc. (the â€œCompanyâ€) that, pursuant to the Inducement Stock Option Award Agreement, dated Â (the â€œAward Agreementâ€), I elect to purchase the number of Shares set forth below for the price set forth below.â€‹â€‹Number of Shares as towhich Option is exercised (the â€œOptioned Sharesâ€):â€‹Exercise Price per Share:â€‹Total Purchase Price:â€‹â€‹2.Delivery of Payment. With this notice, I hereby deliver to the Company the full Purchase Price for the Optioned Shares, in a form permitted by the Award Agreement.3.Representations. By signing and delivering this notice to the Company, I acknowledge that I am the holder of the Option exercised by this notice and have full power and authority to exercise the Option. I further represent that I have received, read, and understood the Award Agreement, and I confirm my agreement to abide by and be bound by their terms and conditions. Capitalized terms used and not otherwise defined in this notice will have the meanings ascribed to those terms in the Award Agreement.4.Compliance with Securities Laws. Notwithstanding any other provision of the Award Agreement to the contrary, the exercise of any rights to purchase any Optioned Shares is expressly conditioned upon compliance with the Securities Act of 1933, as amended (the â€œSecurities Actâ€), all applicable state securities laws and all applicable requirements of any stock exchange or over the counter market on which the Companyâ€™s Common Stock may be listed or traded at the time of exercise and transfer. I agree to cooperate with the Company to ensure compliance with such laws. I further understand that the Optioned Shares cannot be resold and must be held indefinitely unless they are registered under the SecuritiesÂ Act or unless an exemption from such registration is available and that the certificate(s) representing the Optioned Shares may bear a legend to that effect. I understand that the Company is under no obligation to register the Optioned Shares and that an exemption may not be available or may not permit me to transfer Optioned Shares in the amounts or at the times I may desire.â€‹Exhibit A-15.Tax Withholding. I acknowledge that my exercise of the Option may result in Tax Obligations which require the Company to withhold certain amounts to satisfy federal, state, local, and/or foreign taxes. I agree to satisfy such tax withholding obligations as described in Section 9 of the Award Agreement.6.Rights as Stockholder. While the Company will endeavor to process this notice in a timely manner, I acknowledge that, until the issuance of the Optioned Shares (or, in the Companyâ€™s discretion, in un-certificated form, upon the books of the Companyâ€™s transfer agent) and my satisfaction of any other conditions imposed by the Company pursuant to the Award Agreement, no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Optioned Shares, notwithstanding the exercise of my Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance of the Optioned Shares.7.Tax Consultation. I understand that I may experience adverse tax consequences as a result of my exercise of the Option or my disposition of the Optioned Shares. I represent that I have consulted with any tax consultants I deem advisable in connection with the exercise of the Option and/or the disposition of the Optioned Shares and that I am not relying on the Company or its officers, representatives, or agents for any tax advice.8.Interpretation. Any dispute regarding the interpretation of this notice will be resolved by the Committee in its discretion, and the Committeeâ€™s determination will be final and binding on all parties.9.Entire Agreement. The Award Agreement under which the Optioned Shares were granted is incorporated herein by reference and, together with this notice, constitute the entire agreement of the parties with respect to the subject matter of this notice.â€‹â€‹â€‹â€‹GRANTEE:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Print Name:â€‹â€‹â€‹â€‹â€‹Address:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Exhibit A-2 EX-10.8 3 eyen-20240930xex10d8.htm EX-10.8 â€‹Exhibit 10.8INDEMNIFICATION AND ADVANCEMENT AGREEMENTThis Indemnification and Advancement Agreement (â€œAgreementâ€) is made as of Â Â Â Â Â Â Â Â Â Â Â Â , 2024Â Â Â Â Â by and between Eyenovia, Inc., a Delaware corporation (the â€œCompanyâ€), and [name], [a member of the Board of Directors/an officer/an employee/an agent] of the Company (â€œIndemniteeâ€). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement of expenses.RECITALSWHEREAS, the Board of Directors of the Company (the â€œBoardâ€) believes that highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers, or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification and advancement of expenses against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;WHEREAS, the Board has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Third Amended and Restated Certificate of Incorporation (as amended, the â€œCharterâ€) and the Second Amended and Restated Bylaws (the â€œBylawsâ€) of the Company require indemnification of the officers and directors of the Company, and the Bylaws permit indemnification of employees and agents of the Company to the extent not prohibited by the DGCL or other applicable law. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the â€œDGCLâ€). The Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of its board of directors, officers, and other persons with respect to indemnification and advancement of expenses;WHEREAS, the uncertainties relating to such insurance, to indemnification, and to advancement of expenses may increase the difficulty of attracting and retaining such persons;WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;WHEREAS, this Agreement is a supplement to, and in furtherance of, the Charter, the Bylaws, and any resolutions adopted pursuant thereto, as well as any rights of Indemnitee under any directorsâ€™ and officersâ€™ liability insurance policy, and is not a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder; andWHEREAS, Indemnitee may not be willing to serve or continue to serve as an officer, director or employee without adequate additional protection, and the Company desires Indemnitee to serve or continue to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified and be advanced expenses, if that becomes necessary.â€‹â€‹â€‹NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:SectionÂ 1.Services to the Company.Â Indemnitee agrees to serve or continue to serve as a [director/officer/employee/agent] of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law). This Agreement does not create any obligation on the Company to continue Indemnitee in such position and is not an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.SectionÂ 2.Definitions.Â As used in this Agreement:(a)â€œAgentâ€ means any person who is authorized by the Company or an Enterprise to act for or represent the interests of the Company or an Enterprise, respectively.(b)A â€œChange in Controlâ€ occurs upon the earliest to occur after the date of this Agreement of any of the following events:i.Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Companyâ€™s then outstanding securities unless the change in relative beneficial ownership of the Companyâ€™s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;ii.Change in Board of Directors. During any period of three (3)Â consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv) of this Agreement) whose election by the Board or nomination for election by the Companyâ€™s stockholders was approved by a vote of at leastÂ two-thirdsÂ of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;iii.Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;iv.Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Companyâ€™s assets; andv.Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.vi.For purposes of this SectionÂ 2(b), the following terms have the following meanings:1â€œExchange Actâ€ means the Securities Exchange Act of 1934, as amended from time to time.2â€œPersonâ€ has the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person excludes (i) the Company, (ii) any trustee or other â€‹â€‹â€‹fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.3â€œBeneficial Ownerâ€ has the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner excludes any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.(c)â€œCorporate Statusâ€ describes the status of a person who is or was acting as a director, officer, employee, fiduciary, or Agent of the Company or an Enterprise.(d)â€œDelaware Courtâ€ means the Court of Chancery of the State of Delaware.(e)â€œDisinterested Directorâ€ means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.(f)â€œEnterpriseâ€ means any corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity for which Indemnitee is or was serving at the request of the Company as a director, officer, employee, or Agent.(g)â€œExpensesâ€ includes all reasonable attorneysâ€™ fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include (i)Â Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii)Â for purposes of SectionÂ 14(d) of this Agreement only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemniteeâ€™s rights under this Agreement, by litigation or otherwise. Expenses, however, do not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.(h)â€œIndependent Counselâ€ means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i)Â the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii)Â any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term â€œIndependent Counselâ€ does not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemniteeâ€™s rights under this Agreement.(i)â€œProceedingâ€ includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing, or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, regulatory, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is, or will be involved as a party, potential party,Â non-partyÂ witness, or otherwise by reason of Indemniteeâ€™s Corporate Status or by reason of any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemniteeâ€™s part while acting pursuant to Indemniteeâ€™s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. A Proceeding also includes a situation the Indemnitee believes in good faith may lead to, or culminate in, the institution of a Proceeding.â€‹â€‹â€‹SectionÂ 3.Indemnity in Third-Party Proceedings.Â The Company will indemnify Indemnitee in accordance with the provisions of this SectionÂ 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this SectionÂ 3, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemniteeâ€™s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably

believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that Indemniteeâ€™s conduct was unlawful.SectionÂ 4.Indemnity in Proceedings by or in the Right of the Company.Â The Company will indemnify Indemnitee in accordance with the provisions of this SectionÂ 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this SectionÂ 4, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemniteeâ€™s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. The Company will not indemnify Indemnitee for Expenses under this SectionÂ 4 related to any claim, issue or matter in a Proceeding for which Indemnitee has been finally adjudged by a court to be liable to the Company, unless, and only to the extent that, the Delaware Court or any court in which the Proceeding was brought determines upon application by Indemnitee that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.SectionÂ 5.Indemnification for Expenses of a Party Who is Wholly or Partly Successful.Â Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee in connection with any Proceeding to the extent that Indemnitee is successful, on the merits or otherwise. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemniteeâ€™s behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this SectionÂ 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue or matter.SectionÂ 6.Indemnification For Expenses of a Witness.Â Notwithstanding any other provision of this Agreement and to the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemniteeâ€™s behalf in connection with any Proceeding to which Indemnitee is not a party but to which Indemnitee is a witness, deponent, interviewee, or otherwise asked to participate, by reason of Indemniteeâ€™s Corporate Status.SectionÂ 7.Partial Indemnification.Â If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.SectionÂ 8.Additional Indemnification.Â Notwithstanding any limitation in Sections 3, 4, or 5 of this Agreement, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law (including but not limited to, the DGCL and any amendments to or replacements of the DGCL adopted after the date of this Agreement that expand the Companyâ€™s ability to indemnify its officers, directors, employees or Agents) if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor). No indemnification shall be available under this Section 8 on account of Indemniteeâ€™s conduct that constitutes a breach of Indemniteeâ€™s duty of loyalty to the Company or its stockholders or is an act or omission not in good faith or that involves intentional misconduct or a knowing violation of the law.â€‹â€‹â€‹SectionÂ 9.Exclusions.Â Notwithstanding any provision in this Agreement, the Company is not obligated under this Agreement to make any Indemnification payment to Indemnitee in connection with any Proceeding (or any part of any Proceeding):(a)for which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid;(b)for (i)Â an accounting or disgorgement of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of SectionÂ 16(b) of the Exchange Act or similar provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefore (including pursuant to any settlement arrangements), (ii)Â any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to SectionÂ 304 of the Sarbanes-Oxley Act of 2002 (the â€œSarbanes-Oxley Actâ€), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of SectionÂ 306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements) or (iii)Â any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing SectionÂ 10D of the Exchange Act;(c) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, Agents or other indemnitees, unless (i)Â the Board authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii)Â the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii) the Proceeding or part of the Proceeding is to enforce Indemniteeâ€™s rights to indemnification or advancement, of Expenses, including a Proceeding (or any part of a Proceeding) initiated pursuant to Section 14 of this Agreement, or (iv) otherwise required by applicable law; or(d)if prohibited by applicable law.SectionÂ 10.Advances of Expenses.(a)The Company will advance, to the extent not prohibited by law (as determined by a court of competent jurisdiction in a final adjudication not subject to further appeal), the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee or any Proceeding (or any part of any Proceeding) initiated by Indemnitee if (i)Â the Proceeding or part of any Proceeding is to enforce Indemniteeâ€™s rights to obtain indemnification or advancement of Expenses from the Company or an Enterprise, including a proceeding initiated pursuant to SectionÂ 14 or (ii)Â the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation. The Company will advance the Expenses within thirty (30)Â days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding eligible for advancement of expenses.(b)Advances will be unsecured and interest free. Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company, thus Indemnitee qualifies for advances upon the execution of this Agreement and delivery to the Company. No other form of undertaking is required other than the execution of this Agreement. The Company will make advances without regard to Indemniteeâ€™s ability to repay the Expenses and without regard to Indemniteeâ€™s ultimate entitlement to indemnification under the other provisions of this Agreement. (c)Notwithstanding the foregoing, unless otherwise determined pursuant to Section 15(a) of this Agreement, no advance shall be made by the Company to Indemnitee (except by reason of the fact that Indemnitee is or was a director of the Company, in which event this paragraph shall not apply) in any Proceeding if a determination is reasonably and promptly made (i) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (ii) by a committee of Disinterested Directors designated by majority vote of the Disinterested Directors, even though less than a quorum of the Board, or (iii) if there are no such Disinterestedâ€‹â€‹â€‹Directors or, if such Disinterested Directors so direct, by written opinion provided by Independent Counsel selected by the Board, that facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that Indemnitee acted in bad faith or in a manner that Indemnitee did not believe to be in or not opposed to the best interests of the Company.SectionÂ 11.Procedure for Notification of Claim for Indemnification or Advancement. (a)Indemnitee will notify the Company in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. Indemnitee will include in the written notification to the Company a description of the nature of the Proceeding. Indemniteeâ€™s failure to notify the Company will not relieve the Company from any obligation it may have to Indemnitee under this Agreement, and any delay in so notifying the Company will not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company will, promptly upon receipt of such a request for indemnification or advancement, advise the Board in writing that Indemnitee has requested indemnification or advancement. Indemnitee agrees to choose counsel that is a member of the approved list of panel counsel under the Companyâ€™s applicable directorsâ€™ and officersâ€™ insurance policy, should the applicable policy provide for a panel of approved counsel.(b)The Company will be entitled to participate in the Proceeding at its own expense.SectionÂ 12.Procedure Upon Application for Indemnification.(a)Unless a Change of Control has occurred, the determination of Indemniteeâ€™s entitlement to indemnification will be made:i.by a majority vote of the Disinterested Directors, even though less than a quorum of the Board;ii.by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board;iii.if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by written opinion provided by Independent Counsel selected by the Board; oriv.if so directed by the Board, by the stockholders of the Company.(b)If a Change in Control has occurred, the determination of Indemniteeâ€™s entitlement to indemnification will be made by written opinion provided by Independent Counsel selected by Indemnitee (unless Indemnitee requests such selection be made by the Board).(c)The party selecting Independent Counsel pursuant to Section 10(c) of this Agreement or subsection (a)(iii) or (b)Â of this SectionÂ 12 will provide written notice of the selection to the other party. The notified party may, within ten (10)Â days after receiving written notice of the selection of Independent Counsel, deliver to the selecting party a written objection to such selection;Â provided,Â however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of â€œIndependent Counselâ€ as defined in SectionÂ 2 of this Agreement, and the objection will set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected will act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit. If, within thirty (30)Â days after the later of submission by Indemnitee of a written request for indemnification pursuant to SectionÂ 11(a) of this Agreement and the final disposition of the Proceeding, Independent Counsel has not been selected or, if selected, any objection to such selection has not been resolved, either the Company or Indemnitee may petition the Delaware Court for the appointment as Independent Counsel of a person selected by such court or by such other person as such court designates. Upon the due commencement of any judicial proceeding or arbitration pursuant to SectionÂ 14(a) of this Agreement, Independent Counsel will beâ€‹â€‹â€‹discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).(d)Indemnitee will cooperate with the person, persons or entity making the determination with respect to Indemniteeâ€™s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. The Company will advance and pay any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making the indemnification determination irrespective of the determination as to Indemniteeâ€™s entitlement to indemnification and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing of the determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied and providing a copy of any written opinion provided to the Board by Independent Counsel.(e)If it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within thirty (30)Â days after such determination.SectionÂ 13.Presumptions and Effect of Certain Proceedings.(a)In making a determination with respect to entitlement to indemnification under this Agreement, the person, persons, or entity making such determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with SectionÂ 11(a) of this Agreement, and the Company will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper under the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.(b)If a claim for indemnification or advancement of expenses pursuant to this Agreement is not paid by the Company or on its behalf within ninety (90)Â days after receipt by the Company of Indemniteeâ€™s written request therefor pursuant to SectionÂ 11(a) of this Agreement, Indemnitee will be entitled to an adjudication by a court of competent jurisdiction of Indemniteeâ€™s entitlement to such indemnification or advancement of expenses. Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of any claim or Proceeding.(c)The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea ofÂ noloÂ contendereÂ or its equivalent, will not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemniteeâ€™s conduct was unlawful.(d)For purposes of any determination of good faith, Indemnitee will be deemed to have acted in good faith if Indemnitee acted based on the records or books of account of the Company, its subsidiaries, or an Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Company, its subsidiaries, or an Enterprise in the course of their duties, or on the advice of legal counsel for the Company, its subsidiaries, or an Enterprise or on information or records given or reports made to the Company or an Enterprise by an independent certified public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Company, its subsidiaries, or an Enterprise. Further, Indemnitee will be deemed to have acted in a manner â€œnot opposed to the best interests of the Company,â€ as referred to in this Agreement, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan. The provisions of this SectionÂ 13(d) areâ€‹â€‹â€‹not exclusive and do not limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.(e)The knowledge and/or actions, or failure to act, of any other person affiliated with the Company or an Enterprise (including, but not limited to, a director, officer, trustee, partner, managing member, Agent or employee) may not be imputed to Indemnitee for purposes of determining Indemniteeâ€™s right to indemnification under this Agreement.SectionÂ 14.Remedies of Indemnitee.(a)Subject to the last sentence of Section 13(b) of this Agreement, Indemnitee may commence litigation against the Company in the Delaware Court of Chancery to obtain indemnification or advancement of Expenses provided by this Agreement in the event that (i)Â a determination is made pursuant to SectionÂ 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)Â the Company does not advance Expenses pursuant to SectionÂ 10 of this Agreement, (iii)Â the Company does not indemnify Indemnitee pursuant to SectionÂ 5 or 6 or the second to last sentence of SectionÂ 12(d) of this Agreement within thirty (30)Â days after receipt by the Company of a written request therefor, (iv)Â the Company does not indemnify Indemnitee pursuant to SectionÂ 3, 4, 7, or 8 of this Agreement within thirty (30)Â days after a determination has been made that Indemnitee is entitled to indemnification. Alternatively, Indemnitee, at Indemniteeâ€™s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee must commence such Proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such Proceeding pursuant to this SectionÂ 14(a);Â provided,Â however, that the foregoing clause does not apply in respect of a Proceeding brought by Indemnitee to enforce Indemniteeâ€™s rights under SectionÂ 5 of this Agreement. The Company will not oppose Indemniteeâ€™s right to seek any such adjudication or award in arbitration.(b)If a determination is made pursuant to SectionÂ 12 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this SectionÂ 14 will be conducted in all respects as aÂ de novoÂ trial, or arbitration, on the merits and Indemnitee may not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this SectionÂ 14 the Company will have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be, and will not introduce evidence of the determination made pursuant to SectionÂ 12 of this Agreement.(c)If a determination is made pursuant to SectionÂ 12 of this Agreement that Indemnitee is entitled to indemnification, the Company will be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this SectionÂ 14 unless (i)Â a misstatement is made of a material fact, or an omission of a material fact necessary to make Indemniteeâ€™s statement not materially misleading, in connection with Indemniteeâ€™s request for indemnification, or (ii)Â the Company is prohibited from indemnifying Indemnitee under applicable law.(d)The Company is precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this SectionÂ 14 that the procedures and presumptions of this Agreement are not valid, binding, or enforceable and will stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.(e)It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with

the interpretation, enforcement or defense of Indemniteeâ€™s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee under this Agreement. The Company, to the fullest extent permitted by law, will (within thirty (30)Â days after receipt by the Company of a written request therefor) advance to Indemnitee such Expenses which are incurred by Indemnitee in connection with a Proceeding concerning this Agreement, Indemniteeâ€™s other rights to indemnification or advancement of Expenses from the Company, or concerning any directorsâ€™ and officersâ€™ liability insurance policies maintained by the Company, and will indemnify Indemnitee against any and all such Expenses unless the court determines that each of the Indemniteeâ€™s claims in such Proceeding were made in bad faith or frivolous, or that Indemnitee is not entitled toâ€‹â€‹â€‹be indemnified by the Company under the provisions of this Agreement, the Charter, the Bylaws, applicable law or otherwise.SectionÂ 15.Non-exclusivity;Â Survival of Rights; Insurance; Subrogation.(a)The indemnification and advancement of Expenses provided by this Agreement are not exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or Disinterested Directors or otherwise. The indemnification and advancement of Expenses provided by this Agreement may not be limited or restricted by any amendment, alteration or repeal of this Agreement in any way with respect to any action taken or omitted by Indemnitee in Indemniteeâ€™s Corporate Status occurring prior to any amendment, alteration or repeal of this Agreement. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Charter, Bylaws or this Agreement, it is the intent of the parties hereto that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy is cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, will not prevent the concurrent assertion or employment of any other right or remedy.(b)The Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of Expenses and/or insurance provided by one or more Persons with whom or which Indemnitee may be associated.i.The Company hereby acknowledges and agrees:1)the Company is the indemnitor of first resort with respect to any request for indemnification or advancement of Expenses made pursuant to this Agreement concerning any Proceeding arising from or related to Indemniteeâ€™s Corporate Status with the Company;2)the Company is primarily liable for all indemnification or advancement of Expenses obligations for any Proceeding arising from or related to Indemniteeâ€™s Corporate Status, whether created by law, organizational or constituent documents, contract (including this Agreement) or otherwise;3)any obligation of any other Persons with whom or which Indemnitee may be associated to indemnify Indemnitee and/or advance Expenses to Indemnitee in respect of any proceeding are secondary to the Companyâ€™s obligations;4)the Company will indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent provided herein without regard to any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated or an insurer of any such Person; andii.the Company irrevocably waives, relinquishes and releases (A) any other Person with whom or which Indemnitee may be associated from any claim of contribution, subrogation, reimbursement, exoneration or indemnification, or any other recovery of any kind in respect of amounts paid by the Company to Indemnitee pursuant to this Agreement, whether or not such claim, remedy or right arises in equity or under contract, statute or common law.iii.In the event any other Person with whom or which Indemnitee may be associated or their insurers advances or extinguishes any liability or loss for Indemnitee, the payor has a right of subrogation against the Company or its insurers for all amounts so paid which would otherwise be payable by the Company or its insurers under this Agreement. In no event will payment by any other Person with whom or which Indemnitee may be associated or their insurers affect the obligations of the Company hereunder or shift primary liability for the Companyâ€™s obligation to indemnify or advance of Expenses to any other Person with whom or which Indemnitee may be associated.â€‹â€‹â€‹iv.Any indemnification or advancement of Expenses provided by any other Person with whom or which Indemnitee may be associated is specifically in excess over the Companyâ€™s obligation to indemnify and advance Expenses or any valid and collectible insurance (including but not limited to any malpractice insurance or professional errors and omissions insurance) provided by the Company.(c)To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or Agents of the Company or an Enterprise, the Indemnitee will be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or Agent under such policy or policies, including coverage in the event the Company does not or cannot, for any reason, indemnify or advance Expenses to Indemnitee as required by this Agreement. If, at the time of the receipt of a notice of a claim pursuant to this Agreement, the Company has director and officer liability insurance in effect, the Company will give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company will thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Indemnitee agrees to assist the Companyâ€™s efforts to cause the insurers to pay such amounts and will comply with the terms of such policies, including selection of approved panel counsel, if required. In the event of a Change in Control or the Companyâ€™s becoming insolvent, the Company shall maintain in force any and all insurance policies then maintained by the Company in providing insuranceâ€”directorsâ€™ and officersâ€™ liability, fiduciary, employment practices or otherwiseâ€”in respect of the individual directors and officers of the Company, for a fixed period of six years thereafter (a â€œTail Policyâ€). Such coverage shall beÂ non-cancellableÂ and shall be placed and serviced for the duration of its term by the Companyâ€™s incumbent insurance broker. Such broker shall place the Tail Policy with the incumbent insurance carriers using the policies that were in place at the time of the Change in Control (unless the incumbent carriers will not offer such policies, in which case the Tail Policy placed by the Companyâ€™s insurance broker shall be substantially comparable in scope and amount as the expiring policies, and the insurance carriers for the Tail Policy shall have an AM Best rating that is the same or better than the AM Best ratings of the expiring policies).(d)The Companyâ€™s obligation to indemnify or advance Expenses hereunder to Indemnitee for any Proceeding concerning Indemniteeâ€™s Corporate Status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such Enterprise. The Company and Indemnitee intend that any such Enterprise (and its insurers) be the indemnitor of first resort with respect to indemnification and advancement of Expenses for any Proceeding related to or arising from Indemniteeâ€™s Corporate Status with such Enterprise. The Companyâ€™s obligation to indemnify and advance Expenses to Indemnitee is secondary to the obligations the Enterprise or its insurers owe to Indemnitee. Indemnitee agrees to take all reasonably necessary and desirable action to obtain from an Enterprise indemnification and advancement of Expenses for any Proceeding related to or arising from Indemniteeâ€™s Corporate Status with such Enterprise.(e)In the event of any payment made by the Company under this Agreement, the Company will be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee from any Enterprise or insurance carrier. Indemnitee will execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.SectionÂ 16.Duration of Agreement.Â All the rights and privileges afforded by this Agreement, including the right to indemnification and the advancement of legal fees provided under this Agreement, shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified capacity pertaining to an indemnifiable event even though Indemnitee may have ceased to serve in such capacity at the time of any Proceeding. The indemnification and advancement of Expenses rights provided by or granted pursuant to this Agreement will(i) beÂ binding upon and enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), (ii) continue as to an Indemnitee who has ceased to be a director, officer, employee or Agent of the Company or of any other Enterprise, and (iii)Â inure to the benefit of Indemnitee and Indemniteeâ€™s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.SectionÂ 17.Severability.Â If any provision or provisions of this Agreement is held to be invalid, illegal or unenforceable for any reason whatsoever: (a)Â the validity, legality and enforceability of the remaining provisions ofâ€‹â€‹â€‹this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will not in any way be affected or impaired thereby and will remain enforceable to the fullest extent permitted by law; (b)Â such provision or provisions will be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)Â to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will be construed so as to give effect to the intent manifested thereby.SectionÂ 18.Interpretation.Â Any ambiguity in the terms of this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification and advancement of Expenses permitted by law. The Company and Indemnitee intend that this Agreement provide to the fullest extent permitted by law for indemnification and advancement of Expenses in excess of that expressly provided, without limitation, by the Charter, the Bylaws, vote of the Companyâ€™s stockholders or Disinterested Directors, or applicable law.SectionÂ 19.Enforcement.(a)The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer, employee, or Agent of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a director, officer, employee, or Agent of the Company.(b)This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Charter, the Bylaws, any directorsâ€™ and officersâ€™ insurance maintained by the Company, and applicable law, is not a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder.SectionÂ 20.Modification and Waiver.Â No supplement, modification or amendment of this Agreement is binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement will be deemed to constitute a waiver of any other provision of this Agreement nor will any waiver constitute a continuing waiver.SectionÂ 21.Notice by Indemnitee.Â Indemnitee agrees to promptly notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company does not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.SectionÂ 22.Notices.Â All notices, requests, demands and other communications under this Agreement will be in writing and will be deemed to have been duly given if (a)Â delivered by hand to the other party, (b)Â sent by reputable overnight courier to the other party or (c)Â sent by electronic mail, with receipt of oral confirmation that such communication has been received:(a)If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee provides to the Company.(b)If to the Company to:Name:Eyenovia, Inc.Address:295 Madison Avenue, Suite 2400â€‹New York, NY 10017Attention:Corporate SecretaryEmail:ajones@eyenovia.comâ€‹â€‹â€‹or to any other address as may have been furnished to Indemnitee by the Company.SectionÂ 23.Contribution.Â To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)Â the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii)Â the relative fault of the Company (and its directors, officers, employees and Agents) and Indemnitee in connection with such event(s) and/or transaction(s).SectionÂ 24.Applicable Law and Consent to Jurisdiction.Â This Agreement and the legal relations among the parties are governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to SectionÂ 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)Â agree that any action or Proceeding arising out of or in connection with this Agreement may be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other country, (ii)Â consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or Proceeding arising out of or in connection with this Agreement, (iii)Â waive any objection to the laying of venue of any such action or Proceeding in the Delaware Court, and (iv)Â waive, and agree not to plead or to make, any claim that any such action or Proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.SectionÂ 25.Identical Counterparts.Â This Agreement may be executed in one or more counterparts, each of which will for all purposes be deemed to be an original but all of which together constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.SectionÂ 26.Headings.Â The headings of this Agreement are inserted for convenience only and do not constitute part of this Agreement or affect the construction thereof. [Signature Page Follows]â€‹â€‹â€‹â€‹IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.â€‹â€‹â€‹â€‹â€‹EYENOVIA, INC.Â Â Â Â Â INDEMNITEEâ€‹â€‹â€‹By:Â â€‹â€‹Name:â€‹â€‹Name:â€‹Title:â€‹â€‹Address:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Email:â€‹â€‹[Signature Page to Indemnification Agreement] EX-31.1 4 eyen-20240930xex31d1.htm EX-31.1 ExhibitÂ 31.1CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICERPURSUANT TO SECTIONÂ 302 OF THE SARBANES-OXLEY ACT OF 2002I,Â Michael Rowe, certify that:1.I have reviewed this quarterly report on Form 10-Q of Eyenovia, Inc. for the quarterly period ended September 30, 2024;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹Date: November 12, 2024Â Â Â Â Â â€‹â€‹â€‹/s/Â Michael Roweâ€‹â€‹Name:Â Michael Roweâ€‹â€‹Title Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹ EX-31.2 5 eyen-20240930xex31d2.htm EX-31.2 ExhibitÂ 31.2CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERPURSUANT TO SECTIONÂ 302 OF THE SARBANES-OXLEY ACT OF 2002I,Â Andrew Jones, certify that:1.I have reviewed this quarterly report on Form 10-Q of Eyenovia, Inc. for the quarterly period ended September 30, 2024;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and

procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: November 12, 2024Â Â Â Â â€‹â€‹/s/ Andrew Jonesâ€‹â€‹Name: Andrew Jonesâ€‹â€‹Title Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹ EX-32.1 6 eyen-20240930xex32d1.htm EX-32.1 Exhibit 32.1CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICERPURSUANT TO SECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the quarterly report of Eyenovia,Â Inc. (the â€œCompanyâ€) on FormÂ 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€),Â I, Michael Rowe, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:1.The Report fully complies with the requirements of SectionÂ 13(a)Â or 15(d)Â of the Securities Exchange Act of 1934; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Date: November 12, 2024Â Â Â Â â€‹â€‹/s/ Michael Roweâ€‹â€‹Name: Michael Roweâ€‹â€‹Title Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹ EX-32.2 7 eyen-20240930xex32d2.htm EX-32.2 ExhibitÂ 32.2CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICERPURSUANT TO SECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the quarterly report of Eyenovia,Â Inc. (the â€œCompanyâ€) on FormÂ 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€),Â I, Andrew Jones, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:1.The Report fully complies with the requirements of SectionÂ 13(a)Â or 15(d)Â of the Securities Exchange Act of 1934; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Date: November 12, 2024Â Â Â Â â€‹â€‹/s/ Andrew Jonesâ€‹â€‹Name: Andrew Jonesâ€‹â€‹Title Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹ EX-101.SCH 8 eyen-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Accrued Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details) calc 2 link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Statements of Changes in Stockholders' (Deficiency) Equity link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - Condensed Statements of Changes in Stockholders' (Deficiency) Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of Significant Accounting Policies - Net loss per share of common stock (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of notes payable (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Notes Payable and Convertible Notes Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Stockholders' Equity - Summary of offerings (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Stockholders' Equity -Issuance date or modification date fair value of stock warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - Stockholders' Equity - Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941004 - Disclosure - Stockholders' Equity - Related to warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99941006 - Disclosure - Stockholders' Equity - Summary of option activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941007 - Disclosure - Stockholders' Equity - Black Scholes option (Details) link:presentationLink link:calculationLink link:definitionLink 99941008 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details) link:presentationLink link:calculationLink link:definitionLink 99941009 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Accrued Compensation link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Notes Payable and Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Accrued Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Notes Payable and Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Commitments and Contingencies - Company's right-of-use assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 99941005 - Disclosure - Stockholders' Equity - Restricted stock units activity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 eyen-20240930_cal.xml EX-101.CAL EX-101.DEF 10 eyen-20240930_def.xml EX-101.DEF EX-101.LAB 11 eyen-20240930_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Postal Zip Code Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Balance Sheets Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Inventory, Net Inventories Total inventory The carrying value as on the balance sheet date of deferred clinical supply costs, classified as current. Deferred Clinical Supply Costs Deferred clinical supply costs Deferred clinical supply costs Amount of license fee and expense reimbursements receivables classified as current. License Fee and Expense Reimbursements Receivables License fee and expense reimbursements receivable Deposits Assets, Current Security deposits, current Prepaid Expense and Other Assets, Current Total prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total Current Assets Property, Plant and Equipment, Net Property and equipment, net The amount of Security Deposits. Security Deposits Security deposits, non-current Intangible Assets, Net (Excluding Goodwill) Intangible assets Prepaid Expense, Noncurrent Prepaid expenses, non-current Operating Lease, Right-of-Use Asset Operating lease right-of-use asset The carrying amount of the equipment deposits. Equipment Deposits Equipment deposits Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued compensation Total accrued compensation Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities. Accrued Expenses and Other Liabilities, Current Accrued expenses and other current liabilities Operating Lease, Liability, Current Less: current portion Operating lease liabilities - current portion Short-term Bank Loans and Notes Payable Short term notes payable Notes payable - current portion, net of debt discount of $562,711 and $503,914 as of September 30, 2024 and December 31, 2023, respectively Convertible Notes Payable, Current Convertible notes payable - current portion, net of debt discount of $72,467 and $0 as of September 30, 2024 and December 31, 2023, respectively Liabilities, Current Total Current Liabilities Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other non- current liabilities. Accrued Expenses And Other Liabilities NonCurrent Accrued expenses and other non-current liabilities Operating Lease, Liability, Noncurrent Lease liabilities, non-current portion Operating lease liabilities - non-current portion Other Notes Payable, Noncurrent Notes payable - non-current portion, net of debt discount of $0 and $448,367 as of September 30, 2024 and December 31, 2023, respectively Convertible Notes Payable, Noncurrent Convertible notes payable - non-current portion, net of debt discount of $163,051 and $398,569 as of September 30, 2024 and December 31, 2023, respectively Liabilities Total Liabilities Commitments and Contingencies. Commitments and contingencies (Note 8) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock, $0.0001 par value, 300,000,000 shares authorized; 86,375,958 and 45,553,026 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the end Balance at the beginning Total Stockholders' Equity Liabilities and Equity Total Liabilities and Stockholders' Equity Amount of discount on notes payable to be amortized within one year or within the normal operating cycle, if longer. Notes Payable, Unamortized Discount, Current Notes payable - current portion, net of debt discount Amount of discount on convertible notes payable to be amortized within one year or within the normal operating cycle, if longer. Convertible Notes Payable, Unamortized Discount, Current Convertible notes payable - current portion, net of debt discount Amount of discount on notes payable to be amortized after one year or the normal operating cycle, if longer. Notes Payable, Unamortized Discount, Noncurrent Notes payable - non-current portion, net of debt discount Amount of discount on convertible notes payable to be amortized after one year or the normal operating cycle, if longer. Convertible Notes Payable, Unamortized Discount, Noncurrent Convertible notes payable - non-current portion, net of debt discount Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Statements of Operations Revenues [Abstract] Operating Income Revenue from Contract with Customer, Excluding Assessed Tax Revenue Cost of Revenue Cost of revenue Gross Profit Gross Loss Operating Expenses [Abstract] Operating Expenses: Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Amount of expense on reacquisition of license rights. Reacquisition Of License Rights Reacquisition of license rights Operating Expenses Total Operating Expenses Operating Income (Loss) Loss From Operations Nonoperating Income (Expense) [Abstract] Other Income (Expense): Other Nonoperating Income (Expense) Other income (expense), net Amount of change in fair value of equity consideration payable. Change in Fair Value of Equity Consideration Payable Change in fair value of equity consideration payable Change in fair value of equity consideration payable Interest Expense Nonoperating Interest expense Investment Income, Interest Interest income Nonoperating Income (Expense) Total Other Expense Net Loss Net loss Earnings Per Share, Basic and Diluted [Abstract] Net Loss Per Share Earnings Per Share, Basic Net Loss Per Share - Basic (in dollars per share) Basic net loss per common share (in dollars per share) Earnings Per Share, Diluted Net Loss Per Share - Diluted (in dollars per share) Diluted net loss per common share (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted Average Number of Common Shares Outstanding Weighted Average Number of Shares Outstanding, Basic Denominator for basic net loss per share (in shares) Shares Outstanding - Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Denominator for diluted net loss per share (in shares) Shares Outstanding - Diluted (in shares) Condensed Statements of Changes in Stockholders' (Deficiency) Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-In Capital [Member] Additional Paid-In Capital Accumulated Deficit [Member] Accumulated Deficit Shares, Outstanding Balance at the end (in shares) Balance at the beginning (in shares) Stock Issued During Period, Shares, New Issues Net proceeds (in shares) Issuance of common stock in offerings (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock in offerings Common stock value Adjustments to Additional Paid in Capital, Warrant Issued Warrant modification and additional warrants - incremental value Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Warrant modification and additional warrants - in issuance costs for offering Adjustments to additional paid in capital upon stock issuance costs Represent stock issued period shares licensing agreements. Stock Issued During Period, Shares, Licensing Agreements Issuance of common stock as consideration for licensing agreement (in shares) Pursuant to the license and certain milestone achievements issued Represent stock issued during period value licensing agreements. Stock Issued During Period, Value, Licensing Agreements Issuance of common stock as consideration for licensing agreement Pursuant to the license and certain milestone achievements stock Represent stock issued period, shares for reacquisition of licensing agreement. Stock Issued During Period Shares, Reacquisition Of Licensing Agreement Issuance of common stock as consideration for reacquisition of licensing agreement (in shares) Pursuant to the Letter Agreement shares Represent stock issued during the period, value for reacquisition of licensing agreements. Stock Issued During Period Value, Reacquisition Of Licensing Agreement Issuance of common stock as consideration for reacquisition of licensing agreement pursuant to the Letter Agreement stock This represents shares issued at market offering. Stock Issued at Market Offering During Period Shares New Issues Issuance of common stock in At the Market Program (in shares) The amount of common stock issued in at the market offering. Stock Issued at Market Offering During Period Value New Issues Issuance of common stock in At the Market Program Number of cashless shares issued as a result of the exercise of stock options. Stock Issued During Period Shares, Cashless Stock

Options Exercised Cashless exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of Options, Exercised | Shares Exercise of stock options (in shares) Value of stock issued as a result of the cashless exercise of stock options. Stock Issued During Period Value, Cashless Stock Options Exercised Cashless exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation This represents restricted stock units issued during the period. Restricted Stock Issued During Period Shares New Issues Issuance of common stock related to vested restricted stock units (in shares) Amount of restricted stock issued during the period. Restricted Stock Issued During Period Value New Issues Issuance of common stock related to vested restricted stock units Sale of Stock [Axis] Sale of Stock [Domain] At Market Offering [Member] At Market Offering Represents information pertaining to registered direct offering. Registered Direct Offering [Member] Registered direct offering The amount of issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. Proceeds Of Stock Issued During Period Gross Proceeds of stock issued during period gross Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Gross proceeds The cash inflow from the additional capital contribution to the entity. Proceeds from Issuance of Common Stock and Warrants Gross proceeds from common stock warrants Condensed Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows From Operating Activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Depreciation, Depletion and Amortization Depreciation of property and equipment Amount of Amortization of debt discount. Amortization of Debt Discount Amortization of debt discount Tangible Asset Impairment Charges Write-off of property and equipment Inventory Write-down Write-down of inventories to net realizable value Amount of provision for returned deferred clinical supplies. Provision for Returned Deferred Clinical Supplies Provision for returned deferred clinical supplies Amount of non cash expense on reacquisition of license rights. Non cash Expenses On Reacquisition Of License Rights Reacquisition of license rights Amount of expense (income) related to the increase (decrease) in reserve for rent expenses. Non Cash Rent Expense Non-cash rent expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets The increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables. Increase (Decrease) in License Fee and Expense Reimbursements Receivables License fee and expense reimbursement receivables The increase (decrease) during the reporting period in the value of deferred clinical supply costs. Increase (Decrease) in Deferred Clinical Supply Costs Deferred clinical supply costs Increase (Decrease) in Inventories Inventories Increase (Decrease) in Security Deposits Security and equipment deposits Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued compensation Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Operating Lease Liability Lease liabilities Net Cash Provided by (Used in) Operating Activities Cash used in operations Net Cash Used In Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows From Investing Activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Intangible Assets Investment in intangible asset Net Cash Provided by (Used in) Investing Activities Net Cash Used In Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows From Financing Activities The cash inflow from proceeds from sale of common stock and warrants in registered direct offering. Proceeds from Sale of Common Stock and Warrants in Registered Direct Offering Proceeds from sale of common stock and warrants in offerings Payments of Debt Issuance Costs Payment of offerings issuance costs Payment of issuance costs for notes issued to Avenue The amount of proceeds from issuance of common stock at market offering. Proceeds from Issuance of Common Stock at Market Offering Proceeds from sale of common stock in At the Market Program The cash outflow for cost incurred directly in at the market offering with the issuance of an equity security. Payments of Stock Issuance Costs, At the Market Offering Payment of issuance costs for At the Market Program Proceeds from Stock Options Exercised Proceeds from exercise of stock options Proceeds from note payable to Avenue The cash outflow paid to related parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. Payments of Debt Issuance Costs, Related Party Payment of issuance costs for notes issued to Avenue Repayments of Notes Payable Repayments of notes payable Repayments of notes payable Net Cash Provided by (Used in) Financing Activities Net Cash Provided By Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net Decrease in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents - End of Period Cash and Cash Equivalents - Beginning of Period Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information: Interest Paid, Capitalized, Investing Activities Interest Noncash Investing and Financing Items [Abstract] Supplemental Disclosure of Non-Cash Investing and Financing Activities The amount of purchase of insurance premium financed by short term notes payable. Purchase of Insurance Premium Financed by Short Term Note Payable Purchase of insurance policy financed by note payable Amount of accrual related to intangible asset recorded in milestone obligation as part of non-cash investing and financing activity. Accrual for Intangible Assets Milestone Obligation Accrual for intangible asset milestone obligation Amount of reclassification of deferred clinical supply costs to inventories. Reclassification Of Deferred Clinical Supply Costs To Inventories Reclassification of deferred clinical supply costs to inventories Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for lease liabilities Right-of-use assets obtained in exchange for lease obligations: Operating leases Escrow Deposit Disbursements Related to Property Acquisition Vendor deposits applied to purchases of property and equipment Amount of original Issue discount on notes payable. Original Issue Discount On Notes Payable Original issue discount on notes payable Stock Issued Issuance of common stock in consideration of licensing agreement Amount of cashless exercise of stock options. Cashless Exercise of Stock Options Cashless exercise of stock options The fair value of stock issued for reacquisition of licensing agreement in noncash financing activities. Stock issued, Value, Reacquisition Of Licensing Agreement Common stock issued in consideration for reacquisition of licensing agreement The amount of issuance of common stock related to vested restricted stock units. Issuance of Common Stock Related to Vested Restricted Stock Units Issuance of common stock related to vested restricted stock units Business Organization, Nature of Operations and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Business Organization, Nature of Operations and Basis of Presentation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Prepaid Expenses and Other Current Assets The entire disclosure of prepaid expenses and other current assets. Prepaid Expenses and Other Current Assets Disclosure [Text Block] Prepaid Expenses and Other Current Assets Intangible Assets. Intangible Assets Disclosure [Text Block] Intangible Assets Accrued Compensation Compensation Related Costs, General [Text Block] Accrued Compensation Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Notes Payable and Convertible Notes Payable The entire disclosure of notes payable. Notes Payable Disclosure [Text Block] Notes Payable and Convertible Notes Payable Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Employee Benefit Plans Compensation and Employee Benefit Plans [Text Block] Employee Benefit Plans Subsequent Events Subsequent Events [Text Block] Subsequent Events Disclosure of accounting policy for going concern. Liquidity And Going Concern, Policy [Policy Text Block] Liquidity and Going Concern Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Disclosure of accounting policy for Clinical Supply Arrangements. Clinical Supply Arrangements, Policy [Policy Text Block] Clinical Supply Arrangements Inventory, Policy [Policy Text Block] Inventories Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share of Common Stock Subsequent Events, Policy [Policy Text Block] Subsequent Events Disclosure of accounting policy pertaining to new accounting pronouncements issued that may impact the entity's financial reporting. New Accounting Pronouncements Issued, Policy [Policy Text Block] Recently Issued Accounting Standards Schedule of Inventory, Current [Table Text Block] Schedule of inventory Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net loss per common share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of weighted average diluted shares of common stock Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Tabular disclosure of accrued compensation. Disclosure of Accrued compensation [Table Text Block] Schedule of accrued compensation Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Tabular disclosure of notes payable. Schedule of Notes Payable [Table Text Block] Schedule of notes payable and convertible notes payable Lease, Cost [Table Text Block] Summary of company's right-of-use assets and liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of future minimum payments under the company's operating lease agreements Schedule of Stockholders Equity [Table Text Block] Schedule of summary of offerings Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of issuance date or modification date fair value of stock warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of the warrant activity and related information The tabular disclosure of warrants outstanding. Schedule Of Warrants Outstanding [Table Text Block] Schedule of warrants outstanding Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of restricted stock units ("RSUs") activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of the option activity Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Schedule of information related to stock options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Black-Scholes option pricing model to stock options granted Schedule of information pertaining to accounting policies in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Accounting Policies Disclosure [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] This member stands for Clinical Supply Arrangements. Clinical Supply Arrangements Clinical Supply Arrangements Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounting Policies Disclosure [Line Items] Summary of Significant Accounting Policies Treasury Stock, Value Treasury bills Cash, Uninsured Amount Cash, uninsured amount Represents clinical trials, percentage of additional mark-up on cost. Clinical Trials, Percentage of Additional Mark-up on Cost Clinical trials, percentage of additional mark-up on cost Amount of inventory write down adjusted to the list price. Inventory Write Down, Adjustments To List Price Inventory write down of adjustments Amount of write down of short dated inventory to net realizable value. Inventory Write Down, Short Dated Inventory To Net Realizable Value Inventory to net realizable value Inventory, Finished Goods, Gross Finished goods Inventory, Raw Materials and Supplies, Gross Raw materials Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Options Member refers to Convertible notes. Convertible Notes [Member] Convertible notes Restricted Stock Units (RSUs) [Member] Restricted stock units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Summary of Significant Accounting Policies Numerator: Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders Denominator (weighted average quantities): Weighted Average Number of Shares Issued, Basic Common shares issued Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Add: Prefunded warrants Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Add: Undelivered vested restricted shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total potentially dilutive shares Prepaid Insurance Prepaid insurance expenses Amount of Payroll Taxes Receivable. Payroll Taxes Receivable Payroll tax receivable Represents the information pertaining to Prepaid general and administrative expenses. Prepaid General and Administrative Expenses Prepaid general and administrative expenses Amount of prepaid patent expense. Prepaid Patent Expense Prepaid patent expenses Amount of prepaid conference expenses current. Prepaid Conference Expenses Current Prepaid conference expenses Prepaid Research And Development Expenses Prepaid Research And Development Expenses Prepaid research and development expenses Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle. Prepaid Rent and Security Deposit Prepaid rent and security deposit Other Assets Other Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] License Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Formosa Pharmaceuticals Inc. Formosa Pharmaceuticals Inc [Member] Formosa Pharmaceuticals Inc Intangible Assets Percentage of product approved by FDA. Percentage of Product Approved by FDA Percentage of product approved by FDA Amount of upfront payment made. Upfront Payment Upfront payment Upfront payment paid in cash Upfront Payment Paid in Cash Upfront payment paid in cash Legal expenses capitalized. Legal Expenses Capitalized Legal expenses capitalized Maximum amount payable upon achievement of certain development milestones. Maximum Amount Payable Upon Achievement Of Certain Development Milestones Maximum amount payable upon achievement of certain development milestones Maximum amount payable upon achievement of certain sales milestones. Maximum Amount Payable Upon Achievement of Certain Sales Milestones Maximum amount payable upon achievement of certain sales milestones Amount of initial development milestone payment which trigger FDA approval. Initial Development Milestone Payment, Trigger For Fda Approval Initial development milestone payment which trigger FDA approval Period when payment has to be made related to the license agreement from the effective date in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. License Agreement, Payment Period License agreement payment period Accrued Bonuses, Current Accrued bonus expenses Accrued Salaries, Current Accrued payroll expenses Amount of accrual related to intangible asset milestone obligation. Accrued Intangible Asset Milestone Obligation Accrued intangible asset milestone obligation Amount of accrued settlement related to defective clinical supply. Accrued Settlement On Defective Clinical Supply Accrued defective clinical supply settlement, net Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Clinical Studies Costs Accrued clinical studies costs Accrued Professional Fees, Current Accrued professional services Amount of credit card expenses payable by the entity. Credit Card Payable Credit card payable Amount of accrued franchise tax expenses paid by the entity. Accrued Franchise Tax Accrued franchise tax Amount of accrued research and development expenses paid by the entity. Accrued Research and Development Expenses, Current Accrued research and development expenses Other Accrued Liabilities, Current Other Accrued Liabilities and Other Liabilities Total accrued expenses and other current liabilities Schedule reflecting a long term notes to be paid to the borrowers. Schedule of Notes Payable [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] This member stands for director and officer insurance policy loan. Director And Officer Insurance Policy Loan [Member] D&O insurance policy loan Represents the information pertaining to Avenue - Note payable. Avenue - Note Payable [Member] Avenue - Note payable Represents the information pertaining to Avenue - Convertible note payable Avenue - Convertible Note Payable [Member] Avenue - Convertible note payable Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Notes Payable [Line Items] Notes Payable Notes Payable, Current [Abstract] Current portion Notes Payables Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, net of debt discounts, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Notes Payable, Net Of Debt Discount, Total Debt Instrument, Unamortized Discount Notes Payable, Current Notes Payable, Current portion Debt Instrument, Unamortized Discount, Current Debt Discount, Current portion Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable, net of debt discount due within one year or the operating cycle if longer. Notes Payable Current, Net Of Debt Discount Current, Current Portion Net, Current portion Notes Payable, Noncurrent Note payable, Non Current portion Debt Instrument, Unamortized Discount, Noncurrent Debt Discount, Non-Current portion Carrying value as of the balance sheet date of notes payable, net of debt discount (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Notes Payable Non Current, Net Of Debt Discount Non Current, Non Current Portion Net, Non Current portion Schedule of Short-term Debt [Table] Represents the information pertaining to Loan and Security Agreement with Avenue, the Lender. Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P., and Avenue Venture Opportunities Fund, L.P. II [Member] Avenue Ventures Loan Range [Axis] Range [Domain] Maximum [Member] Maximum Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to prefunded warrants in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Pre-funded Warrants [Member] Pre-funded warrants Short-term Debt [Line Items] Notes Payable Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Number of monthly payments. Number Of Monthly Payments Number of monthly payments Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment, Principal Initial principal payment related to loan and security agreement The loan

issuance costs will first be recorded in the balance sheet of the bond issuer. Loan Issuance Costs Loan issuance costs Interest Expense, Debt Interest expense Amortization of Debt Discount (Premium) Amortization of debt discount Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Exercise price Class of Warrant or Right, Number of Securities Called by Warrants or Rights Common stock issued from exercise of warrants Number of warrants issued Interest Expense, Security Sold under Agreement to Repurchase, Increase (Decrease) Interest expense related to the Loan and Security Agreement with Avenue Capital Management Amortization Of Financing Costs Amortization of debt discount related to loans Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Damages from Product Defects [Member] Defective clinical supply returns This member stands for Bausch License Agreement. Bausch License Agreement [Member] Bausch License Agreement Loss Contingencies [Line Items] Commitments and Contingencies Loss Contingency, Estimate of Possible Loss Current estimated loss Reflects the estimated amount of loss net payable from the specified contingency as of the balance sheet date Loss Contingency Estimate Of Possible Loss Net Payable Current estimated net payable amount Receivable related to amount previously held to be received upon completion of milestone. Loss Contingency, Receivable Upon completion of Milestone Receivable upon completion of milestone Purchased related to amount previously held to be received upon completion of milestone. Loss Contingency, Purchased Upon completion of Milestone Purchased upon completion of milestone Represents the number of days of written notice period for the termination of agreement. Written Notice Period For Termination Of Agreement Written notice period The value of stock agreed to be issued. Stock Agreed To Issue, Value, New Issues Issue of common stock Amount of upfront payments received by the entity, pursuant to a license agreement. License Agreements Upfront Payments Received Upfront payment received Loss Contingency, Loss in Period Loss recorded Operating Lease, Payments Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities Operating Lease, Weighted Average Remaining Lease Term Weighted Average Remaining Lease Term (Years): Operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted Average Discount Rate: Operating leases Lessee, Operating Lease, Liability, to be Paid [Abstract] Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Year One 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four 2027 Lessee, Operating Lease, Liability, to be Paid Total future minimum lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Operating Lease, Liability Present value of lease liabilities Amount of monthly consulting fee for the advisory service agreement. Related Party Transaction, Monthly Consulting Fee Monthly consulting fee This table may be used to disclose all the information related to Stockholders Equity. Stockholders Equity [Table] Stockholders' Equity Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References Stockholders' Equity [Line Items] Stockholders' (Deficiency) Equity Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Risk Free Interest Rate [Member] Risk free interest rate Measurement Input, Expected Term [Member] Expected term (years) Measurement Input, Price Volatility [Member] Expected volatility Minimum [Member] Minimum Fair Value Measurement Inputs and Valuation Techniques [Line Items] Share Price Fair value of common stock on date of grant Warrants and Rights Outstanding, Measurement Input Warrants and Rights Outstanding Measurement Input A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Class Of Warrants Or Rights Outstanding [Rollforward] Number of Warrants Class of Warrant or Right, Outstanding Outstanding at ending balance Outstanding at beginning balance Outstanding Number of Warrants Number of warrants or rights granted during the period. Class of Warrant or Right, Granted Granted Number of warrants or rights new repriced during the period. Class of Warrant or Right,New Repriced Repriced - Old Number of warrants or rights old repriced during the period. Class of Warrant or Right, Old Repriced Repriced - New Number of warrants or rights exercisable. Class of Warrant or Right, Exercisable Exercisable Number of warrants Exercisable Number of Warrants A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Class Of Warrants Or Rights, Weighted Average Exercise Price [Rollforward] Weighted Average Exercise Price Weighted average exercise price of warrants or rights outstanding. Class of Warrant or Right, Outstanding, Weighted Average Exercise Price Outstanding at ending balance Outstanding at beginning balance Weighted average exercise price of warrants or rights granted during the period. Class of Warrant or Right, Granted, Weighted Average Exercise Price Granted Weighted average exercise price of warrants or rights old repriced. Class of Warrant or Right, Old Repriced, Weighted Average Exercise Price Repriced - Old Weighted average exercise price of warrants or rights new repriced. Class of Warrant or Right, New Repriced, Weighted Average Exercise Price Repriced - New Weighted average exercise price of warrants or rights exercisable. Class of Warrant or Right, Exercisable, Weighted Average Exercise Price Exercisable Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Outstanding, Weighted Average Remaining Life Weighted Average Remaining Life, Outstanding Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Exercisable, Weighted Average Remaining Life Weighted Average Remaining Life, Exercisable Weighted Average Remaining Life, Exercisable Class of Warrant or Right [Table] This member stands for warrants with the first exercise price. Warrants At Exercise Price One [Member] Warrants at exercise price of $0.5000 This member stands for warrants with the second exercise price. Warrants At Exercise Price Two [Member] Warrants at exercise price of $0.6900 This member stands for warrants with the third exercise price. Warrants At Exercise Price Three [Member] Warrants at exercise price of $2.4696 This member stands for warrants with the fourth exercise price. Warrants At Exercise Price Four [Member] Warrants at exercise price of $2.7240 This member stands for warrants with the fifth exercise price. Warrants At Exercise Price Five [Member] Warrants at exercise price of $4.7600 Class of Warrant or Right [Line Items] Stockholders' Equity Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of RSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number RSUs non-vested June 30, 2024 RSUs non-vested January 1, 2024 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested The number of equity-based payment instruments, excluding stock (or unit) options, that vested RSUs Undelivered numbers during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested R S Us Undelivered, Number Vested RSUs undelivered June 30, 2024 A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price [Roll forward] Weighted Average Grant Date Value Per Share Weighted average price at which grantees can acquire the shares reserved for issuance under the restricted stock unit plan. Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Non Vested, Outstanding, Weighted Average Exercise Price RSUs non-vested June 30, 2024 RSUs non-vested January 1, 2024 Weighted average per share amount at which grantees can acquire shares of common stock by exercise of restricted stock units. Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Grants In Period, Weighted Average Exercise Price Granted Weighted average per share amount at which grantees vested the restricted stock units. Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested In Period, Weighted Average Exercise Price Vested Weighted average per share amount at which grantees vested the restricted stock units undelivered. Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested R S Us Undelivered, Weighted Average Exercise Price Vested RSUs undelivered June 30, 2024 Derivative Instrument [Axis] Derivative Contract [Domain] Stock Option [Member] Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Options, Outstanding | Shares Number of Options, Outstanding | Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Options, Granted | Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of Options, Forfeited | Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Number of Options, Exercisable | Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Outstanding | $ / Shares Weighted Average Exercise Price, Outstanding | $ / Shares Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average estimated grant date fair value Weighted Average Exercise Price, Granted | $ / Shares Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited | $ / Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable | $ / Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Life In Years, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Life In Years, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividends Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] This member represents for exercise price one. Exercise Price One [Member] Exercise Price $0.01 - $0.99 This member represents for exercise price two. Exercise Price Two [Member] Exercise Price $1.00 - $1.99 This member represents for exercise price three. Exercise Price Three [Member] Exercise Price $2.00 - $2.99 This member represents for exercise price four. Exercise Price Four [Member] Exercise Price $3.00 - $3.99 This member represents for exercise price five. Exercise Price Five [Member] Exercise Price $4.00 - $4.99 This member represents for exercise price six. Exercise Price Six [Member] Exercise Price $5.00 - $5.99 This member represents for exercise price seven. Exercise Price Seven [Member] Exercise Price $6.00 - $6.99 This member represents for exercise price eight. Exercise Price Eight [Member] Exercise Price $7.00+ Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Options Outstanding, Outstanding Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Options Outstanding, Outstanding Number of Options Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Options Exercisable, Weighted Average Remaining Life In Years Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Options Exercisable, Exercisable Number of Options This member stands for July offering. July offering [Member] July offering Represents information pertaining to prior warrants. Prior Warrants [Member] Prior Warrants Represents information relating to 2024 registered direct offering. Registered Direct Offering 2024 [Member] Registered Direct Offering Income Statement Location [Axis] Income Statement Location [Domain] Research And Development Expense [Member] Research and Development Expense General And Administrative Expense [Member] General and Administrative Expense The cash inflow from the additional capital contribution net of issuance costs to the entity. Proceeds from Issuance of Common Stock Net of Issuance Costs Net proceeds Shares Issued, Price Per Share Shares Issued price per share Number of additional securities into which the Additional class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Class Of Warrant Or Right Number Of Additional Securities Called By Additional Warrants Or Rights Additional warrants Warrants and Rights Outstanding, Term Term of warrant Exercise price per share or per unit of warrants or rights outstanding. Class of Warrant or Right, Exercise Price of Warrants or Rights 2 Exercise price Sale of Stock, Consideration Received on Transaction Net proceeds from At-the-Market Offering Program The amount of expense provided in the period for placement agent fees in connection with offering. Placement Agent Fees Placement agent fees Legal Fees Legal fees Price per share or per unit of warrants or rights outstanding. Class of Warrant or Right, Price of Warrants or Rights Price of Warrants Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized stock - based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted average period of recognition Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense Aggregate number of shares of common stock offering Stock Issued During Period, Shares, Offerings Number of shares of common stock offering Proceeds from Issuance or Sale of Equity Aggregate gross proceeds Defined Contribution Plan [Table] Defined Contribution Plan Disclosure [Line Items] Employee Benefit Plans Defined Contribution Plan, Employer Matching Contribution, Percent of Match Defined contribution plan, employer matching contribution, percent of match Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage Defined contribution plan, employers matching contribution, annual vesting percentage Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Defined contribution plan, maximum annual contributions per employee, amount Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Subsequent Events Subsequent Event [Line Items] Subsequent Events EX-101.PRE 12 eyen-20240930_pre.xml EX-101.PRE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-38365 Â Entity Registrant Name EYENOVIA,Â INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 47-1178401 Â Entity Address, Postal Zip Code 10017 Â Entity Address, Address Line One 295 Madison Avenue, SuiteÂ 2400 Â Entity Address, City or Town NEW YORK Â Entity Address, State or Province NY Â City Area Code 833 Â Local Phone Number 393-6684 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol EYEN Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 86,441,611 Entity Central Index Key 0001682639 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace

Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current Assets Â Â Cash and cash equivalents $ 7,188,129 $ 14,849,057 Inventories 2,967,256 109,798 Deferred clinical supply costs 408,832 4,256,793 License fee and expense reimbursements receivable 137,594 123,833 Security deposits, current Â 1,506 Prepaid expenses and other current assets 987,754 1,365,731 Total Current Assets 11,689,565 20,706,718 Property and equipment, net 2,752,404 3,374,384 Security deposits, non-current 197,526 197,168 Intangible assets 6,122,945 2,122,945 Prepaid expenses, non-current 46,520 Â Operating lease right-of-use asset 1,275,690 1,666,718 Equipment deposits 711,441 711,441 Total Assets 22,796,091 28,779,374 Current Liabilities: Â Â Accounts payable 1,573,940 1,753,172 Accrued compensation 1,656,832 1,658,613 Accrued expenses and other current liabilities 2,518,086 287,928 Operating lease liabilities - current portion 604,647 501,250 Notes payable - current portion, net of debt discount of $562,711 and $503,914 as of September 30, 2024 and December 31, 2023, respectively 6,168,593 5,329,419 Convertible notes payable - current portion, net of debt discount of $72,467 and $0 as of September 30, 2024 and December 31, 2023, respectively 3,260,866 Â Total Current Liabilities 15,782,964 9,530,382 Accrued expenses and other non-current liabilities 316,275 Â Operating lease liabilities - non-current portion 836,434 1,292,667 Notes payable - non-current portion, net of debt discount of $0 and $448,367 as of September 30, 2024 and December 31, 2023, respectively 637,500 4,355,800 Convertible notes payable - non-current portion, net of debt discount of $163,051 and $398,569 as of September 30, 2024 and December 31, 2023, respectively 1,503,615 4,601,431 Total Liabilities 19,076,788 19,780,280 Commitments and contingencies (Note 8) Stockholders' Equity: Â Â Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 Common stock, $0.0001 par value, 300,000,000 shares authorized; 86,375,958 and 45,553,026 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 8,638 4,555 Additional paid-in capital 179,065,877 154,486,098 Accumulated deficit (175,355,212) (145,491,559) Total Stockholders' Equity 3,719,303 8,999,094 Total Liabilities and Stockholders' Equity $ 22,796,091 $ 28,779,374 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: eyen_AccruedExpensesAndOtherLiabilitiesCurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other non- current liabilities. + ReferencesNo definition available. + Details Name: eyen_AccruedExpensesAndOtherLiabilitiesNoncurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as on the balance sheet date of deferred clinical supply costs, classified as current. + ReferencesNo definition available. + Details Name: eyen_DeferredClinicalSupplyCosts Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe carrying amount of the equipment deposits. + ReferencesNo definition available. + Details Name: eyen_EquipmentDeposits Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of license fee and expense reimbursements receivables classified as current. + ReferencesNo definition available. + Details Name: eyen_LicenseFeeAndExpenseReimbursementsReceivables Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of Security Deposits. + ReferencesNo definition available. + Details Name: eyen_SecurityDeposits Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210

-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_ShortTermBankLoansAndNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Parenthetical) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Condensed Balance Sheets Â Â Notes payable - current portion, net of debt discount $ 562,711 $ 503,914 Convertible notes payable - current portion, net of debt discount 72,467 0 Notes payable - non-current portion, net of debt discount 0 448,367 Convertible notes payable - non-current portion, net of debt discount $ 163,051 $ 398,569 Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 6,000,000 6,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares issued 86,375,958 45,553,026 Common stock, shares outstanding 86,375,958 45,553,026 X - DefinitionAmount of discount on convertible notes payable to be amortized within one year or within the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: eyen_ConvertibleNotesPayableUnamortizedDiscountCurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of discount on convertible notes payable to be amortized after one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: eyen_ConvertibleNotesPayableUnamortizedDiscountNoncurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of discount on notes payable to be amortized within one year or within the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: eyen_NotesPayableUnamortizedDiscountCurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of discount on notes payable to be amortized after one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: eyen_NotesPayableUnamortizedDiscountNoncurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Operations - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating Income Â Â Â Â Revenue $ 1,625 $ 1,198 $ 29,243 $ 1,198 Cost of revenue (132,522) (13,416) (825,910) (13,416) Gross Loss (130,897) (12,218) (796,667) (12,218) Operating Expenses: Â Â Â Â Research and development 3,471,939 3,578,113 12,500,713 8,911,124 Selling, general and administrative 3,729,091 2,929,855 11,125,115 9,016,550 Reacquisition of license rights Â Â 4,864,600 Â Total Operating Expenses 7,201,030 6,507,968 28,490,428 17,927,674 Loss From Operations (7,331,927) (6,520,186) (29,287,095) (17,939,892) Other Income (Expense): Â Â Â Â Other income (expense), net 1,184 (348,226) (93,394) (157,783) Change in fair value of equity consideration payable Â Â 1,240,800 Â Interest expense (602,109) (679,222) (1,954,768) (1,691,228) Interest income 44,999 208,901 230,804 494,944 Total Other Expense (555,926) (818,547) (576,558) (1,354,067) Net Loss $ (7,887,853) $ (7,338,733) $ (29,863,653) $ (19,293,959) Net Loss Per Share Â Â Â Â Net Loss Per Share - Basic (in dollars per share) $ (0.11) $ (0.18) $ (0.53) $ (0.50) Net Loss Per Share - Diluted (in dollars per share) $ (0.11) $ (0.18) $ (0.53) $ (0.50) Weighted Average Number of Common Shares Outstanding Â Â Â Â Shares Outstanding - Basic (in shares) 69,558,325 40,139,697 56,476,876 38,563,074 Shares Outstanding - Diluted (in shares) 69,558,325 40,139,697 56,476,876 38,563,074 X - DefinitionAmount of change in fair value of equity consideration payable. + ReferencesNo definition available. + Details Name: eyen_ChangeInFairValueOfEquityConsiderationPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense on reacquisition of license rights. + ReferencesNo definition available. + Details Name: eyen_ReacquisitionOfLicenseRights Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Changes in Stockholders' (Deficiency) Equity - USD ($) Common Stock Additional Paid-In Capital Accumulated Deficit Total Balance at the beginning (in shares) at Dec. 31, 2022 36,668,980 Â Â Â Balance at the beginning at Dec. 31, 2022 $ 3,667 $ 135,461,361 $ (118,230,463) $ 17,234,565 Issuance of common stock in At the Market Program (in shares) [1] 1,299,947 Â Â Â Issuance of common stock in At the Market Program [1] $ 130 3,499,462 Â 3,499,592 Cashless exercise of stock options (in shares) 19,530 Â Â Â Cashless exercise of stock options $ 2 (2) Â Â Stock-based compensation Â 819,064 Â 819,064 Issuance of common stock related to vested restricted stock units (in shares) 3,289 Â Â Â Net loss Â Â (5,739,366) (5,739,366) Balance at the end (in shares) at Mar. 31, 2023 37,991,746 Â Â Â Balance at the end at Mar. 31, 2023 $ 3,799 139,779,885 (123,969,829) 15,813,855 Balance at the beginning (in shares) at Dec. 31, 2022 36,668,980 Â Â Â Balance at the beginning at Dec. 31, 2022 $ 3,667 135,461,361 (118,230,463) 17,234,565 Warrant modification and additional warrants - incremental value Â Â Â 1,738,700 Net loss Â Â Â (19,293,959) Balance at the end (in shares) at Sep. 30, 2023 42,898,246 Â Â Â Balance at the end at Sep. 30, 2023 $ 4,290 153,299,865 (137,524,422) 15,779,733 Balance at the beginning (in shares) at Mar. 31, 2023 37,991,746 Â Â Â Balance at the beginning at Mar. 31, 2023 $ 3,799 139,779,885 (123,969,829) 15,813,855 Issuance of common stock in At the Market Program (in shares) [2] 121,989 Â Â Â Issuance of common stock in At the Market Program [2] $ 13 403,107 Â 403,120 Cashless exercise of stock options (in shares) 1,219 Â Â Â Exercise of stock options (in shares) 10,000 Â Â Â Exercise of stock options $ 1 27,199 Â 27,200 Stock-based compensation Â 493,632 Â 493,632 Issuance of common stock related to vested restricted stock units (in shares) 44,444 Â Â Â Issuance of common stock related to vested restricted stock units $ 4 (4) Â Â Net loss Â Â (6,215,860) (6,215,860) Balance at the end (in shares) at Jun. 30, 2023 38,169,398 Â Â Â Balance at the end at Jun. 30, 2023 $ 3,817 140,703,819 (130,185,689) 10,521,947 Issuance of common stock in offerings (in shares) [3],[4] 4,198,633 Â Â Â Issuance of common stock in offerings [3],[4] $ 420 10,885,694 Â 10,886,114 Warrant modification and additional warrants - incremental value [5] Â 1,738,700 Â 1,738,700 Warrant modification and additional warrants - in issuance costs for offering [4] Â (1,738,700) Â (1,738,700) Issuance of common stock as consideration for licensing agreement (in shares) [6] 487,805 Â Â Â Issuance of common stock as consideration for licensing agreement [6] $ 49 999,951 Â 1,000,000 Issuance of common stock in At the Market Program (in shares) [7] 42,410 Â Â Â Issuance of common stock in At the Market Program [7] $ 4 97,432 Â 97,436 Stock-based compensation Â 612,969 Â 612,969 Net loss Â Â (7,338,733) (7,338,733) Balance at the end (in shares) at Sep. 30, 2023 42,898,246 Â Â Â Balance at the end at Sep. 30, 2023 $ 4,290 153,299,865 (137,524,422) 15,779,733 Balance at the beginning (in shares) at Dec. 31, 2023 45,553,026 Â Â Â Balance at the beginning at Dec. 31, 2023 $ 4,555 154,486,098 (145,491,559) 8,999,094 Issuance of common stock in At the Market Program (in shares) [8] 1,833,323 Â Â Â Issuance of common stock in At the Market Program [8] $ 183 3,194,364 Â 3,194,547 Stock-based compensation Â 546,232 Â 546,232 Net loss Â Â (10,922,101) (10,922,101) Balance at the end (in shares) at Mar. 31, 2024 47,386,349 Â Â Â Balance at the end at Mar. 31, 2024 $ 4,738 158,226,694 (156,413,660) 1,817,772 Balance at the beginning (in shares) at Dec. 31, 2023 45,553,026 Â Â Â Balance at the beginning at Dec. 31, 2023 $ 4,555 154,486,098 (145,491,559) $ 8,999,094 Issuance of common stock in offerings (in shares) Â Â Â 5,630,556 Warrant modification and additional warrants - incremental value Â Â Â $ 2,868,000 Net loss Â Â Â (29,863,653) Balance at the end (in shares) at Sep. 30, 2024 86,375,958 Â Â Â Balance at the end at Sep. 30, 2024 $ 8,638 179,065,877 (175,355,212) 3,719,303 Balance at the beginning (in shares) at Mar. 31, 2024 47,386,349 Â Â Â Balance at the beginning at Mar. 31, 2024 $ 4,738 158,226,694 (156,413,660) 1,817,772 Issuance of common stock in offerings (in shares) [9] 3,223,726 Â Â Â Issuance of common stock in offerings [9] $ 322 1,888,507 Â 1,888,829 Issuance of common stock as consideration for licensing agreement (in shares) [10] 613,496 Â Â Â Issuance of common stock as consideration for licensing agreement [10] $ 62 436,747 Â 436,809 Issuance of common stock as consideration for reacquisition of licensing agreement (in shares) [11] 2,299,397 Â Â Â Issuance of common stock as consideration for reacquisition of licensing agreement [11] $ 230 2,322,161 Â 2,322,391 Issuance of common stock in At the Market Program (in shares) [12] 2,294,953 Â Â Â Issuance of common stock in At the Market Program [12] $ 230 1,676,709 Â 1,676,939 Stock-based compensation Â 541,056 Â 541,056 Net loss Â Â (11,053,699) (11,053,699) Balance at the end (in shares) at Jun. 30, 2024 55,817,921 Â Â Â Balance at the end at Jun. 30, 2024 $ 5,582 165,091,874 (167,467,359) (2,369,903) Issuance of common stock in offerings (in shares) [13] 29,055,757 Â Â Â Issuance of common stock in offerings [13] $ 2,906 12,345,272 Â 12,348,178 Warrant modification and additional warrants - incremental value [14] Â 2,868,000 Â 2,868,000 Warrant modification and additional warrants - in issuance costs for offering [15] Â (2,868,000) Â (2,868,000) Issuance of common stock in At the Market Program (in shares) [16] 1,502,280 Â Â Â Issuance of common stock in At the Market Program [16] $ 150 1,175,733 Â 1,175,883 Stock-based compensation Â 452,998 Â 452,998 Net loss Â Â (7,887,853) (7,887,853) Balance at the end (in shares) at Sep. 30, 2024 86,375,958 Â Â Â Balance at the end at Sep. 30, 2024 $ 8,638 $ 179,065,877 $ (175,355,212) $ 3,719,303

[1] Includes gross proceeds of $3,607,827 less total issuance costs of $108,235. [2] Includes gross proceeds of $415,588 less total issuance costs of $12,468. [3] Includes gross proceeds of $11,977,468 less total cash issuance costs of $1,091,354. [4] Non-cash warrant modification issuance costs related to the registered direct offering of $1,738,700 are shown on a separate line item. [5] Registered direct offering included modification of warrant originally granted in the March 2022 offering. [6] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. [7] Includes gross proceeds of $100,449 less total issuance costs of $3,013. [8] Includes gross proceeds of $3,293,347 less total issuance costs of $98,800. [9] Includes gross proceeds of $2,000,000, less total issuance costs of $111,171. [10] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. [11] Shares issued as partial consideration for reversion of License Agreement with Bausch & Lomb Ireland Limited. [12] Includes gross proceeds of $1,728,804 less total issuance costs of $51,865. [13] Includes gross proceeds of $14,139,994, less total cash issuance costs of $1,791,816. [14] Offering includes modification of warrants and additional warrants in the July 2024 offering. [15] Non-cash warrant modification and additional warrants issuance costs related to one of the offerings of $2,868,000 are shown on a separate line item. [16] Includes gross proceeds of $1,212,251 less total issuance costs of $36,368. X - DefinitionThis represents restricted stock units issued during the period. + ReferencesNo definition available. + Details Name: eyen_RestrictedStockIssuedDuringPeriodSharesNewIssues Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of restricted stock issued during the period. + ReferencesNo definition available. + Details Name: eyen_RestrictedStockIssuedDuringPeriodValueNewIssues Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis represents shares issued at market offering. + ReferencesNo definition available. + Details Name: eyen_StockIssuedAtMarketOfferingDuringPeriodSharesNewIssues Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of common stock issued in at the market offering. + ReferencesNo definition available. + Details Name: eyen_StockIssuedAtMarketOfferingDuringPeriodValueNewIssues Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of cashless shares issued as a result of the exercise of stock options. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesCashlessStockOptionsExercised Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresent stock issued period shares licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesLicensingAgreements Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresent stock issued period, shares for reacquisition of licensing agreement. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesReacquisitionOfLicensingAgreement Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued as a result of the cashless exercise of stock options. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodValueCashlessStockOptionsExercised Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent stock issued during period value licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodValueLicensingAgreements Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent stock issued during the period, value for reacquisition of licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodValueReacquisitionOfLicensingAgreement Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Changes in Stockholders' (Deficiency) Equity (Parenthetical) - USD ($) 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Adjustments to additional paid in capital upon stock issuance costs $ 2,868,000 [1] Â Â $ 1,738,700 [2] Â Â At Market Offering Â Â Â Â Â Â Proceeds of stock issued during period gross 1,212,251 $ 1,728,804 $ 3,293,347 Â $ 415,588 $ 3,607,827 Adjustments to additional paid in capital upon stock issuance costs 36,368 51,865 $ 98,800 3,013 $ 12,468 $ 108,235 Gross proceeds Â Â Â 100,449 Â Â Gross proceeds from common stock warrants 14,139,994 Â Â Â Â Â Registered direct offering Â Â Â Â Â Â Proceeds of stock issued during period gross Â 2,000,000 Â 11,977,468 Â Â Adjustments to additional paid in capital upon stock issuance costs $ 1,791,816 $ 111,171 Â $ 1,091,354 Â Â [1] Non-cash warrant modification and additional warrants issuance costs related to one of the offerings of $2,868,000 are shown on a separate line item. [2] Non-cash warrant modification issuance costs related to the registered direct offering of $1,738,700 are shown on a separate line item. X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesNo definition available. + Details Name: eyen_ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + ReferencesNo definition available. + Details Name: eyen_ProceedsOfStockIssuedDuringPeriodGross Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=eyen_RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Cash Flows - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash Flows From Operating Activities Â Â Net loss $ (29,863,653) $ (19,293,959) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Stock-based compensation 1,540,286 1,925,665 Change in fair value of equity consideration payable (1,240,800) Â Depreciation of property and equipment 830,605 505,684 Amortization of debt discount 552,620 497,654 Write-off of property and equipment 88,251 Â Write-down of inventories to net realizable value 769,217 12,218 Provision for returned deferred clinical supplies Â 400,000 Reacquisition of license rights 2,864,600 Â Non-cash rent expense 391,028 403,362 Changes in operating assets and liabilities: Â Â Prepaid expenses and other current assets 836,507 39,035 License fee and expense reimbursement receivables (13,761) 786,772 Deferred clinical supply costs 1,272,309 (1,637,756) Inventories (1,051,023) (62,514) Security and equipment deposits 1,148 1,750 Accounts payable (179,232) (2,255) Accrued compensation (1,781) (371,359) Accrued expenses and other current liabilities (453,567) (307,373) Lease liabilities (352,836) (411,266) Net Cash Used In Operating Activities (24,010,082) (17,514,342) Cash Flows From Investing Activities Â Â Purchases of property and equipment (161,476) (2,702,361) Investment in intangible asset Â (1,122,945) Net Cash Used In Investing Activities (161,476) (3,825,306) Cash Flows From Financing Activities Â Â Proceeds from sale of common stock and warrants in offerings 16,139,994 11,977,468 Payment of offerings issuance costs (1,902,987) (1,091,354) Proceeds from sale of common stock in At the Market Program 6,234,402 4,123,864 Payment of issuance costs for At the Market Program (187,033) (123,716) Proceeds from exercise of stock options Â 27,200 Proceeds from note payable to Avenue Â 5,000,000 Payment of issuance costs for notes issued to Avenue Â (125,982) Repayments of notes payable (3,773,746) (609,140) Net Cash Provided By Financing Activities 16,510,630 19,178,340 Net Decrease in Cash and Cash Equivalents (7,660,928) (2,161,308) Cash and Cash Equivalents - Beginning of Period 14,849,057 22,863,520 Cash and Cash Equivalents - End of Period 7,188,129 20,702,212 Supplemental Disclosure of Cash Flow Information: Â Â Interest 1,402,147 1,194,132 Supplemental Disclosure of Non-Cash Investing and Financing Activities Â Â Purchase of insurance policy financed by note payable 505,050 609,140 Accrual for intangible asset milestone obligation 2,000,000 Â Reclassification of deferred clinical supply costs to inventories 2,575,652 Â Right-of-use assets obtained in exchange for lease liabilities Â 904,437 Vendor deposits applied to purchases of property and equipment Â 39,573 Original issue discount on notes payable Â 212,500 Warrant modification and additional warrants - incremental value 2,868,000 1,738,700 Issuance of common stock in consideration of licensing agreement 436,809 1,000,000 Cashless exercise of stock options Â 2 Common stock issued in consideration for reacquisition of licensing agreement $ 2,322,391 Â Issuance of common stock related to vested restricted stock units Â $ 4 X - DefinitionAmount of accrual related to intangible asset recorded in milestone obligation as part of non-cash investing and financing activity. + ReferencesNo definition available. + Details Name: eyen_AccrualForIntangibleAssetsMilestoneObligation Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of Amortization of debt discount. + ReferencesNo definition available. + Details Name: eyen_AmortizationOfDebtDiscount Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cashless exercise of stock options. + ReferencesNo definition available. + Details Name: eyen_CashlessExerciseOfStockOptions Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of change in fair value of equity consideration payable. + ReferencesNo definition available. + Details Name: eyen_ChangeInFairValueOfEquityConsiderationPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the value of deferred clinical supply costs. + ReferencesNo definition available. + Details Name: eyen_IncreaseDecreaseInDeferredClinicalSupplyCosts Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables. + ReferencesNo definition available. + Details Name: eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of issuance of common stock related to vested restricted stock units. + ReferencesNo definition available. + Details Name: eyen_IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of non cash expense on reacquisition of license rights. + ReferencesNo definition available. + Details Name: eyen_NonCashExpensesOnReacquisitionOfLicenseRights Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to the increase (decrease) in reserve for rent expenses. + ReferencesNo definition available. + Details Name: eyen_NonCashRentExpense Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of original Issue discount on notes payable. + ReferencesNo definition available. + Details Name: eyen_OriginalIssueDiscountOnNotesPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow paid to related parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesNo definition available. + Details Name: eyen_PaymentsOfDebtIssuanceCostsRelatedParty Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly in at the market offering with the issuance of an equity security. + ReferencesNo definition available. + Details Name: eyen_PaymentsOfStockIssuanceCostsAtMarketOffering Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of proceeds from issuance of common stock at market offering. + ReferencesNo definition available. + Details Name: eyen_ProceedsFromIssuanceOfCommonStockAtMarketOffering Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from proceeds from sale of common stock and warrants in registered direct offering. + ReferencesNo definition available. + Details Name: eyen_ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of provision for returned deferred clinical supplies. + ReferencesNo definition available. + Details Name: eyen_ProvisionForReturnedDeferredClinicalSupplies Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of purchase of insurance premium financed by short term notes payable. + ReferencesNo definition available. + Details Name: eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of reclassification of deferred clinical supply costs to inventories. + ReferencesNo definition available. + Details Name: eyen_ReclassificationOfDeferredClinicalSupplyCostsToInventories Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued for reacquisition of licensing agreement in noncash financing activities. + ReferencesNo definition available. + Details Name: eyen_StockIssuedValueReacquisitionOfLicensingAgreement Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in security deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInSecurityDeposits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash paid for interest capitalized, classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidCapitalized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_TangibleAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Business Organization, Nature of Operations and Basis of Presentation 9 Months Ended Sep. 30, 2024 Business Organization, Nature of Operations and Basis of Presentation Â Business Organization, Nature of Operations and Basis of Presentation NoteÂ 1Â â€“ Business Organization, Nature of Operations and Basis of PresentationEyenovia, Inc. (â€œEyenoviaâ€ or the â€œCompanyâ€) is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in the treatment of chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The companyâ€™s pre-NDA candidate, MicroPine, is being developed for pediatric progressive myopia, a global epidemic impacting hundreds of millions of children worldwide and representing a multi-billion-dollar addressable market. The companyâ€™s current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and MydcombiÂ® for mydriasis. Eyenovia has also secured licensing and development agreements for additional multi-billion-dollar indications where the Optejet may be advantageous, including dry eye.The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the full year ending December 31, 2024 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2023 and for the year then ended, which were included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (â€œSECâ€) on March 18, 2024 (the â€œ2023 Form 10-Kâ€), as amended by Amendment No. 1, filed with the SEC on April 26, 2024 (the â€œ2023 Form 10-K Amendmentâ€). X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies NoteÂ 2Â â€“ Summary of Significant Accounting PoliciesThe Company disclosed its significant accounting policies in Note 2 â€“ Summary of Significant Accounting Policies included in the 2023 Form 10-K. There have been no material changes to the Companyâ€™s significant accounting policies during the nine months ended September 30, 2024, except as disclosed below. Liquidity and Going ConcernAs of September 30, 2024, the Company had unrestricted cash and cash equivalents of approximately $7.2 million and an accumulated deficit of approximately $175.4 million. For the nine months ended September 30, 2024 and 2023, the Company incurred net losses of approximately $29.9 million and $19.3 million, respectively, and used cash in operations of approximately $24.0 million and $17.5 million, respectively. The Company does not have recurring significant revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations for the near future. The Company expects that it will continue to incur significant research and development and selling, general and administrative expenses and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Companyâ€™s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Companyâ€™s plans and its ability to continue as a going concern will depend on many factors, including the Companyâ€™s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies, or acquire other companies or technologies to enhance or complement its product and service offerings. Additionally, the Company will need to raise further capital, through the sale of additional equity or debt securities. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.â€‹Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2024 and December 31, 2023, the Company had Treasury bills with original maturity dates of three months or less in the amounts of $0 and $5,450,118, respectively.The Company has cash deposits in financial institutions that, at times, may be in excess of Federal Deposit Insurance Corporation (â€œFDICâ€) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2024 and December 31, 2023, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $6,784,903 and $14,243,870, respectively.Clinical Supply ArrangementsBausch + Lomb Ireland Limited (â€œBausch + Lombâ€) and Arctic Vision had contracted with the Company to manufacture and supply them with the appropriate drug-device combination products to conduct their clinical trials on a cost plus 10% mark-up basis. Pursuant to the Letter Agreement (as defined below) with Bausch + Lomb, as referenced in Note 8 â€“ Commitments and Contingencies â€“ Bausch License Agreements, the arrangement with Bausch + Lomb has been terminated, and all rights have been repurchased by Eyenovia. The arrangement with Arctic Vision is still in place. The Companyâ€™s licensing agreement with Arctic Vision represents a collaborative arrangement and Arctic Vision is not a customer with respect to the clinical supply arrangements. The Companyâ€™s policy is to (a) defer the materials and manufacturing costs in order to properly match them up against the income from the clinical supply arrangements; and (b) report the net income from the clinical supply arrangements as other income. Deferred clinical supply costs were $0.4 million and $4.3 million at September 30, 2024 and December 31, 2023, respectively. See Note 8 â€“ Commitments and Contingencies â€“Defective Clinical Supply for additional information.InventoriesInventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The cost of inventory that is sold commercially to third parties is included within cost of sales. The Company will periodically review for slow-moving, excess or obsolete inventories.Inventory is primarily comprised of drug-device combination products, which are available for commercial sale, as follows:â€‹â€‹â€‹

the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-07.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect it to have a material impact on its financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets 9 Months Ended Sep. 30, 2024 Prepaid Expenses and Other Current Assets Â Prepaid Expenses and Other Current Assets NoteÂ 3Â â€“ Prepaid Expenses and Other Current AssetsAs of September 30, 2024 and December 31, 2023, prepaid expenses and other current assets consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â 2024Â 2023Prepaid insurance expensesâ€‹$ 356,214â€‹$ 167,338Payroll tax receivableâ€‹â€‹ 288,705â€‹â€‹ 500,684Prepaid general and administrative expensesâ€‹â€‹ 131,606â€‹â€‹ 85,938Prepaid patent expensesâ€‹Â 71,073â€‹Â 48,409Prepaid conference expensesâ€‹Â 54,810â€‹Â 123,556Prepaid research and development expensesâ€‹â€‹ 48,172â€‹â€‹ 421,056Prepaid rent and security depositâ€‹Â 18,750â€‹Â 18,750Otherâ€‹â€‹ 18,424â€‹â€‹ â€”Total prepaid expenses and other current assetsâ€‹$ 987,754â€‹$ 1,365,731â€‹ X - DefinitionThe entire disclosure of prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock Namespace Prefix: eyen_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets 9 Months Ended Sep. 30, 2024 Intangible Assets. Â Intangible Assets Note 4 - Intangible AssetsOn August 15, 2023, the Company entered into a license agreement (the â€œFormosa Licenseâ€) with Formosa Pharmaceuticals Inc. (â€œFormosaâ€), whereby the Company acquired the exclusive U.S. rights to commercialize any product related to a novel formulation of clobetasol propionate ophthalmic suspension, 0.05% (the â€œFormosa Licensed Productâ€), which was approved by the FDA for ophthalmic use for inflammation and pain after ocular surgery and supplemental disease indications, if any, associated with the New Drug Application for the Formosa Licensed Product. The Formosa License will remain in effect for ten years from the date of the first commercial sale of a Formosa Licensed Product, unless earlier terminated. The Company paid Formosa the aggregate amount of $2.0 million (the â€œUpfront Paymentâ€), consisting of (a) cash in the amount of $1.0 million and (b) 487,805 shares of common stock, which is included in Intangible Assets on the accompanying balance sheet. The Company also capitalized $122,945 of transaction costs, which were primarily legal expenses. In addition to the Upfront Payment, the Company must pay Formosa up to $4.0 million upon the achievement of certain development milestones and up to $80.0 million upon the achievement of certain sales milestones. The trigger for the initial $2.0 million development milestone payments was FDA approval of the Formosa Licensed Product and the effective date of the acceptance by the Company of the transfer and assignment of the FDA approval. This occurred on March 14, 2024. Under the provisions of the Formosa License, the Company had 45 days from the effective date of acceptance of the transfer and assignment of FDA approval to make the payment half in cash and half in common stock, otherwise the payment due would revert to be fully in cash. The Company paid Formosa the aggregate amount of $2.0 million, consisting of (a) cash in the amount of $1.0 million on April 26, 2024 and (b) 613,496 shares of common stock on April 29, 2024 (calculated pursuant to the Formosa License using a five-day volume-weighted average price on March 14, 2024, but valued at $0.4 million on the April 29, 2024 settlement date, resulting in a $0.6 million change in fair value of the equity consideration payable), which is included in Intangible Assets on the accompanying balance sheet as of September 30, 2024. The second $2.0 million development milestone (to be fully paid in cash) was earned upon FDA approval of the Formosa Licensed Product and payment was triggered on the earlier of twelve months after FDA approval or six months following the first commercial sale of the Formosa Licensed Product. Because the payment became probable and estimable, the Company recorded an additional $2.0 million increase in the intangible asset and the related accrual on March 14, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Compensation 9 Months Ended Sep. 30, 2024 Accrued Compensation Â Accrued Compensation NoteÂ 5Â â€“ Accrued CompensationAs of September 30, 2024 and December 31, 2023, accrued compensation consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â 2024Â 2023Accrued bonus expensesâ€‹$ 1,141,884â€‹$ 1,302,997Accrued payroll expensesâ€‹Â 514,948â€‹Â 355,616Total accrued compensationâ€‹$ 1,656,832â€‹$ 1,658,613â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_CompensationRelatedCostsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482969/710-10-50-1 + Details Name: us-gaap_CompensationRelatedCostsGeneralTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities 9 Months Ended Sep. 30, 2024 Accrued Expenses and Other Current Liabilities Â Accrued Expenses and Other Current Liabilities NoteÂ 6Â â€“ Accrued Expenses and Other Current LiabilitiesAs of September 30, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â 2024Â 2023Accrued intangible asset milestone obligationâ€‹$ 2,000,000â€‹$ â€”Accrued defective clinical supply settlement, netâ€‹â€‹ 250,000â€‹â€‹ 100,000Accrued clinical studies costsâ€‹â€‹ 121,588â€‹â€‹ â€”Accrued professional servicesâ€‹â€‹ 79,042â€‹â€‹ 63,028Credit card payableâ€‹â€‹ 29,502â€‹â€‹ 27,193Accrued franchise taxâ€‹â€‹ 15,000â€‹â€‹ â€”Accrued research and development expensesâ€‹â€‹ 13,550â€‹â€‹ 89,872Otherâ€‹â€‹ 9,404â€‹â€‹ 7,835Total accrued expenses and other current liabilitiesâ€‹$ 2,518,086â€‹$ 287,928â€‹ X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Notes Payable and Convertible Notes Payable 9 Months Ended Sep. 30, 2024 Notes Payable and Convertible Notes Payable Â Notes Payable and Convertible Notes Payable NoteÂ 7Â â€“ Notes Payable and Convertible Notes PayableAs of September 30, 2024 and December 31, 2023, notes payable and convertible notes payable consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions Â Related Party Transactions NoteÂ 9Â â€“ Related Party TransactionsThe Company has an advisory service agreement with a member of the board of directors. The agreement calls for a monthly consulting fee of $5,000, paid on a quarterly basis, which is in addition to the compensation paid to the individual pursuant to the Companyâ€™s non - employee director compensation policy while such individual remains a member of the board of directors. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity Â Stockholders' Equity Note 10 â€“ Stockholdersâ€™ EquityIncrease in Authorized Number of Shares of Common StockOn June 12, 2024, at the Annual Shareholdersâ€™ Meeting, the Company proposed and the shareholders approved an increase in the authorized number of shares of the Companyâ€™s common stock from 90,000,000 to 300,000,000 at the same par value of $0.0001 per share.Common Stock IssuancesPursuant to the License and certain milestone achievements, the Company issued 613,496 shares of common stock valued at $0.4 million on April 29, 2024 to Formosa (see Note 4 â€“ Intangible Assets).On May 3, 2024, the Company issued Bausch + Lomb 2,299,397 shares of the Companyâ€™s common stock, valued at $2.3 million, in satisfaction of its obligations pursuant to the Letter Agreement (see Note 8 â€“ Commitments and Contingencies).At-The-Market ProgramDuring the nine months ended September 30, 2024, the Company received approximately $6.0 million in net proceeds from the sale of 5,630,556 shares of its common stock pursuant to a sales agreement (the â€œSales Agreementâ€) with Leerink Partners, LLC, formerly known as SVB Securities LLC (â€œLeerink Partnersâ€) in an â€at-the-marketâ€ offering.OfferingsSecond Quarter OfferingOn April 8, 2024, the Company entered into a securities purchase agreement (the â€œPurchase Agreementâ€) with a single fundamentals-based healthcare investor (the â€œPurchaserâ€), pursuant to which the Company agreed to sell, in a registered direct offering by the Company directly to the Purchaser (the â€œApril Offeringâ€), 3,223,726 shares of common stock. The price per share in the April Offering was $0.6204. The aggregate gross proceeds to the Company from the April Offering were $2.0 million, and net proceeds after offering costs were approximately $1.9 million.Third Quarter OfferingsA summary of the offerings for the third quarter is presented below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹Â Â Â Â AdditionalÂ Â Â Â Totalâ€‹â€‹CommonÂ Stockâ€‹Paid-Inâ€‹Stockholdersâ€™â€‹Â Â Â Â SharesÂ Â Â Â AmountÂ Â Â Â CapitalÂ Â Â Â EquityJuly OfferingÂ 7,575,757â€‹$ 758â€‹$ 4,298,643â€‹$ 4,299,401August OfferingÂ 12,850,000â€‹Â 1,285â€‹Â 4,449,822â€‹Â 4,451,107September OfferingÂ 8,630,000â€‹Â 863Â Â 3,596,807â€‹Â 3,597,670â€‹Â 29,055,757â€‹$ 2,906â€‹$ 12,345,272â€‹$ 12,348,178â€‹July Offering and Warrant AmendmentOn July 1, 2024, the Company closed on a registered direct offering (the â€œJuly Offeringâ€) with certain institutional and accredited investors (the â€œJuly Investorsâ€), pursuant to which the Company sold 7,575,757 shares of common stock and warrants to purchase up to 7,575,757 shares of common stock. The combined offering price for each share of common stock and accompanying warrant was $0.66. The Company also agreed to issue warrants to purchase an additional 1,749,780 shares of common stock (the â€œAdditional Warrantsâ€) to one of the July Investors. All of the new warrants become exercisable six months following their issuance, at an exercise price of $0.69 per share, and may be exercised until January 2, 2030.In connection with the July Offering, the Company entered into warrant amendment agreements (the â€œAmendmentsâ€) with the holders of previously issued warrants (the â€œPrior Warrantsâ€) to purchase up to an aggregate of 10,386,269 shares of common stock, whereby the Company agreed to amend the Prior Warrants to reduce the exercise price of the Prior Warrants from $2.23 and $2.47 per share of common stock to $0.69 per share of common stock, extend the term of the Prior Warrants until January 2, 2030 and prohibit exercise of the Prior Warrants for the six-month period following the effective date of the Amendments.The aggregate gross proceeds to the Company from the July Offering were approximately $5.0 million, and net proceeds after cash offering costs were approximately $4.3 million. Offering costs include placement agent fees of $0.4 million and Company legal fees of $0.3 million. In addition, there were $2.9 million of non-cash issuance costs which represents the value of the Additional Warrants, plus the modification date incremental value of the modified Prior Warrants as compared to the original Prior Warrants, as an issuance cost of the warrant exercise.August OfferingOn August 21, 2024, the Company agreed to sell 12,850,000 shares of common stock to certain institutional and accredited investors (the â€œAugust Investorsâ€), in some cases pursuant to a securities purchase agreement (the â€œAugust Offeringâ€). The price per share in the August Offering was $0.40. The aggregate gross proceeds to the Company from the August Offering were approximately $5.1 million, and net proceeds after offering costs were approximately $4.5 million.September OfferingOn September 30, 2024, the Company closed on a registered direct offering (the â€œSeptember Offeringâ€) with a certain purchaser, pursuant to which the Company sold to the purchaser 8,630,000 shares of common stock; pre-funded warrants to purchase up to 65,653 shares of common stock; and warrants to purchase up to 8,695,653 shares of common stock at an exercise price of $0.50 per share. The combined offering price for each share and accompanying warrant was $0.46. The combined offering price for each pre-funded warrant and accompanying Warrant was $0.4599, which is equal to the purchase price per share in the September Offering, minus $0.0001, the exercise price per share of the pre-funded warrants. The warrants will be exercisable beginning six months following the date of issuance and may be exercised until March 31, 2030. The aggregate gross proceeds to the Company from the September Offering were approximately $4.0 million, and net proceeds after offering costs were approximately $3.6 million.WarrantsThe issuance date or modification date fair value of stock warrants issued or modified during the three and nine months ended September 30, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â For the Three Months Endedâ€‹For the Nine Months EndedÂ â€‹â€‹September 30,â€‹September 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Fair value of common stock on date of grantÂ $0.68â€‹$1.97Â $0.68â€‹$1.97â€‹Risk free interest rateÂ 4.39% - 5.22%â€‹4.48%â€‹4.39% - 5.22%â€‹4.48%â€‹Expected term (years)Â 0.7 - 5.5 yearsâ€‹4.0 - 5.5 yearsâ€‹0.7 - 5.5 yearsâ€‹4.0 - 5.5 yearsâ€‹Expected volatilityÂ 86% - 118%â€‹81%â€‹86% - 118%â€‹81%â€‹Expected dividendsÂ n/aâ€‹n/aâ€‹n/aâ€‹n/aâ€‹â€‹A summary of the warrant activity during the nine months ended September 30, 2024 is presented below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹Â Â Â Â Weightedâ€‹â€‹â€‹Weighted â€‹Averageâ€‹â€‹â€‹Averageâ€‹Remainingâ€‹â€‹NumberÂ ofâ€‹Exerciseâ€‹Lifeâ€‹Â Â Â Â WarrantsÂ Â Â Â PriceÂ Â Â Â InÂ YearsOutstanding January 1, 2024Â 10,926,554â€‹$ 2.28Â Â Â Granted (1)Â 18,021,190â€‹Â 0.60Â Â Â Repriced - (Old) (2)Â (10,386,269)â€‹Â 2.25Â Â Â Repriced - (New) (2)Â 10,386,269â€‹Â 0.69Â Â Â ExercisedÂ â€”â€‹Â â€”Â Â Â Outstanding September 30, 2024 (1)Â 28,947,744â€‹$ 0.67Â 5.1â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Exercisable September 30, 2024 (1)Â 540,285â€‹$ 2.96Â 1.4(1) - Warrants granted, outstanding and exercisable exclude 65,653 pre-funded warrants with an exercise price of $0.0001.(2) - Repriced warrants represent the reset of the exercise price of certain warrants to purchase 10,386,269 shares of common stock to a price of $0.69 per share.The following table presents information related to warrants as of September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Warrants Outstanding (1)Â Â Â Â WarrantsÂ ExercisableÂ (1)â€‹â€‹Weightedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Outstandingâ€‹Averageâ€‹ExercisableExerciseâ€‹Number ofâ€‹Remaining Lifeâ€‹Number ofPriceÂ Â Â Â WarrantsÂ Â Â Â In YearsÂ Â Â Â Warrants$0.5000 Â 8,695,653(2) â€”Â â€”$0.6900 Â 19,711,806(3) â€”Â â€”$2.4696 Â 232,021Â 0.5Â 232,021$2.7240 Â 216,380Â 0.5Â 216,380$4.7600 Â 91,884Â 6.6Â 91,884â€‹Â 28,947,744Â 1.4Â 540,285(1) - Warrants outstanding and exercisable exclude 65,653 Pre-Funded Warrants with an exercise price of $0.0001.(2) - These warrants become exercisable on March 26, 2025.(3) - These warrants become exercisable on January 1, 2025.â€‹Stock-Based Compensation ExpenseThe Company records stock-based compensation expense related to stock options and restricted stock units (â€œRSUsâ€). For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $452,998 ($179,776 of which was included within research and development expenses and $273,222 was included within selling, general and administrative expenses on the statements of operations) and $612,969 ($235,731 of which was included within research and development expenses and $377,238 of which was included within selling, general and administrative expenses on the statements of operations), respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $1,540,286 ($618,516 of which was included within research and development expenses and $921,770 of which was included within selling, general and administrative expenses on the statements of operations) and $1,925,665 ($647,058 of which was included within research and development expenses and $1,278,607 of which was included within selling, general and administrative expenses on the statements of operations), respectively.Restricted Stock UnitsA summary of the restricted stock units (â€œRSUsâ€) activity during the nine months ended September 30, 2024 is presented below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Averageâ€‹â€‹NumberÂ ofâ€‹Exerciseâ€‹Â Â Â Â RSUsÂ Â Â Â PriceRSUs non-vested January 1, 2024Â 106,019â€‹$ 2.12GrantedÂ 368,886â€‹Â 0.65VestedÂ (106,019)â€‹Â 2.12ForfeitedÂ â€”â€‹Â â€”RSUs non-vested SeptemberÂ 30,Â 2024Â 368,886â€‹$ 0.65Vested RSUs undelivered SeptemberÂ 30,Â 2024Â 241,764â€‹$ 2.17â€‹To date, RSUs have only been granted to directors in accordance with the Companyâ€™s Amended and Restated 2018 Omnibus Stock Incentive Plan. The Companyâ€™s policy is not to deliver shares underlying the RSUs until a directorâ€™s termination of service.As of September 30, 2024, there was $169,739 of unrecognized stock-based compensation expense related to RSUs which will be recognized over a weighted average period of 0.7 years.Stock OptionsA summary of the option activity during the nine months ended September 30, 2024 is presented below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â

-Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plans 9 Months Ended Sep. 30, 2024 Employee Benefit Plans Â Employee Benefit Plans NoteÂ 11Â â€“ Employee Benefit Plans401(k) PlanIn April 2019, the Company adopted the Eyenovia 401(k) Plan (the â€œPlanâ€), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. The Companyâ€™s Board of Directors approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents.During the three months ended September 30, 2024 and 2023, the Company recorded expense of $56,493 ($41,186 which was included within research and development expenses and $15,307 was included within selling, general and administrative expenses on the statements of operations) and $46,636 ($37,383 of which was included within research and development expenses and $9,253 of which was included within selling, general and administrative expenses on the statements of operations), respectively, associated with its matching contributions. During the nine months ended September 30, 2024 and 2023, the Company recorded expense of $220,682 ($136,598 of which was included within research and development expenses and $84,084 of which was included within selling, general and administrative expenses on the statements of operations) and $171,800 ($115,559 of which was included within research and development expenses and $56,241 of which was included within selling, general and administrative expenses on the statements of operations) associated with its matching contributions, respectively. X - DefinitionThe entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events Â Subsequent Events Note 12 - Subsequent EventsExercise of Pre-Funded WarrantsOn October 1, 2024, the holder of the 65,653 pre-funded warrants issued in the September Offering, exercised the pre-funded warrants at a price of $0.0001 per share of common stock (see Note 10 - Stockholdersâ€™ Equity - Offerings). X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ (7,887,853) $ (11,053,699) $ (10,922,101) $ (7,338,733) $ (6,215,860) $ (5,739,366) $ (29,863,653) $ (19,293,959) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Trading Arrangements, by Individual Â Â Â Rule 10b5-1 Arrangement Adopted false false false Non-Rule 10b5-1 Arrangement Adopted false false false Rule 10b5-1 Arrangement Terminated false false false Non-Rule 10b5-1 Arrangement Terminated false false false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Liquidity and Going Concern Liquidity and Going ConcernAs of September 30, 2024, the Company had unrestricted cash and cash equivalents of approximately $7.2 million and an accumulated deficit of approximately $175.4 million. For the nine months ended September 30, 2024 and 2023, the Company incurred net losses of approximately $29.9 million and $19.3 million, respectively, and used cash in operations of approximately $24.0 million and $17.5 million, respectively. The Company does not have recurring significant revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations for the near future. The Company expects that it will continue to incur significant research and development and selling, general and administrative expenses and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Companyâ€™s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Companyâ€™s plans and its ability to continue as a going concern will depend on many factors, including the Companyâ€™s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies, or acquire other companies or technologies to enhance or complement its product and service offerings. Additionally, the Company will need to raise further capital, through the sale of additional equity or debt securities. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. Cash and Cash Equivalents

Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2024 and December 31, 2023, the Company had Treasury bills with original maturity dates of three months or less in the amounts of $0 and $5,450,118, respectively.The Company has cash deposits in financial institutions that, at times, may be in excess of Federal Deposit Insurance Corporation (â€œFDICâ€) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2024 and December 31, 2023, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $6,784,903 and $14,243,870, respectively. Clinical Supply Arrangements Clinical Supply ArrangementsBausch + Lomb Ireland Limited (â€œBausch + Lombâ€) and Arctic Vision had contracted with the Company to manufacture and supply them with the appropriate drug-device combination products to conduct their clinical trials on a cost plus 10% mark-up basis. Pursuant to the Letter Agreement (as defined below) with Bausch + Lomb, as referenced in Note 8 â€“ Commitments and Contingencies â€“ Bausch License Agreements, the arrangement with Bausch + Lomb has been terminated, and all rights have been repurchased by Eyenovia. The arrangement with Arctic Vision is still in place. The Companyâ€™s licensing agreement with Arctic Vision represents a collaborative arrangement and Arctic Vision is not a customer with respect to the clinical supply arrangements. The Companyâ€™s policy is to (a) defer the materials and manufacturing costs in order to properly match them up against the income from the clinical supply arrangements; and (b) report the net income from the clinical supply arrangements as other income. Deferred clinical supply costs were $0.4 million and $4.3 million at September 30, 2024 and December 31, 2023, respectively. See Note 8 â€“ Commitments and Contingencies â€“Defective Clinical Supply for additional information. Inventories InventoriesInventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The cost of inventory that is sold commercially to third parties is included within cost of sales. The Company will periodically review for slow-moving, excess or obsolete inventories.Inventory is primarily comprised of drug-device combination products, which are available for commercial sale, as follows:â€‹â€‹â€‹

servicesâ€‹â€‹ 79,042â€‹â€‹ 63,028Credit card payableâ€‹â€‹ 29,502â€‹â€‹ 27,193Accrued franchise taxâ€‹â€‹ 15,000â€‹â€‹ â€”Accrued research and development expensesâ€‹â€‹ 13,550â€‹â€‹ 89,872Otherâ€‹â€‹ 9,404â€‹â€‹ 7,835Total accrued expenses and other current liabilitiesâ€‹$ 2,518,086â€‹$ 287,928â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Notes Payable and Convertible Notes Payable (Tables) 9 Months Ended Sep. 30, 2024 Notes Payable and Convertible Notes Payable Â Schedule of notes payable and convertible notes payable â€‹â€‹â€‹

DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap_CashUninsuredAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=eyen_ClinicalSupplyArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Inventories (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Summary of Significant Accounting Policies Â Â Finished goods $ 427,217 $ 30,683 Raw materials 2,540,039 79,115 Total inventory $ 2,967,256 $ 109,798 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Net loss per share of common stock (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Net loss attributable to common stockholders $ (7,887,853) $ (7,338,733) $ (29,863,653) $ (19,293,959) Denominator (weighted average quantities): Â Â Â Â Common shares issued 69,316,561 39,107,338 56,298,569 38,192,414 Add: Prefunded warrants Â 926,225 Â 305,349 Add: Undelivered vested restricted shares 241,764 106,134 178,307 65,311 Denominator for basic net loss per share (in shares) 69,558,325 40,139,697 56,476,876 38,563,074 Denominator for diluted net loss per share (in shares) 69,558,325 40,139,697 56,476,876 38,563,074 Basic net loss per common share (in dollars per share) $ (0.11) $ (0.18) $ (0.53) $ (0.50) Diluted net loss per common share (in dollars per share) $ (0.11) $ (0.18) $ (0.53) $ (0.50) Total potentially dilutive shares Â Â 38,339,419 18,559,192 Warrants Â Â Â Â Denominator (weighted average quantities): Â Â Â Â Total potentially dilutive shares Â Â 28,947,744 10,926,554 Options Â Â Â Â Denominator (weighted average quantities): Â Â Â Â Total potentially dilutive shares Â Â 6,695,042 5,218,686 Convertible notes Â Â Â Â Denominator (weighted average quantities): Â Â Â Â Total potentially dilutive shares Â Â 2,327,747 2,327,747 Restricted stock units Â Â Â Â Denominator (weighted average quantities): Â Â Â Â Total potentially dilutive shares Â Â 368,886 86,205 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the

reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26 + Details Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThis element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eyen_ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Prepaid Expenses and Other Current Assets Â Â Prepaid insurance expenses $ 356,214 $ 167,338 Payroll tax receivable 288,705 500,684 Prepaid general and administrative expenses 131,606 85,938 Prepaid patent expenses 71,073 48,409 Prepaid conference expenses 54,810 123,556 Prepaid research and development expenses 48,172 421,056 Prepaid rent and security deposit 18,750 18,750 Other 18,424 Â Total prepaid expenses and other current assets $ 987,754 $ 1,365,731 X - DefinitionAmount of Payroll Taxes Receivable. + ReferencesNo definition available. + Details Name: eyen_PayrollTaxesReceivable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of prepaid conference expenses current. + ReferencesNo definition available. + Details Name: eyen_PrepaidConferenceExpensesCurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the information pertaining to Prepaid general and administrative expenses. + ReferencesNo definition available. + Details Name: eyen_PrepaidGeneralAndAdministrativeExpenses Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of prepaid patent expense. + ReferencesNo definition available. + Details Name: eyen_PrepaidPatentExpense Namespace Prefix: eyen_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle. + ReferencesNo definition available. + Details Name: eyen_PrepaidRentAndSecurityDeposit Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid Research And Development Expenses + ReferencesNo definition available. + Details Name: eyen_PrepaidResearchAndDevelopmentExpenses Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets (Details) - USD ($) 3 Months Ended 9 Months Ended Apr. 29, 2024 Apr. 26, 2024 Mar. 14, 2024 Aug. 15, 2023 Jun. 30, 2024 [1] Sep. 30, 2023 [2] Sep. 30, 2024 Intangible Assets Â Â Â Â Â Â Â Â Issuance of common stock as consideration for licensing agreement Â Â Â Â $ 436,809 $ 1,000,000 Â Change in fair value of equity consideration payable Â Â Â Â Â Â $ (1,240,800) Accrual for intangible asset milestone obligation Â Â Â Â Â Â Â 2,000,000 License | Formosa Pharmaceuticals Inc Â Â Â Â Â Â Â Intangible Assets Â Â Â Â Â Â Â Percentage of product approved by FDA Â Â Â 0.05% Â Â Â Upfront payment Â Â Â $ 2,000,000.0 Â Â Â Upfront payment paid in cash Â $ 1,000,000.0 Â $ 1,000,000.0 Â Â Â Issuance of common stock as consideration for licensing agreement (in shares) 613,496 Â Â 487,805 Â Â Â Issuance of common stock as consideration for licensing agreement $ 400,000 Â Â Â Â Â Â Legal expenses capitalized Â Â Â $ 122,945 Â Â Â Maximum amount payable upon achievement of certain development milestones Â Â Â 4,000,000.0 Â Â Â Maximum amount payable upon achievement of certain sales milestones Â Â Â 80,000,000.0 Â Â Â Change in fair value of equity consideration payable Â Â Â Â Â Â 600,000 Initial development milestone payment which trigger FDA approval Â Â Â $ 2,000,000.0 Â Â $ 2,000,000.0 License agreement payment period Â Â 45 days Â Â Â Â Accrual for intangible asset milestone obligation Â $ 2,000,000.0 $ 2,000,000.0 Â Â Â Â [1] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. [2] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. X - DefinitionAmount of accrual related to intangible asset recorded in milestone obligation as part of non-cash investing and financing activity. + ReferencesNo definition available. + Details Name: eyen_AccrualForIntangibleAssetsMilestoneObligation Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of change in fair value of equity consideration payable. + ReferencesNo definition available. + Details Name: eyen_ChangeInFairValueOfEquityConsiderationPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of initial development milestone payment which trigger FDA approval. + ReferencesNo definition available. + Details Name: eyen_InitialDevelopmentMilestonePaymentTriggerForFdaApproval Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLegal expenses capitalized. + ReferencesNo definition available. + Details Name: eyen_LegalExpensesCapitalized Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod when payment has to be made related to the license agreement from the effective date in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: eyen_LicenseAgreementPaymentPeriod Namespace Prefix: eyen_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMaximum amount payable upon achievement of certain development milestones. + ReferencesNo definition available. + Details Name: eyen_MaximumAmountPayableUponAchievementOfCertainDevelopmentMilestones Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum amount payable upon achievement of certain sales milestones. + ReferencesNo definition available. + Details Name: eyen_MaximumAmountPayableUponAchievementOfCertainSalesMilestones Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of product approved by FDA. + ReferencesNo definition available. + Details Name: eyen_PercentageOfProductApprovedByFda Namespace Prefix: eyen_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresent stock issued period shares licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesLicensingAgreements Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresent stock issued during period value licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodValueLicensingAgreements Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of upfront payment made. + ReferencesNo definition available. + Details Name: eyen_UpfrontPayment Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUpfront payment paid in cash + ReferencesNo definition available. + Details Name: eyen_UpfrontPaymentPaidInCash Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=eyen_FormosaPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Compensation (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Accrued Compensation Â Â Accrued bonus expenses $ 1,141,884 $ 1,302,997 Accrued payroll expenses 514,948 355,616 Total accrued compensation $ 1,656,832 $ 1,658,613 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CompensationRelatedCostsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Accrued Expenses and Other Current Liabilities Â Â Accrued intangible asset milestone obligation $ 2,000,000 Â Accrued defective clinical supply settlement, net 250,000 $ 100,000 Accrued clinical studies costs 121,588 Â Accrued professional services 79,042 63,028 Credit card payable 29,502 27,193 Accrued franchise tax 15,000 Â Accrued research and development expenses 13,550 89,872 Other 9,404 7,835 Total accrued expenses and other current liabilities $ 2,518,086 $ 287,928 X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: eyen_AccruedClinicalStudiesCosts Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued franchise tax expenses paid by the entity. + ReferencesNo definition available. + Details Name: eyen_AccruedFranchiseTax Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrual related to intangible asset milestone obligation. + ReferencesNo definition available. + Details Name: eyen_AccruedIntangibleAssetMilestoneObligation Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued research and development expenses paid by the entity. + ReferencesNo definition available. + Details Name: eyen_AccruedResearchAndDevelopmentExpensesCurrent Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued settlement related to defective clinical supply. + ReferencesNo definition available. + Details Name: eyen_AccruedSettlementOnDefectiveClinicalSupply Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of credit card expenses payable by the entity. + ReferencesNo definition available. + Details Name: eyen_CreditCardPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Notes Payable and Convertible Notes Payable - Schedule of notes payable (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current portion Â Â Notes Payable, Current portion $ 10,064,637 $ 5,833,333 Debt Discount, Current portion (635,178) (503,914) Net, Current portion 9,429,459 5,329,419 Note payable, Non Current portion 2,304,166 9,804,167 Debt Discount, Non-Current portion (163,051) (846,936) Net, Non Current portion 2,141,115 8,957,231 D&O insurance policy loan Â Â Current portion Â Â Notes Payables 64,637 0 Notes Payable, Net Of Debt Discount, Total 64,637 0 Debt Instrument, Unamortized Discount 0 0 Avenue - Note payable Â Â Current portion Â Â Notes Payable, Current portion 6,666,667 5,833,333 Debt Discount, Current portion (562,711) (503,914) Net, Current portion 6,103,956 5,329,419 Note payable, Non Current portion 637,500 4,804,167 Debt Discount, Non-Current portion 0 (448,367) Net, Non Current portion 637,500 4,355,800 Avenue - Convertible note payable Â Â Current portion Â Â Notes Payable, Current portion 3,333,333 0 Debt Discount, Current portion (72,467) 0 Net, Current portion 3,260,866 0 Note payable, Non Current portion 1,666,666 5,000,000 Debt Discount, Non-Current portion (163,051) (398,569) Net, Non Current portion $ 1,503,615 $ 4,601,431 X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable, net of debt discount due within one year or the operating cycle if longer. + ReferencesNo definition available. + Details Name: eyen_NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, net of debt discounts, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: eyen_NotesPayableNetOfDebtDiscountTotal Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of notes payable, net of debt discount (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesNo definition available. + Details Name: eyen_NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-

gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of debt discount to be amortized within one year or within the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of debt discount to be amortized after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_NotesPayableCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=eyen_DirectorAndOfficerInsurancePolicyLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=eyen_AvenueNotePayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=eyen_AvenueConvertibleNotePayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Notes Payable and Convertible Notes Payable - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Feb. 24, 2024 Jun. 30, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Jul. 01, 2024 Dec. 31, 2023 Notes Payable Â Â Â Â Â Â Â Â Â Short term notes payable Â Â $ 6,168,593 $ 6,168,593 Â Â $ 5,329,419 Repayments of notes payable Â Â Â $ 3,773,746 $ 609,140 Â Â Exercise price Â Â $ 0.0001 $ 0.0001 Â $ 0.69 Â Payment of issuance costs for notes issued to Avenue Â Â Â $ 1,902,987 $ 1,091,354 Â Â Number of warrants issued Â Â Â Â Â Â 7,575,757 Â Pre-funded warrants Â Â Â Â Â Â Â Â Notes Payable Â Â Â Â Â Â Â Exercise price Â Â $ 0.0001 $ 0.0001 Â Â Â Number of warrants issued Â Â 10,386,269 10,386,269 Â Â Â Maximum | Pre-funded warrants Â Â Â Â Â Â Â Â Notes Payable Â Â Â Â Â Â Â Number of warrants issued Â Â 65,653 65,653 Â Â Â Avenue Ventures Loan Â Â Â Â Â Â Â Â Notes Payable Â Â Â Â Â Â Â Initial principal payment related to loan and security agreement Â $ 833,333 Â Â Â Â Â Loan issuance costs Â Â Â Â $ 1,939,650 Â Â Interest expense Â Â $ 602,109 1,954,768 Â Â Â Interest expense related to the Loan and Security Agreement with Avenue Capital Management Â Â 598,188 Â Â Â Â D&O insurance policy loan Â Â Â Â Â Â Â Notes Payable Â Â Â Â Â Â Â Short term notes payable $ 505,050 Â Â Â Â Â Â Interest rate (as a percent) 8.15% Â Â Â Â Â Â Number of monthly payments 8 months Â Â Â Â Â Â Debt Instrument, Periodic Payment $ 65,076 Â Â Â Â Â Â Repayments of notes payable Â Â Â 440,413 Â Â Â Amortization of debt discount Â Â 184,207 552,620 Â Â Â Amortization of debt discount related to loans Â Â $ 3,921 $ 15,118 Â Â Â X - DefinitionThe loan issuance costs will first be recorded in the balance sheet of the bond issuer. + ReferencesNo definition available. + Details Name: eyen_LoanIssuanceCosts Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of monthly payments. + ReferencesNo definition available. + Details Name: eyen_NumberOfMonthlyPayments Namespace Prefix: eyen_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in interest expense on security sold under agreement to repurchase. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph c -Subparagraph (2)(iii) -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph c -Subparagraph (2)(ii) -Publisher SECReference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph c -Subparagraph (2)(i) -Publisher SEC + Details Name: us-gaap_InterestExpenseSecuritySoldUnderAgreementToRepurchaseIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_ShortTermBankLoansAndNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=eyen_LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=eyen_DirectorAndOfficerInsurancePolicyLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Aug. 21, 2024 Jul. 01, 2024 May 03, 2024 Apr. 11, 2024 Jan. 22, 2024 Oct. 09, 2020 Sep. 30, 2024 Aug. 31, 2024 Jul. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 [2] Sep. 30, 2023 [3],[4] Sep. 30, 2024 Dec. 31, 2023 Apr. 23, 2024 Commitments and Contingencies Â Â Â Â Â Â Â Â Â Â Â Â Â Net proceeds (in shares) 8,630,000 12,850,000 7,575,757 Â Â Â Â Â Â Â Â Â 5,630,556 Â Â Common stock value Â Â Â Â Â Â Â $ 3,597,670 $ 4,451,107 $ 4,299,401 $ 12,348,178 [1] $ 1,888,829 $ 10,886,114 Â Â Â Change in fair value of equity consideration payable Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,240,800 Â Â Written notice period Â Â Â Â Â Â 90 days Â Â Â Â Â Â Â Â Â Bausch License Agreement [Member] | License Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments and Contingencies Â Â Â Â Â Â Â Â Â Â Â Â Â Net proceeds (in shares) Â Â Â 2,299,397 Â Â Â Â Â Â Â Â Â Â Common stock value Â Â Â $ 2,300,000 $ 3,000,000.0 Â Â Â Â Â Â Â Â Â Â Change in fair value of equity consideration payable Â Â Â Â Â Â Â Â Â Â Â 700,000 Â Â Current estimated loss Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500,000 Current estimated net payable amount Â Â Â Â Â Â Â Â Â Â Â Â Â 250,000 Receivable upon completion of milestone Â Â Â Â Â Â Â Â Â Â Â Â Â 250,000 Purchased upon completion of milestone Â Â Â Â Â Â Â Â Â Â Â Â Â 500,000 Issue of common stock Â Â Â Â Â $ 2,000,000.0 Â Â Â Â Â Â Â Â Â Â Upfront payment received Â Â Â Â Â $ 3,000,000.0 Â Â Â Â Â Â Â Â Â Â Defective clinical supply returns Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitments and Contingencies Â Â Â Â Â Â Â Â Â Â Â Â Â Â Current estimated loss Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500,000 Loss recorded Â Â Â Â Â Â Â Â Â Â $ 0 Â Â $ 100,000 $ 400,000 Â [1] Includes gross proceeds of $14,139,994, less total cash issuance costs of $1,791,816. [2] Includes gross proceeds of $2,000,000, less total issuance costs of

$111,171. [3] Includes gross proceeds of $11,977,468 less total cash issuance costs of $1,091,354. [4] Non-cash warrant modification issuance costs related to the registered direct offering of $1,738,700 are shown on a separate line item. X - DefinitionAmount of change in fair value of equity consideration payable. + ReferencesNo definition available. + Details Name: eyen_ChangeInFairValueOfEquityConsiderationPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of upfront payments received by the entity, pursuant to a license agreement. + ReferencesNo definition available. + Details Name: eyen_LicenseAgreementsUpfrontPaymentsReceived Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReflects the estimated amount of loss net payable from the specified contingency as of the balance sheet date + ReferencesNo definition available. + Details Name: eyen_LossContingencyEstimateOfPossibleLossNetPayable Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPurchased related to amount previously held to be received upon completion of milestone. + ReferencesNo definition available. + Details Name: eyen_LossContingencyPurchasedUponCompletionOfMilestone Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReceivable related to amount previously held to be received upon completion of milestone. + ReferencesNo definition available. + Details Name: eyen_LossContingencyReceivableUponCompletionOfMilestone Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe value of stock agreed to be issued. + ReferencesNo definition available. + Details Name: eyen_StockAgreedToIssueValueNewIssues Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the number of days of written notice period for the termination of agreement. + ReferencesNo definition available. + Details Name: eyen_WrittenNoticePeriodForTerminationOfAgreement Namespace Prefix: eyen_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionReflects the estimated amount of loss from the specified contingency as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2 + Details Name: us-gaap_LossContingencyEstimateOfPossibleLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyLossInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Company's right-of-use assets and liabilities (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Â Â Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 352,836 $ 411,266 Right-of-use assets obtained in exchange for lease obligations: Operating leases Â $ 904,437 Weighted Average Remaining Lease Term (Years): Operating leases 2 years 4 months 13 days 3 years 3 months 10 days Weighted Average Discount Rate: Operating leases 10.00% 10.00% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Minimum Lease Payments Â Â 2024 $ 183,092 Â 2025 675,400 Â 2026 560,996 Â 2027 214,618 Â Total future minimum lease payments 1,634,106 Â Less: Imputed interest (193,025) Â Present value of lease liabilities 1,441,081 Â Less: current portion (604,647) $ (501,250) Lease liabilities, non-current portion $ 836,434 $ 1,292,667 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions (Details) 9 Months Ended Sep. 30, 2024 USD ($) Related Party Transactions Â Monthly consulting fee $ 5,000 X - DefinitionAmount of monthly consulting fee for the advisory service agreement. + ReferencesNo definition available. + Details Name: eyen_RelatedPartyTransactionMonthlyConsultingFee Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of offerings (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Sep. 30, 2024 Aug. 21, 2024 Jul. 01, 2024 Sep. 30, 2024 Aug. 31, 2024 Jul. 31, 2024 Sep. 30, 2024 [1] Jun. 30, 2024 [2] Sep. 30, 2023 [3],[4] Sep. 30, 2024 Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Net proceeds (in shares) 8,630,000 12,850,000 7,575,757 Â Â Â Â Â Â 5,630,556 Issuance of common stock in offerings Â Â Â $ 3,597,670 $ 4,451,107 $ 4,299,401 $ 12,348,178 $ 1,888,829 $ 10,886,114 Â Common Stock Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Net proceeds (in shares) Â Â Â 8,630,000 12,850,000 7,575,757 29,055,757 3,223,726 4,198,633 Â Issuance of common stock in offerings Â Â Â $ 863 $ 1,285 $ 758 $ 2,906 $ 322 $ 420 Â Additional Paid-In Capital Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Issuance of common stock in offerings Â Â Â $ 3,596,807 $ 4,449,822 $ 4,298,643 $ 12,345,272 $ 1,888,507 $ 10,885,694 Â [1] Includes gross proceeds of $14,139,994, less total cash issuance costs of $1,791,816. [2] Includes gross proceeds of $2,000,000, less total issuance costs of $111,171. [3] Includes gross proceeds of $11,977,468 less total cash issuance costs of $1,091,354. [4] Non-cash warrant modification issuance costs related to the registered direct offering of $1,738,700 are shown on a separate line item. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References + ReferencesNo definition available. + Details Name: eyen_StockholdersEquityLineItems Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity -Issuance date or modification date fair value of stock warrants (Details) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) $ / shares Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Fair value of common stock on date of grant | $ / shares $ 0.68 $ 1.97 Risk free interest rate Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input Â 4.48 Risk free interest rate | Minimum Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input 4.39 4.39 Risk free interest rate | Maximum Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input 5.22 5.22 Expected term (years) | Minimum Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input 0.7 4.0 Expected term (years) | Maximum Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input 5.5 5.5 Expected volatility Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input Â 81 Expected volatility | Minimum Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input 86 Â Expected volatility | Maximum Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrants and Rights Outstanding Measurement Input 118 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Warrants Activity (Details) - $ / shares 9 Months Ended Sep. 30, 2024 Jul. 01, 2024 Number of Warrants Â Â Outstanding at beginning balance 10,926,554 Â Granted 18,021,190 Â Repriced - Old (10,386,269) Â Repriced - New 10,386,269 Â Outstanding at ending balance 28,947,744 Â Exercisable Number of warrants 540,285 Â Weighted Average Exercise Price Â Â Outstanding at beginning balance $ 2.28 Â Granted 0.60 Â Repriced - Old 2.25 Â Repriced - New 0.69 Â Outstanding at ending balance 0.67 Â Exercisable $ 2.96 Â Weighted Average Remaining Life, Outstanding 5 years 1 month 6 days Â Weighted Average Remaining Life, Exercisable 1 year 4 months 24 days Â Exercise price $ 0.0001 $ 0.69 Number of warrants issued Â 7,575,757 Pre-funded warrants Â Â Number of Warrants Â Â Granted 65,653 Â Weighted Average Exercise Price Â Â Repriced - New $ 0.69 Â Exercise price $ 0.0001 Â Number of warrants issued 10,386,269 Â X - DefinitionNumber of warrants or rights exercisable. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisable Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average exercise price of warrants or rights exercisable. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife Namespace Prefix: eyen_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights granted during the period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightGranted Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price of warrants or rights granted during the period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights new repriced during the period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightNewRepriced Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price of warrants or rights new repriced. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights old repriced during the period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightOldRepriced Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price of warrants or rights old repriced. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightOldRepricedWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife Namespace Prefix: eyen_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantsOrRightsOutstandingRollforward Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Related to warrants (Details) - $ / shares 9 Months Ended Sep. 30, 2024 Jul. 01, 2024 Dec. 31, 2023 Stockholders' Equity Â Â Â Exercise price $ 0.0001 $ 0.69 Â Outstanding Number of Warrants 28,947,744 Â 10,926,554 Weighted Average Remaining Life, Exercisable 1 year 4 months 24 days Â Â Exercisable Number of Warrants 540,285 Â Â Granted 18,021,190 Â Â Warrants at exercise price of $0.5000 Â Â Â Stockholders' Equity Â Â Â Exercise price $ 0.5000 Â Â Outstanding Number of Warrants 8,695,653 Â Â Warrants at exercise price of $0.6900 Â Â Â Stockholders' Equity Â Â Â Exercise price $ 0.6900 Â Â Outstanding Number of Warrants 19,711,806 Â Â Warrants at exercise price of $2.4696 Â Â Â Stockholders' Equity Â Â Â Exercise price $ 2.4696 Â Â Outstanding Number of Warrants 232,021 Â Â Weighted Average Remaining Life, Exercisable 6 months Â Â Exercisable Number of Warrants 232,021 Â Â Warrants at exercise price of $2.7240 Â Â Â Stockholders' Equity Â Â Â Exercise price $ 2.7240 Â Â Outstanding Number of Warrants 216,380 Â Â Weighted Average Remaining Life, Exercisable 6 months Â Â Exercisable Number of Warrants 216,380 Â Â Warrants at exercise price of $4.7600 Â Â Â Stockholders' Equity Â Â Â Exercise price $ 4.7600 Â Â Outstanding Number of Warrants 91,884 Â Â Weighted Average Remaining Life, Exercisable 6 years 7 months 6 days Â Â Exercisable Number of Warrants 91,884 Â Â Pre-funded warrants Â Â Â Stockholders' Equity Â Â Â Exercise price $ 0.0001 Â Â Granted 65,653 Â Â X - DefinitionNumber of warrants or rights exercisable. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisable Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife Namespace Prefix: eyen_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights granted during the period. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightGranted Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of

warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Restricted stock units activity (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Number of RSUs Â RSUs non-vested January 1, 2024 | shares 106,019 Granted | shares 368,886 Vested | shares (106,019) RSUs non-vested June 30, 2024 | shares 368,886 Vested RSUs undelivered June 30, 2024 | shares 241,764 Weighted Average Grant Date Value Per Share Â RSUs non-vested January 1, 2024 | $ / shares $ 2.12 Granted | $ / shares 0.65 Vested | $ / shares 2.12 RSUs non-vested June 30, 2024 | $ / shares 0.65 Vested RSUs undelivered June 30, 2024 | $ / shares $ 2.17 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested RSUs Undelivered numbers during the reporting period. + ReferencesNo definition available. + Details Name: eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of restricted stock units. + ReferencesNo definition available. + Details Name: eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the restricted stock unit plan. + ReferencesNo definition available. + Details Name: eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees vested the restricted stock units. + ReferencesNo definition available. + Details Name: eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees vested the restricted stock units undelivered. + ReferencesNo definition available. + Details Name: eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of option activity (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Stockholders' (Deficiency) Equity Â Â Â Weighted Average Exercise Price, Granted | $ / Shares $ 0.40 $ 0.79 $ 1.70 Stock Options Â Â Â Stockholders' (Deficiency) Equity Â Â Â Number of Options, Outstanding | Shares Â 5,306,377 Â Number of Options, Granted | Shares Â 2,188,136 Â Number of Options, Forfeited | Shares Â (799,471) Â Number of Options, Outstanding | Shares 6,695,042 6,695,042 Â Number of Options, Exercisable | Shares 4,022,998 4,022,998 Â Weighted Average Exercise Price, Outstanding | $ / Shares Â $ 3.31 Â Weighted Average Exercise Price, Granted | $ / Shares Â 1.10 Â Weighted Average Exercise Price, Forfeited | $ / Shares Â 3.26 Â Weighted Average Exercise Price, Outstanding | $ / Shares $ 2.59 2.59 Â Weighted Average Exercise Price, Exercisable | $ / Shares $ 3.46 $ 3.46 Â Weighted Average Remaining Life In Years, Outstanding Â 7 years 2 months 12 days Â Weighted Average Remaining Life In Years, Exercisable Â 5 years 9 months 18 days Â Aggregate Intrinsic Value, Outstanding $ 44,053 $ 44,053 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References + ReferencesNo definition available. + Details Name: eyen_StockholdersEquityLineItems Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Black Scholes option (Details) - $ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Share Price $ 0.68 $ 0.68 $ 1.97 Expected dividends 0.00% 0.00% 0.00% Minimum Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Expected term (years) 5 years 10 months 6 days 5 years 6 months 5 years 6 months Risk free interest rate 3.47% 3.47% 3.44% Expected volatility 87.00% 80.00% 82.00% Maximum Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Expected term (years) 6 years 3 months 10 years 10 years Risk free interest rate 3.80% 4.72% 4.18% Expected volatility Â 87.00% 95.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These

concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of information related to stock options (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 6,695,042 Options Exercisable, Weighted Average Remaining Life In Years 5 years 9 months 18 days Options Exercisable, Exercisable Number of Options 4,022,998 Exercise Price $0.01 - $0.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 1,315,136 Exercise Price $0.01 - $0.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 0.01 Exercise Price $0.01 - $0.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 0.99 Exercise Price $1.00 - $1.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 2,224,213 Options Exercisable, Weighted Average Remaining Life In Years 5 years 4 months 24 days Options Exercisable, Exercisable Number of Options 1,160,055 Exercise Price $1.00 - $1.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 1.00 Exercise Price $1.00 - $1.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 1.99 Exercise Price $2.00 - $2.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 1,249,586 Options Exercisable, Weighted Average Remaining Life In Years 6 years 8 months 12 days Options Exercisable, Exercisable Number of Options 1,026,448 Exercise Price $2.00 - $2.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 2.00 Exercise Price $2.00 - $2.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 2.99 Exercise Price $3.00 - $3.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 758,637 Options Exercisable, Weighted Average Remaining Life In Years 6 years Options Exercisable, Exercisable Number of Options 703,605 Exercise Price $3.00 - $3.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 3.00 Exercise Price $3.00 - $3.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 3.99 Exercise Price $4.00 - $4.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 279,000 Options Exercisable, Weighted Average Remaining Life In Years 7 years Options Exercisable, Exercisable Number of Options 264,420 Exercise Price $4.00 - $4.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 4.00 Exercise Price $4.00 - $4.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 4.99 Exercise Price $5.00 - $5.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 26,668 Options Exercisable, Weighted Average Remaining Life In Years 2 years Options Exercisable, Exercisable Number of Options 26,668 Exercise Price $5.00 - $5.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 5.00 Exercise Price $5.00 - $5.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 5.99 Exercise Price $6.00 - $6.99 Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Number of Options 691,162 Options Exercisable, Weighted Average Remaining Life In Years 5 years 2 months 12 days Options Exercisable, Exercisable Number of Options 691,162 Exercise Price $6.00 - $6.99 | Minimum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 6.00 Exercise Price $6.00 - $6.99 | Maximum Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares 6.99 Exercise Price $7.00+ Â Stockholders' (Deficiency) Equity Â Options Outstanding, Outstanding Exercise Price | $ / shares $ 7.00 Options Outstanding, Outstanding Number of Options 150,640 Options Exercisable, Weighted Average Remaining Life In Years 3 years 6 months Options Exercisable, Exercisable Number of Options 150,640 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References + ReferencesNo definition available. + Details Name: eyen_StockholdersEquityLineItems Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Aug. 21, 2024 Jul. 01, 2024 May 03, 2024 Apr. 29, 2024 Apr. 08, 2024 Aug. 15, 2023 Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 12, 2024 Jun. 11, 2024 Dec. 31, 2023 Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized 300,000,000 Â Â Â Â Â Â 300,000,000 Â Â 300,000,000 Â 300,000,000 90,000,000 300,000,000 Common stock, par value $ 0.0001 Â Â Â Â Â Â Â $ 0.0001 Â Â $ 0.0001 Â $ 0.0001 Â $ 0.0001 Pursuant to the license and certain milestone achievements stock Â Â Â Â Â Â Â Â Â Â Â $ 436,809 [1] $ 1,000,000 [2] Â Â Â Â Â pursuant to the Letter Agreement stock [3] Â Â Â Â Â Â Â Â Â $ 2,322,391 Â Â Â Â Â Â Net proceeds Â Â Â Â Â Â Â Â Â Â $ 6,000,000.0 Â Â Â Â Number of warrants issued Â Â 7,575,757 Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued price per share 0.46 $ 0.40 $ 0.66 Â Â Â Â 0.46 Â Â $ 0.46 Â Â Â Â Additional warrants Â Â 1,749,780 Â Â Â Â Â Â Â Â Â Â Â Â Term of warrant Â Â 6 months Â Â Â Â Â Â Â Â Â Â Â Â Exercise price $ 0.0001 Â $ 0.69 Â Â Â Â $ 0.0001 Â Â 0.0001 Â Â Â Repriced - New Â Â Â Â Â Â Â Â Â Â 0.69 Â Â Â Net proceeds from At-the-Market Offering Program $ 3,600,000 $ 4,500,000 $ 4,300,000 Â Â Â Â Â Â Â Â Â Â Â Placement agent fees Â Â 400,000 Â Â Â Â Â Â Â Â Â Â Â Legal fees Â Â 300,000 Â Â Â Â Â Â Â Â Â Â Â Adjustments to additional paid in capital upon stock issuance costs Â Â $ 2,900,000 Â Â Â Â Â $ 2,868,000 [4] Â 1,738,700 [5] Â Â Â Â Â Price of Warrants $ 0.4599 Â Â Â Â Â Â Â $ 0.4599 Â Â $ 0.4599 Â Â Â Net proceeds (in shares) 8,630,000 12,850,000 7,575,757 Â Â Â Â Â Â Â 5,630,556 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Â $ 452,998 Â $ 612,969 $ 1,540,286 $ 1,925,665 Â Â Â Unrecognized stock - based compensation expense $ 2,042,227 Â Â Â Â Â Â $ 2,042,227 Â Â $ 2,042,227 Â Â Â Â Weighted average period of recognition Â Â Â Â Â Â Â Â Â Â 1 year 9 months 18 days Â Â Â Â Weighted average estimated grant date fair value Â Â Â Â Â Â Â Â $ 0.40 Â Â $ 0.79 $ 1.70 Â Â Â Fair value of common stock on date of grant $ 0.68 Â Â Â Â Â Â Â $ 0.68 Â $ 1.97 $ 0.68 $ 1.97 Â Â Â Proceeds from issuance of common stock $ 4,000,000.0 $ 5,100,000 Â Â Â Â Â Â Â Â Â Â Â Â Research and Development Expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock-based compensation Â Â Â Â Â Â $ 179,776 Â $ 235,731 $ 618,516 $ 647,058 Â Â Â General and Administrative Expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock-based compensation Â Â Â Â Â Â Â Â Â Â Â 273,222 Â $ 377,238 $ 921,770 $ 1,278,607 Â Â Â Restricted stock units Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted

average period of recognition Â Â Â Â Â Â Â Â Â Â 8 months 12 days Â Â Â Â Unrecognized stock-based compensation expense $ 169,739 Â Â Â Â Â Â $ 169,739 Â Â $ 169,739 Â Â Â Â Registered Direct Offering Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net proceeds Â Â Â Â Â $ 1,900,000 Â Â Â Â Â Â Â Â Â Number of shares of common stock offering Â Â Â Â Â 3,223,726 Â Â Â Â Â Â Â Â Â Fair value of common stock on date of grant Â Â Â Â Â $ 0.6204 Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â $ 2,000,000.0 Â Â Â Â Â Â Â Â Â July offering Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Aggregate gross proceeds Â Â $ 5,000,000.0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price $ 0.50 Â Â Â Â Â Â $ 0.50 Â Â $ 0.50 Â Â Â Â Warrants | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants issued 8,695,653 Â Â Â Â Â Â 8,695,653 Â Â 8,695,653 Â Â Â Â Pre-funded warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants issued 10,386,269 Â Â Â Â Â Â 10,386,269 Â Â 10,386,269 Â Â Â Â Exercise price $ 0.0001 Â Â Â Â Â Â $ 0.0001 Â Â $ 0.0001 Â Â Â Â Repriced - New Â Â Â Â Â Â Â Â Â Â $ 0.69 Â Â Â Â Pre-funded warrants | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants issued 65,653 Â Â Â Â Â Â 65,653 Â Â 65,653 Â Â Â Â Prior Warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants issued Â Â 10,386,269 Â Â Â Â Â Â Â Â Â Â Exercise price Â Â $ 2.23 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price Â Â 2.47 Â Â Â Â Â Â Â Â Â Â Â Â Â Repriced - New Â Â $ 0.69 Â Â Â Â Â Â Â Â Â Â Â License | Bausch License Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pursuant to the Letter Agreement shares Â Â Â 2,299,397 Â Â Â Â Â Â Â Â Â pursuant to the Letter Agreement stock Â Â Â $ 2,300,000 Â Â Â Â Â Â Â Â Â Net proceeds (in shares) Â Â Â 2,299,397 Â Â Â Â Â Â Â Â Â License | Formosa Pharmaceuticals Inc Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' (Deficiency) Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pursuant to the license and certain milestone achievements issued Â Â Â Â 613,496 Â 487,805 Â Â Â Â Â Â Â Â Pursuant to the license and certain milestone achievements stock Â Â Â Â $ 400,000 Â Â Â Â Â Â Â Â Â [1] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. [2] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. [3] Shares issued as partial consideration for reversion of License Agreement with Bausch & Lomb Ireland Limited. [4] Non-cash warrant modification and additional warrants issuance costs related to one of the offerings of $2,868,000 are shown on a separate line item. [5] Non-cash warrant modification issuance costs related to the registered direct offering of $1,738,700 are shown on a separate line item. X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2 Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price of warrants or rights new repriced. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional securities into which the Additional class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByAdditionalWarrantsOrRights Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPrice per share or per unit of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightPriceOfWarrantsOrRights Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe amount of expense provided in the period for placement agent fees in connection with offering. + ReferencesNo definition available. + Details Name: eyen_PlacementAgentFees Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution net of issuance costs to the entity. + ReferencesNo definition available. + Details Name: eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresent stock issued period shares licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesLicensingAgreements Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of shares of common stock offering + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesOfferings Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresent stock issued period, shares for reacquisition of licensing agreement. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodSharesReacquisitionOfLicensingAgreement Namespace Prefix: eyen_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresent stock issued during period value licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodValueLicensingAgreements Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent stock issued during the period, value for reacquisition of licensing agreements. + ReferencesNo definition available. + Details Name: eyen_StockIssuedDuringPeriodValueReacquisitionOfLicensingAgreement Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References + ReferencesNo definition available. + Details Name: eyen_StockholdersEquityLineItems Namespace Prefix: eyen_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=eyen_RegisteredDirectOffering2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_JulyOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PriorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=eyen_FormosaPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plans (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Apr. 30, 2019 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Benefit Plans Â Â Â Â Â Defined contribution plan, employer matching contribution, percent of match 100.00% Â Â Â Â Defined contribution plan, employers matching contribution, annual vesting percentage 4.00% Â Â Â Â Defined contribution plan, maximum annual contributions per employee, amount Â $ 56,493 $ 46,636 $ 220,682 $ 171,800 General and Administrative Expense Â Â Â Â Â Employee Benefit Plans Â Â Â Â Â Defined contribution plan, maximum annual contributions per employee, amount Â 15,307 9,253 84,084 56,241 Research and Development Expense Â Â Â Â Â Employee Benefit Plans Â Â Â Â Â Defined contribution plan, maximum annual contributions per employee, amount Â $ 41,186 $ 37,383 $ 136,598 $ 115,559 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of employer's matching contributions to a defined contribution plan that vests in a given year. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum amount the employee may contribute to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) - USD ($) 9 Months Ended Oct. 01, 2024 Sep. 30, 2024 Aug. 21, 2024 Jul. 01, 2024 Sep. 30, 2024 Sep. 30, 2023 Subsequent Events Â Â Â Â Â Net proceeds (in shares) Â 8,630,000 12,850,000 7,575,757 5,630,556 Â Common stock issued from exercise of warrants Â Â Â 7,575,757 Â Â Shares Issued price per share Â $ 0.46 $ 0.40 $ 0.66 $ 0.46 Â Exercise price of warrants Â $ 0.0001 Â $ 0.69 $ 0.0001 Â Proceeds from sale of common stock and warrants in offerings Â Â Â Â $ 16,139,994 $ 11,977,468 Prior Warrants Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Common stock issued from exercise of warrants Â Â Â 10,386,269 Â Â Exercise price of warrants Â Â Â $ 2.23 Â Â Exercise price Â Â Â $ 2.47 Â Â Pre-funded warrants Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Common stock issued from exercise of warrants Â 10,386,269 Â Â 10,386,269 Â Â Exercise price of warrants Â $ 0.0001 Â Â $ 0.0001 Â Pre-funded warrants | Maximum Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Common stock issued from exercise of warrants Â 65,653 Â Â 65,653 Â Subsequent Events | Pre-funded warrants Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Common stock issued from exercise of warrants 65,653 Â Â Â Â Â Â Exercise price $ 0.0001 Â Â Â Â Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: eyen_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2 Namespace Prefix: eyen_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from proceeds from sale of common stock and warrants in registered direct offering. + ReferencesNo definition available. + Details Name: eyen_ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering Namespace Prefix: eyen_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PriorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=eyen_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`Q4EF\XFQS94U*0E*G6J-Z^S#^PT]2"!S1 :QR1_MN89>2:0B$YG%6KW MV^M@0;WJVL:,2YJB_PJ;-!]D! X,YGZT$N#1> 5:./^ M46ZP[)V*3T=]AUJY47%;7E9Q,QY3UJ.7'=*KH/8L[(CG1*CI1//'D33B&27))I\4-AJYKQ3I$ M4*)54J)XO/DD/1B+[E8RQI)$@XE[YG8'@Z$U!^+2MGQ54*)XRGD(-&0DN2"4 M_?KT&YD++U/0DE9(W&DBHP@&HF6WO[OBAK7+#;BN+6@5?QB>7G;MN!+0 MCA@>;E./=X@8Q*H8Q/ $LQMFW[SCY_FB-[G--$S88O,"M1+_H("SK8?"[21W M,]LOZ]%PT._3 86I[=K&6$4AMM>BT02&4P69;QK[XIE\%/9F;%H[KV8F?X,S?ORY2$8@%2Y_@4!CQ5;+86)UHF^7[ED]1:1OGA2G!?*',#_+Z0 M4N].S!^46]ZC?P%02P,$% @ ^XEL6>C;)[5L!P)2$!@ !X;"]W M;W)KLJCPW<5K>+NJQ4O&H&Y=F"(,07 M>9P6L^5Y\^RJ6I[KK*LR?7\QP[/'!Q_3VXVQ#Q;+\S*^ M5=?*?"JO*KA;=%Y6::Z*.M5%4*GUQ>P-?G5)A1W06/R5JOMZ[SJPH=QH_=G> MO%]=S)!%I#*5&.LBAC]WZE)EF?4$.+ZT3F?==]!^]>/WG]I@H=@;N):7>KL M[W1E-A>S:!:LU#K>9N:COO]5M0$QZR_16=W\#NY;6S0+DFUM=-X.!@1Y6NS^ MQE_;1.P-P.'$ -(.($\=0-L!METAZP)ZUULXN5YI>^#RE]#-WO1Y*89#=&D MA9W&:U/!IRF,,\M+7:Q@4M0]>!MG<9&HX-KZJH.SX-/UN^#'%S^=+PQ\C[5> M)*W/MSN?9,+GM2I?!A3- X)(Z!A^Z1_^3B4P'#? #Z>'P!437A4BZ$$GCCTZ% MN*TJ59C@35U#8*YP=N-#]WB[D5[599RHBQGLE%I5=VJV_/X[S-%K5W GZ&^;-.[./8G5'O7/'&E=WM=TN!HP@3>;ZXVP]H M;(?#*)2(B<[P &S8@0V]8-\7=P!-5ZERPML-9GM?2R07A/$!O+$=1E+(R V. M=>"8%]P[M5:P;"'3\$F:Q!D4NK+,'H)$U^YTLA&.$\41)0.X#C.(24CJQLL[MO-R+]T.:V&TZ$C609!4\&B:=8\U+O2 MKO-Y4"CGJFF']'2 1C(1HF%F'(:4BI%$X@7B/;_%SEWFABS//4F\=`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

MX*BC9HQ1=XHS+#^Y>J/"(Y9:/Y06'OF%\#AET#MB8RA\/BR:\+FA\[F-D<0, M0=V9SG 9)D<%-BN&E@6XQ46.=SPR+#5Y!.<3HN"2>@B!:C4=M]IWI,4U?OF: M:3CK9,>AKIER8"64Q FE)"9N#WY.TOZ!?HM@XJ6KIJ>[9CGD9>%3#5=,2^;- M^83+,M6#J&HIEEH_#I;@Q"6KIN.^]U=-6]^[?@>6-X6F5/HK14#2.1&2$R:] MQ7Q(5A.EU$"C%A;)!/X=-N#
(2P!@!H]]PR6:7#=1P0Q+K1\-"V8"YR8;. (MGOEC7P%Q%#SV!9(.CGT!X\&QK[!T)L)TAK&L?Q.V,?7YA*JV0%5+A<^@0K)8 MB($Y1'%R)7G(<-9)_L7%>M0 MU5(!G(>D[?8;*08FB(1E-
H%Y'A(>/OA\8\JF1*"\(03]JE4M11+K1\'BW+B MI>GGB&L0 4S5+442ZU_BYC%.XES'!*,@/2/0P)P(<%SBR!< $D'X0*2 M#<&%M*@E+S\->?:.S!$;=0D5XUR6!.VLH9>65ZQM
M8B/V[T@,1\.'/TG,$\%K/Z@G*E'54BRU?F@MN M"'?I,ZP_N7FADC>66C^6EKPE\IY;,'XC^VR'XN?C.]!Z 'J72JK8W6<8+L3D ML,!F3=\]T'HLWV[SS*\>NG]L:<'3L'9#>6SN!":J(2Z%U>$
MRS+9@Z@PCJ76CX.%<77)_;'COO>AVOC>NRX=P%LIXH1HY5'(]B4JZXU;[KP&RI*LO)]UPUJF.0U5;: !?E=9* MNS-TZ3DI^\ZSG*M?RKFC^TRTS[D#>WS"99GL/U3.Q5+KQ\%RKKZ$<\=][W,N
ML,<'2#6TQP=(.KC'!T@;W..C6\SM?V*Y28_QS< 1^=URO5OE=?10F>8>/57E M,L]7W2MA \QF,E8S57AW:?;M.\Z=<>);3H2ZQEE(GH55.-SP?/Z9%9USJ
M$2E"9HE27<(3M656/X*2LS@A,R:X4?UGN9UWZ9ZA ;*3^>2FQ+;^5/E#43=Y M93Y9%56^;(X#Y(,9Q?1,Q7%DFKEI[.6SH4\SZ([J_"FKC%#4^C\JFGSS*OII M6*O8?_%5OVC&PII?
#:&+YV+U6M:/W=)5'GU_7*5\+IK'J'VECM#'-==>84JWK M-D0C<8KC&>?)2,C9+"9L).)L1A,V8WRL*B9Z9D;A(V)T9@;J[;_1;*PVFII& M%(F^NA;FO"7;//TM^C'M]69M,!_EAL3 U<
MC<1MIFCK2#[B'D%F6HZU>\)GA"6S).%]=P\W5V6:J8;2Z/[+:13U4*.H!^'V MT#1^V)GFTO;X)RTCW!D,"@YV$N6V&^JWYNR\X;[*&3CL*MP974,X,.:),:.' MC#4I.6-
M+PH]1J]/7AZ^R:N'[C7O[]%&F]ZK-%[@WYN)7[1Q(M7\=_/Z7IGSJ7E_^J6R: M+++".>)7M,2%?+*@+$=" MWK*EQ4N&45J!\LQR;#NP5*J 9K-"S1$C]C\:E\9/+.:EA2DN."$UH AAN E0]_B1X
MP_>N@0KE,Z4OZF:>W@QLY1'.<"(4!9(_K_@>9YEBDGY\J4D'C4T%W+_>L4^K MX&4PGQ"]S3[BZ1B=3.(!B#%"[3.Q!=S' =D*_X$IKQZAMLZK[V "1K+FA> M@Z4'.2FVO^AK/1!['
,FC!S@UP.D"W", MP:X78!W!..#5 .]4@%\#_%,!00T(M3HTAK 'AJ1:B&A"="HAK0%S)89N_*OEC)-!HR.@&,-5;LJF+2D$56N:<%$KL MSX+)IT3BQ.B>%JF4+D[!LT "2QD++#N@"W*]0L<02DQ0 M@-
4J(,E BDBJI):@D0MZO2UD'N=(=()RO49%@D% NN$Y06Z-!9535]M>1 M$P61;=M#ZW6OWWV_B:ERC!-P.YU'#,7O%@]/-/,+!_U6G% M)-GT,&P8NE'8#?OC=\)V=&'/3'HZ-T36TIS7:.[KUYP
4L8O*;*_=;W+8SW5BU_7"=K]I M;U3G9O/0J =]/XK:-N<:WP([C)PWWUHI")H4!#]B90@.,N,&;M"):7S8RX=1 MX'>RAQ'LO<=8KM5&/1AFZ[T^R0"CI>UZVYII<=.;ZO'^FP&>FP=Z0_*A6#
MLI:\;M!Z\>?60I-D$Y-DT_!PUMJVY\6=7)FT.3=$UDI\U"0^.B/Q8,%H+B=. MGC?3:8,80X5^(D6'@^5!-X[C3NT:]_IP;KY-DDU-DLU,DLT-D;54$3>JB'M5 M\827A O,U&I'&$Z$7 2/;Y-ZNKX]:5679T
M\:O\@)>A&UV&)_FA&W=K[U0VQVQ9'>ESZ&PO=V]R:W-H965T&ULM5MM M;]LX$OXK@F]QN /.M?BBMUX2($E;7('M;M"@V\^*1,>\RJ*7DI/F?OT-*=NT MQ9?8@;<%&MD9CF8XY#S/#-
F+9R%_= O&^NCGLFF[R\FB[U?O9[.N6K!EV;T3 M*];";^9"+LL>/LK'6;>2K*SUH4&SPW&+YJ2CAQQ.[94VC M-(&=?VZ43G;O5 /WG[?:/VGGP9F'LF.WHOG.ZWYQ.@#<#\'@]0P@
MFP%$.SI8IMWZ4/;EU844SY%4TJ!-/>BYT:/!&]ZJ,-[W$G[+85Q_=2O:&H+" MZNB^+WL& >J[2,RCV[);1)\@R%TTC;[=?XC\\#=NS1 M7D1?1-LONN@CO*4^'#\#2W?FXJVY-
SBH\)ZMWD4D_E>$8TP=]MP>/YP$S"&[MV2-:'_'-GIFE3U(LH]]73)8];Q^C:[4\><]9YYJU02MU:U4[]WVW*BMV.8&M MV3'YQ"97?_\;2N-_NUP^D[*#":"[": A[5>_0:)I1.=T9-$:9Q'L3<5\?MH<;
[0>3'*.$S2R.OSR-ZX@M ?PZ CG:O&L0\';)_!&2$AI MV]P'[*^!8,$^&7:3TU5DN9JE!4;9V%=;#F&,RA5P%?(U]J9(6#.!5V0 =T:T:#^J&WW%JOMYH.UB-L?KC\=5P"A1$[*NO
MK*Q@V75\NWT:7BF*%DE%2=V>$;]1RB!0(4&;LCRU'8T)2[F"(0XHS!P&F.E&=*#K&#)E1@:7C[P MQD\-T%FYP;FT'4Z&80

#K/O-O8CG"&25R,;;8%IR@E69:D M'JL-#T!A(O#9H(W31!O0IRA.D"[.#FUT2*8 M1[HQP;Z<1CZ[QFL8#Y&>P"6 ME8 $[+0:V["/$!UG)I=4EGC 1LTQV$TOZXTB>I"U!;;(#Q%68$)'MOH$,0X M\6PY;- :A]$:C)3K(TH);$,H&)J/-Y5+C&2(^*I#;* 6AZ%V:V@@L>TE>J<+ M-O).:4*2=)S>7((DSDA&/$X84,5A4/V50=WVJITV4$Y)@B$3C^UT"%*$<.I) M!MA *@ZBE.X5Z(;)-U5F?FZ/[I9L]!XN4QJC.,ZM%>T0A6V'&>%(P-"N+T MI&:/2F[=,>8'P?54*G N;8>38- 4A]'T;BVK1:FVRDFE$G;A9XIH9BT_AR#. M !#VH/;0= .A. RA0[QT>@=6Q]L>&!Y758_F+DZK@PI/CIP+9Z$Z*J@OX1J< MQ6&C*1C>U $"74 -VJCVG-]ES*66IX%_5)7.@A#!- M[LEQ%.(I(D51T%%D79*HR#*:>JIV8G@ >:5J+U_T=A-S8VS$NVX-\65^YDI< MM*"(<9&/0=4I&1=
#3S$D.QU]L/4X(B 0 RN^PC80O2EE#]@"*81UDNG3[9 M\)]B0FD\1C"'($680#7O\5K 1%#-^ M@ZWHV9;OJZ;=-115[C9=6.W)WMD5>1('6ES$L CR"HL(+D7E[Y G ,S"_IZI M.;_QUWDFD!2YASH20SU(F!\9:O!8TV;!O\"!1QQ, 6HQPGDY/$>.&I$NR@!J0^#R@AE?0<&FO//C M*JG+
(\C5VAL%HOKA(]#5)\CJK1N#J%V^3[,4IM9J0;HDL<+:V(.?U) "&B8% M7HNC:73#'GG;JE# BKH#;!6UTP\'NM.<%G$RQE*'),9Y"D6B+Q*&!] P#PCY
M\5%5W$$/;(S/4)XC/.YC.01Q#*4#1I[]2PT9H.%S_GO5:].-PK*)/O"N:D2W MENS@H@1P[N%6#4"/LR5,SWKJ?RYMAS.R=^X?)A.?VYZ!7F?
91&W@AX2$H:H8 M1\PAB J*B"]@AB'00*1%"WX^-/S1VX^D-@' (*S<>.ON!1 #9V@K]&)J@'/^)Q7 M>V?LH0,"1:-XN!E/;2J!DRQ)DW&%$C;NKV)G'CH
M2]X.MW?8SVJX(]*60G-,;S3\PI.WM,UHBIA2DKF7>&+X3!+F,W^PM@:7MD<3 M4:E/NC5#7KVM*Q=^XYY:A34FXA_)Y6]LY.B>'%[5VMQPT'#]*
MQKQKUM$?(>#6F TZY%"H>$T,]4G"U$>1!\"3[K3&0UCIR2O19DX>SI3LW94, M=U5N#R(T5-]6H(;K-\X+*J^';GC__CU/3# FQ?C
+VSH&Q$F,:PH";,B[[*5 MK"G[(>,JZ@A/B@)+7JG'063=>DZ-P^\\.?ZI-97C_N!L[U+XDLE'?5>^BW3N M'"Y<[[[=W<>_UK?01]_?
H/>WPZUZHV:XY/^EE)"9.T#9.:B,WV40-SG&PO=V]R:W-H965T&ULO5=K M/O7OL/ M$CMBV>A(-]
[^PY2INAR=C51)6]W:],'O_T)=/"]97^%ME%^USWM?ST>J:&/R M=2<,#VKC\K_^TN%P)'#V-8%E)[4O[,A\?*M3OKJ(OB]"KP;VOA#0A5I.&<< M)V6=
E8-Y-+5=1LQ$Z/Z*>RT,[]JQFJLWNO4E)^JWYJ*,AD5-J5ZEI'$WG^ M+E DEV3I8I;@"BN<%9W9ZVQV^16S?U+OO$M55+>NI/*Q_ PA#'$L^SBNE\\J
M7%,S52?SL5K.EZ?/Z#L9<#D1?2?_;URRV=.GS7()OHF-+NARU+"B<$^CJ^^^ M6;R:GS\3U.D0U.ESVO]W03UQ]KU/I!;JNV_.EHO%N?
JO>*%N#^3\O=%C]:,K MINH%:U_.S_MI&<*8#RI5I+K5&U\WVAVZQ>^580O*-U6JM*U-H1(5E?/6[PZJ MR'M1XO=H78UQ._$&TS6%PFAK?
I6Y\EZ[@DK5!%^V18K*0B#H'2\:##'?!$,) M+0^1)?J$3IN@K]#VV')-):8DM-+$AML>%#16)^Z\4_4W1-&+PVW"%G;"'E0;
M:=M:99Q$FM":$[IF8L2**G@'Y5O\I8G?3K!C0@=B$X1>%E790L2+HSS!0M W M5N2J'%;46TH"'3UYB\ VQIT&,M,@\RZ!#<4G$1C1^(,/A@Z:UA>
8K81A43 MMNM0*C$.1"(B\CN"/V',?L/TAAQMV9%:"_H;L(1]R\#R>DH4C@-L'DB"\P8B M"(@=:8 C-N05B-^;$FYD#(L'"BQ>GW-Z:/+^[4H5V&M*G1#
[.U,$?P?K8T9Z M0YR(C@4 1 P@63H%(OM.] RXFA1]0%I!2&UVEF_ 2C4P# GU\ FCA_HJ5I7 M!BJ%S[6Q5@*03!F+!<>'F"UQ!I
X'ZC)I!>JJ1IGC9ELLMRD]-;] :6[('> M6+B@PV=*3T=:M"$P; \,1OX"Z 5E8$]AVQ+X%7 =9(TXB9BYL -,CHF*=#;Y M4!ZK^73^\MMQAL3'-(EMV
FQ&UP') #CME;CO,\USC/O#J4D%UWM]>FYR-:' M,ABN\NE0UJK22)^-7D6"X\#=FJ(K"M;2Y4-XH)$!JB7AK UX'-Y[$R[B^ MTJ+:@W\D==/7%I-
O0[FL$ZXEOHWC#AWA :H8'X(ZZ+#F%=:I[E;<('&HN M,E>,0Q4PTBB U/E8Z7LF,W*-W#::8V.PH"N44C-[DRH9MSGO:!]0TEAD9X<: M"5+U6*-
B"FV1@4-=\JU(+>:3GV7;*B13@(%G;/L#[5J;5:PG_YRJ ME02'6.Q!JAU=U2OG4T\[9-JR7#;SV#Y:%3@)9B&L0+^TA@';'-00C\0A+8? MU*<@G^*,$-W?
X',@J62%.^0!.AQ M[*R%9UQ>N>=3';\'LPR4(KM*A-" X+:C@BL5'!*BJJTV037'QUH'PA]0J-O5 M'6=*R\R:^5!OT"+[>Y#@M^V.P%2A2F3&
<6.M_V+^/[U-5%\G&2FPT64DICQ M#Z?S?ZH:H'#R>S0,D.R+\I[ZX#H[0+0WWIO#:6?5@5#*,,$;WD)1-K'H3#"Z M
,;S^:+D5"HE$!PS_W:=QLJWMN1FP*\=KC,(?&I=?DX,9=%K>U)'[N$H!7I, MY"<3^-LP3A[E3P+&A\O CCN&[;F!=80=FL'-;UK_RKD6CGT@;OB@[E"[?
WVL M/J?L=WZ@PQM+1ZU@S6Q'DZ4V7 K>%G=BM390'6]]VUK+WKMW>L)T5FJ95RU=_:.=! M86]Q^M1->W;TQ$)CW;!N?\R3SPH,I, ;L+[UN'9U
S8PO."O_@502P,$% M @ ^XEL6;E14_J #P /BT !@ !X;"]W;W)KN*L=)=EV;R:;BS,QGB(0D3$A"(4 [FE^_ MKQL$#TD^DIGYD%BB@$:?KP_PQ:TIOMB-
4DY\R]+GYYG4^?]'KCZ,'YJQ=;N5;7ROVR_5C@VWE-)=&9RJTVN2C4 MZN7)Q>#9ZS&MYP6_:G5K6Y\%2;(TY@M]N4I>GO2)(96JV!$%B3\WZE*E*1$"
M&U\KFB?UD;2Q_3E0?\>R0Y:EM.K2I+_IQ&U>GLQ/1*)6LDS=)W/['U7),R%Z ML4DM_R]N_=KQZ3I74FJS:#@TSG_J_\5NFAM6'>OV/#L-HP9+
[]0%N14%K08U^L"B\FXPIW,RRK4K*O&/O?JVAM#F)6XUNM=Q1?NUISV\@_9"_&QRM['B;9ZHI+O_''S6S X# MLZ^']Q*\5MN>&/4C,>P/Q_?
0&]7"CYC>Z&\1WM,>'Z=-P?3,;F6L7IX@6JPJ M;M3)JY_^,9CVG]_#^;CF?'P?]3_)^?VT/QBGQ%#\|(_Y<#!X+AY_E/B\4>+2
M9%N9[T2B;9P:JQ*AG16VM5,V.[=AI\[%CQ^K\S@M$SHI%PXLP#M&@F)6#/IG M_^T16X42&WFCQ%*I7.0&$>14H64JXHW,UZ#A#&^MN&X14YO("
[.I4M55'[;"34MQA/A;0M!2T)&GOBO?Y:ZD2[G9!Y(OYMB/"E MR6-5Y.+"LB*.$&QQ#1$34>;P-E?HV(%R+.V&J?$'!?HW,E6Y8VIRNRW,-TVJ M2'?
BR:PW!,"D*6,EMDB"S+C,RE02*2 =1'9'-@YFD]XX;.V1XA^M#SZ(S-65 M P8MBP([[5EOU*A;E1>*B:\D7[Y3I&'
M;31^2@1X66DGESJ%.W3IJV]T,#ML;,@;00>?665>-J3>%1S*BE5ALK:8JV 9 M)0NQ*EU9J#MH;Z1#V"(5I>F14[JB6%"+O98'6
MDC*NUH="4R4MX@=1L6,#D'6(:D)RL,H=<[72.1BB\\$(H;C50+! MM+6E2GKB*MNF_)CM2MY[C+EM*G/6*@/P(UEE?2<*)DG *6 27K%"Y60*&U4X
M&_#N'F78,H9"[:HDD\4FRU1!\N@_%/-2V ILT3G+F*:P6_#\6^T0%UA;\"DRUW0@F24& M)D*U>[_13PT3WI-4OB$_H9]HG;=
6YZV.##*2E'_55EX5N06[IK2^L*4ZPWOLP!O!JN:(F,ZE ZF$@5?M80W^$WAW*M5%U0M MLJ@,(9)FB:A]9LX;XS.0.Z0L;6(TL!Y8[J5/6S)WH M 1 A!$
>"]P\DOGC RQ@F-9\:!;0J.QL8X+!5,D4)!W9*ZK^"B"OAY7#_W1 M-M*?&V\(P(:Q, ##+%! 0]_33D-XR#PYGSPL?M(.EFO-;,G':EY MYV.O4'6B@\)2>#YQ!
[4<9-VJ0#D6X;T[R=?%<,RHPJ'5[VI._SWR0:3_K18#"_+E1,F.A 2'&:B]Q(ZW. MK=.N]#%)B!<1+CHT>8C&RI6P@6HDRX>_4PGGC3>>G+C*
(2!'X:4IME5XBZ=D M]6'_^;LW5Y?\#],7RW*C3 /!K$\H][Y^T MRB0$1_ 0!7.6K$;250S_U Z]I]N@XO%\D^3'Q?[S9KZKID-SFOI$UE4AE'*@ M##;L-)K-
Q]&B/ZH*G'$T'(^B^:R_;^%+)'%&XNMRNX7\%T5!1;./C=>RM-#6 MO\1[DRW%5:%2HO:>CH%.@VDZJVH;TO[,-M!3@J
MW?.24A*C$B&N9PJKLF8]EW-;5/B N*0HUV< '\T@DBUA%W:;.@UY*&$(QUX- M\ T".^H1+&5"R?
B#I%I:=!7_Y(1T5FYI(J!AU()E84NJ0:H^XKURE(LNUH@Q M!KRG5/&CA,Y#O7_JF>THANN?0B%S>(\,7=&\[HJ@!RBV*@D(WCB7 \VY&PFK
M*J+O(3$0LN'">F^2C?V.,,&QP7T2),A(62KQN99 LJ IAVTU4X7:ED!XR8W, M3KS=J=S<:.G#[>"DKK61DA 9*44(E2MQMQRM*XN4Y:#$)&M]'J$&3BC?
L&K: M!"V0U;X'=F'H5!,&DM5-4#M>B:8_SS5TB)UZ0>"I/R0&4+\%# M_VFKZB:XM*_%]A,=^;(J<":VQ1OOZO]N98$+4P0M1DX;XK*^[A]SH<^79Z2
MRH!;51'EOHL(N:JOFORN'K +TE$1L+_-"W1+3?B3?M,J>M@9-RT;)8/'XV(7 MHZZ1RWXD5HAI)G* GK3F)^3V\+M C\K-O;S) M%6LG&:)6I-
DK::4C6E@AL4G:S2E:_0*YE9"@;6%2 !;?&SNDC\LW^[OMIQT;"$ M';CU923>4?.[@7QK8Q);__9$C(>S"+C1>@*JT_E(?)*W+;RHB463<3_JCQ;U
MD]D"Y=E$?#:.W36HMZ$WC!93G#&9MIX-^HMHMIC73_:+I%#K)#5([#MOZ#]; M*J\/|\YSB\)3G27F-O>!
<+B.W/(H[3"RZ!2K#TZ3Q"TX!]0,NE#3;V8ZQXK8 M1["Y^I'95N!F_OWA:AX=Y!7=!#8TRI.-F3KBHEXULL2E\W:+S6\+B2G8L-*0O?.78H(QG1
MO(RIM:;A/D=$OF#V@R#JIT&YHL,:X7Q9+G^ORBP:<'&70L9)M7,ICUMH7F_ M*5T'A):]2L1O=,HR[8F/&CJM)IE@!65!-<^CU>0V?#C:.V1'$]-
(4Z]:HQ-. M6E5I8UU1UH'! [BN^&Q3]8TLR4F+4@_,67AW9P=I5GNW\GF(%<7^6%>M%8K" M2O5@;\D&YNE))6G'V($X"?W7Y;7O_1LF_I\9I-MW?
@=+/A" '5UQ/*G>_Y0Q M@2&V^?0!YH)WF.+OU\>'8 KIT"@N2Q>F:VV;;U""T82I2;E/9]%\CG^3T6GW
MZ6@TCV:C[M/A(II/1]%T;_%@$0T7HV@Q69S^[6*&OV_0V7$_"%L^/0"*K]3^ M5EL:GTQ OB4P:M$!M#Y='}X(C8]GTV@^FQ[3^ 3>W9\=\O]W_7W]
M>$1M!QR*CL'IWH/YWH.]&,6#?O.@B_RM9",Y@50=6--ZRS2FF],[VAF#WS:?'F+\@@#\'T;R&.AO-H,9Y%L_$8
M#AQ1]$PF8_&_K1\-3^%'DZ@_'HH)6J(YNJ I=>^45C5!;&Y<.R+@B$1J=N3) MIU82IDMO;PYN&;IME&W6JILJ[3K!7C%]A@"N/\:W7/:ZIRI1%0A,7\
<'<>#]K9N3O M+JY?A]1P9GZ*Y/V*R/5RQ;\ID6W7:1>BUY?83\. 4G:R7[V>ZG^6WQK5GXSZ*M/VX:%:VPZ$:Y&-5DC5WF'29 MS#$1#%7=ET(M)
(:B@2^Y7&80%PZ8;]'WJCS>5?Y>39H=SFH-5NM(T7NLM9:W MM=>$F&^XDS"KYZMM C-8,]6>MG?G0(=V2[[F;8UU/[?E2JT)DU$85-&E=EZU
MA2UM$'.>68^_(>#JF\"CG!]3:LMJOB;X\=A]..(>XZ]\K8 EL:L#R588' ET M.P>QIUT394V,!1+[(=:Z^C[V0N1YZYU6=`1K?G.7IAA(!_[UUOII_7+PA7\G
MMEGNWRS^61;0EQ6I6F%KOS>;G/A[K/#%F2V_(0N4=2;CCQLET;;1 OR^,B@- MJB]T0/W*]*O_ U!+ P04 " #[B6Q9;/=2;"T# !J" &0 'AL+W=O
MANVAVY! MN\NS8C.Q45OR)"5I_WZ4[#C)D@8%BKU$%D4>'HH4F=%:R&=5 &CR4E=4%E"9>S4KN3$96-I63D5CJ
MJN0PE40MZYK)UQNHQ'KL^,Y&\%@N"FT$WF34L 4\@?[93"7NO!XE+VO@JA2< M2)B/G6O_ZB8R^E;A5PEKM?--3"0S(9[-YFL^=J@A!!5DVB
P7%9P"U5E@)#& MGP[3Z5T:P]WO#?IG&SO&,F,*;D7UN\QU,792A^0P9\M*/XKU%^CBB0U>)BIE M?
\FZU8T"AV1+I47=&2.#NN3MREZZ>]@Q2.D;!D%G$%C>K2/+\HYI-AE)L2;2 M:".:^;"A6FLD5W*3E"@4^L>(GX;^)C20D)R?
I8'O#\F[/>%"Q)Q@BC34,SS>Y,E:W$'627TK#5W2 M=,BPBRPL]E:8KSE@ H_=2QRYJ4^W/+ 2XCCI3I71&^$*O66"MYV3/_=MJ5^ M<'T8WT_]KD L[
MYV@_2ZW9^;-7;*?S Y +KFE0P1U-Z,8@=(MO)UFZT:.PTF0F- ML\E^%OAG *11P/.YP [2;8R#_N_%Y"]02P,$% @ ^XEL6=NAM0H]!@ MW@\ !D
!X;"]W;W)K&ULK5=K;]LV%/TK%VY7 M)(#K5YPT:9, 2;MB!=8N:);M,RU1%A%*5$G*CO?K=RXI*7(>7KL-*!J+XCWW M>0ZIT[6QMRZ7TM-=H4MW-
LB]K]Z.QR()92'#\-*Q=V?-34WNM2GEER=5%(>SF4FJS/AM,!^W"5[7,/2^,
MST\KL937TM]45Q9/XPXE584LG3(E69F=#2ZF;R_GO#]L^$/)M>O])LYD8/*,P:PQF(6XHZ,0Y0?AQ?FI-6NRO!MH_".D&JP1G"JY*=?>XJV"G3__
M5'I1+M5"2[IP3GIW.O: Y9?CI(&XC!"S9R!.Z+,I?>[HYS*5Z;;]&.%T,09?C0< [^-X<1T\E&3'F3V,P-]ZZ2B3R;(#A M=]*NY.#\U8OIT>3=C@CG783S7>C?
UX7=$%^,ES2GU_0(BWXKZ:)>8I9H>AB* M>C DGTMZ;XI*E!N2I9=6IJ1*;TB05@E()TDLK93@GZ<]WOWJQ?%L-GG'7#!.
MT*]Q5UB=OMO'V/J;K9A$\JU6 M'!0ORKM$UP[LI9O1]8@L,\T1@DU,44B;**'57P@8=I4U:9UXZ(46GLTYH]*L MI"96L!JK+ 8FHT2;A?3"@7(PJK *
S)5[G.A"Y5 IUP5U6=(D]'D*===4CI M*GKNIZ62G-;"D:C@884]39(?/UQP-'UG-0K.2ZK,M(^1LDJ4ZH@K"0R=(A, M@O!94.U2VDUXZ^JJTJ%)0E.JG(1
2-%V1G!#4EE7)<,"L4U":WB.+Y M-#_8>DD70&E,0A0AR<&2'-'OC]\"4VL4G8\!^">999#=B"5+VDAA'676% $Z M#97.PN],60SF?
2/)"1U>BFXM]FA^_&1Y/#LF!(M*%043NV "I3V[;J5$.3(23H]77.]\SQR'\;-O#\WU"&%(':!.BQV?9J@ MT;+RH;T/E++9$)J8(6C&
=G5LFR3;26G#863Q("9)*DM2RR2^2PL^CV=QS-W M1#GQ_7%*O73^.?ZM,J+%A;B5,;98;#C5 M&=,DT)#MNX4M:AG8V#5$IM8IY&N%L6

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

AZ,H\M%0C0X&XW>)A@Y0DL6_ M-)K_71VOZZIW['[O'SR]*M0K_\ T1--(V[["]E_W;]BK]NGVU;Q] -\SO>)T M#0A<$C3JG0\"T.VCLIU85?
N'W$)9>A;Z84GO<-3.@-:7BF[];N(<[%_VLW\! M4$L#!!0 (/N);%DSZWA1@@(*D% 9 >&PO=V]R:W-H965T;2"PS:2)05;0^,BFKCV4U.&HO$
M#K;3P+??L9-FG0;5I+TD/K>?_R?.\:R1ZDGGB 9>RD+HN9<;4UWZODYR+)D> MR@H%13*I2F;(5%M?5PI9ZHK*PH^"8.J7C LOGCG?
2L4S69N""UPIT'59,O6Z MP$(V8%%8$,EX[IA>OZ4M/%SOZ;>N M=^IEPS3>R.*1IR:?>Q<>I)BQNC /LOF*73\3RTMDH=T3FC8WI.2DUD:673$I
M*+EHW^RE^PX'!1?!.P515Q YW>U&3N479E@\4[(!9;.)9A>N55=-XKBPA[(V MBJ*NJ9;PAK@W[2(18M(GH'\1GNI#"YAJ5(,?
VSWBF%+/Q>P'WB9$;5!"V'WT)D?(99&2CZJL-9T,II,14/MG60MH]@"N=4TV M%RZ1CL]@:6GW68:*B^T L).0NHRW&,P HP!/G,P/P3 (@A
JHNB<*>=,9%G2 M(--,)$_P42-"VW5@N[;.5K ^/;F(PO,K6#[7W+Q2<*]#?QJ^=5K^P?B4J+;N
MDM"T72U,.TF]M[^'KMOQ^YW>7F)W3&VYT%!@1J7!\'SB@6HOAM8PLG+#N)&& M1MLM<[I+4=D$BF>26NH,NT%_.\>_ %!+ P04 " #
[B6Q9H>H]Y.T" !8 M"P &0 'AL+W=O:\(]HF2]=0).R*E(#%G26A1<)%EZY,5E)(%@HJ9QAF%+%-423T90 YV?4-V]@/W&>K-9<#9MPKDQ7,
M@3^4,RIZ9N.RR K +",845CVC6N[._6D7@E^9[!C!VTD(WDDY$EVIHN^8.\ ;@VX;0&O!KRV@%\#?EL@J(&@+="I@4[;IQ360-AVAJ@&(I4.U?ZI
MS1\F/(E[E.P0E6KA)ALJ@Q0M]CS#,M?GG(J[F>!X%W>T):A&5#UWN 4T#!C M:4[8A@*Z1 _S(;KX_+5GG\;N$"MQ^%[]MOWA7
M@X_:+UZ'C]LO7H=/_N_)3S\<^UBNW*N\K/_4C*ZQ*]LO/T=O(PZK(R2:%O MB-.& =V"$7_Y9 ?6=UV6G=-L>$ZSVW.:C2<9M,SF1WEL=?DL7?* M/?
XE*J$I3DD!Z.(G84S[D:XL F4AZYYM?-D)PT[HBS=I>YB7&J%M6[X;1-&Q MZZH?@="T<:8>#8?AA8Q*Q1NAWW,@-@F/A1"-THC!P
M@[>!3W7A1$[D1OYKX-7^F ?'; %TI6HTAE*RP;SZ_#2C31EXK:J?-^,#NSNV M->,343965=ZK?55SBB_P*L,,Y; 44UE7'5%.T*J.JSJ7A/!]1T[0%-/Q/U!+
P04 " #[B6Q9/ZBP99H" #4"0 &0 M 'AL+W=O>U@\]BQ\63S $4 M>BDHDTLG5ZJ\=%V9Y%!@><%+8'IFRT6!E>Z*S)6E)Q:J*"N[WDSM\"$.='"
MCMV):,$K10F#.X%D5118O*Z!\MW2F3C[@7N2Y=!&)I,-YT^F_5O-G>=RP9+N.+T-TE5OG0^.2B%+:ZHNN>[[]#D M,S5Z":?
2_J)=O3;X[*"DDHH7#:PC* BKG_BE\>$ T#K=@-\ _EL@[&"!@C^ M%P@;(+3.U*E8'V*L<+00?(>$6:W53,.::6F=/F%FVQ^4T+-
$$96@E!&89Z(U5H!>B6,Y5+])6ED![SKHZL#<_? MA[?V!P4?H+Q @7>&?,\/.^*Y&L9O*C:(Q\/X+18:GW3A1]D$K=F!U0MZ]+I, M/D.;5W3-
4O),T@K3+L]KT;!;U'P7+F6)$U@Z^H\O03R#$WW\,)EY7[H,>T^Q M^)W$CLP,6S/#(?7HOJ*)MYF>CXY-!2M4EZJMX>O-G)8<(NIA"[+QF'QR=B1
M#=/6ANF@S@_.SD=8,2S::\4X+#X9.[)BUEHQ&W4B'D'H+R?N<6)8L]>)<5A\ M,G;DQ+QU8C[Z4 R[,:S;Z\8X+#X9]UP#^Z[
D1FZP:)$EXQ5=\M[6A;FJSL MC?QF?*U+EKK"^"=3USOZTY\1)A&%K9;T+N;Z"(NZAJ@[BI?V5MUPI>]HV\QU MV07"+-#S6\[5OF->T!9RT5]02P,$% @
^XEL64&B*">=#P !2\ !D M !X;"]W;W)K&ULM5II<]LX$OTK*$]VRJZE95*W MYY?/L\+&.E7O[%27!2/?B@UQM+#RXN MGV_E6MTJ^_OV?
8YO%S652",4?6NU,Z[,@4999 M]HF^W$0O3GSB2,4JM$1"XL^=>JGBF"B!C\\ET9/Z3-K8_EQ1?\/"0YBE-.IE M%O^I([MY<3(_$9%:R2*V'[+=?
U4IT(3HA5EL^'^Q-??;RUEE#9"MQJ]>I7NE0IE9SYQ<61Q.! MB[\YMH=,WS@F(7X+4OMQHC7::2B[OX+L%SS/:SXOAX>)7BKM@,Q\CTQ](?C
M(_1&M1Y&3&_TPWKH$)[1'O?3IL!Z:K8R5"].$#E&Y7?JY/+77X*I_^P(Y^.: M_$QZI=O]>="1]KNA4PC\9^,>'V9I:'*TSY6OYN8N#*L';6U*EFJO-:^)^Q&
M856RE>E>;&0DBA1BVER'5D4BE&;#U/B# OT[&:O4,C6YW>;9%XWH4O%>/)D- MAG#R..9XQ19)81L621%+(H5H@PELS\9@-AF,JZT#@8!EIE*
()Q+G>8H\KX=] M/@@?1ETY=!H6>8X=*: QSHQ1?0P/%X-%A^,GP6(PJIYXP"VS50P\\=[C!86I M=*)3 7#-):%3+^WQP#^@/1M,^FD/Q,
<6[U$&9M/,PAAW"NM($K*D:7EVKNY4 M6B@FO)%N^1ZBRG"C\5,DP,M*6[G4,=RA2U]]H8.-L)D(,XH.T,%G5IF3#?B_ M N ;LV*M4G 1.[^* *4:+BI)?
7QF2@;&;[2_A)-X+I7UE&ITAZ-&B5"GV\?<-I8I:Q5Z_&I6 M6=^1@DDB<(ID!Z]8(7MGN?'(^G$1T?)'E&&*$ HUJX),%F9)HG*21_^MF)?2 M3J;TD?
Q.8[5'"[>*X=ZJ<)-F<;:&79W3(#]\0H"T',RXD?;^[)P"3X$M.F49 MXQAVJSQ_IRWB FMS/D6FF@XDLX3 1*CVX#?ZJ6'">9)*-
^0G]!.M2.%;F%N\:T/L^*]8;W&8 W@U5- MD3$=2@=3D8*O&L(;_*9P[LVJ"ZH&N4$N8]6-GV)%N*XXE"NLJ@,(9)FB:A]9 MLX;X3.1>+
GF6(TL!Y9;J6/6S(/H 1 A!$."^P\E/GC 2Q@F-9\:!;0*-A M9D"1@#N/H"#GR)S0^2B"OL&1E#ZI4_KD:!9^6:5,_O"Z29E]"?T[275 EZ30 MD
B*@#=L4,DB:&*N!2 M%&0= K /2Q)?KS7K2%JR]=X!0*[J; NKQ0@_4A%L M>9!ODL& M94+E'R][XKLD//'&$]\+@OFQ#$P9E84&CF5&.XD;:75JK+:%
P:"78_ V:+= M 224_HP-Z@M!&!W^1D6;_8/V[FAPI+=&FQRZ9=%4(I]Y3!AIUZL_G86_BC MLLH:>\/QR)O/_ ,+'XGL:1W9T^/AB ><4&Z+[18:O,K!S=HY?
E]P?S\U<2T+ M]/#BW^)MEBS%3:YBDNXMB0T;5Z[2657[#*V\RB%W*/[0W("SPA$BN>2BGF.J
M;1#$.1)U07F:H9K2D&,*JY)F/=>XVUP3[D=YL3X'(FM&UF0)/V$WKG.SPU?. M:]BKD9$J@=%<2(0V%<8,RJ@T"B,"_U^D+!6Y H1 M.Z?Q@W$5/R_*U;9
VI/4;RSWXO5>I=F=EB[\[YW4M3;R-"(UIHBE&B[LUNAU MN16S')2M9:W/'FK@A)(PJZ9=%=UU^;CO=-IADRP'(; ;4R^#LC)I[12EP[5H
MFGZ^M]3*4X$]O"C7-U^)Y< M2X(Z)HB"%9PWE?8Q;I_QH:?+,U(9<+2L+.TW$2%7=:6DVS4 ED(ZJHP.MSF! M=O!J9+>F?W8P.&
[Z6$I.7X_3W:QXB]SZ/;%"3#,1<8ARW,HT99I.W6R2&O\C M"#VK$7IV%%-O4NKT4"[T3WJ^>K-H?Z;.B2N<2+@6"SD6:J?
LP^@%BSTKFQYSKURD_4(B;*;K+(N;TCO>(*CCC9 METTU@CN+HU93%.]=+.D<"5[F5+K3*M=KE6@/MZ_H40MP4$9P%]&I#5"_TTR6
MC&4@['D"*VOK($'X)-B!7S9_K&&IF-74U&GBN70>'+X1E8."QQ.&)W493 MY4*9Z Z- *MTY;JF4F:6@G%]!43*=N8I>YX_>O;#?
[NATHF0:@G'3^O+2+RA M@<0&\]VS+#+U;T_$>#CS %NM)Z ZG8_$![EKP55-S)N,?<\?+>HGLP6JU8GX MF%F.EDJ]#;VAMYCBC,FT]2SP%]YL,:^?'-
:,5>D7U1AUZ+S53*"E\OIPYSP[MU.'J/,IVJ0N$^^O(+7MI5V.D3NW^Z(1/[, YD"[H(IW?S-GZ:OJO8'/U/?/&
MBIOYMW,CS@7S\TWG#RKKM5T]F@TEN(A=Z.OM;105A<'5HH+^L^LM-6%PD<] MB]#PX* NZ.5@)H_*$&BD*^M6AY7UF-70J(**<.LF"B[,&9 Y
1/N/NA?D2M MF(4C.6Y>Y[CYT33U#H*_19,GWD.TVPW!)$ZFM S5W=HL_-27^GZ4)JI9@]JN MFJ=3NH 7E M#M]#P0B _X7UA7>D:Z3O-
([]ZZW+O=,YW;I14[] =KQ$'!;L\ MNY?,77O?H8P429-5IE8JE0BYS.6Y+L*-#&GH](HE%M) MC M!T?.SD(:?NM5:\C&J;2L]XS-
BSI<>53;%9\]37TA_^)42@D13I:[(&2W;58[M9W?9D17%45*7\B6VPTKU"'C)!N8Y6REIQ]@5<1+ZYV7;;_U;W0U]Y-31OI:\ MM^0=P6KOBOY4?
_PI(Q4#?_/I'5G8:@[;MOD&A2&- M 9M"X'3FS>?X-QF==9^.1G-O-NH^'2Z\^73D30\6!PMON!AYB\GB[!\7L_K[M"NTN-\FPY>D]H/A,,P$.G[.?
K_F7+3\WY8U)_>-TX8V"J3>9!O6C$0HTGQ5Z MC]1D"LW-L7IQ[R>H/U,O7$PING^4_$>,%*PD^ZX';2FLR48-EL7OY =3GH% M:*^KC_(GWFB\<.?\CC-
B%"344)8@V;KM+86N?7X<>+-I4^H&_M0+1N-[)P2S MN3?R9_>>3W%P$'2,26C["- X6&UI?#(!^9; J) #:'VZN\B-#Z>3;WY;-JG M\0F\VY_=Y_^?
^GO]]8C:#CB40L'9P8/YP8.#&,4#OWG01?Y6LI&<0,J^L)E' MR#BD._HR#]P+MXKY![+R4H6R,*H<\G';R?.?'>>\9J1%,7ONTN+=3\@@C\'T MGU4<#>?
>8CSS9N,Q'-BCZ)E,QN)_6S>_G*/)IX_'HH)&K4Y>K,IC30HK6J" MV#2S[8B (Q*I6<^3#ZTX8L44*AQ39S5SOE.=QFM2?9D8YXZHBZ#?I=T9LP MKM1?
I_IO5S2E67K>>M+')Y7UC??6=Y--1\77I=J$B&4:F!^Y$',SDZVE'J+< M 7&.F#/PFY>__*/6^*!"G /NG%)JO6ZTRV5R3*/>FW\$\B*&YJAW[GX:RYX
MWES=7E;#5N.L2I:U*U3<3J,KWRCOXJ+7'E.]GM%\$J2C7[Y; [9:9 MNSZ5:5J4+Q5H>E])]5U!07#NM 1]Q6 Q2S!3K6J1J&4^U8X%IOI_0VZ#ECK
M-.4)_(KZU'K8%$S<.+9SB&MS3#7/^R9*Z.IY^([%-'".LJT;N=%8TEJ*KUM- M3(.R09+:L?5D%$$[3GK&J5IC!S%7O;#DWOYQER'5$3Q' E$B",-S0-
&F:O95 MZHK MHJ2Y@*?7,3@F*D.5E_U0"XFAZ': 7"[)$!<6N=!L)=V [4M_+Z\E+,YJ3>'K M2-
$'K+66M[77A)@;CT35Q0Z_'$(X"VO&VM%V[ES1H=V2WU%H[@ @:4NNV&35 M'!L&5?1:2%JVRRUM$'..69<:JH"KK[%
[.>]3:LMJKE;Z_MA]/.*^QE_Y#@I+ M0EL'DBDQV!/H N_%GK9-E#4Q5I$X#+'6>QM]&>FB]68R.MTUOW]-TQVD _>2 M38HOO0;!"GVV=:HBTBDJB2E-
W_0XE6Y9CU9M%DP>;Y&CNB\/)1JHG MG7%NT,\B+_5TE!E378['.LEXP?2%K'@)7Y92%K[FN=Q,1V2T SR(568L8#R;5&S%Y]Q\ MJ^X5G,8=EU04O-
1"EDCQY71T12ZOJ<5O$/X1?*-[>V0M64CY9]_I=.18Q7B M.4^,Y6$:CQ8\MSU(FTA/W]COOGQG:P9<$TOY'Y=Y&:;#J*1BCE
M2U;GYD%NOO"M/8'EE\A<-_]HT^*&(#&IM9'%EAC.A2C;E?W<^J%'$#F_('"W M!&ZC=RNHT?*6&3:;*+E!RF(#-[MI3&VH03E1VJ#,C8*O NC,;-X&
\DEFHM5 M*98B8:5!5TDBZ]*(V2+G.OSR=B 8$L^3K9"KELA[B^$Q.BK M+$VFT9]ERM-#^C$HW&GM[K2^=D\RG//J GD.1J[C^B?
X>9T7O(?}]M>&#*^ MY>T/\[95=:DKEO#I",I&<[7FH]G'#X0ZGTYH(G>;^Z>XS^90I6F=\ M-%(]#REYKF'Y'K>)_0[ZX0&,.+!5=-
=&YYLCT0W*'8D/4/'OHL2@$9G**5 ME*GNOOV!?#?$+@E[$.!*(P\]L T4@>%*L'Q/X.+ =[#CQ1TDC##$A 7J4AN5[
M]_3XN3BF("./@/1AQ8AS&T8G@!%UP@E<')Y%%51O6M"(X0B<1"6)EBE*1UP:, M+Z$#YU)K5('# +L 1)TQQ8>B>5KN6T7S_Z[0)Y').'K,%.
<'-7^$<@%^^N]UWN] Q8Y180)BA42(CNS .F3QE,D^YZJ?W M68BC"'Z!=WX(];P(A]XAU(UQ1#U,7R"3&+NQA^,@/G]W,W?K+2\E7$76M^AL
MT]Q[$#^V!G>O./I10^L4!GKE^=M[_J97%QH)K>M>YM 8>X3B@)(.Y$$#$1W *@@DY"";,>/_5F!HE^AX/ F#?,Q@Z, &OT_A8(GC<#RF.0CKD
M\0"RVPF/]7^O]?KU';A?<,X%(>>A5E'4)JDL!XCT:03>F M*(+Z=78C0P5Z3&($^01#;GC$4W7%O.H<P0=XP>$E-)<)BBS1=Q.J.3[M9XN7D&P-
4[P6%HAC3U-.Q4D/O:7D2X(97H=DK> 1VT7K_?Z2Q1/@/"Z**7"Y MB,LY'2KW[>$BGJ6SJ:/B,B_(-^W0F_^N>%%XE6I&5<5I>'N^5\WA!QWB>JO/D
MZ.UNP.Q"A_+YT2G7/^/C[M@$;_JW_^5ZWT$_[,3RA()6Q1-+^9%1$S?E?J% MTVWH!!OML*^$:8V-'(R_@.=;K=UAX16,?PW6_P!02P,$% @ ^XEL62-*
ML>B* P -@P !D !X;"]W;W)K&ULU5=?;]LV M$/\JA!H$"9Y/W]W?%..D_V4GW66\X-^%(60D^#K3'5=1CJ;,M+IJ]DQ87EK*4JF;%'
MM0EUI3A;>:6R"".$:%BR7 2SB:<]J-E$[DR1"_Z@@-Z5)5//=[R0^VF @Q?" MQWRS-8X0SB85V_!';OZL'I0]A:V555YRH7,I@.+K:7"+K^]B)^\%_LKY7G?V
MP$6RE/*S._R^F@;(>(%SXRSP.SRQ.>*)PA"^.?QF;0NG2*W?V+]7<^=AO+ MDFD^E\7?^]$DSA[F2RT_P7[6C:A FT++A?N4AZ-
MLMSAQ"ST^97WV:/MTM;,H MY1H(#[3JA)%UPCC@#H5QVM'YFS1"Y ;*JNM$]M<__#H7Z^+ QI"248?
@=CBZ^3Z1XY3;)RYV'+SU&6U+]35:"BEUSZC' MN4AH!$<87P[H8$3@.*$]3@)30B A9,":4\%QWUH"232&,1Y_0SQ_U4M'T7M? MP_Y&$8SIJ.^.P(@BF-
(^^->I_*_T3]*PPGY"#NJR*/KO]CZ[T4;W_ZYCW=-+8CR0@F")WNVIY,#%,4 M0TP/"B".4TBZ%>KD2&(OW.I^?RO@H'[=7V!*8$H&6AD#%TE49P,-
"5"R#U] M:V2@:92"?:4SA MF-"N;FI?4B,8$3ST]0\[LUS)U<9K!KX+TT]UK74=BB^K6?!;^+U1/V!J8U] MW8."KZTJNAHE 5#UE%H?C*S\9+B4QLZ9?
KNU@SU73L#RU])>;7-P#MJ_"K.O M4$L#!!0 (/N);%ETELDFVP, !T+ 9 >&PO=V]R:W-H965TGN/=PYMLI/JL2P!#G@2O]-0KC:DO@D#G M)0BJ!
[*&"O^LI!+4X%*M UTKH(53$CR(PS +!&65-YLXV5S-)K(QG%4P5T0W M0E#U? U<;J9>Y&T%"[8NC14$LTE-UW /YH]ZKG 5]%8*)J#23%9$P6KJ7447
MUT.[WVWXD\%&[WT3BV0IY6>[^%A,O= &!!QR8RU0?#W"#7!N#6$8?W:2 %6VX6F=U((9C!++!M-:%60&UD95JVARAEHQT<-WD,]

($GHDSB,TR/VDAYX MXNPEWP+\$-[67'K8G.V="UW3'*8>-H<&]0C>[,.[* LOCP2;]L&FQZS/[MN6 M(7)%-!D*UA@X)9W3).#.OX#CNZ<.
[41PFE^2MWM@Z MQ)1 ?D,_+TJ"X($:$$M0[E1?T[>G;1])+[FANB0U905!2B)4R,8>(:MRWEBS MK'+^!%#=*+#G:[/&
<0G[F;GX:@2_UZ"H+0V26\\KI#%-,.7.E>Q_.GIQIGO- M]R09QOXHR?8D:13Y<9:]67X7!XI +@VR<1L@/.4EQ;)VR6JS()>_7^
;IG.;1V3!37P_0BB9!@CH>PW\E'E<5 MEG*L^UO(.\])?'+7A=[6T'P+P#'.KIBC4>*'X]B*A[TX.Q_Z:1A:X:Z5AUGH MC\>9%>[J)XY2/XM&Y$$:RK],6IN-
/G7]>?E9DOI1F&%H&IGJHZ@;X]K9 -XM MYE]83Z(Q!AD/3\GNFE_>QWU8X\ MN^WMX'A'U9HAEW%8H6HX.,<"4NTPUBZ,K-T
M)0&QRGW6>+\"LINP\K*5I.SDWW<7)$%0HFDYO=SU@RU@L=A= /OL+L"SAZ*\]J92 MUN1+EN;5^6Q=UYN7\WFU6,LLJJQB(W,8619E%M70+5?
S:E/**%:3LG3.;=N; M9U&2SR[.%.VJO#@KMG6:Y/*J)-4VRZ+RZRN9%@_G,S;K"-?):ETC87YQMHE6 M\D;6OV^N2NC-M90XR61>)45.2KD\GUVREZ^8FJ
X/B7RH3+:!)=R6Q1WV'D7 MG\]LM$BFSXHQ4ZTSIQHMGNI+]5BX?%W$:5?%VDGY.X
M7I_/@AF)Y3+:IO5U\?!OV2Y(H+Q%D5;J/WEH>'UO1A;;]BZR=C)8D"5Y\QM] M:3?"F!#8CTS@[02N[&X4*2M_CNKHXJPL'DB)W" -
&VJI:C88E^1X*C=U";,) MS*LO;NIB<;SF[^/$'YMD_3=CH:AO=*>D7-P"]>)M*4BP[MM&"S6"YEF>2K:LS>:8D__A!PV_F)_%U^+^,X05!&*?
E8U/!_E^%UD66 675: MFG@5)?'INUSWS;:$&O-[3?K" Z&?&;%-J_)ZVB3H)K6OW_9IE_)AW8[B4^% M+Z@O?#WYB/@B,'HNY6% /=?9H874M1FYW*X
I[T\QFD@;&K;MF9GE -"]USJ MNB$-.#:#9&8H+/(#>S>:J3XU/-[/AY26^PN MC=/0]HP^F.NX@G*?[Q(#ROQ@PI^%]F=QL#\G5;6-\H4D<50#H219$2?
+9!&I M&*V(RR@IR7V4;AL *!=XB,HRRNM1UY]6_KU=&7(#J=>2?%R74@ZBWQ[+>S!M MG$-[K3Y]#'G35 R(^,\Q6F\'6[=H0-3L8+>
[0%_A5I(CV_(,)V=6Z(_2NMYU M4MV1)2XRR6L)X*I)B0)=RPE?D%,B+,Y?]!YMN8'9>YKGS9<-9&K8%!">D>.O M,BJK$V);OIHGB"(8<^U1^G/YM=;
[(@4?3#$\!![:RIAA7,",]O2PEA@G]TDL M\[@B^3S2PP>T)R#G:^/KLZJK1K#R)./EO2RAL'PZ&>WP74NL9C'R[G*^WRH4PI[VARW+15+UDW]-
MEGWG:[/#C]W$OOFNH9!2RT-#>858S?-H?VJK9,TH*8UF(&VEHD5\6Z3:6Q!/4 M$PZ!:O!TN56QO4M94-#7:YC739-
$[3EZ$81;2.O,4MM^VI^&GEI*55X":A5DUIM)L@@#L:F :L&]@Q6Y-Q"1? MQR3_X)BD;33V=BSV3$O\"/NP+%*X6>+1U.I
V@VKS*BF(QVL46N.U!;L>\G+ M;P]5G6@3!^A4,*#HIGLB_9MCW>ZOJ?"QL&8JWPM;^Y&MCX*#D-8S-C%-KUD' M-
TT!%Q)8M4+]&C;H0#;L;9]Y%J^!^)#$!VXQ+.\KJD#81^1, AT\6$G&#PC!EQ! M#'C;Q(#/SXX!X-*5[)WT5@)&Y4 ;N/-O$:":0)9 AQ66VK #IP[3C9C"=:!Q
M'4SCNK^B8E4("T,7;H+*_D_ E./9]Q$EQ[C4)]6\G\O+QZK)@ZH"7#0 M+5Q4,R_RTWO8*="ZG_T]:K,^\36)V8ERG?L<+P'?[VQM@1Y!/C:CC=JZ9XF$J
M7#Z6,JDGLO:N32.),2N,NH[PUK&N9/>%^HO2\\U/LP M+1:;_K'O$4>;EO>]Z]F_7M\>6M<^YL%]9+]Z7M)W7Y-/(1W?-Q01WP5,?W]RQT+*>O 3N?
YY0% 65.[WW,8GW9 M^W15VO4U$N9P14O03X]]?,+Q1S*Q8W'OR0T=K'+$YSL^3R5 VS4?6+@E>I3[MECGDNM06SK./]QMJY%&K03OG- S-!S
'DB\4Z":IW=T)!#.[?X.V#W\@&B_; MVD>,QNE&WZ6G57Q+J3C0^1WJQ3U_:C69U5Q',ZNW_WHNTUCOX;]3_NV6?9U9 M_96V)6 YPZ 8@=\P!,@[3
RPNU?7,2A_D)\A/Z>K9 JO$AM-5 M5OCAX+G5!T[NN=3E4$^*EE,H3H"V\6#&%:,B'7DMGX=\7HAKX,:JN*8=^[T>Q?*TYO]UBOY;/?&./Y,:QRW
ZSQ\W'D_O]S3+N!*AH^7 M>.F8'GSLN;=W2]?'=U#"'NS^\7-,9\<)-S'C\=<8=9M1?% =>X[M. -_6@_: M<3K@TB,<1T+Q8NQQMF/"54\K&'(,J&.(FAM?
93-9KM2WYXHL\(M4\X%64_7W M[&^+NBXRU5S+*)8E M,L#XLBCJKH,*]%?_BS\!4$L#!!0 (/N);%D'*XJ/9 8 @Q 9 M>&PO=V]R:W-H965TO-
SY%JS6K;DQG MUQNRHH^4?=X\Y/S3M*,LHH2F192E**?+F\DMO@JP41G4)?Z.Z+;8NT9559ZR
M[&OUP5_<3*0J(AK3D%4(PG\]TWL:QQ6)Q_&MA4XZGY7A_O4KW:DKSROS1 IZ MG\5?
H@5;WTS,"5K0)2EC]BG;>K2MD%;QPBPNZO_1MBTK35!8%BQ+6F,>01*E MS6_RO7T0>P:<(S:06P.Y;Z">,%!: V6L@=H:J&,-M-9 &VN@MP;Z6 .C-3#&
M/B6S-3#'>K!: VNL 99>6TZJ%=0T>:V7.6%D=IUG6Y17Y3FONJA%5]MSF41I ME1^/+.??1MR.S1Z;O$#9$CU&J$1:1B%)&;H-
PZQ,692NT$,61V%$"W2!;A>+ MJ%(UB9&?-KE9:?S=G#(2Q<5[7N3SXQR]^_7]]93QX"H7T[-Y*X)1#X1B((^ M9BE;%\A.%W0AL/>&[:T!^RE_*-V3D5^?
S)T\"'RDFTND2!^0+,FJ()[[8?.@ M3 ?-Y\/F'TG.S?%)HZK)W_/,P*:)9>MZ^KRO]4&7YVH=$F9#PAQ(F L)\T8VE _I-#AVBE53 MM23-Z+P>2%3K)*H-
2I3WUF52QH31137[YMTU$XFS@6C[[@U-T309RSUY#KH[M5YZ0,!L2YD#"7$B8-[JI?$BW@<"MJJD6UC1+K%"]4Z@^J-_^5K:3\,LH>C=_M'UE1"*?
@^I'W"\,T#5-3>O+4C_+H F-)4W2KE[YS44G)DF4LX<.2MJ"DH2@F M_SDLZ @*ZC+63%TZ+.@*"FJ&8BFZ?EC0$]1;MDQ=T?L5]T75L61+L;1>Q8/!
MYOC!$=/H&MMX>\0L"]X912G*-C2O%V+"\7(0=.X$&A(VAX39D# '$N9"PCQ# M(&15PI)D]GLM04G>P6%547LE Z #X1L=D(V!X7\5TY)4?
+5T5,4QT+]FD?U MZ/4"]X,>SA4E),R&A#F0,!<2YKW91#ZDN^#8G:9J$L:F> "U.BE:;_:I'U"9 M1BD7).]925*MST62M(X"T(UJDMD?1 ?]G2M,2)@-
"7,@82XDS!O94#ZDT^#8 M*59EE<]S)+$^L;1[52L-*G1.ES2OI!GR;Z*0Q*@H-YOX!859(5XLM\#]8%3) M-
)7^:F38\;E2!:79H#0'E.:"TKR1K>6#>@U$7F5--RSEA%[WMA;PH%Z_Y!&C M%XMLFU8O/Z/TF:8LRZNM!):AE*]7^. ?1_^2IYBB9Q*75"AA?)Q/4O6O+^'!
M6,Z6,"3-;FGZZ1'2 77H@M(\0?B&;LG8Z.ORN!SF"T&S-]^$"NO?).E?*@ M*OU6AR]H6^D3O>J3+/XI"Y:<>N\X3#UW(05*F[>T_06*M8H-
Q^.\>S^%73[")3F@M(\ M4)H/2@N@:(>ZWFTBX3=VD5XGQ8_-I/@VSTFZHJ<[=,B-AWM0VAR49H/2'%": M"TKS0&D^*"V HAVFQVX#"VO_XS$$#+D)
<@]*FX/2;%": TIS06D>*,T'I050 MM,-DV>VEX>'-M&XL87E$XN(#VM \Y ,)6=%FJ="=@^,Y]?6BW* LK=_"'",'
M:*>HS1U(VAR49H/2'%":"TKS6IJUOZ*_Q/WU,*3+ (IVF!*['4<\O.7X R\? MC:.U@"I<,X#N*H+2;%": TIS06G>R-;R0;T&(J_*H=M&K].](\X)S5?UD?H"
MU9.7YBQF=[<[MG];'U;OW;_#5RX6W/?PE=\56 ?[_,O;ZH7+0_?'#[#]02P,$ M% @ ^XEL6:72?-%N @ 708 !D
!X;"]W;W)K&ULK55=,YLP%/TK%INF5MK"=V@Z@M0FJM:'25&S;L\3A(A58S/;">V_ MGVT(2A,.3=I>@]]S_$YE]Q+VG+Q+#<
"KW4E,FYLU&JN79=F6^@QG+"&V#Z MI.2BQDJ'HG)E(P 7%E13-_"\J5MCPIPLM7LKD:5\JRAAL!)(;NL:B]=;H+R= M.
[ZSWW@@U4:9#3=+&US!&M1CLQ(Z<@>6@M3).$,"2CGSHU_O8A-ODWX2:"5 M!VMDG#QQ_FR"^V+N>$804,B58<#ZL8,%4&J(M(S?/: 00](/A;0-
@#0FNT4V9M+;'"62IXBX3)UFQF86MCT=H-8>8M MKI70IT3C5+;NWA[B)5J3BI&2Y)@I=)/G?,L4815:<4IR A)]0?=L!TQQ8:*+
M)2A,J+S4^X_K);KX>)FZ2BLRO&[>WW[;W1Z\=SLT$Q1ZGU'@!=$(?'$>OH1< MPWT+#]_"75V'H1C!4(S \H7_7(PQJQUW-,YMNO%:-CB'N:/;38+8@9-
]^N!/MO:]CQO\3V9LRA$,9PG/LV1UA1/^C"E1Q7HQ:[?!3BS=S8I=%01+X2>KN#DV< MIH7>]"H!//(;.[D.[F62[?28@VYH" MDV*VNJKNW;'5%3WP
MC!3XCH'RD.6.^NMK'6_R_^>?]'1.?YBU*2G)< ME(06@.'-]>P&+B/D2H?*XE^"C^7)-9!++>:3TJ_SP5WH]L^2,<(83+B%B\><) MKW&6220QCV\-
Z*P=4SJ>7C^C?Z@6+Q;S&)=X3;,O).6[ZYD_ RG>Q(>,W]/C MG[A94#7!A&9E]1L<&UMK!I)#R6G>.(L9Y*2H_\;?&R).' 2.V@$U#FCHX$PX MV(V#_=
(1G,;!>>D(;N-0+7U>K[TB+HQYO+IB] B8M!9H\J)BO_(6?)%")LH# M9^);(OSXZJ%.$$ WX(%L"[(A25QP<),D]%!P4FS!'7P+9^!\A"CF(^ MZY>
[VZKE_+_1HU>/WB/#;E/&KO#L";Q/AQRSF%.V5$6V]G74OK+L+++;Z[1?H67^H:#4)%IH$BPR!]0+@M %P=.BK=AO&G#/R>.#Q8X8!
MI[V=N*-9BEFI"E&-[E7H\D'RM'J_\V%[XKL>#JE7V5HV{[XZ1N&"D,4^)[M M#2$CA24,4& ';M!:]DAQ6U)<;5:&N*"B/LJ\!!?'ZOF 4Q _B53=8O#M(*H:
MX:*,O5-FK6LR:TV"A2;!(D-@O0!Y;8 \;=:NF^24CXT2D+(*$O[;8WBGF2(M%]C0V 6 M*LP6OFTM!KDT-
A/%$$(U#4%+0Z"EX;3("9$@6V22@&+IL9Z;.A8T Z\8+#<<&SH>L["\Q?>@)>QH2UVHN!O8H]!J^MDK;/(24EV MD(EQ/CW-
0"_@1V$Y09#"5/*#I!J&6HMMQOB0G9;GB):59%K,3MM04 MU0/YIP]RZQ(.:_2$V;!"J\U&S<.$V00KJ&,%Z1-'E2BOY06]C!>UV8@7I=F8 M%
[79!"]=GP^U7>SJ\KC#.PIQZ)WBK/L1[VE1 76%%L]YKE/,*-H88/6WUFV M'3APV DH+*'ONH'H!B98[9IWJ_>OVB>_GK7L\DSB18:18M,H?6#T(D%^)9J
M 1J5"T;10J-HD2FT?I@ZR0#UFN%U%4B+>79T3**%<"PQD!\XBX7C#"O0V!): MHGUWW:DNH%,C4"]'_M[+=[1J[HSJ#Z-
HH5&TR!1:/P:=GH'^6Q8@K5HZ.TPF MT4*C:)$IM'Z8.KT%]8+K=05(BWEV=$RBA5 A_82VL1PTK#*18>@[_F>NOR@ M3J?D5;WO;(:&57-
1M'"!JWW9LCS?7_X;E9AYWO(&KYJFY\WFU/V]Q49TP&]V_A<@T5]T.XC.JS-!U\?;3G8\RVI"A!AC=B M*.MR(>;*ZM,R]0=.]]5QD$?*.&PO=V]R:W-
H965T.]I*6PN"%XAJ9?#:3:ZMM20.MONP M;X_M9"%MTJX"WK1QFG%B2%L]UGJ ,*M+^$9<+\HEUE&[H62C9" MLKP6*X*<%M4_V=>): FP?
T+@U@+W4H%7"SP3:$5FPIH22<9#SG:(:VOE33^8 MW!BUBH86>AGGDJNO5.GD>,:A)#1%'_=J8P@0B!0I^B;7P-%DPSD4$MT* 5*@
MJRE(0C/Q%KU'#_,INGK]=FA+A: =V4D]W5TUG7MBNCF4U\ASWB'7^>2\ M? J)DF,C]P[EM@J\B=YMHG>-/^]?H^^+M'+M]
[O6Q^]&E"2!D:7.EP"^!6O\ MYA4.G0)].>\-UF@A=AP4B2 H,Y'7]B5K]#XTD5B._:"T,5J M-;?M@+IF.
(P\+V[,#E#]!M4_CTJ>.,LR),E>%9$$Z)8L,NC#K/P$K?G=.(Z< MX BS:Q:H AC[_9A!@QEJ<
MOK!GH^XJ^S%VCDB[5MCU@B#L1XT;U/@B5'UN"4_69C.DL%4=M,Q?2G'F9T'>/:]9Y]W]9A7&K%>.S^-^95+6BK-,.[9[3]*ZIY$
M3O:D>H9VV1W$411T(NW:82\,(@\?K8'=NEKH>]U7PE>]2F,,EDKI?$XNYG&MKI? M8'ZOF1,/@_T!:,YL(Y_ U!+ P04 " #[MB6Q9J@^ 7UX' !L-P &0
'AL+W=OBCXP,F,+U:T2G,JJ ML[S@&5@>\C)E B[+9;\J2LX6M5..]$W#&/53%F>]V7E==EO.SO.U2.*,WY:D M6J)(_7?
1H[[7@4[Q<"5G0GYT7;,GON/A2OW>?Y-7@2+BYXA6\03'@F)8/#RR*]YDD@2 MM.-[^VU,:7C[OM7NE??/-S,/:OX=9[\%2_$ZJ(WZ9$%?
V#K1'S*GWS>W-!0 M\J(\J>K_Y*FI:_1(M*Y$GC;.T((TSC:O[+GY('8L#3[ZI15?[@TSB3'X_[D0)UAC\Q"S(!,N6\7W"
MR655<5&1=PX7+$ZJ]^0#^7SGD'>_OC_O"P@E'?I1@_4V6/, =D!N\DRL*N)F M"[Y0^(=Z_ZG&OP^WV-ZG^7J?5Z86>%F49\2<_DY,P[04[;D^QGUTT-
W1N]\P M<*?607?W!]'72W ?UNX#56?HW<-U=D8&QL'H<[W[%_I5X>3KG>YXT<94-3GX M04Q3%3,\J:ET6_V
MVR]T9/RABFS,&$N9@P#Q/F8\)")%A';E8K-TM'GP55M699Q$G^0*(\36'U M !-_](VP"JYA1;+@):L7%; L(DD7CS-
K,)H8T_/^XZ[PIJM1H_[KU@N1VM;1U+#5U%"KJ>L5C&"< MQ* 9%I?DD27K6E_\^SH6+V]D5; 7!H.=2D;;**?*"!/F8,)<3)B'"?,Q8>%P M3[D?
J&D9DQWI=M0V:M4VTJKM,HK*-4OJ\2G>3IY,3IZP?$TXC&<9Z.\^B9>U MY%12TX8X56J8, <3YF+"/$R8CPD+-[#ACM3,-X-D1VGC5FECK=(^UK,?)_\0
MN4O-*T9N5PRVRQ%?BSAB246'+%*I2XLJ55V8, <3YF+"/$R8CPD+6_="4Y:
M"4[^_^Y@@BDW3)B#"7,Q81XFS,>$A4BPCMRFK=RFVA'OEI:V<:XPSFF6%W->YA!O4Q M82$2K*,N:FSS@(967Y^+AS+/A-P$'-
I+Z@FG2@F5YJ#2W(8VTBQ;FBPH9E@? ME19BT;J"VDDLTU,$!:_Q0FY$(U:ME.K2XDY6%SUN=^Z@AG6/#>NAAO51:2$6
MK2L<J8XNKIKXNYN2$1U8TU&WCZ[U[3QYA,*DN8I[ML";CR=YTAQK51Z6%6+2NSK;9?:K-YOZ+_ACW'Z3HE+,W7FT683.V3=5'_M)F45\\?
-5"G'/EX*!C/F LJ2O*B+VV2M,JNACWVR$E'/ U!I;D,;[@WG>^LY MU&P_*BW$HG6EN#T4H/I3@?\@Q8J!_'XD0M2# E2:@TISZ7X2?6*H58AZ$(!* M"
[%H715N#PRH_L0 ZR14'^9DV:$>(:#27%2:ATKS46EA0^ML"#6'5'1[1$"U M*>%9D,4BAB6>NR1"E U#,%5)J#2G,;VA%9 M.-0C U1:>,1-
=,6U/1"@^A.!US/0;=ZC3;7Q,L[5>PC4TP!4FO.#V[6&9,%> M5$L!%[4=']BK-1Z6%6+3N;WBWAP2F_I Y0<>^ABG:M \,E7O'%O116V?ATKS
M46DA%JVK)GE"T"W9IGY-?>KW"_U*[NK$+8FK:LT7,A=7L+*>1/=S4#>SY0E/L#.U"5>Y8]MU3U+3M0E7M#>SY4U1_:@:K<&]GSD:K^R Y4 MY=
[8GH]5]<=VH"KW)O9\HJH_L0-5N3>UYU-5_:D=J,H]:MCSS0,6;SW $B@M M'J7@H^H=G\IN4_8;-<%'U=,^6 *EQ:/0V539VV)E!:/0H=398^#)5!:/ J=
M3I6]#I9 :8'])_@H>QXL@=("&P/P4?8^6 *E!19\X*-4 %@"I06F=?!1J@ L M@=("@[<]-Y4Z $N@M%R:\GDQ56_#X/?Z)%E_.PYLGD.[8>4RSBJ2\ <8$XRS
M,>Q%RLVC79L+D1?U0SSWN1!Y6K]=<0;#E:P]#<\%Z\7,D#[@-WL7U!+ P04 M " #[B6Q9WD,PU," !%!@ &0 'AL+W=OFR=,<2LQGM(9*[FPI M*
[&0(=N9O&: ,PTJB>E85F"6N*B,)-)K*Y9$M!&DJ&#%$&_*$K/G>R"TC0W; M."X\%+M%(!1S/C^Q?M'?I98,Y M+"CY560BCXW00!EL<4/$
VV_0N]'"TPIX?J)VB[7DR>F#1>T[,$R+HNJ&_&A MOX<1P/9> 3@]P'DKP.T!KC;:*=.VEEC@)&*T14QE2S8UT7>CT=)-4:FWN!9, M[A82)Y*[-&4-
9&A!2_EA<*SO]FH) A>$7Z-/Z'&]1%?OKR-3R-,4QDQ[YON. MV7F%>0WU#+G61^18CC915;]/;-NSPU"^M?W8S42>:SGS^E?/B3_Y6T%?A"ZSIG6
MR;PPL-TSL>:HR%6#_8[9KJ@X(K"52&MV(XE8U[2Z0-!:U_V&"ME%]#27?1Z8 M2I#[6TK%,5"M9/AS)'\ 4$L#!!0 (-/N);%D&PO=V]R:W-H965T2Z+(Q??
9 V@ MT&/#6KGT:J6Z6]^7I(8&RQO>0:N_;+EHL-);L?-E)P!75JEA?A0$F=]@VGJK MA7UW+U8+OE>,MG OD-PW#19/'X#QX](+O>
<77^BN5N:%OUIT> 4M$K!=>N_#VW5H%:S$/Q2.\F2-#)4-Y]_,YL]JZ04&$3 @RIC M^G&
-3!F+&D<_PU&O=&G43Q=/UO_:,EK,ALL8"P&M0G]1O*&,*]J_OKD#A2F3;]&OZ.O#'7KS\]N%KS0. M8\TG@\\/O<_H!9\/T-V@.'B'HB!*'.KK>?
4[(%H]M.KQN;JOV8\AB,801-9> M_$-"X*+;VT_<]DTBWLH.$UAZ.M,DB -XJU]^"K/@-Q?Y'V3L+!3Q&(IXSOH8 M"MHJW.[HA@'"4NIBTE
&^BZV@/B&T1TV*>B*1&\^L^9-!3FL=#TQOX5_.'4Y M"^.5)).19'(529WL8(L((EJ$$LQT,>LZ]H0T8\5 %ROU#K6@7$1[%^DIT=3!
M,YG$(SP/QQF#=&207L7@.VZUKTQZ$BZ5\X:F$[AA%*9%<0%WUNTKCR4;2657 MD>H$WX(T;<(0TTXH<6==-N&4ET$275":2F5Q$!7N \A'K/DLUK6
BBI$L-!X M\1/6B>)"F$\O29D&EP@=4GE8QFZ$Q8BPN"J:6X%;4E,)2.%"%\9B>C/2Z3V> M=?;*BU&.5,JKJ!C+6)#:UN<*#GH$Z4R.
(A@*MXM>.:47I^DEO:E4419YY#Z" M,/C>6X-9Y+:),/MC,"%8)D%R@H.;LV*?AD509)<\'()%7DZ2T#\98\P,^0F+'6TE8K#5BL%-KB,A

*MAVH^J@6H%}):A&HQJB64U@^V;L[5#YGX.[58&N.^ 9S#?WD %0S4,ULM9;O$R5H(ZR35WPOLJ6Z;I4G.UR,-;0F0>H M9J":B6H6]MFHYJ":BVH>JOFH%J!:B&H1JL6HEE!:/_NT+OLT_NV&&3H# =4, M5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-422NOG7C=+82:? 1;#_=L.Z/09, MMRME*8HJK4]H-]E:E%6^K9]=WF;BZ^YRG6QFEKSFV;F(3FQ -1/5K%;KW6M" MU<>+:?^;HN6M5#-1_5 E0+42U""M1C5$DKK9UDW:.%^ M^"=EV='W'N0ESXXR4C-0S40UJ]5>OI,Q'G@CPT:K.JCFHJJ':CZJ!.@6HE]$ M:C&|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|K$= M);@C_LGAP$^.D7J49TJ_},_LZ5AJ3N" E*A$%A^[>$>BD*1Y'W\UT*-+J<2 MGAX? Z4G]\/)AGC&'>UK\FV=BNS1" V6PQKM"/-+#7] ^D*]X*2UX_8D.;:QE MH'3'!2U;L;R#,B?--WYI"W$BD)QQ@=,*G/<*W%;@#@7>&P*O%7COS>"W O^] M&8)6$-2U;XI55SK" J\6C!X04]&2I@Y]NVJU+'!.U,QZ$DQ>S:5.K.*R*NA7 M.'0'!-:Y0 \%)AQJB$#@O._?T>_H\U.$/OSZ<6$*F4^IS+1EWS5LYPVVC3Y1 M(K86.-R*/WB]WQZKQ8]F3[\|>JZ7;33RWYKD73;RQ2=9PO'&.ZKPWO,(I M+ W96CFP/1BKWWZQ ^N/,8=TPB*=L%@G+-$$ZSGK=W._LA?F M_M3CR=N[U&.=L%@G+-$$ZWGL=Q{|/^HQ?\MD3,@.%V@/7*B+K>=R&3/FMG_F MMG5M>0/#) ^_U4L-UPF*=L$03K&=XT!D>? *_A3R+^>"8;461_&+_'/!1W\SD\Q+:ZD3 M%NF$Q3IAB298S^6P>?L_*=VS-7?\06N-SX_"SPH'K^WD/,H/',\>;YFV]?J/UIHL^J-|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{'89BW@1<9 MH)P!RG$L'S*Q'RR/GY.8RS_3)(FB.,96=#+Q.IA@ZQ;'\.-7P[P! \L#F?YN MK?'=QBODWJH0K"9X16(S11?:T#\ZP:,)/'O-I8'&-@N8+4#^? UYH*;\ MG"B"7<6\84\PCB0)AD M^FLTCI'5B>'CWQ_1*8FB)/$C@/D=1!&&P-.((Y@# M\(A463?@WOOHW#SG@JW_Z4<_P%02P,$% @-^XEL69>*NQS $P(M L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y? YVX$G1H2)8%II%R=.B';5_'[&(ULM86&VU_U#I0_L];FXH9XFXX39K7[Z71OQK)7C4T20\GOH)QHGK5O R0]WQE MNQ;'5U^X!YDFD[&_X%H8Z[H>W? 6Y9WP$W_EPU#K]64@'YIH[^,WH=B?4)ES& MW4HNHTN#L?70Q OS(^$4;_7HH)K7;4-*'>(HP$9)7=BIU-F.(-3)-C%\95 MS6Z4\T%BTF',O5[4)7\HNK>TG\!3U"[%@ M_&B:UD^6F6Y" %^I#[-+2JR7(JL/C"WFEY18,+>^$+-LP?<\#&]@]#GH,51. MX?@VQL0,DY(KIFF$.^3#? R"=K[U 5:(GF!0S3$JLF"^AT0^YKQ]\.79ON'\D MNR*W1XCI)27VR]+IZF&K90W&_L1NOK6^;HS9,*NDQ%JY.792[P'8%2A8"\<6 MOBKK10[324KNDY6%;VTHN6\>PV,8@V$*2:D=PO?LT<]@,_W'0QU[+6PEM?4V MCBMMS" 9N4&L\,]P3'S M&!/S2D;L%;2TZ4<3\TI& [)53%00[NP\RM#_'D)A7,F*OH*5$/Y:87#)BN:"E M1\}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{Q)]323UW98I()HPC%W/9W#Y2 WY\G-Y/EMT0S/;]*VD* M05H_R"#(Z@BV?M =!- W5#[]'H/OZ03)%&:<$ M22.L";06Y%H(O!8$6PC$%B1;"_P61%L(U!9D6PC<%H1;".06I%L(I!;$6PCT M5M1;"216U%L)]- ;1QS:!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN! MWHIZ*X'>AGH;@=Z&>AN!WH9Z&X'>-MHL(=#;4&\CT-M0;R/0VU!O(]#;4&\C MT-M0;R/0VU!O(]#;46\GT-M1;R?0VU%O)]#;46\GT-M'F]T$>COJ[01Z.^KM M:'H[ZNT$>COJ[01Z.^KM:'I'U#L2Z:U1[TB@=T2]{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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)? w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p,;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 205 332 1 true 46 0 false 4 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Condensed Balance Sheets Sheet http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Condensed Statements of Operations Sheet*

http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations Condensed Statements of Operations Statements 4 false false R5.htm 995200300 - Statement - Condensed Statements of Changes in Stockholders' (Deficiency) Equity Sheet http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity Condensed Statements of Changes in Stockholders' (Deficiency) Equity Statements 5 false false R6.htm 995200305 - Statement - Condensed Statements of Changes in Stockholders' (Deficiency) Equity (Parenthetical) Sheet http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical Condensed Statements of Changes in Stockholders' (Deficiency) Equity (Parenthetical) Statements 6 false false R7.htm 995200400 - Statement - Condensed Statements of Cash Flows Sheet http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 7 false false R8.htm 995210101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation Sheet http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation Business Organization, Nature of Operations and Basis of Presentation Notes 8 false false R9.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995210301 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 995210401 - Disclosure - Intangible Assets Sheet http://www.eyenoviabio.com/role/DisclosureIntangibleAssets Intangible Assets Notes 11 false false R12.htm 995210501 - Disclosure - Accrued Compensation Sheet http://www.eyenoviabio.com/role/DisclosureAccruedCompensation Accrued Compensation Notes 12 false false R13.htm 995210601 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 995210701 - Disclosure - Notes Payable and Convertible Notes Payable Notes http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayable Notes Payable and Convertible Notes Payable Notes 14 false false R15.htm 995210801 - Disclosure - Commitments and Contingencies Sheet http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995210901 - Disclosure - Related Party Transactions Sheet http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 995211001 - Disclosure - Stockholders' Equity Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 995211101 - Disclosure - Employee Benefit Plans Sheet http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans Employee Benefit Plans Notes 18 false false R19.htm 995211201 - Disclosure - Subsequent Events Sheet http://www.eyenoviabio.com/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 99930303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 24 false false R25.htm 99930503 - Disclosure - Accrued Compensation (Tables) Sheet http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables Accrued Compensation (Tables) Tables http://www.eyenoviabio.com/role/DisclosureAccruedCompensation 25 false false R26.htm 99930603 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 26 false false R27.htm 99930703 - Disclosure - Notes Payable and Convertible Notes Payable (Tables) Notes http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableTables Notes Payable and Convertible Notes Payable (Tables) Tables http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayable 27 false false R28.htm 99930803 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies 28 false false R29.htm 99931003 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.eyenoviabio.com/role/DisclosureStockholdersEquity 29 false false R30.htm 99940201 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 30 false false R31.htm 99940202 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details) Sheet http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoriesDetails Summary of Significant Accounting Policies - Inventories (Details) Details 31 false false R32.htm 99940203 - Disclosure - Summary of Significant Accounting Policies - Net loss per share of common stock (Details) Sheet http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails Summary of Significant Accounting Policies - Net loss per share of common stock (Details) Details 32 false false R33.htm 99940301 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 33 false false R34.htm 99940401 - Disclosure - Intangible Assets (Details) Sheet http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) Details http://www.eyenoviabio.com/role/DisclosureIntangibleAssets 34 false false R35.htm 99940501 - Disclosure - Accrued Compensation (Details) Sheet http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails Accrued Compensation (Details) Details http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables 35 false false R36.htm 99940601 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 36 false false R37.htm 99940701 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of notes payable (Details) Notes http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails Notes Payable and Convertible Notes Payable - Schedule of notes payable (Details) Details 37 false false R38.htm 99940702 - Disclosure - Notes Payable and Convertible Notes Payable - Additional Information (Details) Notes http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails Notes Payable and Convertible Notes Payable - Additional Information (Details) Details 38 false false R39.htm 99940801 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 39 false false R40.htm 99940802 - Disclosure - Commitments and Contingencies - Company's right-of-use assets and liabilities (Details) Sheet http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesCompanySRightOfUseAssetsAndLiabilitiesDetails Commitments and Contingencies - Company's right-of-use assets and liabilities (Details) Details 40 false false R41.htm 99940803 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details) Sheet http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details) Details 41 false false R42.htm 99940901 - Disclosure - Related Party Transactions (Details) Sheet http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions 42 false false R43.htm 99941001 - Disclosure - Stockholders' Equity - Summary of offerings (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails Stockholders' Equity - Summary of offerings (Details) Details 43 false false R44.htm 99941002 - Disclosure - Stockholders' Equity -Issuance date or modification date fair value of stock warrants (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails Stockholders' Equity -Issuance date or modification date fair value of stock warrants (Details) Details 44 false false R45.htm 99941003 - Disclosure - Stockholders' Equity - Warrants Activity (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails Stockholders' Equity - Warrants Activity (Details) Details 45 false false R46.htm 99941004 - Disclosure - Stockholders' Equity - Related to warrants (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails Stockholders' Equity - Related to warrants (Details) Details 46 false false R47.htm 99941005 - Disclosure - Stockholders' Equity - Restricted stock units activity (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails Stockholders' Equity - Restricted stock units activity (Details) Details 47 false false R48.htm 99941006 - Disclosure - Stockholders' Equity - Summary of option activity (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails Stockholders' Equity - Summary of option activity (Details) Details 48 false false R49.htm 99941007 - Disclosure - Stockholders' Equity - Black Scholes option (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails Stockholders' Equity - Black Scholes option (Details) Details 49 false false R50.htm 99941008 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details) Sheet

http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails Stockholders' Equity - Summary of information related to stock options (Details) Details 50 false false R51.htm 99941009 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 51 false false R52.htm 99941101 - Disclosure - Employee Benefit Plans (Details) Sheet http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails Employee Benefit Plans (Details) Details http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans 52 false false R53.htm 99941201 - Disclosure - Subsequent Events (Details) Sheet http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.eyenoviabio.com/role/DisclosureSubsequentEvents 53 false false All Reports Book All Reports eyen-20240930.xsd eyen-20240930_cal.xml eyen-20240930_def.xml eyen-20240930_lab.xml eyen-20240930_pre.xml eyen-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "eyen-20240930x10q.htm": { "nsprefix": "eyen", "nsuri": "http://www.eyenoviabio.com/20240930", "dts": { "schema": { "local": ["eyen-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["eyen-20240930_cal.xml"] }, "definitionLink": { "local": ["eyen-20240930_def.xml"] }, "labelLink": { "local": ["eyen-20240930_lab.xml"] }, "presentationLink": { "local": ["eyen-20240930_pre.xml"] }, "inline": { "local": ["eyen-20240930x10q.htm"] } }, "keyStandard": 226, "keyCustom": 106, "axisStandard": 16, "axisCustom": 0, "memberStandard": 17, "memberCustom": 27, "hidden": { "total": 15, "http://fasb.org/us-gaap/2024": 8, "http://xbrl.sec.gov/dei/2024": 6, "http://www.eyenoviabio.com/20240930": 1 }, "contextCount": 205, "entityCount": 1, "segmentCount": 46, "elementCount": 577, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 649, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 12 }, "report": { "R1": { "role": "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets", "longName": "995200100 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "eyen:LicenseFeeAndExpenseReimbursementsReceivables", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "eyen:NotesPayableUnamortizedDiscountCurrent", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "eyen:NotesPayableUnamortizedDiscountCurrent", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations", "longName": "995200200 - Statement - Condensed Statements of Operations", "shortName": "Condensed Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity", "longName": "995200300 - Statement - Condensed Statements of Changes in Stockholders' (Deficiency) Equity", "shortName": "Condensed Statements of Changes in Stockholders' (Deficiency) Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59tHIwNSoUSs6Zd2kh_tdg", "name": "us-gaap:SharesOutstanding", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hBakLQ5Ddkyv3QUM_CaXKg", "name": "eyen:StockIssuedAtMarketOfferingDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical", "longName": "995200305 - Statement - Condensed Statements of Changes in Stockholders' (Deficiency) Equity (Parenthetical)", "shortName": "Condensed Statements of Changes in Stockholders' (Deficiency) Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "link:footnote", "p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_MzJlRUeb_EWkHAtFKH9nGw", "name": "eyen:ProceedsOfStockIssuedDuringPeriodGross", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "link:footnote", "p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R7": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "longName": "995200400 - Statement - Condensed Statements of Cash Flows", "shortName": "Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R8": { "role": "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation", "longName": "995210101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation", "shortName": "Business Organization, Nature of Operations and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 -

{ "Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995210301 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.eyenoviabio.com/role/DisclosureIntangibleAssets", "longName": "995210401 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedCompensation", "longName": "995210501 - Disclosure - Accrued Compensation", "shortName": "Accrued Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995210601 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayable", "longName": "995210701 - Disclosure - Notes Payable and Convertible Notes Payable", "shortName": "Notes Payable and Convertible Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:NotesPayableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:NotesPayableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210801 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions", "longName": "995210901 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquity", "longName": "995211001 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans", "longName": "995211101 - Disclosure - Employee Benefit Plans", "shortName": "Employee Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.eyenoviabio.com/role/DisclosureSubsequentEvents", "longName": "995211201 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:Rule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrAdoptedFlag", "p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:Rule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrAdoptedFlag", "p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role":

"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:LiquidityAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:LiquidityAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "99930303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables", "longName": "99930503 - Disclosure - Accrued Compensation (Tables)", "shortName": "Accrued Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:DisclosureOfAccruedCompensationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CompensationRelatedCostsGeneralTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:DisclosureOfAccruedCompensationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CompensationRelatedCostsGeneralTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930603 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableTables", "longName": "99930703 - Disclosure - Notes Payable and Convertible Notes Payable (Tables)", "shortName": "Notes Payable and Convertible Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:ScheduleOfNotesPayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["eyen:NotesPayableDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:ScheduleOfNotesPayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["eyen:NotesPayableDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930803 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables", "longName": "99931003 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_bY1luAOYEkSnwPOT8ZLVvA", "name": "us-gaap:TreasuryStockValue", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoriesDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details)", "shortName": "Summary of Significant Accounting Policies - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails", "longName": "99940203 - Disclosure - Summary of Significant Accounting Policies - Net loss per share of common stock (Details)", "shortName": "Summary of Significant Accounting Policies - Net loss per share of common stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw",

"name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "99940301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:PrepaidInsurance", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:PrepaidInsurance", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "longName": "99940401 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mUCsOsF5ZUqU8Mf3D5krbg", "name": "eyen:StockIssuedDuringPeriodValueLicensingAgreements", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_8_15_2023_srt_CounterpartyNameAxis_eyen_FormosaPharmaceuticalsIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_Maq2VFnBckWoIp_rqydi3A", "name": "eyen:PercentageOfProductApprovedByFda", "unitRef": "Unit_Standard_pure_JBxAEpNrIkuUD4KN5_72vw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails", "longName": "99940501 - Disclosure - Accrued Compensation (Details)", "shortName": "Accrued Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "eyen:DisclosureOfAccruedCompensationTableTextBlock", "us-gaap:CompensationRelatedCostsGeneralTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "eyen:DisclosureOfAccruedCompensationTableTextBlock", "us-gaap:CompensationRelatedCostsGeneralTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "99940601 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "eyen:AccruedIntangibleAssetMilestoneObligation", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "eyen:AccruedIntangibleAssetMilestoneObligation", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails", "longName": "99940701 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of notes payable (Details)", "shortName": "Notes Payable and Convertible Notes Payable - Schedule of notes payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:NotesPayableCurrent", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "eyen:ScheduleOfNotesPayableTableTextBlock", "eyen:NotesPayableDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:NotesPayableCurrent", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "eyen:ScheduleOfNotesPayableTableTextBlock", "eyen:NotesPayableDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails", "longName": "99940702 - Disclosure - Notes Payable and Convertible Notes Payable - Additional Information (Details)", "shortName": "Notes Payable and Convertible Notes Payable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:ShortTermBankLoansAndNotesPayable", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2024_To_6_30_2024_us-gaap_DebtInstrumentAxis_eyen_LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiM "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R39": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "99940801 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_9_30_2024_To_9_30_2024_bRybB0waYUeSImQ14jRT0w", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_9_2020_To_10_9_2020_f3lTxKqWrUOWB1C45vYxmw", "name": "eyen:WrittenNoticePeriodForTerminationOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R40": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesCompanySRightOfUseAssetsAndLiabilitiesDetails", "longName": "99940802 - Disclosure - Commitments and Contingencies - Company's right-of-use assets and liabilities (Details)", "shortName": "Commitments and Contingencies - Company's right-of-use assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails", "longName": "99940803 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)", "shortName": "Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-

gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99940901 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:RelatedPartyTransactionMonthlyConsultingFee", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:RelatedPartyTransactionMonthlyConsultingFee", "unitRef": "Unit_Standard_USD_XVtkG61i006m1O-bWEUzNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails", "longName": "99941001 - Disclosure - Stockholders' Equity - Summary of offerings (Details)", "shortName": "Stockholders' Equity - Summary of offerings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_9_30_2024_To_9_30_2024_bRybB0waYUeSImQ14jRT0w", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ebyWD78UN0y5Ak9fs59FBw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails", "longName": "99941002 - Disclosure - Stockholders' Equity -Issuance date or modification date fair value of stock warrants (Details)", "shortName": "Stockholders' Equity -Issuance date or modification date fair value of stock warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_wSzlz4KHcUantfzAXZKmAw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_E8xvbtw9PU6X7ji7iZOAFg", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Standard_pure_JBxAEpNrIkuUD4KN5_72vw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R45": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "longName": "99941003 - Disclosure - Stockholders' Equity - Warrants Activity (Details)", "shortName": "Stockholders' Equity - Warrants Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_12_31_2023_bY1luAOYEkSnwPOT8ZLVvA", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_eiykr57VvkiOzle5Ts3amA", "name": "eyen:ClassOfWarrantOrRightNewRepriced", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R46": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "longName": "99941004 - Disclosure - Stockholders' Equity - Related to warrants (Details)", "shortName": "Stockholders' Equity - Related to warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_wSzlz4KHcUantfzAXZKmAw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_Gg_6J3POXU2ADYx5Qu7YPg", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_wSzlz4KHcUantfzAXZKmAw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "td", "tr", "table", "eyen:ScheduleOfWarrantsOutstandingTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R47": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails", "longName": "99941005 - Disclosure - Stockholders' Equity - Restricted stock units activity (Details)", "shortName": "Stockholders' Equity - Restricted stock units activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_12_31_2023_bY1luAOYEkSnwPOT8ZLVvA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_bY1luAOYEkSnwPOT8ZLVvA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "longName": "99941006 - Disclosure - Stockholders' Equity - Summary of option activity (Details)", "shortName": "Stockholders' Equity - Summary of option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "Unit_Divide_USD_shares_wSzlz4KHcUantfzAXZKmAw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_SMpd2CRRL0OI5bMZ6dso5Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R49": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails", "longName": "99941007 - Disclosure - Stockholders' Equity - Black Scholes option (Details)", "shortName": "Stockholders' Equity - Black Scholes option (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_wSzlz4KHcUantfzAXZKmAw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_gho22St_60W-nSeDsA6cnw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_JBxAEpNrIkuUD4KN5_72vw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R50": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails", "longName": "99941008 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)", "shortName": "Stockholders' Equity - Summary of information related to stock options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",

"order": "50", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExerciseRangeNumberOfOutstandingOptions", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExerciseRangeNumberOfOutstandingOptions", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "99941009 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_9_30_2024_UvWjrpsofkitDc8YYKT56g", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_12_2024_eO-qlU0gKEmGWDyFoBd_9g", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } }, "R52": { "role": "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails", "longName": "99941101 - Disclosure - Employee Benefit Plans (Details)", "shortName": "Employee Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_4_1_2019_To_4_30_2019_g4NmG_4iDUS1f83Ml0Qfhg", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_JBxAEpNrIkuUD4KN5_72vw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2019_To_4_30_2019_g4NmG_4iDUS1f83Ml0Qfhg", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_JBxAEpNrIkuUD4KN5_72vw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "longName": "99941201 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_9_30_2024_To_9_30_2024_bRybB0waYUeSImQ14jRT0w", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_1_2024_us-gaap_ClassOfWarrantOrRightAxis_eyen_PrefundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_n83HLrMtsk-776RR4K-gcA", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_oJj6QWNifEKvCi_6jqTXGw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "eyen-20240930x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "eyen_AccountingPoliciesDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccountingPoliciesDisclosureLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounting Policies Disclosure [Line Items]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "eyen_AccountingPoliciesDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccountingPoliciesDisclosureTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to accounting policies in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Accounting Policies Disclosure [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "verboseLabel": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r286"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r42", "r495"] }, "eyen_AccrualForIntangibleAssetsMilestoneObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccrualForIntangibleAssetsMilestoneObligation", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of accrual related to intangible asset recorded in milestone obligation as part of non-cash investing and financing activity.", "label": "Accrual for Intangible Assets Milestone Obligation", "terseLabel": "Accrual for intangible asset milestone obligation" } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "verboseLabel": "Accrued bonus expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "eyen_AccruedClinicalStudiesCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedClinicalStudiesCosts", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Clinical Studies Costs", "terseLabel": "Accrued clinical studies costs" } } }, "auth_ref": [] }, "eyen_AccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "eyen_AccruedExpensesAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedExpensesAndOtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other non- current liabilities.", "label": "Accrued Expenses And Other Liabilities NonCurrent", "terseLabel": "Accrued expenses and other non-current liabilities" } } }, "auth_ref": [] }, "eyen_AccruedFranchiseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedFranchiseTax", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued franchise tax expenses paid by the entity.", "label": "Accrued Franchise Tax", "verboseLabel": "Accrued franchise tax" } } }, "auth_ref": [] }, "eyen_AccruedIntangibleAssetMilestoneObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedIntangibleAssetMilestoneObligation", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrual related to intangible asset milestone obligation.", "label": "Accrued Intangible Asset Milestone Obligation", "terseLabel": "Accrued intangible asset milestone obligation" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued

Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "eyen_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued research and development expenses paid by the entity.", "label": "Accrued Research and Development Expenses, Current", "verboseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Accrued Salaries, Current", "verboseLabel": "Accrued payroll expenses", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44", "r466"] }, "eyen_AccruedSettlementOnDefectiveClinicalSupply": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AccruedSettlementOnDefectiveClinicalSupply", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued settlement related to defective clinical supply.", "label": "Accrued Settlement On Defective Clinical Supply", "terseLabel": "Accrued defective clinical supply settlement, net" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r544"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r53", "r495", "r678"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r386", "r608", "r609", "r610", "r611", "r645", "r679"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r557"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r557"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r557"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r557"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r32", "r33", "r255"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Warrant modification and additional warrants - in issuance costs for offering", "terseLabel": "Adjustments to additional paid in capital upon stock issuance costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r6", "r78"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "verboseLabel": "Warrant modification and additional warrants - incremental value", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": ["r6", "r23", "r78"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r590"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r516", "r526", "r536", "r568"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r519", "r529", "r539", "r571"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r591"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r557"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r564"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r520", "r530", "r540", "r564", "r572", "r576", "r584"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r582"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":

"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] },
"eyen_AmortizationOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"AmortizationOfDebtDiscount", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"],
"lang": { "en-us": { "role": { "documentation": "Amount of Amortization of debt discount.", "label": "Amortization of Debt Discount", "terseLabel":
"Amortization of debt discount" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense
included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of
financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r3", "r66", "r229", "r660"] }, "us-
gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"label": "Amortization Of Financing Costs", "terseLabel": "Amortization of debt discount related to loans", "documentation": "Amount of
amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r66", "r229", "r604", "r660"] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-
us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially
dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute
basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because
to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r160"] },
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-
us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r21"] },
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-
us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Summary of
Significant Accounting Policies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-
us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that
were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the
period presented." } } }, "auth_ref": ["r21"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation":
["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and
arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r298"] }, "us-gaap_Assets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets",
"documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r92", "r101", "r114", "r129", "r163",
"r165", "r172", "r173", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r299", "r301", "r319", "r358", "r412", "r475",
"r476", "r495", "r507", "r639", "r640", "r664"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": {
"role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total
Current Assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [
"r109", "r117", "r129", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r299", "r301", "r319", "r495", "r639", "r640",
"r664"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrentAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": {
"label": "Assets, Current [Abstract]", "verboseLabel": "Current Assets" } } }, "auth_ref": [] }, "eyen_AtMarketOfferingMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AtMarketOfferingMember", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical"], "lang": { "en-us": {
"role": { "documentation": "At Market Offering [Member]", "label": "At Market Offering" } } }, "auth_ref": [] },
"eyen_AvenueConvertibleNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"AvenueConvertibleNotePayableMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": {
"role": { "documentation": "Represents the information pertaining to Avenue - Convertible note payable", "label": "Avenue - Convertible Note
Payable [Member]", "terseLabel": "Avenue - Convertible note payable" } } }, "auth_ref": [] }, "eyen_AvenueNotePayableMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "AvenueNotePayableMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": {
"role": { "documentation": "Represents the information pertaining to Avenue - Note payable.", "label": "Avenue - Note Payable [Member]",
"terseLabel": "Avenue - Note payable" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": {
"en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r579"] }, "ecd_AwardGrantDateFairValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair
Value as of Grant Date" } } }, "auth_ref": ["r580"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line
Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r575"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]",
"terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r575"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel":
"Award Timing Method" } } }, "auth_ref": ["r575"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"],
"lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [
"r575"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label":
"Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r575"] },
"ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined
[Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r575"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type",
"documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r258", "r259", "r260", "r261",
"r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280",

```
"r281", "r282", "r283" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label":
"Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r578" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label":
"Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r577" ] },
"ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label":
"Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r576" ] },
"ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } },
"auth_ref": [ "r576" ] }, "eyen_BauschLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "BauschLicenseAgreementMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"This member stands for Bausch License Agreement.", "label": "Bausch License Agreement [Member]", "terseLabel": "Bausch License Agreement"
} } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at
Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with
banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-
term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present
insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and
discontinued operation." } } }, "auth_ref": [ "r14", "r112", "r463" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and
Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation":
"Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held
as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention
with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted
deposits." } } }, "auth_ref": [ "r15", "r90" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents - End of
Period", "periodStartLabel": "Cash and Cash Equivalents - Beginning of Period", "documentation": "Amount of cash and cash equivalents, and cash
and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not
limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand
deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts
of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [
"r14", "r70", "r126" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash,
Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel":
"Net Decrease in Cash and Cash Equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash
equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand,
demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents
include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their
maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r70" ] }, "us-
gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount",
"crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Cash, Uninsured Amount", "terseLabel": "Cash, uninsured amount", "documentation": "The amount of cash as of the balance sheet date
that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "eyen_CashlessExerciseOfStockOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "CashlessExerciseOfStockOptions", "crdr": "debit",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation":
"Amount of cashless exercise of stock options.", "label": "Cashless Exercise of Stock Options", "terseLabel": "Cashless exercise of stock options" } }
}, "auth_ref": [] }, "eyen_ChangeInFairValueOfEquityConsiderationPayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ChangeInFairValueOfEquityConsiderationPayable", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of
change in fair value of equity consideration payable.", "label": "Change in Fair Value of Equity Consideration Payable", "negatedLabel": "Change in
fair value of equity consideration payable", "terseLabel": "Change in fair value of equity consideration payable" } } }, "auth_ref": [] },
"ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed
Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r555" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
"terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r552" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and
Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and
Unvested" } } }, "auth_ref": [ "r550" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CityAreaCode", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]",
"documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ClassOfWarrantOrRightDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right
[Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that
give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often
included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that
```

warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightExercisable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercisable.", "label": "Class of Warrant or Right, Exercisable", "terseLabel": "Exercisable Number of warrants", "verboseLabel": "Exercisable Number of Warrants" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants or rights exercisable.", "label": "Class of Warrant or Right, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Exercisable, Weighted Average Remaining Life", "terseLabel": "Weighted Average Remaining Life, Exercisable", "verboseLabel": "Weighted Average Remaining Life, Exercisable" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "verboseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r245"] }, "eyen_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights 2", "terseLabel": "Exercise price" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightGranted", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights granted during the period.", "label": "Class of Warrant or Right, Granted", "terseLabel": "Granted" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants or rights granted during the period.", "label": "Class of Warrant or Right, Granted, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "verboseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightNewRepriced": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightNewRepriced", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights new repriced during the period.", "label": "Class of Warrant or Right,New Repriced", "terseLabel": "Repriced - Old" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants or rights new repriced.", "label": "Class of Warrant or Right, New Repriced, Weighted Average Exercise Price", "terseLabel": "Repriced - New" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByAdditionalWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByAdditionalWarrantsOrRights", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of additional securities into which the Additional class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Additional Securities Called By Additional Warrants Or Rights", "terseLabel": "Additional warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Common stock issued from exercise of warrants", "verboseLabel": "Number of warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r245"] }, "eyen_ClassOfWarrantOrRightOldRepriced": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightOldRepriced", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights old repriced during the period.", "label": "Class of Warrant or Right, Old Repriced", "terseLabel": "Repriced - New" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightOldRepricedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightOldRepricedWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants or rights old repriced.", "label": "Class of Warrant or Right, Old Repriced, Weighted Average Exercise Price", "terseLabel": "Repriced - Old" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding at ending balance", "periodStartLabel": "Outstanding at beginning balance", "verboseLabel": "Outstanding Number of Warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at ending balance", "periodStartLabel": "Outstanding at beginning balance" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Outstanding, Weighted Average Remaining Life", "terseLabel": "Weighted Average Remaining Life, Outstanding" } } }, "auth_ref": [] }, "eyen_ClassOfWarrantOrRightPriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights", "presentation": [

```
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Price of Warrants or Rights", "terseLabel": "Price of Warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r26" ] }, "eyen_ClassOfWarrantsOrRightsOutstandingRollforward": {
"xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantsOrRightsOutstandingRollforward", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Class Of Warrants Or Rights Outstanding [Rollforward]", "terseLabel": "Number of Warrants" } } }, "auth_ref": [] },
"eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Class Of Warrants Or Rights, Weighted Average Exercise Price [Rollforward]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] },
"eyen_ClinicalSupplyArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"ClinicalSupplyArrangementsMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "This member stands for Clinical Supply Arrangements.", "label": "Clinical Supply Arrangements", "terseLabel": "Clinical Supply Arrangements" } } }, "auth_ref": [] }, "eyen_ClinicalSupplyArrangementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ClinicalSupplyArrangementsPolicyPolicyTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation":
"Disclosure of accounting policy for Clinical Supply Arrangements.", "label": "Clinical Supply Arrangements, Policy [Policy Text Block]",
"terseLabel": "Clinical Supply Arrangements" } } }, "auth_ref": [] }, "eyen_ClinicalTrialsPercentageOfAdditionalMarkUpOnCost": { "xbrltype":
"percentItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ClinicalTrialsPercentageOfAdditionalMarkUpOnCost",
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Represents clinical trials, percentage of additional mark-up on cost.", "label": "Clinical Trials, Percentage of Additional Mark-up on Cost", "terseLabel": "Clinical trials, percentage of additional mark-up on cost" } } }, "auth_ref": [] },
"ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount",
"terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r556" ] }, "ecd_CoSelectedMeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r556" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.",
"verboseLabel": "Commitments and contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r49", "r95", "r359", "r399" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] },
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r76", "r196", "r197", "r458", "r630", "r635" ] }, "us-gaap_CommonStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." }
} }, "auth_ref": [ "r497", "r498", "r499", "r501", "r502", "r503", "r504", "r608", "r609", "r611", "r645", "r677", "r679" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } }
}, "auth_ref": [ "r52" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r52", "r400" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r52", "r400", "r418", "r679", "r680" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr":
"credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 300,000,000 shares authorized; 86,375,958 and 45,553,026 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r52", "r361", "r495" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r561" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r560" ]
}, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [
"r562" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r559" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" ], "lang": { "en-us": { "role": { "label": "Compensation and Employee Benefit Plans [Text Block]", "verboseLabel": "Employee Benefit Plans", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution
```

plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": ["r79", "r80", "r81", "r82"] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Compensation" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsGeneralTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsGeneralTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedCompensation"], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, General [Text Block]", "verboseLabel": "Accrued Compensation", "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": ["r249", "r250"] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes payable - non-current portion, net of debt discount of $163,051 and $398,569 as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r10"] }, "eyen_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ConvertibleNotesMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Member refers to Convertible notes.", "label": "Convertible Notes [Member]", "terseLabel": "Convertible notes" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable, Current", "terseLabel": "Convertible notes payable - current portion, net of debt discount of $72,467 and $0 as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r44"] }, "eyen_ConvertibleNotesPayableUnamortizedDiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ConvertibleNotesPayableUnamortizedDiscountCurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Amount of discount on convertible notes payable to be amortized within one year or within the normal operating cycle, if longer.", "label": "Convertible Notes Payable, Unamortized Discount, Current", "terseLabel": "Convertible notes payable - current portion, net of debt discount" } } }, "auth_ref": [] }, "eyen_ConvertibleNotesPayableUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ConvertibleNotesPayableUnamortizedDiscountNoncurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Amount of discount on convertible notes payable to be amortized after one year or the normal operating cycle, if longer.", "label": "Convertible Notes Payable, Unamortized Discount, Noncurrent", "terseLabel": "Convertible notes payable - non-current portion, net of debt discount" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "negatedLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r62", "r129", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r319", "r475", "r639"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r130", "r131", "r217", "r234", "r343", "r350", "r356", "r467", "r469"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "eyen_CreditCardPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "CreditCardPayable", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of credit card expenses payable by the entity.", "label": "Credit Card Payable", "verboseLabel": "Credit card payable" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DamagesFromProductDefectsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DamagesFromProductDefectsMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Damages from Product Defects [Member]", "terseLabel": "Defective clinical supply returns", "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters." } } }, "auth_ref": ["r636"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r10", "r43", "r44", "r93", "r94", "r132", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r481", "r482", "r483", "r484", "r485", "r493", "r606", "r631", "r632", "r633", "r659", "r661"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r46", "r215"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r10", "r132", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r481", "r482", "r483", "r484", "r485", "r493", "r606", "r631", "r632", "r633", "r659", "r661"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "verboseLabel": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r10", "r38"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Initial principal payment related to loan and security agreement", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r10"] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r642", "r658", "r659", "r661"] }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountCurrent", "crdr": "debit", "presentation": [

"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount, Current", "negatedLabel": "Debt Discount, Current portion", "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer." } } }, "auth_ref": ["r658", "r659", "r661"] }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount, Noncurrent", "negatedLabel": "Debt Discount, Non-Current portion", "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r658", "r659", "r661"] }, "eyen_DeferredClinicalSupplyCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "DeferredClinicalSupplyCosts", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "The carrying value as on the balance sheet date of deferred clinical supply costs, classified as current.", "label": "Deferred Clinical Supply Costs", "terseLabel": "Deferred clinical supply costs", "verboseLabel": "Deferred clinical supply costs" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "verboseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Employee Benefit Plans", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r252"] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Defined contribution plan, employer matching contribution, percent of match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "presentation": ["http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Defined contribution plan, employers matching contribution, annual vesting percentage", "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount", "terseLabel": "Defined contribution plan, maximum annual contributions per employee, amount", "documentation": "Maximum amount the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": ["r252"] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits Assets, Current", "terseLabel": "Security deposits, current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": ["r599"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation of property and equipment", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r3", "r163", "r170", "r173", "r475", "r476"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r388", "r390", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r428", "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r451", "r452", "r453", "r454", "r497", "r499", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r35", "r36", "r37", "r89", "r388", "r390", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r428", "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r451", "r452", "r453", "r454", "r469", "r497", "r499", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656"] }, "eyen_DirectorAndOfficerInsurancePolicyLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "DirectorAndOfficerInsurancePolicyLoanMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for director and officer insurance policy loan.", "label": "Director And Officer Insurance Policy Loan [Member]", "terseLabel": "D&O insurance policy loan" } } }, "auth_ref": [] }, "eyen_DisclosureOfAccruedCompensationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "DisclosureOfAccruedCompensationTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued compensation.", "label": "Disclosure of Accrued compensation [Table Text Block]", "verboseLabel": "Schedule of accrued compensation" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of restricted stock units (\"RSUs\") activity", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": ["r5", "r27"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r511"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"DocumentTransitionReport", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r543"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r554"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net Loss Per Share - Basic (in dollars per share)", "verboseLabel": "Basic net loss per common share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r123", "r138", "r139", "r140", "r141", "r142", "r143", "r147", "r150", "r157", "r158", "r159", "r162", "r294", "r297", "r311", "r312", "r354", "r367", "r472"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net Loss Per Share - Diluted (in dollars per share)", "verboseLabel": "Diluted net loss per common share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r123", "r138", "r139", "r140", "r141", "r142", "r143", "r150", "r157", "r158", "r159", "r162", "r294", "r297", "r311", "r312", "r354", "r367", "r472"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net Loss Per Share of Common Stock", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r21", "r22", "r161"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Total accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period of recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r284"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r643"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized stock - based compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r643"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r509"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [

```
"http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r509" ] },
"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber",
"presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] },
"dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory",
"presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r509" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype":
"edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInteractiveDataCurrent", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us":
{ "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r593" ] }, "dei_EntityRegistrantName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } },
"auth_ref": [ "r509" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityShellCompany", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role":
{ "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r509" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r509" ] },
"dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-
us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r509" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]",
"terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r548" ] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r589" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r589" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r589" ] }, "eyen_EquipmentDeposits": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "EquipmentDeposits", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equipment deposits.", "label": "Equipment Deposits", "terseLabel": "Equipment deposits" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label":
"Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r107", "r120", "r121", "r122", "r133", "r134",
"r135", "r137", "r142", "r144", "r146", "r164", "r179", "r180", "r192", "r246", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r303",
"r304", "r305", "r306", "r307", "r308", "r310", "r320", "r321", "r322", "r323", "r324", "r325", "r327", "r328", "r338", "r366", "r372", "r373", "r374",
"r386", "r440" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r558" ] }, "ecd_ErrCompAnalysisTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]",
"terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r516", "r526", "r536", "r568" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]",
"terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r513", "r523", "r533", "r565" ] }, "us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EscrowDepositDisbursementsRelatedToPropertyAcquisition1", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Escrow Deposit Disbursements Related to Property Acquisition", "terseLabel": "Vendor deposits applied to purchases of property and equipment",
"documentation": "Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions." } } },
"auth_ref": [ "r16", "r17", "r18" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r564" ] }, "eyen_ExercisePriceEightMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceEightMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "This member represents for exercise price eight.", "label": "Exercise Price Eight [Member]", "terseLabel": "Exercise Price $7.00+" } } }, "auth_ref": [] }, "eyen_ExercisePriceFiveMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceFiveMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "This member represents for exercise price five.", "label": "Exercise Price Five [Member]", "verboseLabel": "Exercise Price $4.00 - $4.99" } } }, "auth_ref": [] }, "eyen_ExercisePriceFourMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceFourMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "This member represents for exercise price four.", "label": "Exercise Price Four [Member]", "verboseLabel": "Exercise Price $3.00 - $3.99" } } }, "auth_ref": [] }, "eyen_ExercisePriceOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceOneMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "This member represents for exercise price one.", "label": "Exercise Price One [Member]", "verboseLabel": "Exercise Price $0.01 - $0.99" } } }, "auth_ref": [] }, "eyen_ExercisePriceSevenMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceSevenMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "This member represents for exercise price seven.", "label": "Exercise Price Seven [Member]", "terseLabel": "Exercise Price $6.00 - $6.99" } } }, "auth_ref": [] }, "eyen_ExercisePriceSixMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceSixMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": {
```

```
"role": { "documentation": "This member represents for exercise price six.", "label": "Exercise Price Six [Member]", "verboseLabel": "Exercise Price $5.00 - $5.99" } } }, "auth_ref": [] }, "eyen_ExercisePriceThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceThreeMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents for exercise price three.", "label": "Exercise Price Three [Member]", "verboseLabel": "Exercise Price $2.00 - $2.99" } } }, "auth_ref": [] }, "eyen_ExercisePriceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ExercisePriceTwoMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents for exercise price two.", "label": "Exercise Price Two [Member]", "verboseLabel": "Exercise Price $1.00 - $1.99" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r313", "r314", "r315", "r489" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r313", "r314", "r315", "r489" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of issuance date or modification date fair value of stock warrants", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r313", "r314", "r489" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r520", "r530", "r540", "r572" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r520", "r530", "r540", "r572" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r520", "r530", "r540", "r572" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r520", "r530", "r540", "r572" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r520", "r530", "r540", "r572" ] }, "eyen_FormosaPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "FormosaPharmaceuticalsIncMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Formosa Pharmaceuticals Inc.", "label": "Formosa Pharmaceuticals Inc [Member]", "terseLabel": "Formosa Pharmaceuticals Inc" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r553" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative Expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r64" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross Loss", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r61", "r62", "r100", "r129", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r319", "r474", "r475", "r613", "r614", "r615", "r616", "r617", "r639" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r193", "r194", "r195", "r316", "r317", "r318", "r369", "r371", "r425", "r462", "r488", "r676" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r194", "r195", "r316", "r317", "r318", "r369", "r371", "r425", "r462", "r488", "r676" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued compensation", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "eyen_IncreaseDecreaseInDeferredClinicalSupplyCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "IncreaseDecreaseInDeferredClinicalSupplyCosts", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of deferred clinical supply costs.", "label": "Increase (Decrease) in Deferred Clinical Supply Costs", "negatedLabel": "Deferred clinical supply costs" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in
```

Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r2"] }, "eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables.", "label": "Increase (Decrease) in License Fee and Expense Reimbursements Receivables", "negatedLabel": "License fee and expense reimbursement receivables" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r594", "r603"] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInSecurityDeposits", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Security Deposits", "verboseLabel": "Security and equipment deposits", "documentation": "The increase (decrease) during the reporting period in security deposits." } } }, "auth_ref": ["r2"] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Add: Prefunded warrants", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": ["r151", "r152", "r153", "r159"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Add: Undelivered vested restricted shares", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r151", "r152", "r154", "r159", "r257"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r186", "r187", "r188", "r479"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r186", "r188", "r190", "r479"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r186", "r187", "r188", "r479"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r520", "r530", "r540", "r564", "r572", "r576", "r584"] }, "eyen_InitialDevelopmentMilestonePaymentTriggerForFdaApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "InitialDevelopmentMilestonePaymentTriggerForFdaApproval", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of initial development milestone payment which trigger FDA approval.", "label": "Initial Development Milestone Payment, Trigger For Fda Approval", "terseLabel": "Initial development milestone payment which trigger FDA approval" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r582"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r512", "r588"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r512", "r588"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r512", "r588"] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r185", "r189", "r191", "r461", "r462"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r186", "r626", "r627"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r66", "r227", "r230", "r484", "r485"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Expense Nonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r169", "r602"] }, "us-gaap_InterestExpenseSecuritySoldUnderAgreementToRepurchaseIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseSecuritySoldUnderAgreementToRepurchaseIncreaseDecrease", "crdr": "debit",

```
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Security Sold under Agreement to Repurchase, Increase (Decrease)", "terseLabel": "Interest expense related to the Loan and Security Agreement with Avenue Capital Management", "documentation": "Amount of increase (decrease) in interest expense on security sold under agreement to repurchase." } } }, "auth_ref": [ "r103", "r104", "r105", "r106" ] }, "us-gaap_InterestPaidCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidCapitalized", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Interest", "documentation": "Amount of cash paid for interest capitalized, classified as investing activity." } } }, "auth_ref": [ "r470", "r605" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r597" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoriesDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r116", "r464", "r495" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r102", "r111", "r115", "r181", "r182", "r184", "r352", "r471" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r598" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Write-down of inventories to net realizable value", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r183" ] }, "eyen_InventoryWriteDownAdjustmentsToListPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "InventoryWriteDownAdjustmentsToListPrice", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of inventory write down adjusted to the list price.", "label": "Inventory Write Down, Adjustments To List Price", "terseLabel": "Inventory write down of adjustments" } } }, "auth_ref": [] }, "eyen_InventoryWriteDownShortDatedInventoryToNetRealizableValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "InventoryWriteDownShortDatedInventoryToNetRealizableValue", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of write down of short dated inventory to net realizable value.", "label": "Inventory Write Down, Short Dated Inventory To Net Realizable Value", "terseLabel": "Inventory to net realizable value" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r163", "r168", "r173", "r475", "r601" ] },
"eyen_IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of issuance of common stock related to vested restricted stock units.", "label": "Issuance of Common Stock Related to Vested Restricted Stock Units", "terseLabel": "Issuance of common stock related to vested restricted stock units" } } }, "auth_ref": [] },
"eyen_JulyOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "JulyOfferingMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for July offering.", "label": "July offering [Member]", "terseLabel": "July offering" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of company's right-of-use assets and liabilities", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r662" ] },
"eyen_LegalExpensesCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LegalExpensesCapitalized", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Legal expenses capitalized.", "label": "Legal Expenses Capitalized", "terseLabel": "Legal expenses capitalized" } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Fees", "terseLabel": "Legal fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r595" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of future minimum payments under the company's operating lease agreements", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r663" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r336" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r336" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r336" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r336" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025", "documentation": "Amount of
```

lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r336"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r336"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r10", "r43", "r44", "r45", "r47", "r48", "r49", "r50", "r129", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r300", "r301", "r302", "r319", "r398", "r473", "r507", "r639", "r664", "r665"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r57", "r96", "r363", "r495", "r607", "r618", "r657"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r45", "r110", "r129", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r300", "r301", "r302", "r319", "r495", "r639", "r664", "r665"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "auth_ref": [] }, "eyen_LicenseAgreementPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LicenseAgreementPaymentPeriod", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Period when payment has to be made related to the license agreement from the effective date in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "License Agreement, Payment Period", "terseLabel": "License agreement payment period" } } }, "auth_ref": [] }, "eyen_LicenseAgreementsUpfrontPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LicenseAgreementsUpfrontPaymentsReceived", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of upfront payments received by the entity, pursuant to a license agreement.", "label": "License Agreements Upfront Payments Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "eyen_LicenseFeeAndExpenseReimbursementsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LicenseFeeAndExpenseReimbursementsReceivables", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of license fee and expense reimbursements receivables classified as current.", "label": "License Fee and Expense Reimbursements Receivables", "terseLabel": "License fee and expense reimbursements receivable" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "terseLabel": "License", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": ["r34", "r288", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r644"] }, "eyen_LiquidityAndGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LiquidityAndGoingConcernTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for going concern.", "label": "Liquidity And Going Concern, Policy [Policy Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "auth_ref": [] }, "eyen_LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Loan and Security Agreement with Avenue, the Lender.", "label": "Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P., and Avenue Venture Opportunities Fund, L.P. II [Member]", "terseLabel": "Avenue Ventures Loan" } } }, "auth_ref": [] }, "eyen_LoanIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LoanIssuanceCosts", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The loan issuance costs will first be recorded in the balance sheet of the bond issuer.", "label": "Loan Issuance Costs", "terseLabel": "Loan issuance costs" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Notes Payable, Noncurrent", "verboseLabel": "Note payable, Non Current portion", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r10"] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r198", "r199", "r200", "r204", "r285", "r377", "r480", "r637", "r638"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r198", "r199", "r200", "r204", "r285", "r480", "r637", "r638"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r198", "r199", "r200", "r204", "r285", "r480", "r637", "r638"] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Current estimated loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": ["r199", "r200", "r203", "r204", "r285", "r480"] }, "eyen_LossContingencyEstimateOfPossibleLossNetPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LossContingencyEstimateOfPossibleLossNetPayable", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss net payable from the specified contingency as of the balance sheet date", "label": "Loss Contingency Estimate Of Possible Loss Net Payable", "terseLabel": "Current estimated net payable amount" } } }, "auth_ref": [] }, "us-gaap_LossContingencyLossInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyLossInPeriod", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":

"Loss Contingency, Loss in Period", "terseLabel": "Loss recorded", "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates." } } }, "auth_ref": ["r636"] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": ["r198", "r199", "r200", "r204", "r285", "r377", "r480", "r637", "r638"] }, "eyen_LossContingencyPurchasedUponCompletionOfMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "LossContingencyPurchasedUponCompletionOfMilestone", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Purchased related to amount previously held to be received upon completion of milestone.", "label": "Loss Contingency, Purchased Upon completion of Milestone", "verboseLabel": "Purchased upon completion of milestone" } } }, "auth_ref": [] },
"eyen_LossContingencyReceivableUponCompletionOfMilestone": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "LossContingencyReceivableUponCompletionOfMilestone", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Receivable related to amount previously held to be received upon completion of milestone.", "label": "Loss Contingency, Receivable Upon completion of Milestone", "terseLabel": "Receivable upon completion of milestone" } } }, "auth_ref": [] },
"eyen_MaximumAmountPayableUponAchievementOfCertainDevelopmentMilestones": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "MaximumAmountPayableUponAchievementOfCertainDevelopmentMilestones", "crdr":
"credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation":
"Maximum amount payable upon achievement of certain development milestones.", "label": "Maximum Amount Payable Upon Achievement Of Certain Development Milestones", "terseLabel": "Maximum amount payable upon achievement of certain development milestones" } } },
"auth_ref": [] }, "eyen_MaximumAmountPayableUponAchievementOfCertainSalesMilestones": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "MaximumAmountPayableUponAchievementOfCertainSalesMilestones", "crdr": "credit",
"presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount payable upon achievement of certain sales milestones.", "label": "Maximum Amount Payable Upon Achievement of Certain Sales Milestones", "terseLabel": "Maximum amount payable upon achievement of certain sales milestones" } } }, "auth_ref": [] },
"srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r253", "r285", "r315", "r351", "r368", "r370", "r377", "r389", "r390", "r447", "r448", "r449", "r450", "r455", "r459", "r460", "r477", "r486", "r487", "r489", "r490", "r491", "r492", "r496", "r641", "r666", "r667", "r668", "r669", "r670", "r671"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [
"r556"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r556"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails"], "lang": {
"en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected term (years)", "documentation":
"Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r646", "r647", "r648"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails"], "lang": {
"en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r489", "r646", "r647", "r648"] },
"us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputRiskFreeInterestRateMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails"], "lang": {
"en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk free interest rate", "documentation":
"Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r646", "r647", "r648"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputTypeAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails"], "lang": {
"en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r313", "r314", "r315", "r489"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails"], "lang": {
"en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r313", "r314", "r315", "r489"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"], "lang": { "en-us": {
"role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r253", "r285", "r315", "r351", "r368", "r370", "r377", "r389", "r390", "r447", "r448", "r449", "r450", "r455", "r459", "r460", "r477", "r486", "r487", "r489", "r490", "r491", "r496", "r641", "r666", "r667", "r668", "r669", "r670", "r671"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r575"] }, "ecd_MtrlTermsOfTrdArrTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r583"] }, "ecd_NamedExecutiveOfficersFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r557"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit",
"presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided By Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r125"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used In Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r125"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [

```
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows From Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash used in operations", "totalLabel": "Net Cash Used In Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r70", "r71", "r72" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r63", "r72", "r97", "r108", "r118", "r119", "r122", "r129", "r136", "r138", "r139", "r140", "r141", "r142", "r145", "r146", "r155", "r178", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r294", "r297", "r312", "r319", "r365", "r420", "r438", "r439", "r505", "r639" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r124", "r138", "r139", "r140", "r141", "r147", "r148", "r156", "r159", "r297" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "auth_ref": [] }, "eyen_NewAccountingPronouncementsIssuedPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NewAccountingPronouncementsIssuedPolicyPolicyTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements issued that may impact the entity's financial reporting.", "label": "New Accounting Pronouncements Issued, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "auth_ref": [] }, "eyen_NonCashExpensesOnReacquisitionOfLicenseRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NonCashExpensesOnReacquisitionOfLicenseRights", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of non cash expense on reacquisition of license rights.", "label": "Non cash Expenses On Reacquisition Of License Rights", "terseLabel": "Reacquisition of license rights" } } }, "auth_ref": [] }, "eyen_NonCashRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NonCashRentExpense", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for rent expenses.", "label": "Non Cash Rent Expense", "terseLabel": "Non-cash rent expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r556" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r520", "r530", "r540", "r564", "r572" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r547" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r546" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r564" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r583" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r583" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r65" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other Income (Expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payables", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r10", "r94", "r674", "r675" ] }, "us-gaap_NotesPayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable and Convertible Notes Payable" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Current", "terseLabel": "Notes Payable, Current portion", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_NotesPayableCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrentAbstract", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Current [Abstract]", "terseLabel": "Current portion" } } }, "auth_ref": [] }, "eyen_NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable, net of debt discount due within one year or the operating cycle if longer.", "label": "Notes Payable Current, Net Of Debt Discount Current, Current Portion", "terseLabel": "Net, Current portion" } } }, "auth_ref": [] }, "eyen_NotesPayableDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableDisclosureTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "documentation": "The
```

entire disclosure of notes payable.", "label": "Notes Payable Disclosure [Text Block]", "terseLabel": "Notes Payable and Convertible Notes Payable" } } }, "auth_ref": [] }, "eyen_NotesPayableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Notes Payable [Line Items]", "terseLabel": "Notes Payable" } } }, "auth_ref": [] }, "eyen_NotesPayableNetOfDebtDiscountTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableNetOfDebtDiscountTotal", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, net of debt discounts, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable, Net Of Debt Discount, Total" } } }, "auth_ref": [] }, "eyen_NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable, net of debt discount (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable Non Current, Net Of Debt Discount Non Current, Non Current Portion", "terseLabel": "Net, Non Current portion" } } }, "auth_ref": [] }, "eyen_NotesPayableUnamortizedDiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableUnamortizedDiscountCurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Amount of discount on notes payable to be amortized within one year or within the normal operating cycle, if longer.", "label": "Notes Payable, Unamortized Discount, Current", "terseLabel": "Notes payable - current portion, net of debt discount" } } }, "auth_ref": [] }, "eyen_NotesPayableUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NotesPayableUnamortizedDiscountNoncurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Amount of discount on notes payable to be amortized after one year or the normal operating cycle, if longer.", "label": "Notes Payable, Unamortized Discount, Noncurrent", "terseLabel": "Notes payable - non-current portion, net of debt discount" } } }, "auth_ref": [] }, "eyen_NumberOfMonthlyPayments": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "NumberOfMonthlyPayments", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of monthly payments.", "label": "Number Of Monthly Payments", "terseLabel": "Number of monthly payments" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating Expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss From Operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r100", "r474", "r613", "r614", "r615", "r616", "r617"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Minimum Lease Payments" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r330"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion", "terseLabel": "Operating lease liabilities - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r330"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, non-current portion", "verboseLabel": "Operating lease liabilities - non-current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r330"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesCompanySRightOfUseAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r331", "r332"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r329"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesCompanySRightOfUseAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate: Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r335", "r494"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesCompanySRightOfUseAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted Average Remaining Lease Term (Years): Operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r334", "r494"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Business Organization, Nature of Operations and Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Business Organization, Nature of Operations and Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r39", "r88", "r378", "r379"] }, "eyen_OriginalIssueDiscountOnNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "OriginalIssueDiscountOnNotesPayable", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of original Issue discount on notes payable.", "label": "Original Issue Discount On Notes Payable", "terseLabel": "Original issue discount on notes payable" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within

{"one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r44"] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets", "terseLabel": "Other", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r91", "r113", "r357", "r476", "r507"] }, "us-gaap_OtherLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Notes Payable, Noncurrent", "terseLabel": "Notes payable - non-current portion, net of debt discount of $0 and $448,367 as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r10"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r67"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r556"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r518", "r528", "r538", "r570"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [
"r521", "r531", "r541", "r573"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r521", "r531", "r541", "r573"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r545"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of offerings issuance costs", "verboseLabel": "Payment of issuance costs for notes issued to Avenue", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r13"] }, "eyen_PaymentsOfDebtIssuanceCostsRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PaymentsOfDebtIssuanceCostsRelatedParty", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to related parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs, Related Party", "negatedLabel": "Payment of issuance costs for notes issued to Avenue" } } }, "auth_ref": [] }, "eyen_PaymentsOfStockIssuanceCostsAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PaymentsOfStockIssuanceCostsAtMarketOffering", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly in at the market offering with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs, At the Market Offering", "negatedLabel": "Payment of issuance costs for At the Market Program" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Investment in intangible asset", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r68"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r68"] }, "eyen_PayrollTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PayrollTaxesReceivable", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": {
"documentation": "Amount of Payroll Taxes Receivable.", "label": "Payroll Taxes Receivable", "verboseLabel": "Payroll tax receivable" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r555"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r555"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r547"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r564"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [
"r557"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r546"] }, "eyen_PercentageOfProductApprovedByFda": { "xbrltype": "percentItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PercentageOfProductApprovedByFda", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of product approved by FDA.", "label": "Percentage of Product Approved by FDA", "terseLabel": "Percentage of product approved by FDA" } } }, "auth_ref": [] }, "eyen_PlacementAgentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PlacementAgentFees", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for placement agent fees in connection with offering.", "label": "Placement Agent Fees", "terseLabel": "Placement agent fees" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r548"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r592"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r547"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value",
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r51", "r232"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref":

{ "r51", "r400"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r51", "r232"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r51", "r400", "r418", "r679", "r680"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r51", "r360", "r495"] }, "eyen_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to prefunded warrants in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Pre-funded Warrants [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "eyen_PrepaidConferenceExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrepaidConferenceExpensesCurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of prepaid conference expenses current.", "label": "Prepaid Conference Expenses Current", "terseLabel": "Prepaid conference expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Total prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r600"] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid expenses, non-current", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r596"] }, "eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "eyen_PrepaidGeneralAndAdministrativeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrepaidGeneralAndAdministrativeExpenses", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Prepaid general and administrative expenses.", "label": "Prepaid General and Administrative Expenses", "terseLabel": "Prepaid general and administrative expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance expenses", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r465", "r478", "r619"] }, "eyen_PrepaidPatentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrepaidPatentExpense", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of prepaid patent expense.", "label": "Prepaid Patent Expense", "terseLabel": "Prepaid patent expenses" } } }, "auth_ref": [] }, "eyen_PrepaidRentAndSecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrepaidRentAndSecurityDeposit", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.", "label": "Prepaid Rent and Security Deposit", "verboseLabel": "Prepaid rent and security deposit" } } }, "auth_ref": [] }, "eyen_PrepaidResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PrepaidResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Prepaid Research And Development Expenses", "label": "Prepaid Research And Development Expenses", "terseLabel": "Prepaid research and development expenses" } } }, "auth_ref": [] }, "eyen_PriorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "PriorWarrantsMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to prior warrants.", "label": "Prior Warrants [Member]", "terseLabel": "Prior Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "eyen_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock and Warrants", "terseLabel": "Gross proceeds from common stock warrants" } } }, "auth_ref": [] }, "eyen_ProceedsFromIssuanceOfCommonStockAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAtMarketOffering", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from issuance of common stock at market offering.", "label": "Proceeds from Issuance of Common Stock at Market Offering", "terseLabel": "Proceeds from sale of common stock in At the Market Program" } } }, "auth_ref": [] }, "eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution net of issuance costs to the entity.", "label": "Proceeds from Issuance of Common Stock Net of Issuance Costs", "terseLabel": "Net proceeds" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Aggregate gross proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r1", "r381"] }, "us-

```
gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromNotesPayable", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "label": "Proceeds from note payable to Avenue", "documentation": "The cash inflow from a borrowing supported by a
written promise to pay an obligation." } } }, "auth_ref": [ "r12" ] },
"eyen_ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering", "crdr":
"debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow
from proceeds from sale of common stock and warrants in registered direct offering.", "label": "Proceeds from Sale of Common Stock and Warrants
in Registered Direct Offering", "terseLabel": "Proceeds from sale of common stock and warrants in offerings" } } }, "auth_ref": [] }, "us-
gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock
Options Exercised", "verboseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option
under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r9" ] }, "eyen_ProceedsOfStockIssuedDuringPeriodGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ProceedsOfStockIssuedDuringPeriodGross", "crdr": "debit",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical" ],
"lang": { "en-us": { "role": { "documentation": "The amount of issuance of preferred stocks identified as being convertible into another form of
financial instrument, typically the entity's common stock.", "label": "Proceeds Of Stock Issued During Period Gross", "terseLabel": "Proceeds of
stock issued during period gross" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment,
Net", "verboseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of
physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not
limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r337", "r355", "r364",
"r495" ] }, "eyen_ProvisionForReturnedDeferredClinicalSupplies": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ProvisionForReturnedDeferredClinicalSupplies", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of
provision for returned deferred clinical supplies.", "label": "Provision for Returned Deferred Clinical Supplies", "terseLabel": "Provision for
returned deferred clinical supplies" } } }, "auth_ref": [] }, "eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"PurchaseOfInsurancePremiumFinancedByShortTermNotePayable", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of
purchase of insurance premium financed by short term notes payable.", "label": "Purchase of Insurance Premium Financed by Short Term Note
Payable", "terseLabel": "Purchase of insurance policy financed by note payable" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [
"r545" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]",
"terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r545" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": [
"r199", "r200", "r201", "r202", "r251", "r253", "r280", "r281", "r282", "r285", "r315", "r348", "r349", "r351", "r368", "r370", "r377", "r389", "r390",
"r447", "r448", "r449", "r450", "r455", "r459", "r460", "r477", "r486", "r487", "r489", "r490", "r491", "r492", "r496", "r499", "r634", "r641", "r647",
"r667", "r668", "r669", "r670", "r671" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RangeMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth_ref": [
"r199", "r200", "r201", "r202", "r251", "r253", "r280", "r281", "r282", "r285", "r315", "r348", "r349", "r351", "r368", "r370", "r377", "r389", "r390",
"r447", "r448", "r449", "r450", "r455", "r459", "r460", "r477", "r486", "r487", "r489", "r490", "r491", "r492", "r496", "r499", "r634", "r641", "r647",
"r667", "r668", "r669", "r670", "r671" ] }, "eyen_ReacquisitionOfLicenseRights": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ReacquisitionOfLicenseRights", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of
expense on reacquisition of license rights.", "label": "Reacquisition Of License Rights", "terseLabel": "Reacquisition of license rights" } } },
"auth_ref": [] }, "eyen_ReclassificationOfDeferredClinicalSupplyCostsToInventories": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "ReclassificationOfDeferredClinicalSupplyCostsToInventories", "crdr": "debit",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation":
"Amount of reclassification of deferred clinical supply costs to inventories.", "label": "Reclassification Of Deferred Clinical Supply Costs To
Inventories", "terseLabel": "Reclassification of deferred clinical supply costs to inventories" } } }, "auth_ref": [] },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line
Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r513", "r523", "r533", "r565" ] },
"eyen_RegisteredDirectOffering2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"RegisteredDirectOffering2024Member", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents information relating to 2024 registered direct offering.", "label": "Registered Direct Offering 2024 [Member]", "terseLabel":
"Registered Direct Offering" } } }, "auth_ref": [] }, "eyen_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "RegisteredDirectOfferingMember", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical" ], "lang": { "en-us": {
"role": { "documentation": "Represents information pertaining to registered direct offering.", "label": "Registered Direct Offering [Member]",
"terseLabel": "Registered direct offering" } } }, "auth_ref": [] }, "eyen_RelatedPartyTransactionMonthlyConsultingFee": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "RelatedPartyTransactionMonthlyConsultingFee", "crdr":
"debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": {
"documentation": "Amount of monthly consulting fee for the advisory service agreement.", "label": "Related Party Transaction, Monthly Consulting
Fee", "terseLabel": "Monthly consulting fee" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party
Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions
Disclosure [Text Block]", "verboseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions.
Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent;
(c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r344", "r383", "r384", "r385", "r423",
"r424", "r425", "r444", "r446" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Notes
Payable", "negatedLabel": "Repayments of notes payable", "terseLabel": "Repayments of notes payable", "documentation": "The cash outflow for a
borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r69" ] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails",
```

"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r130", "r131", "r217", "r234", "r343", "r350", "r356", "r468", "r469"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [
"r287", "r462", "r475", "r672"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r514", "r524", "r534", "r566"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r515", "r525", "r535", "r567"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r522", "r532", "r542", "r574"] }, "eyen_RestrictedStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "RestrictedStockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "documentation": "This represents restricted stock units issued during the period.", "label": "Restricted Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock related to vested restricted stock units (in shares)" } } }, "auth_ref": [] }, "eyen_RestrictedStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "RestrictedStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "documentation": "Amount of restricted stock issued during the period.", "label": "Restricted Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock related to vested restricted stock units" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r54", "r78", "r362", "r375", "r376", "r382", "r401", "r495"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r107", "r133", "r134", "r135", "r137", "r142", "r144", "r146", "r179", "r180", "r192", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r303", "r305", "r306", "r308", "r310", "r327", "r328", "r372", "r374", "r386", "r679"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r98", "r99", "r163", "r166", "r167", "r171", "r173", "r174", "r175", "r176", "r247", "r248", "r353"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Operating Income" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesCompanySRightOfUseAssetsAndLiabilitiesDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities", "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations: Operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r333", "r494"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r583"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r583"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from At-the-Market Offering Program", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accrued expenses and other current liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of weighted average diluted shares of common stock", "documentation": "Tabular disclosure of securities (including those issuable pursuant to

contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net loss per common share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r612"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": ["r186", "r188", "r190", "r479"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r11", "r58", "r59", "r60"] }, "eyen_ScheduleOfNotesPayableTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ScheduleOfNotesPayableTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableScheduleOfNotesPayableDetails"], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a long term notes to be paid to the borrowers.", "label": "Schedule of Notes Payable [Table]" } } }, "auth_ref": [] }, "eyen_ScheduleOfNotesPayableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ScheduleOfNotesPayableTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of notes payable.", "label": "Schedule of Notes Payable [Table Text Block]", "terseLabel": "Schedule of notes payable and convertible notes payable" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r254", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "verboseLabel": "Schedule of information related to stock options", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r27"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of the option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r7", "r8", "r83"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Schedule of Black-Scholes option pricing model to stock options granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r87"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Short-term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r43"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of the warrant activity and related information", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of summary of offerings", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": ["r6"] }, "eyen_ScheduleOfWarrantsOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ScheduleOfWarrantsOutstandingTableTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of warrants outstanding.", "label": "Schedule Of Warrants Outstanding [Table Text Block]", "terseLabel": "Schedule of warrants outstanding" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r508"] }, "eyen_SecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "SecurityDeposits", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "The amount of Security Deposits.", "label": "Security Deposits", "terseLabel": "Security deposits, non-current" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r510"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r64"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment

Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "RSUs non-vested June 30, 2024", "periodStartLabel": "RSUs non-vested January 1, 2024", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r269", "r270"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of RSUs", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r273"] }, "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested RSUs Undelivered numbers during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested R S Us Undelivered, Number", "verboseLabel": "Vested RSUs undelivered June 30, 2024" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r281"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r280"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r254", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Number of Options, Exercisable | Shares", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Exercisable | $ / Shares", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Options, Forfeited | Shares", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r267"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of Options, Granted | Shares", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r265"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r27"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options, Outstanding | Shares", "periodStartLabel": "Number of Options, Outstanding | Shares", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r261", "r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding | $ / Shares", "periodStartLabel": "Weighted Average Exercise Price, Outstanding | $ / Shares", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r261", "r262"] }, "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of restricted stock units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Grants In Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "auth_ref": [] }, "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the restricted stock unit plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Non Vested, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "RSUs non-vested June 30, 2024", "periodStartLabel": "RSUs non-vested January 1, 2024" } } }, "auth_ref": [] }, "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price [Roll forward]", "terseLabel": "Weighted Average Grant Date Value Per Share" } } }, "auth_ref": [] }, "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees vested the restricted stock units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested In Period, Weighted Average Exercise Price", "terseLabel": "Vested" } } }, "auth_ref": [] }, "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees vested the restricted stock units undelivered.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested R S Us Undelivered, Weighted Average Exercise Price", "terseLabel": "Vested RSUs undelivered June 30, 2024" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited | $ / Shares", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r267"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average estimated grant date fair value", "verboseLabel": "Weighted Average Exercise Price, Granted | $ / Shares", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r265"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r30"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r31"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "verboseLabel": "Options Exercisable, Exercisable Number of Options", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": ["r29"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "verboseLabel": "Options Outstanding, Outstanding Number of Options", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": ["r84", "r85"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [

```
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails" ], "lang": {
"en-us": { "role": { "label": "Share Price", "verboseLabel": "Fair value of common stock on date of grant", "documentation": "Price of a single share
of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-based
Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (years)",
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r279" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual
Term", "verboseLabel": "Weighted Average Remaining Life In Years, Exercisable", "documentation": "Weighted average remaining contractual term
for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r27" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual
Term", "verboseLabel": "Weighted Average Remaining Life In Years, Outstanding", "documentation": "Weighted average remaining contractual
term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days." } } }, "auth_ref": [ "r86" ] }, "us-
gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1":
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": {
"en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options,
Weighted Average Exercise Price", "verboseLabel": "Options Outstanding, Outstanding Exercise Price", "documentation": "Weighted average
exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r28" ] },
"us-
gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContra
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractual
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" ], "lang": {
"en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining
Contractual Term", "verboseLabel": "Options Exercisable, Weighted Average Remaining Life In Years", "documentation": "Weighted average
remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of
one year, five months, and thirteen days." } } }, "auth_ref": [ "r86" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share",
"terseLabel": "Shares Issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] },
"us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us":
{ "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in
shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-
gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermBankLoansAndNotesPayable", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term Bank Loans and Notes
Payable", "terseLabel": "Short term notes payable", "verboseLabel": "Notes payable - current portion, net of debt discount of $562,711 and
$503,914 as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Amount of borrowings from a bank classified as
other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": [ "r41", "r395", "r673" ] }, "us-gaap_ShortTermDebtLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureNotesPayableAndConvertibleNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Short-term Debt [Line Items]", "terseLabel": "Notes Payable", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant
Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all
significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r73", "r127" ] }, "us-gaap_StatementEquityComponentsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r52", "r55", "r56", "r107",
"r120", "r121", "r122", "r133", "r134", "r135", "r137", "r142", "r144", "r146", "r164", "r179", "r180", "r192", "r246", "r289", "r290", "r291", "r292",
"r293", "r295", "r296", "r297", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r320", "r321", "r322", "r323", "r324", "r325", "r327", "r328",
"r338", "r366", "r372", "r373", "r374", "r386", "r440" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical" ], "lang": { "en-us": {
"role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r133", "r134", "r135", "r164", "r328", "r353", "r380", "r387", "r391", "r392", "r393", "r394", "r396", "r397", "r400", "r403", "r404",
"r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r419", "r421", "r422", "r426", "r427", "r428", "r429",
"r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r500" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label":
"Condensed Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed
Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed
Statements of Changes in Stockholders' (Deficiency) Equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical" ], "lang": { "en-us": {
"role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other
comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r133", "r134", "r135", "r164", "r177", "r328",
"r353", "r380", "r387", "r391", "r392", "r393", "r394", "r396", "r397", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411",
"r413", "r414", "r415", "r416", "r417", "r419", "r421", "r422", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436",
"r437", "r440", "r500" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]",
```

```
"terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r517", "r527", "r537", "r569" ] },
"eyen_StockAgreedToIssueValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"StockAgreedToIssueValueNewIssues", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "The value of stock agreed to be issued.", "label": "Stock Agreed To Issue, Value, New Issues", "terseLabel": "Issue of common
stock" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation":
"Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } },
"auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1",
"crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Stock Issued", "terseLabel": "Issuance of common stock in consideration of licensing agreement", "documentation": "The fair value of
stock issued in noncash financing activities." } } }, "auth_ref": [ "r16", "r17", "r18" ] },
"eyen_StockIssuedAtMarketOfferingDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "StockIssuedAtMarketOfferingDuringPeriodSharesNewIssues", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"documentation": "This represents shares issued at market offering.", "label": "Stock Issued at Market Offering During Period Shares New Issues",
"terseLabel": "Issuance of common stock in At the Market Program (in shares)" } } }, "auth_ref": [] },
"eyen_StockIssuedAtMarketOfferingDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "StockIssuedAtMarketOfferingDuringPeriodValueNewIssues", "crdr": "credit",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us":
{ "role": { "documentation": "The amount of common stock issued in at the market offering.", "label": "Stock Issued at Market Offering During
Period Value New Issues", "terseLabel": "Issuance of common stock in At the Market Program" } } }, "auth_ref": [] },
"eyen_StockIssuedDuringPeriodSharesCashlessStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "StockIssuedDuringPeriodSharesCashlessStockOptionsExercised", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"documentation": "Number of cashless shares issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Shares,
Cashless Stock Options Exercised", "terseLabel": "Cashless exercise of stock options (in shares)" } } }, "auth_ref": [] },
"eyen_StockIssuedDuringPeriodSharesLicensingAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930",
"localname": "StockIssuedDuringPeriodSharesLicensingAgreements", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"documentation": "Represent stock issued period shares licensing agreements.", "label": "Stock Issued During Period, Shares, Licensing
Agreements", "terseLabel": "Issuance of common stock as consideration for licensing agreement (in shares)", "verboseLabel": "Pursuant to the
license and certain milestone achievements issued" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails",
"http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Net proceeds (in shares)", "verboseLabel": "Issuance of common stock in
offerings (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r51", "r52", "r78", "r381",
"r440", "r456" ] }, "eyen_StockIssuedDuringPeriodSharesOfferings": { "xbrltype": "sharesItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "StockIssuedDuringPeriodSharesOfferings", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Aggregate number of shares of common stock offering", "label": "Stock Issued During Period, Shares, Offerings", "terseLabel": "Number of shares
of common stock offering" } } }, "auth_ref": [] }, "eyen_StockIssuedDuringPeriodSharesReacquisitionOfLicensingAgreement": { "xbrltype":
"sharesItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname":
"StockIssuedDuringPeriodSharesReacquisitionOfLicensingAgreement", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"documentation": "Represent stock issued period, shares for reacquisition of licensing agreement.", "label": "Stock Issued During Period Shares,
Reacquisition Of Licensing Agreement", "terseLabel": "Issuance of common stock as consideration for reacquisition of licensing agreement (in
shares)", "verboseLabel": "Pursuant to the Letter Agreement shares" } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of
Options, Exercised | Shares", "verboseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units)
exercised during the current period." } } }, "auth_ref": [ "r6", "r51", "r52", "r78", "r266" ] },
"eyen_StockIssuedDuringPeriodValueCashlessStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "StockIssuedDuringPeriodValueCashlessStockOptionsExercised", "crdr": "credit",
"presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us":
{ "role": { "documentation": "Value of stock issued as a result of the cashless exercise of stock options.", "label": "Stock Issued During Period
Value, Cashless Stock Options Exercised", "terseLabel": "Cashless exercise of stock options" } } }, "auth_ref": [] },
"eyen_StockIssuedDuringPeriodValueLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930",
"localname": "StockIssuedDuringPeriodValueLicensingAgreements", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"documentation": "Represent stock issued during period value licensing agreements.", "label": "Stock Issued During Period, Value, Licensing
Agreements", "terseLabel": "Issuance of common stock as consideration for licensing agreement", "verboseLabel": "Pursuant to the license and
certain milestone achievements stock" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit",
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in offerings", "verboseLabel": "Common stock
value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a
secondary public offering." } } }, "auth_ref": [ "r6", "r51", "r52", "r78", "r386", "r440", "r456", "r506" ] },
"eyen_StockIssuedDuringPeriodValueReacquisitionOfLicensingAgreement": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.eyenoviabio.com/20240930", "localname": "StockIssuedDuringPeriodValueReacquisitionOfLicensingAgreement", "crdr": "credit",
"presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"documentation": "Represent stock issued during the period, value for reacquisition of licensing agreements.", "label": "Stock Issued During
Period Value, Reacquisition Of Licensing Agreement", "terseLabel": "Issuance of common stock as consideration for reacquisition of licensing
agreement", "verboseLabel": "pursuant to the Letter Agreement stock" } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity" ], "lang": { "en-us": { "role": {
"label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options", "documentation": "Value of
stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r6", "r52", "r55", "r56", "r78" ] },
"eyen_StockIssuedValueReacquisitionOfLicensingAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930",
"localname": "StockIssuedValueReacquisitionOfLicensingAgreement", "crdr": "credit", "presentation": [
"http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The fair value of
stock issued for reacquisition of licensing agreement in noncash financing activities.", "label": "Stock issued, Value, Reacquisition Of Licensing
```

Agreement", "terseLabel": "Common stock issued in consideration for reacquisition of licensing agreement" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Stock Option [Member]", "terseLabel": "Stock Options", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r499"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Stockholders' Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r52", "r55", "r56", "r74", "r402", "r418", "r441", "r442", "r495", "r507", "r607", "r618", "r657", "r679"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "auth_ref": [] }, "eyen_StockholdersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "StockholdersEquityLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.\n References", "label": "Stockholders' Equity [Line Items]", "terseLabel": "Stockholders' (Deficiency) Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r77", "r128", "r231", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r309", "r443", "r445", "r457"] }, "eyen_StockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "StockholdersEquityTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOfferingsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to Stockholders Equity.", "label": "Stockholders Equity [Table]", "terseLabel": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r326", "r346"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event", "terseLabel": "Subsequent Events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r326", "r346"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r326", "r346"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r326", "r346"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r326", "r346"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r345", "r347"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficiencyEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r563"] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Tangible Asset Impairment Charges", "terseLabel": "Write-off of property and equipment", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": ["r40", "r75"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r555"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r562"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r582"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r584"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r585"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r586"] },

"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r586"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r584"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r584"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r587"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r585"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value", "terseLabel": "Treasury bills", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r24", "r25", "r52", "r55"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r298"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r581"] }, "eyen_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "UpfrontPayment", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of upfront payment made.", "label": "Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "eyen_UpfrontPaymentPaidInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "UpfrontPaymentPaidInCash", "crdr": "debit", "presentation": ["http://www.eyenoviabio.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront payment paid in cash", "label": "Upfront Payment Paid in Cash", "terseLabel": "Upfront payment paid in cash" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r551"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "verboseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r497", "r498", "r501", "r502", "r503", "r504"] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityIssuanceDateOrModificationDateFairValueOfStockWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and Rights Outstanding Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r646", "r647", "r648"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Term of warrant", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r646", "r647", "r648"] }, "eyen_WarrantsAtExercisePriceFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "WarrantsAtExercisePriceFiveMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with the fifth exercise price.", "label": "Warrants At Exercise Price Five [Member]", "terseLabel": "Warrants at exercise price of $4.7600" } } }, "auth_ref": [] }, "eyen_WarrantsAtExercisePriceFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "WarrantsAtExercisePriceFourMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with the fourth exercise price.", "label": "Warrants At Exercise Price Four [Member]", "terseLabel": "Warrants at exercise price of $2.7240" } } }, "auth_ref": [] }, "eyen_WarrantsAtExercisePriceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "WarrantsAtExercisePriceOneMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with the first exercise price.", "label": "Warrants At Exercise Price One [Member]", "terseLabel": "Warrants at exercise price of $0.5000" } } }, "auth_ref": [] }, "eyen_WarrantsAtExercisePriceThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "WarrantsAtExercisePriceThreeMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with the third exercise price.", "label": "Warrants At Exercise Price Three [Member]", "terseLabel": "Warrants at exercise price of $2.4696" } } }, "auth_ref": [] }, "eyen_WarrantsAtExercisePriceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "WarrantsAtExercisePriceTwoMember", "presentation": ["http://www.eyenoviabio.com/role/DisclosureStockholdersEquityRelatedToWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for warrants with the second exercise price.", "label": "Warrants At Exercise Price Two [Member]", "terseLabel": "Warrants at exercise price of $0.6900" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Denominator for diluted net loss per share (in shares)", "verboseLabel": "Shares Outstanding - Diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r149", "r159"] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Common shares issued", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": ["r19", "r20"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Denominator (weighted average quantities):" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number

{"of Shares Outstanding, Basic", "terseLabel": "Denominator for basic net loss per share (in shares)", "verboseLabel": "Shares Outstanding - Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r147", "r159"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted Average Number of Common Shares Outstanding" } } }, "auth_ref": [] }, "eyen_WrittenNoticePeriodForTerminationOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20240930", "localname": "WrittenNoticePeriodForTerminationOfAgreement", "presentation": ["http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of days of written notice period for the termination of agreement.", "label": "Written Notice Period For Termination Of Agreement", "terseLabel": "Written notice period" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r549"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(19)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",

```
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r182": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r183": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r184": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r185": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB",
"URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic":
"30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
```

"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r236": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482969/710-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
```

"r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r334": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r470": { "role":

```
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r471": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r472": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r473": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r474": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r475": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r476": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r477": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r478": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05",
"Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r479": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r480": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r481": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r482": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r483": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r484": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r485": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r486": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r487": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r488": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r489": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r490": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r491": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r492": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r493": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r494": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r495": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r496": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r497": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r498": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r499": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r500": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r501": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)
(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r503": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)
(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r505": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r506": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r507": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r508": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b"
}, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "b-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number":
"240", "Section": "12", "Subsection": "d1-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r514": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r517": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph":
"1", "Subparagraph": "i", "Sentence": "C" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r519": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r522": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" },
"r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" },
"r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
```

"Subparagraph": "1" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subseection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r592": { "role":

{"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards

*Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 75 0001410578-24-001894-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-24-001894-xbrl.zip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

MJ6%TL.>$7G.^3;$]V>/"61=@81Z"]20<.$S%SI$XIYC3[;>AP4A"70FHEJP M/LKN00&6BH'?J204BT*1K $?$S[I%S&935;)N%4%5 6U$;'C&L0V,I$_0QNI M W9-L+O 8G'E^2]6T&V(C8KR>S!SIGX PYF 5C M1_GM,'F=^AYU*!'7[!EJQ.?P\Y(§F'K%,:^MG/J!\ ,TU./"6!CE)2'6)1'/1:/$OD('"*D=K1B*+/)% 32H[*@N# H*0T*97%06AZD"H32$@U&]BY&=@'5 M^:S7R^K)O!;D&B.4A5F TU"E)M,D=: [H/WNBUSN2/!C2_$E/"'!;1#Z#G M!_2C;J.3U=@(-AM/P45M9#Q0!@2< H%GBH0LAN1S5$&0D"49#,EL2->@*)O+_M_1*U0HK&&'K1' M_6L%I-L0:8+_YR+\2@R*Y203T23G7"KT"'VLFDSE;:*TP:CV9+1-/$1MB#1 M;#*%A:]F)C,X%6\0$FMB)&W%F..GA<[$%-,:;*']_]_-U"Z:RZ6>X60V(QQJ MN7)-O &K ?.CPY(91F;2&<\S,]ZCG^0R -T&Z&LA0AD5O(19_X1'6^:=J*7" MERM,^>_8"\$C4*Q_8,!2;,/EAC'6:# 'JKQEGR!E2Q2X^9LX#P\Q=,RN59E@@[:\RK681A MBTF K42S6?S2O!>@VC20;X:#R+F+#&88$UI93*.UJ6;<9DLXM;2$(2#0%O"O MRY7GKPDY)PQ*$4P]7-GVZTA-4!X5)_R).!3+0TK@@)G-*N&3(-]#T/>K/ U0 M?8BAG,R$5>GR;R(*1;(&F"IABB]#2/X?,_!R>]M.5 MR14,VD\9.8T$ZIWB@%=5LSH/!65$B F?8T,_HPI_A^7N2?TP'J!TC@45D]E4 MJYQ\V^LDRX Y]*7%%HDB/0<_P=%>68/_BG#4/G* [WK.@VUTVYC1;M>%&>]. M&W(&4+N<#FMS+,P,:)<#80.>MIM>3+M=S#C9[',9\&AP+,_B/)X9% ,P MG<_?M3YX9P:Q\Y&[=YN&X3:;0(R]MM<]B :HMM/ VIZCG5;[H?9T"L"K&X M##[%/%@_<@S#DJ,F8'FX^NF,6)T6L4H60Y4TI(L;@+*/>ILCVT9P;#Z)=@Q;SW4)QW/>_T4Y3(W2E(60YS TX3R'=%D!M<8#5@W#Q05@YI M-:$)P8]%!,MOKQK VE;PK!9":W83L)^J@;6]NFJ ?"L!M7*\&_&:P/ZY"':3 M4W0#TAV";.7PFAE,F#:^TVE L7D\I\ (1KJ(S8&9]_F2 JD.#DWX)9NN'>SI? M!)/9-Q$OVP*=^8K(K!N"S"R)^-H+81CMQER>$-_M-TMN(!>81LF!ONP)NES)1>?HVT(JOR/-8I0\ M _1O4'7_=>DE)%)\S;--RH3RM1-GG(C W"E(*;Q6!4+\E?27B3A("K^'#K:E M%=1G4ZVR$/10)P_-=4)6(C74W6@J315)]>ZMJ[4YX/<\S_QA\PC0>])(-#. MYP%BV:?%1.X%K1.]Q*.C_:,]%+V$=^-'1^,W;#F-BZS[D&U695W*(OJ*'^0:R4^CH^/12<,:+SP$ M:)E_PB S_MA:\? RC93:9>YQGN&0)3J7J1Y_:E:/T63HK@R_A5'\+ZX)4/3M7 M:X"ESP8>$"\0J9AF]ECQ#F&'0J@7T=J58?/=U#T.BDGAX]6_H,G$*^O@[(4KI2>P@_@1<) M/N.7O1GVU/N@BA &"NJ[CXHUZB! $J.>)^,+7_8"R#SRA^7(]N\&I0'U1$"# M4%;':]P/5TG1*!0IR?TIND_ZRY[#B4N#LFI(\YYRWR'$%? %%+_(^%N)>AO+B MGJE2 G(1X+Q'J69-G5.UOA*ME-*KU UYO#TYI[!+GJ2^!51J*\#BX9AT/O%(M7H-S#U3?U$A;]MQJ2M_O/ L2TJW44TT%;$HWF54M6!74;LKTSLIFL+J/#N\] M$ <,5TXM5[Z@/Z:E&TK0K'7'QEZI+5[#0.0]XE2:>OY(T27M\AV[+EOE6= ($Y^3LBD\E^&_I<^2%_/W7TW+>B#7U^1W#TW+>AS0-]?3]E MM,RWH@L,!NP=M=&$WX8^7^5BV/OID\F^C\75V/OID\F^C\75BPPBU -G@L^QE'8Q<4M]& MSE23S1WAR=5]DS"0TER8G95[\'SX)'PI=P-E//E.O"_ M[Y2\#D_]2OOJF;.9K"\&6GY;OZD)UM+V1;5S' IG<0/]+]->Q$NZX4@E XU! ME? S(8="CRW,YR\PC4HG5@V9:EJ@7(MF\ZV@ MEZ\1:ZWC\O\F?Y,*)0LT=3K)UV#$6UMD:?EB3R$S"S;3O:4NZ<#>W C_(/(_ MXHZ?"<=SDO&" [*W27LINF*G6RNI4JX7??H:ATUK%3S#]4 /)ML76E6#'__85 ML)76WKH6[&7TV!2J[?F>R%%5/F5+9VW;1%Y&#]SIAE#:UX*]C!{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{ *FF&QC/4\J\%1FWTWRUP,U"7?@)^JA:" 2<)U;KDYT;P?V M$(YS^I2\(>;Q#;DXGNQ^GEVH3L1O@5330QQ!Q,K=L)Y#LK=S,J* M4QU,/RB9\(@E$ M"&.P->7NC8L%-2*UZ#ZS)#A-QJ4A"V]>:C"RKG^G2&K$HB(_MJ8>_4O TW:?DKX@HR25Q7:Q.#$IAT[0;7MLV7FHR-+%]3_KF"'NFZ!:-0#H) M^+S;:5\>+)DJ$#6=WX[X8SP"X[|)"*S"7)@&^#,_V"&_06-L8='R-+]@G9C> M$JWT?/?7LW6#/,#?=_784)0?($Y YJO#=L:KP_*#3HV8M7OW[F?D'=/P ZP M0'&SGB&NR56Y2234-T-2HXZ68=6,O9\<*)K.9GYGH/"0T;$P1L8D-.)(U?R,MQ.7A.H3GA2/TAHB/[L_D_#D[,RWO#^Q-O- ^[!K@3'8ZFXLOST&_]HOYH=P)%2N M*6FU"UB0?ZG:&_(X31L3R\%]"-["'_D-QB%BX;(E)E,+AO,1Y:Y4&AJ0MPIT MT>96WM :R6E(XO9!6PZ=%*&5A&L7@9WX>_<;\$>'!E=W0RC"P)Q11F=N,QE*_M"'2J.'>J\|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|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|&X]->%+^0; ZC7I($D.1;%UM"$,5VVA:@U1,(2V/?WT-84)86>%3TFV@CC7X-N(I#KRM.-W ME*2G8;3:\1S$<3_!J?@6F??OIQRY?+3A0-%_,Y11O $T%)$JB0MV2 M/\LY&%Q#U;:* 63M0ACN?HU2-L&^^Z32?U*8L\GGG,)$$UJS!ED*_OOW[_. M)B>3_(-S;'+-?]M:X_.'W MO6LZ!H24QU$&VW:>&#S#^..;SO:_GS=8[32HS7J B(C=_JT+K;"VVZEF1FR(!4$V&/U00'JR1.: MR*%%F.ZV/KYQ(QD[R(L3Q!5:K5&2^^X4] (*7!ULG1+T<8-\ 1:H:W+9";(6M MC2E(!_&1 BSN](0/?%57A$"[51=ZV(O"'.#-(XBAPM(A:BJ6$UD/%QCOH(@# M*_K/)TP/YB#(70LR?>GN**:!4M?!FJ3 &Z0+E'V5$F-152$*#'F@X5<0RWN@>8+HUW8,G44=)#Z'H=?3Q M!V_IMD_:1Q=WGQT.AISX]S/HZ]%B&M.&SKH1*'%6541$1IRJY"^B_ MW.1OFO+;;8DB"ML+Q4W:PR7&Q1NNSQ"P8)=PECS (,/LQ0<]B4;D2X*>"<0O M]G/-%EG*?V,DB"*H_P 6T5&JJEC3==- [Q$F'&H35*0'V4'%NOF0X%XU&F/B M[-327,/G=)]0%&<=Y]EV0Z&L\YLZ1Z[302IJKHBH64>EE-Y(#0;KVL0#NJI& M,F#=7I O$4Z?*

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}(J\0.I0^3 9RM#H>ZJE8/NV(/+BVC- M?R7EENXO&'Y)*(B5)$5Y*IS+S:>O$ <1@?/1 M(\Y]T$QC\$,5;) ^\'KH86W..*BPH9T'1 2-=565@,J)""("VVW$9?EN M1A9:66DBCAEL-'*(BCPN4NW-F/G77@(J(MF<]B,8:T#60A4MO*_2X+4@C)FN M@-4O^D'XG %TX](%0S@FDG)VW!X=]YG"/O[@K7"- *^BCB[OI"]TNAK1N=240.;K:%:#0OM^5@&[]!NR) M(<72J(?12Q1FPMLO;CONW9"PI2N,?HO29;[.L@5Y&:V?T*$\(X(@].WV@ M!QR9 ZG13.QYX31TC);+' L"S@7(=(N,=1[LM%7*OWD'U1 M!RM0#W"L;ISX\.]2T>G [39':OA'1HI"L3<(W\'72M5GC!+ZSZ!,]B5>*;3& M$-I:[5'P GP,'^.I6M MLCB/B_TTG\,@+5{@[D$3K5L*W?CKF&)'3] 7+FIJ''7N1P-!RIL.A-N%CEJ*,(HS!N@C2\5#\87DT]<@SD(8WE!.LG#++,W=U+/Y)X 3 M5CR<8E,$9&[X \B6Q?%F%"^BX\|I#=\Z \FZNFE2T'!J<2N2@?20LK^@CTF% M6W:!>S=NC=1LDC54@KQFHK}>H+&'] H=V1R&RNC:=!I*: Y69'5\ MMNTW^ ^GVE@FMF4>MSQ_;<>^5=1<*&*R#IZ@*U4K<0U'@*OZ8L@"!L MT.G}^Y_>G9W]<'8V.9GL9J#_WDV[_Y5,T'Q2SCR)DDEUO^8_.=^^O^:E X MK(+^Q&Z4!6K5;/0M5&OOH]O*RK:D/7&0/<.3G=I558%G*?B,J#WFEZ/3, ^' M6%-^5)Y4#& YF2)#9!+766S>! [Y0D%:HL'S2VU-.NS'YD=/G9%7.)&>&5+1J MS^';,+AGP -,*;@PW'I3I5P0-;;.BG<#62%"Q#T_+L(P*J:_!Q$]AU^!=92" M6%XP3] [':G=^&,B=#GS<,VG_%HP*T93^LW.9KS0QKG8_C<#' M)E*>L;$2S/B$!/N?,B%5@5MWZ*WJ.-;9^[5(JE" MP'6/(:T+P-_'%@ QKF9E05"62+J4W$8!_4DB]U+ &Y%)?TQK+/QYSYL[(F< M2|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}+J75 MTO73[>%[DA9*5ER7VS/)$XY S"I(!'0W!!9Y4:BM=X-3' M\(#)01]9*WRD.QV(J?#4SYB\ZY_NYJY? 8@_@CA0OSRS>-'FAHH/PYC<* M%+Q&K^+Z ^V&$I]6#S-X/)2LZ$E[XMK5X&U$TGL[W;E#Q#*$T5_>C".$ 8/ZQ?D$$T(VG(-=WP@*Q@"<.,19H-MK#4FC5XV/(DW-?8.M#:B+S>7XPIA=W4_0\1TOX,@%C10IQZD#VPO M(V:D]JZ--MY}57:$+Y(T!K-6X7H M;A6GK!S;'4JA+*I T-+U55D7RA%RPMIQESH4^60I*-XY"4S$.K=?;$, M?=5!F>LUK#WC-C5D17%3$)?F*P?YQ{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{57!V?/*.Q3]A&;CRB,/R2 M4)KM0CB>T#[Q>5X-$[!=1?%_M:U4W[M2TEOOXQAS#V3E?H.Y29*J,&+DH7, MZ,N[V.?L8#^.'"$O0H19@=HHS=>F(D(XI0!"'B8D9N*"?VZG&*K,N8T*WL_J M9R3P+2*D!J8L!EC4V,F3F@8HEYL[D(?+S? <_;R0!#CH#^!4M+&=9_2&..H[N M#6L=VA)2:?"#M(='P0_ZPBKF8@-+]VR[!BNP@(35C"R+0%S#.0PZBG=U]O(E ME$)!*FN.URZ\W#/LB8X]FU>JLDNLI*'M7U&CZ@91@(Y[GE1 *H("$K#_Y8G^ MBX" @2=7*NU1/+*14JFL[3UUD1SK6N,29"18- I.IBJ/&Y.U]L7<|)7%W"R+'-MTKVF?5\U9@6>'G6+>:PE>ZPE>ZPEZX-A/MA:LD-.]2TO5-;UD-K9X,;?;U)?[7"#^;R!T+ MUYC@F.!*2HUC[JO3F':1?B)IM (I*[J*/[" &N@YBP5!24EJ'C(^BE$SE*X MHP(L=S"5Z*V+Y$&&MHNC\B

*MJ2/?"F|)W:$Z>YKC0!.GM'\&.FE3L%@?M$F_+7_.UAF\ZV92Z PBX<7{D] MN7G*4GW&K L"\X%UK%8?^?#WQ3^TFH'.QV9@B,$!{#_N<+C+B;]}^>{A/BX3 ME35W06 ^N([5ZH,?_K[X!U4K=&;[[Y^^ 956$M^]?L\H!5+=_O- M0Z:2Y.!WF.^M9++ZV*T?%__2BM&[GYG#(X$8=/O/H5/A".LR8*KP6!M6\7R MH7W+,& VWF6BHP 5**I@@;+@9[L\QVG)C]^HUI+(<5=HHU(=.&2(;Q:A'>*K M88%"?!,SNA!?X* :"7$LB/.3$M-JL/@9GP=E(!@SI/75X+ G)B81#H]*5+!@ M9R1Z9O2'(S4.+<8(*E6".7//S\@.]3'+]\;39 D*^N2]PW#W\+T& 3Q_/^#! M= 2?HPIV>16XVP1\G97Q"DN]*O- 12D"B@9;JM "P1(!10\Z%2 @:(*=GD5 M>+?!^2-9P'[)LY?RZ2S;;(-4[PTTT) J812@K1I*4" 5,?"B4Y4*!7$<-))*
MW,833A*;JK2!0)V&@MT#GR%!0+F,#@M:CT$AX3X^&7A#*T*R\(^[IX!,Q/6N MI'>&Z$9:'V;,D4"W+0[B'&Q>#!A06Q@K2]J-#,-$#'6%.#*2L 'TBP3#>9!< MIA'^]'}CO7_IP(%]D9KI \5I T'IBHH+K7IP8,2@$0%?] 2+[XPNXB(,DK_C M(-=?)]"# IUL65BO3{DT<,N?>!D9Z9Y^B?P'AT<4 ?1Z0C $.-W@=V#$B8@QG@2J"/;@=QA]4#)9Z4#KQ\6_NV+TSK>N81 %FN[KKH/B M@;&Y*TX>@V#+/S%.RJ+Z2_.MQ1_^P:IR*"_7ZXLX#=
(P)MJ;\0M0FKOI_5"7 MUY AHE'EZ8.WJ%[U9ZP;HF0D9DUI:XZW04);6M"-,RXG="VCE.\^>.A41B4F0_TH<.V4B=J
M*%B].&##I!L4%#%8O8),PGB)\P)?3{#M@\Z*9(:3ZG9@H358PWQ7D0\ ?59 MR8E&/U9UJ8UW^NTF1L6^#^1^%A1/IVE$_^?
=G{OX.4@(9)5I>1;D?3Y.'W\- MDITN)G7$A3.'7L+)YN&&"&(N/3CKZAU!8BW V#\D]!4*2E110(PN%-(FA(M_X$;=%A;NTR?"1-9OO^ =2M*&P3. HPP+ [PE1:BVO?_K^-;,8^I=_G.,U)@ME=$9 MXS!([G;;;;(_RXKR<&-L!U_>DEQ%H%9E@YW-PJHVMZR-0L])U2G&$R9N5RPE MS]1)HZ"@K7!+\L.#2+L5-.V&
(G85E_W.)X\[CWXE:8G&+0TS"E8<$*[U<3P) ?F^0F+4G[(4-YQL'L*DX M!*,-D*@33#@UM,:8A:Z8$T1YBR+YSYJD7WYQBMD0--"%F -!!K7I((D0I/><
M4F+GKPZ[@SG'6WK25K2R'9H@4@,+MZ*Q8S#HH,L&?#& MIX\{}=7+2""M*J\&J_8W.=X&<67CQ-JO23";NQB!$R:<2?003#80!S00<:@O9L@+6Y-
M9SY<0KYAWPHYQ3I3,$$S)JBP-!)*&+/22^7_QC_+ MX3(N?]#DM?3QKQP,ZMG5E3'$\6J'6>S*"C;ZN\5%%X!OPL]XIA/1AC]+>
MA'T@"MLCVR&+Y+BZ(}@SVLTL!XD,PZ9L64PB"4&,#F,%"0:OONT4IS36+, M@+;VNL)!@6_CQZ?R>OVQX&-M8=Z" V<83L+(UF%$
#$1!XXZZE7C((:T0@SM M)%N?$$2^LH!O@,;)E5 DE%=B{0JQELRQ$:JW9J:=D ((:"ND9;?>"W4@X#9# M&E;,%3?-
MHC6V]0[X3INA]H;N0I3PWFQ.^K/=63C>L'1 ?/' MPVZF+)DO-B:*24@07\7!0YS$98R+TS1B;82>LB0BAD;.I-Q;+M6XH\,I<%\1 M915WQ04Q@G[,*3.
K(:PWMN=VA-$8*ANQH'Q'+V1D&YK]9;D1 MX%W74%'XABSH(]"(1)R8.)%D+ZIZ.:O1]T4&2MSU%]].Z#ECPB7Z>K*HN.[< MN6ZW-
ERWRQZ2^)$Q4Z"8'\9$;#NSK19? E3IK:&(,FGX@\HJCIVXRMV\DZ7D M=;\>.=5)177[H#Z=LU4B[LUABPW)EY,VG3CZH[9## _.VM0LV0_;:KRY;>HG
M+E&*]FB/;5@5[@H?]X-ASWX-'N@8HNY1GXA?FPH^0!TXBS@,OWQG@@7]SC? MO W2/ZZR(*5.\$-6XFISIID7!SS
{GFN0K6:Z=F08'KKN7'5K2VD>"=$O3>(M8B*&RI8GAESE!*![[XV1#C'I4B:.+3>P5&9CJ$?9"FZ/H+57/.N#@\DYHR+ ML#J0_O*''[];_?7-&_9IO_SA}?
>KG]|\142K=\1,,'U$%WW_>H6HZ3.HYO;4U=M]T;V.<-G+8M>.,E';ZZ/*]-G MG<%.LN]4E>RC=?-'D>YSEE?S=8\EZV>]=>*
YUWNSWP/Q8KD4P;0JH>F)* W MEU2&"G=UF#5K75=9)C/8^T;!D&^G2@_VD709%\)\9)8^TKR&0VK0_H,FQ"
MM%R%#AC&19BYZ:H76XT.]MS^^(2>TAQFQA3F8=AIO^,;[+_\Y6^K[^F.^VBW MVE+BH8WO M?_K;ZH7AD=$"
MA3(.^IHN1>AO^J8D"STNV/,:GI\7[_I=M?/LOWY"M1\Y/=E;HQQ7Y"_W_J'@B
MMDW6E%WYE.7Q/W'T7U#]QY@)SG/ZN[(HR3]8_X=>NP[X$"Y+K2;6!8,-UE0L M'T9H,@Q86-9E0AFZ9*F/-M5/ +TU?<]M26=/?_MQ]?U??UC]],/?
F(7\Y8?5 M#S^0S?QW/TYJ9S[M|D^CB+V5'B0W01Q=IF?!-B8[.\UGT$(#7HWA;0R,*CN(4"01@NQPL!FW]=D+$""UB+&($M[@,XA1'[X()>9< MG(;A;K-
C%_S.\3H.8]VVR 41SC3W86ZZTHV0M*WJ4OG3G8YMS?E4%>SL'_ WZ,4VKVP&<8SOSSHPRONS/M'_F 8;>BI/ MMO#GXB#>T-["%1.H_KV?
8'7ENQL:7,U[_X,[ZCVA1;1094&6?H?V#L&@#'IZ MB MF1V99YMPQ7Y7XXO)EF8/!=$9]&F^"_#]_*?FY&RNON<'Y'2UX<:IPTR/[M4OEH$T]?#*C&#]*
^TLR:O63RAGLM3H$7>R%" S$B7I50#I94U('5]5\^F1R3 MH#BMB|\^<9J*+Y(N)Z<31FJ8AA@NM@5E#G(M?0NEYZ;("=.+NRI]MD,,:-_W
M6GIN#]J77'S>!8V6T:_]CR2.X^;'B.&%*;EL>PS@T*;CN#5HFXQONYW!\OBY MS^F(8]SD:*$],@_]]D8#ZH=9&+
<"*I/P[ZZDNR#^;6@Z8MAW,V84CRS"LH\Q MP?MA&_9(7VT@_NQ?AHODZ<[E,@VS#68Q(CU#M31TT4+#68E% -E -* @MF'D M175T&-'^RQ&J,=C=
<=%:-4N!&VG=XF><{D@,95:?+ACD-5FM445NAFAZJ M"")"T0\#G6X.H$/_HKQ>"U:T\5L+!C*X5S#;CN8E_*#PO<.!(C I6(V230'&
M,>O>#J$/S[D/2OM+GA7%39ZMM=U"6A!P"JM@5%97Z6<09>V,W_GI#)Q$."[MLZ[,7I'_X\E[*O4C,N8(WP#OP?LI.B&4[Z8< L.^EZ+FQA!,UR\4+;4?
Z/." MR&!@'MZWN("$\5[.DVC<|)Z)-F6;L4%<]HHRX@#&?$["-..[0T(0%&\E2-% MK,IQ1)>]&JO2,7 K&2U4U& !]T""2'W^ M.B1TG1)
{3:!.G,;5YVL70;#>N MR(#]DG]}U^JAY(0)TU>I!VO=7DL<>84$.E'_H%ES,S>87H2,1\E,8,6@3GN MJJWB(/QS%Q>L&^+U^BH.*8^W\>-3>?
A>@0,\T/TS%R']>V8F8+C[9':N#/?& MQ$N*]-I8+M.AOR6<$LH9*:A+7P/$:Z&@ZS422(AC05[@&BU-Y[MXMB-SC;6] MVH$Y[;S\V'$Y[TV
DPJNC/,.7#W8T:M^2$0S7$9O\A/5#M+N-*Y6[8-7[MD_KN1SZF@+/U?&VMY9;^:<_{7JVX8ZJFC6'B,&9.&U59!V\;46'*@ V\)/1]T"+,(;7-
0PP+9@HD9A>)4X")07Z$* M _A4K[<@P@)B#RK/^VYEO=S%]MK_^K5W[;N[ ]RP6K.D?6419P)LOVH[GU_& M&'!I/0@X@ %4>A6S+467 693;KM6=-
GH:C4NS66GB^4J'9E-P&MDJ_?JJNX: MEFR^'AQ.@VTBR,JL@P5QVF9F.@I3/^98-VM9H;=!$8>\&#!.=K2?BS;|-4T)
M15F2!'F!2"3${]W#GR/T$8]+DHHUCDD1BEX"3-:O^XD(8O+"I3K.1@WMC]D? M"& R? 'JA>FW>'$R?H'AF?F;Y5
Z@&H5/Q878!:QDN:XW,!OF%9*XNB4S$?P MB#_L-@\XOUYW6J8(Z6@+?2+<+L>7)=[8[IA-11S.R4P[/;)/FH8RB N;DO5A M@?]*9$
:TAYUTYAU>BKB2%!'G#P]2:LZ,KEWDO7*PYCV'#UI^.|OM'N47@2\
MMGY3P&S0XJ[Z^K'=F4+L5+QS5C:!'=R5CH1/#LO,XUB7Y<.*^ZVR#QS+1_Y5.61$0[>)F699OFB MX?;N/<*W;VRZ(,)>W
MW3ES{C')2^P*JI,RS:_0U^=X'8HNU&O2G0K6+(#)]#ZW?VV .?9)H@/Z[8ML(1 M;1/SK82V"A FG:WGQ*HQZ'<.#JPR4J?
H]YC&"!I1%7!>M!QO,ZWI,\Z!H)N+ MRUP8.X]CWSDH="YO".^PVGP:1.P,0I#3":B@X8LCFI6U=,1+ ^I%Y[)=C
M6O#UE"W.XRQZEQKO*;ER_S8@_QEB%)2H?,((I]%R:4 N"-F^YN4,HCS@QSBE M=NTDT$*9$Q)A\@>?SGV&SP#C{0-^83_I4RANR)"YE#[BM9,J+IA
V15W MUKJ^@6V'.#;BZ(CC-ZN$1H<_I[.VR22TAJQ;9KM[@H M\SBDO?=-6T_C86)_&D";LZ'"UGNRO@3@MF+#.+66/^0U6;%{{X@Z%]IB.:A= MUT32-
V208=_E5?W#1))KSPISS%ME$L?_3(8B_]*HQ,QI)JN<]AJ{WB1\]5J6 MNH>>^:|[[+*=C[M.ZSJ&CF4?GIIP$=O-2/E4U3"/W:!\%G!O:/11Q% ?Y_BY(
ML'AQQO34BAX>,_=C$Z*5T]$!P^1NS-QTHW("Q1X68PKDP[,J$M\?@@WYYWT> MD*U"2/VK\8T5%T1 G7(6JZ5<5BP8+7-
DRZ9N4SS*H@FE#@O+E*WVC9! @9&9 M\3K^48/!A3DF?KK13+=:<9DN^]J@923[\VP&'F.RSN?TW>8Q,X9"!OYTM-
8^6GZRS?,/K6+:\9P$+V#,2R%644<1(@]0"^@E6NP(W-#B7T(<_ MR_6%6-KW$9=!="RO]G7$=42$BW@=\SJ1!TQ-BDSY,_$B\0.)J.*4=AY,,[+Y
M9^_F;BB5=9P2@G&0D)_)1%\LD)D-N(P2)*}>&CC,O]5T5XJPGE=$;-9H5, M+ ^<:$@:,!*07FD;(P^JA=@^H1Z.0B^SB*DXOB
^H4AK7:^F-.|W.P@$/;@_G M+)2\A;,B@>S@'+G2:R"=&20GJYS>)9S7P*85+M9DXL /<(>*QSQ+_>[)G/&+ MEK/3-
!+MA(U1C!L^<"S31\A.1.."#!_7N'.IC&YH 2O=]B39"S;'(N M^R(\$8\HZ 71SN+T@43(07C84LD-Q8/WX VB*) ^#5\##O@:O94CQ $T:T=Z/ M]%Q0(+-XF.
(C1@!6O3[@DK)"[.F9;-NBM_N/A-?+|'K+NN6DCZ=A&3\3#XAM M2C>$$)PJ#A=;5M#^5$#4=BB;RH?HF.)6I.BMMJ\I-,)N?H-J@JBAB'ZO:$*_
M2#O9++#2FB^CRHQ3;HX)I6O"8AG&"R018;RI#!ZXJG3 M%D-/_ Y\ ?2D@MB*GNO!$/5+?#CT-1WP&_JSKXZJ;\WSHG.:UW.:DCE-:(1,
M_DK_S7'9'.SZ#**LG,*@'^MF#)[O?'M: ZP(Y#3#PX]U:JCLO>'<@X9[QUK"B MN27_MGW[O;D@OT(?R"Q1)7OWB9+2/^"V37+C03[8Y;@N,-
HES>IH;QHP3\N\$ MTW^0C?'I)LO+^)\F W%#A3.7/J+)QN."!V)*[HQUE$]&7:$:F>5J9'1@@YI(M0G[B2!>@M M3#@M"A)C;
{9!G%.M/",AD*/V47<;$MSBZ":.O"R:,4 61!>6NLS[3TC3:?R_29\)#E>\;I>?:BBRI5@'!FHF=;-HTN M%(@YZ-CIWLBI !'7FXB FN], ^|-
QZS&3*#1Y(Q(0N0X2,@20BU_"/?^JJ MY{@@B]1%EM_BG.#H7%6YG!)W6H]WMMMLD5E]I([7AF!R6Q$3KT=PP"XZ-75V2DM!@8]]>G-^PIR4/.'0
MFW"N$^=" Z3#8_$ERU+)T8< Y*:jKYCMS;PK-M FOQ]|BLU_Y2+.91?1U#L(M,OY498T6^>R)GB 7!U4)-+]6L!Q9$@)#A4)7U)L<;X.XW]\(GW.:1M?T
M:AQ+$NJRST.) ^62Y?<0W6[$+)4\LVIU55^L6%*L%E&D](\:SX'-%Q^[O!TPZ M"96T593#Q.572<-
=SM;CP"SVB*BY*XD({R\PY5[(<8OCS<...#Y65G6+0QP_ MTYREJX=*-(G|/0KI MP/YXN/ZSH_%GFI.9/6*T?/-=_<4^-
WY0WS9UE\VQM7,\W,+Q:8NF$,.\$Y,0 M/-EP=3AR-2L)T<,ME(M8=OZ!;.0.D[U:7.[/B2\OXAY)CBZB3]:B$\ML,H=8 MGMB-FBU7XZFP484.?
JEJL(2U**V2.Q)F6 0#LJW3D%74%C?!GH;MSK/1P?/) MLC1"F0WK ,D3NU)RY6I6%3(2V-YE[]VDJ\786L2 LZ%\1U;DYNR@SP1T4#VS M)
(UH5F,ZP//GI2,]3 IBH\D AZN5>)Z?;DU_FXFQ]^2R5_#[DTL8^Y !\Y*Q4,AI.R!('\;&K M5J[H?U?2[ON7#QSB>V7W9B$=2U;;R+
{8M(F[_@4KC$IMKGO_C+67N%P:,ZS/ MO2629C[Z$#B&9E\J W3'}KRYQ4,I-O8ZFDY>I@]=!+QO3*\?3B)6503*K6/67 M9!_O,O6P,YE&1]JJ+J9H-
V@DY)T'&:F2\X$^\+C=]=&@EY9ZH. M8CN8K(&*3Z9K9;.O"=<$CZF9??]9.-Q;JL2>^^TE_CZS^O&6RU3W$,;!S$Q& MU8-WFL9-
B/+UIF$D_7C3:0SO;B\|M5\!*L2SWZW7@.B>KGH1B+==\.T5W-FF MK/TV5/4HNO9=*#H[^L=U?7DU:L89ZB5NC\JQ<^E+,:(&3CIWH@
[JHWESJMV[9KN1[-[* TJ647AG? MYF;V7XTWQZ037A%K3NZSQNR]Y0TJEOMZR2K1WGW >Q@6.=%&H'0]P)^8J M5&L_9D."V96Y<67+F#
;%*BHQH7?RTPB'1;0U.IX>)!MS>64BYO6![K),M^' MU8/84@J$?73V(\."FTV7&8L^T1UQ=2]TYAVQ?B]_RUOOW@1YY^I)/U3P@-)) M-$4L:<3S(8QT8-
>0;)6@NS=4]YJ>4N08]Y-E$QQ2F))VI&;A8SLO:HLCQ_C M5#RU]_(4AT_DQR1!#VS?3-^W(D0RXGM%JZ)-$*\A('H6$5_)6K45 M14;?M2-(298^GI
=WH8-!!J]#IE>2TIRA00-Q(CX$FZ.D'2Y1-[H]? 6;VN) M'=9#/3C<>F@305X/=; @ZZ&9&<5S %O)D!C"S/T>W+/ZHT3A=F'K^;!,!<4"
M@GA6\S2ZE.0X:IS&U39Y7M,T72V3G^6(8T1^NY^^>FFT>5(6V?LP?^[BYR#A MK5F+,H]#XFCI#Z=IU/Z#!'G#@L7NI>,PV45$R'>?0M;|_I8X[7?K-
=:6,R[- M!)R;@)ENV=4LRP&(NX(045FXN.(>0*).MQC5P/Q'6G=S^+<6 F<(*3H1K%#- M%JKX0I0QQ#D#=J%>? ;JABMLNFNNY_QPHH_8#<\Q_T?K)"?
W>I<:WES58[2;_3]"YE&3'NDY:0_ZX,\M*G&7B+'^.490WH!"(PV1= MN=D3 $%"^:57!"[3=99O6/+3> 9G7OGK*\O,M[?0D .3[1>V'!N; ";W5;;M=*
M.+6ZD*S,.FV+Z%N*61[QKJ.;:@R4U8,0,%: QBL,Q OS<6MM7]=K>\#7=K![M"I-,GY@T6C/5:5Z%:CJH(03IU*.6N*,?*IV8PXO=XC A(\;K.&1CT!(X[9M\
M]YG^0;O1U(#!\V_@)]}W=<%)PGF\LSP8WF!^0MK_'R3UE/0*4.YM\3@X)HNNU MY:%.=)\M\..@ZN;?S;ZZ@5P\6S|^%1>KS\6W.%?/Y1!G-
)ZI>J5H2YTW3R/ M"_G9>K9]NL^J1LRL;RR!(F*\T.37!JU0.S MJ$6OOFE$HHB*)))H GO,:2?B5YQ&Q.RK!VE10**HF,M>I5/GZD^NV6%>|VMR
M";U6A>FA!=T?7*>&>T?N:$![QAXBU9M*!QRX7: S/8Q/<2Y\&S8W4*!KF]Q M
K6N#1*L0JH[T#3]H:XM'5L66,S&B31/$QJ-F4O>Z=<@V>%;'#1!^O7ZJG(V MIY6O4E. HYH<.K4NWPNXJJF$/VN%+5PQ
M.M&+JZ;,X>B4;43K#,6ON"#_V]R"8;]^3./.A;F1M(#69#H+RY)<=!=G04*)\W\:QHVPI+J4M.5+XMR$$874@7..-< M#-()V$3%=?
X8I/$_F3V=$>^=)7'$KR"ET0UAN+*UZ[6HS0Z2._(7GO&U7%>8 MB#9<:F32R9%S*I,0!DG&3,AYQY3>[DA<0+=+$\B K](9VH&/V=5V_=\[. =X&
M13;/K_3 1$;$?I"TT(S^!GXL=.0G:J0;=H-O:I@?W;2 MA #G6^QBR%Y"#PUB[S9V%/?M-IL@W[/<:/R8LHI%LG%IZ*"*$/#A6,.<5T;;
MTN>*#'B@UDN\UE&;$R,,(5P/UK]*:=;&!9<{E]8,HR0]$A,D*PWM'_WNTQ:G M^2;+W2M#CG M=3Y-^X"MT&LLZW7&]#H4>LTKC>&>
MWKAL9+4LM#UIP*VX@X25E]Y>!$#6X $)ZI81J MYE1E5S5Z76PA'J@2)/Q*IHV4US_C$Y=3Z#9&-$2QYLM,&(!I,KL@K>R8'APF
M*6;C1ZM+AIWCE<-%["6/WZJK4()UB;UJ%RW]J0F:A#BVA6#J0<"/^2:>+L71*

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{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`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{4&B]*^G;-UNP(V9$X8'=00$J;F1[L_B[AO]^^# M_\CRLX2$%H86?KVI0-8K#A*X79S8BP10)>('A5EAW8M]J {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}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

*I/!5L,!)JM-# ULN$Y#>$X7 MG;! N#K&!$M(]Q*RS7H=PGM@TV/DF/,DF0UTEJ7/1 =H^7D/$S9C@5JSBT ' MAFU"@;9Q.V\CS+VQ=VD8MK>W*MX2IC]=J5 GGJ$J<1S^EXC'(6<2+G2O)=@ M @1R!T:V:P^@A((S>@,[BFOH*%N"M"T%$#K,"5'VVA(>:'E6(GNPCS=\91 MR99T=/]$X!N8(,=H)^]MH[@(DZSHCL!LQK9B01%D9$1Z.406E.-(K9]%?N+ M K'W&/AH[Y3CC9!ND?!)YXPI"ZIA PK^DSQ03Z0S3B#!W4?@R6 353);(OC MP-.'HLR#4'< ;<2 2U*

*+WG"RKM#Z,'YY.NHQ&TZ=IEA[<3:-MFQX?<_Q([R%U4VZH*D1 M3!)$9627ZOAYZK;RL"EF(!$]+X@$7Y2>X0+>B@=C53\]$JOM#N8TI4@RC./W%4M<>ETZ*3$\^4HSR"4_DQ/@>3!X9Z6*_LIGX1:;Z_$8>Y!E0)Z4?\8:CV5("! M1R/F"DAUB.U?7-UOA^!%>&VU8[,%N*_[!'4-MN**ZZV]I^XF*FM+!*,3/8VA;0=]28Q0H>-CABN$Z]}OXO_N>',V *^GL0\V!8-$E^Y6^I%R8]- MU "6NW68NTVUNPE;?4<*:^,,1^DNUZZ+_338#3^PX1T)P)-FSF#J8DA2=RRB[PVX0OA3=0IT M<.3CPZY@TH_2WAY(8)FB]*&D.()S[8*TTX2+CT,GIJ+D'=/A!\;$5(Q51=O MW5#@PB,74>1XR0/$@#9&3+>2F5(/)_!S&V*>ZFZMZZR(#U-HSL<4I^YKY_% M^8UX4EY\^BOYKUV.K[=4RWK5]13#M0)>QOKI\T>&AWN%:?HJ;M5[V6&QOPC;"EA1Q8@5]F_X9+1^IF&T>R>+E')R5%2-SA=,(+O,(/ZN.DX7$ M$*@U!J*#K-#5JYM7_#DU1V!T>>G%E0'XZ6]/6,%T=X80I\A+*;PA_]6$-N0_M_G%+6,**+@@'ORWOVY7,4(X9E&Z9OP&,#]T2IC*QZ#7LW8CN>&_$BB;1R) M40MJ*D0+"I2VL+!>IQ@T<'#I "-#IJV!?MN^K4BB%T'S/]U#X/UFE4"?B!FK MX*&CEG%25-\=.,7TC^ZV,OA(2)I=O8*6;Q3_,W%^!WR ? M)(='M\C;A167*1$4%^5M4.*[DA9EW&R4V0Y>.2=6#YE7-WU10<*5;!C9KVIPE'# 9;6F!CJNF0&34/%#8>GQ3 , :P* M90C_UVLDX%&% %HD,M$W\&F-),XE$J(%%,(XN:@.CB\KH488_>)W@.#!>J?D MR+[$56B5G8-7FB\K%;SAW.1Q&L;;3O..OLB>FE)'/&>;JC'],ZX#UOKK(_E+ M1<*K&+*GG)>B+VT4N<)&@=YV3'\4 ;899 M+CH(=DNR]SIM6CI-R<#6*+E(S2])*D#XE])[L=W^4+#+9;4K%4_E40^E<5Y* M2+B%T,"XO.HIP$"6."T2^CR! %VQO"/PRC6 ??%>%?"3 MQ+N-1EX'/,"GX%R%:CT#9T.">0+.C2O5.ZTU'EV]VG=8OA;(^KS:,E8SE72M M.U$>EDN\^X3S,"XP"6%#7/]8B%^+-WV_.VT/"NQ6GQA(^1/688;I^X%M&RM4442,I 13U$!0\=T<,U&+NZW$M9Y&+Y42FD],#QU7E2L6-?GTD=L@27#T M=G\H8I_9ZD/5,V?6?T*L;LV=I#\.KB_/?5Q=<^+04$>19L8_KR M^/L@#1'GQU,G2Y5_C(^J P M%<6)$-DHM*#]>+2^(\3;_8> 73Q?-W_>&Z[=]2'@D8)9Q30JG1;,#T6TL&=3 MSCWBZ%Y6QZ> BT235Y;KJB8$7\(ME1C&"/*].JJC1VG[>65-S=8>XM# MCXWBDMW/89G,%K)/YK%_5Y3Q)BC)5NN&_$!?>:< ;C&T#M<7H[$(9]BMJ!$] M,"4C9PX[F J=Y@,K HB">65A_:2LFB%C@12AQ"30J'L$#EQ^P*7Z\91A),#N M(P25;JAT L?\O[" $85S5S6"=NJT0.L1A&;-WBI2K+>\:*1/_H4>ABB\-X M'1/H4,I@F;K2@]UYF&*F.KFZVB5=`[@DUOC=U@EB@1TYK$K4P?>4%7->-*#.)QG@N%R)^."YW<75^RT[!&[?ERFJW M4UJ%^%DZK<'3TO59S43!N2Q#">M,2K&TR_HMC\L2IQ^R,@XQOSE_D>6T^5F< MBMJ=.DVJFH%^^$":.HB0M8_J@PSGGOIS:7N:(ZVKJ&DS359-S<>@#XS1VS5; M-@H[ZZ#P93,6!0Z@SSLFF!%! G$:H@$&(E201(9N ^TG"0M$4!,*W/K"<[B= M.WH_@7$3W6?T@C_^E;YM]P&_L/]0]KNPXP"Y%U=A:I=B0X!S(VZ<*7ME\,<) MB>7SNR?,_JL0AE^_@/($ X5B:-RT(W2?L:X8>(48+GWD[X7_!;0_QD#1V(_T M6X72=;%9=D0'Q[/%QRTQG+2LNL?=BMA6&5PYXT+M?WH*UVQ['!$!=SN].%15 M/(D9.1*?4H$"" M0-W3$54D0+,OX\3\V/[*]4?VZN28_N=ER@,CMU.]-H8WI\0J00QGPS*X#R?" M77XN;,_M[I0F(11]HFNP:KB99H%:V'&8-)W_^Y=LY+345/PWX .!A]BM(.&U MN;9XG,9*";DCL5*S\,16?C@BXR1C:EL=]:=S) 8]"SW81"D1_XVTX7(B,Z4$ MC\E0#1:_+.?'XS'5"S*1$TPO)W,MQV.C(>3@&FQQCBU[;X"2V-[/96603&%PNKI/2A^M=ZS+V$:DD?@IKA_/ MO1KE^YA6S45Q].Y32$!YW=J0N=+3\M1";<([FZN.D'^V:^9TD"'+)!&GB4[-M5Z/'S<%/? Y2_$COC@TV[0%3\3.ZW&QW):N\X/VP?3R_V?=*D^_].Y79JPQ0 M^K16]42T1O#RW$0GQ@V_&=5<!'FYO\^#M*!E3EDJ M7F_R])BEU 1+CKIF/[H0#7T T2LR^A[X,)5TO=FTE!,O^%(M.^^P$)KC.L;M>$'T'!=9OD<%SI_I_2WPZOGQP@L*B)% $HT5$E100P9=@*69)A+WO?(+SW8# M[RE+(B+1NSJWQ/6I.MB;02'OV^E9;U^SZ\(!WZ[3,:3N*UJR1A:;8$\WC*SN ME>P=:>R69/1Z3)(PRX]3X@,V_#JJU%9 '@_Q 4'OX#F+KF#+L17 M0HIE+/E*TT#4#NZ-17=$,%CUU>RM0P=8]H6M@2AM%AI3 &*QXN(]6O-G4H($ MB1EKE\[V'W!V\0O=/!+Z|"7*%;R!4LYR[#JD]!$61D1&HAV!O$T6L-;SH7UR@M"!,>1'4]89!$%IL@W:/@$RZJYXXX#_^";O&:; ,)"S-?3.CA4VR3KC))'_JV M3B+.U^?DVX4QO9'TS13N9O0._2*(7_V(KM-;^FI6 M3D(= O A2_/J/|\&15Q0?*:X]SA\2N,_=^:7=N8=$BY7L,14R@F'.<<#R5K, M+U#'.NF0O%L >B_=<[I,MSO19;DFB!J*?KQ2)#',^+TG8QG>)-*#PYE,3019 MW76P(*IJ9J:[93S4+401O'A*2"6)\24A$X)?FJ1_1T@/[8TV&5\1TNF3%V\(M'4IS&Q=_7.085T]TTHLFQN>$^A#P1^/L8IHT4(_MA4;:V+-KZ I1&H@20?5C MK90,]$,EDXG,Y%M3^:K#-Y2;&FN#&"-]>S6%L.K91SB7[.$[!'HV60OF]+@ M^F-61N%,EJ5$],*X#)RYV!=#1PV^KR;61\S:RIYK^!ELK,A+R;{(?S6V1?[C*

M'^*"H]>^%+\O;R-:)JD=='Y<5-,D)-EC2]+X$] .#,+%/ING!0[KB+R#\B\;C=8QY /T3Z6Y!3}JBMW]).+L4U ML3GZH"VQY\,84#,9_4C J?
\0464#Z8,/8D+]&>RV\Q$DF-?E1)!$9=5UT,#[ME/EE[B'RB(*>LR0HBNMUQF'# M%08-8+-, (S(6 D20"@FVLEZR:8A"
<>:!S>J>J#FI<8'_!BGK+L>^UT\V""* M>##1<.G/4(6!4TP0HT'?X:C-]SI76>_O$BG04I\IA/Y0O\]2D8&-'MHR"9$D MB31.VXX&%R6XBB1'!C8I*-
JMY#8E[IW>I\:[;0/ED MWQ"4U"/2?XGW:Y<0ZZX,\G)^P9IU8!'9'#9-$\@UL?]SBL4$H[_0?ZL?+3'#
M>Q%IJ870!%9M8%_B*!57A@7RI0H+B/_*>5CPR%%1M*/9*A80^10'.0EH<,\" MT9\8QTD@&]=3V_$'_$(?O8O#'K;B)AUC,Z-]]PGD8%[H+SG8(8S9
MZ"4$SXR^PUD_H\<-NE<6;A?+8.$2LG<&;A=,@D#=;P?[6OND(BV7=*C3PP^+^AV[,W(DYXOO',;W_SI5&CUCAF,FQ4L_%7%1UNO[MV=.X];%
{O}SNKDD0FP1RCVA=Z7GA((=-@F7'Z$;,%^Z"*+!C'W[$.& VECY^E-*ETP2KKO1\|F8])\'Y M>..(O%HOKJ<*5J7S$J^+ZXDCXYN)Z3X'Q6 M?40.KA?
7$SFX(SC\GM:_282/S[V-FQ67FH#ECE)N,>T$2)].B==3'*4(:&$8-F/4E:T%?E7-^G?T_?I^7WZ[^1_[KY"
MO)_YBCU]@C\%FRWU"5_=O/G[#^_??'_^5=-2O6!).]X+G7"Q#D+VD@KM;4X[M?A$*\3/F#ZL4*W;KMWR*"2BF-_/WA5>>==R7&'R04Q-
'E+IWGG4B_51+ZW;1 M;;FPW>77OG^AA_;G_K[I[0FMQYGD>0E-+%.5%)Z6 MK3WM=:INR>Z(Q23N I3QQTV!+C8PHTS]?
MS_%THQ$+@GJWY=O%_0&]RJ9 M;V\@X?CE#3K"V+Q!C>"=-SC@;+@W*.@=@LAO=V 3UN .'*K/[L!9,IT[^/&G M9=T!0>H?'K2P(',)78&L3J%.|
<\M'/(VW#'0W;WO?L$JKH<+,C&]G8.,Y)=OZ(IC>X9"U$?L'0HG\TVO/8)76 MX!@HKL]^P5TVG5OX*['G)=U"_ P_9I"1/',+'7&L;J'&\,\M'+ V)[VP]MXK
MV(0U>05Z^N&S5W"63>T5_O+JKS^.W$K,D[N^LCR/8D/R+(?=$<>:Q[X"25C$ MA:4^^>RKI5YO'JK6U";;ZE%Z#]XP>1L4.#K+-
EN<%FP1.*5"/;+>]V_W#GNO/>R& =P,\HL+*+ZW9J3!SH$DME $A_H88]D.,$+8LRLA'] $C^(M,41"IB!%@J45JIE:23V+&-F"MR)!%
{"]2+SZ+LT4W=Y}!.ZCO\"$<"A/D@U_M_F?ME13_$R*T][,]L MX5$)![CN<'9H<39G"#SM 3SS4_1M\=AS_LK6"3#/>3C\Y^@YU5.\C.=LC_V9
M>4Z5<(">D[,SN^?\B4]YBA\#,AR,YW2:>0XTQ\GMW(+1*/IC&N)DNN3)J,! MR0C0'3/HM->GUB\C39UE\B;M%
M=ZC]J99)4MFNTOGT47Z5='HGZ;1;S@IB<3R4V;&=[ZWY<0A0=HYMH9SN$XQ? M+L?SI9.4+ M8K=X7$^Y^/9Y_"UY.
(IIFK#^8>YPHGT<"19(]&'CV$.(_E,^??#@SL-G$#;T M%=8A8* WO=@N+MAD.[(HF6,'$3>037.8,39DD>)A 5G@ZEM&Y#=EV #6-,Z? MV9\I6! U)Y?
5R:G7'9C]^1HS/BDTF9#MDV*P1:T/&\>^J/6?\ND7-7<>/H-% MK:^PDRQJ(L#5;G*/?[4:/:TSK5;B9._V6HU^FMX6 [D=,H+O&;UXN;S6+H& M?("Y5K
>K'PV"UEOF9=9S^0JBL]D:1L_T_N<:HZG_\|:JWXS_ #=#HFP7G M9#E_)O/TC)OJ!JNX^./T4ZQK86)&@:O@=Q%%KKHWP8-4RML9ZFA8@R+5[J'?
M*<;X+MP3*M99EI9Y$);W9+3SC#:BM\JO0O%!L?2BJ!6K"P^L6#J&3(15X:#? M.0:P8K&.-MQ1*]NT&> ;Q?IF&Y=_SH$@KFOH^9"W5E(A
S0K<;&\'ZL'3FZ M55GS=-[0CW.$E_5LDS;)K3S=(,=U_Q\)P%;@LVRTC'Z\X-$S>E0U<,3843$T?XGXD#N\CR-8[+'1%DKHX2II&.UX$9)FY*!Z88
MYB@=F%:.61V8-.KGT.2A]UPJW)=_FPOJ#'*4 MCDLCQ:QNJ_4(,/ M_:7G4>&R)-3/Q&D-NWVX^.C'Z^ &W"]<>.BC=(;PJ]:4 M^49_+ZCY,?
&6^3E,S'V)OOU,$Y9>S)T?*U31*TKU333W2OU6JZ MX?U.$:..63KEX]>3C.)6R0D/.N8\K$^F>_ MF$WS(:SN64[1'XV#=D__ 62\G$?WV!U/.\$S)?
J/S_E.*=MRAP*@CG;9TX(Y M/&S[1,$K'_M@G[2'WHFN6TQO 9"_5Q<#=D%RC_/-=Z;/MS0GP+X79N(?GA9 M-N!\,H2<@"<2-6=
(8@U1WOSPU5Y\#L.L7<5K>E\._1T'>7NRC]MGZQ2] MF>DS#N+D>'WVB(F?TFG;\!X(=77'!B3Q\? MIY;RF(@[CK*;EONN< M!'U:\
[&.J'KN(47Y9X,_DE4HGP$88,G6F9)#:H MJ1Y7$'# MF:U-QN1Q8;H$(B-X8,A#=GF7 1QSE;BTZ+8;:H]SQ;3#G6S)%$< M!CS"7(GS-
$Z2$K&.=ER9#T=QY@C7Z=#B72YI<+H%Y\,?>1)CZ,S6XI<$"'V] MIWF);S5P<$.6 =4";4?.6[(UF7KY<1_W" .-OI,Z21SB.NAQ
MA2G]I%K2"5(N$&4#57P@RH@?[A!@JME\K.E\Q-5\Y*;Y.#Z_6/G]7[.DGB MOW\TR042)C:,?(8NLM=LUU/R7$._A@[R/'Z. M(YQ&2[O']KB?F7-
43>KLKE$>]/-QC%VIID]_.,C%BBL]D:1L_T_N<:HZG_\|:JWXS_ #=#HFP7G M9#E_)O/TC)OJ!JNX^./T4ZQK86)&@:O@=Q%%KKHWP8-4RML9ZFA8@R+5[J'?
M*<;X+MP3*M99EI9Y$);W9+3SC#:BM\JO0O%!L?2BJ!6K"P^L6#J&3(15X:#? M.0:P8K&.-MQ1*]NT&> ;Q?IF&Y=_SH$@KFOH^9"W5E(A
S0K<;&\'ZL'3FZ M55GS=-[0CW.$E_5LDS;)K3S=(,=U_Q\)P%;@LVRTC'Z\X-$S>E0U<,3843$T?XGXD#N\CR-8[+'1%DKHX2II&.UX$9)FY*!Z88
MYB@=F%:.61V8-.KGT.2A]UPJW)=_FPOJ#'*4 MCDLCQ:QNJ_4(,/ M_:7G4>&R)-3/Q&D-NWVX^.C'Z^ &W"]<>.BC=(;PJ]:4 M^49_+ZCY,?
&6^3E,S'V)OOU,$Y9>S)T?*U31*TKU333W2OU6JZ MX?U.$:...

*M"W*ZGD&V*"Q)+MOI.B>OD+H8K^LK7Y=DJL)\KD0.S:B/ZR<"GI%(XDI%.8_+4RG[^9G%YA>JRFAESO] J*-XGNS&[;+ZAD MCC^]0O(^/E@=R11%2*^#:.X4"#@FVB)V+Q/$C8$ODG;6"__D46GX$ M5P:D@QAG2^^H)R:XQ-L"CVYD"TR]@;$5U-_@6P/F"2WUE%8W;M1R0?-\4A@$6M9]9Z.E&KH[!^I1S"DO@F>_D\;_$TXJEOQG0 M$$/V(!'Y2FW35O1R[04_-ZAA,#D?LF?PA:-/LN&5&I W5/+9C1O=?D!TJ'I' M1I.!>'YUH5C.W[]#9M_XF[*Y9_#B]@K/3("CL/M 6FT'?()]?9 60;X9"FU/-MYP1-3@9!(N5R7A + ^6^"Q7E&WG^^;;K@0K]3X&8_4?&IZJR.=4C2[$T6 [& M02FU#51YYIS7W5Y){CF-QEHB;# @8+Q\V+BDQ5&I86GMW061(,X96!'M$L"Y MVVY*.OQO#Z1 \)VS51#&[K])^Q9+UP| 5G>QSCR3D.A;3D!BF9+YXA(\QZAD M4I"T?9 S_M_Y 3OF%FX]-!B9U?()[MPOWY;,H@MQ>K>$>GAJ8H%:PQ&8")7?Z M0%AU;^K +5%%HS4"VHW_"HD.PO??X2S 9? 3=_PU&WX J@HH1@Y)J#LM[47D MU8W@Y*Z#\ \$2>@#YS*?X@7LCMR6'Y/UVG/;8[5X^G}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}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{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})W7+@AB[QY M3'1G@63O70E M60K:<$)H;C D>*F6_!:J.(7W[W 6X#+XZ6,.D69#,Z'!26\.BE/MMX0F/6?. MOY(H"SM["F[=*$Z=5MKV!].^9B*B/PL*L]G>"%'R^!*$\26RM&Q^>PK@!>T! MH)Q5R&+==AWI-]A.X:@/3PI@R8WFTLL[!^ 2D@&_3TZ?BE:?)Z5OC\,1AZ6# M2JWC&JI>T0MP?@T"!V<5:V]<70]':O<(=KFTJAATP@R,VMQ0_V#]_ :WO_1B M=N8[J1J.MY'2NIF$"QX2#\A*] C M4I%Z>;Y Z3+RR)(."D"?J@V?)W R$}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{)!L!'"G-'XBV&H3:LB]4,3 M;H@/,''R9C1^9[=@:?D;3SIK[<:HR%8C0H[8=J?0P<4$J;YF(F'PS7IS5\DJ M"XR"IR^ZRWU?0V%!#H/?%.CSQ04(8$OU2XYVWUP/1'@M[LF]AYTIX EAUNC MJ=#+0_ZC!6D6A[W:XRQ4L)T)![7&!@.!A5)-MJDP)*T"6<^H6;?Q>FD.)# IJ/Q/QT8UH"86I51SYF-Q1)29P*P+'>$6 D$"J M]$6U6:0RLP5B2*XE,B6/PO?ZL7]0S\?3^U;04(5Y;@0LG;5=YU1&MVGZG2C6 MPNV1#(1'$,.EE]IQH"4A@Z&T:%+J2K$69+C(6 M-E3$B8..+W0 $H3?UMPT:3/3:$;YR9SJ^S!8@"A**;@&C%ME&I1<1+WQ@6_[L875NB0WK'JC4P0* =E@EQU)%4.SA%YC3)9OK@1>++>"#MV MN9DQ8F2E34H"<]&")">L(B1\X^EOFNB[$VU6QJ>,&\S6&G(G$T#2@U()CBKJ MJ+D2S86AIO0GLEI'[FL22KH3//,4'=!#**<8Y#FB\"'.UJ,S!WE7[:A?N6_ M)!\P->Z5IE# {]?.DF,)7HZFTXU**[*!N:4"E48D4K;/^\=$-@P\;H MJ%\L7!N$FUH1]X'GVN^W@>7CDT-P=!^!&"G2J&V[?6G7^L'D%?A)JA#E^Q8> M IBFQHF;ATZMWS}2.FIJ+Z.42;T,%3@WR5H\CF!D7]9$;C%96_-M9)P3QV+ MDTJI61;4:&=EXHLJ:.Q7N5H/_:#!+MNFCL9+J'()5H2B@P$.6LF_JQC)0) I M>4]F;$29B#L0SQ?H4$0F*13F^(3,<+03H+V783+O0[78;)"JUWY5:?KN6ZL M*D#_!D{!"*8+?$L_PQ#3CVZQZ=I48Z:%B^Q:A*&X8*54OV0{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}\SO!,99] "VA MP"$V!IGST:[:0U(P>'+:B4ZSA![C@_>?A&F0H3-@]!BYM%;6$D37D*WW8> D M=IQ506WWNV7L-0*LT$?;\C+9@6HSO'&Z>CSQ1DR)2P!)9B_M>T@($,%YN+"3 MJ6<\',\]=4MDYD'J6]N_/,'_BJ >!FDB[QFJ):] 'NL Q:N[\,@UGT%S@T4 MH;]$697.H@C$4'7[9OTK"%/[-N%XX1Q%2SCU.GA$,&#T\8 4)FQ90$T]TV&D M*DM/9].9!LF)1,""&VS,W!G]Y15MU'#!,K9JLK:#;3]&\#"+N>5"S<4',VY+MC>W]EA*_B.^@)5K$&N7(M$J(8%01M!@']A_(,00XETD(2<_1Q((0N[B98>M!L8QXCAQF^6EX".**KVW2D0,9"N8S9PS!W\X@7= M1V_|:\L-4\KFBZL_$_@9R+K(A62D(FN/3.(?P"R@"*)?QS?HA^1KJ+87<'1 MS1?W\ >D(G{&;,])[7W-@E)_TO6KE8,_8F(@\0[$A#V'S?;V9M/C$\. TY$'@{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{I+X$'28JR\-W' M9+6RPO?Y8KZ U$^<*_P_;WF"BJ_YR^3[$OHS|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

M^TV>'!$^F6><@ M*1Q!L!/_FB_UVB7A4ZC6(GU#6XW0\X\I$IXQ=3EDG9+2?Q'[C0>8/2^E)-I%]3V MX:RF&MWJU;T=Z0PO,CJDO""=#I%KU/$TCB"WXS'$XURR9O6X4[X49B (CDL M$707U@%>72"THS"1>356!@4A23W,A@")9 FW8[T\"J(8JFR0^O2W{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{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}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{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{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l.T<6?5I3EE8DS5HXA"T$N-SF M6GZ+Z8POW6-]D2D[C[1+0AGI+UB#1:@)[;4#K3*>.@F;,SGQX.]3:NQ$2UE^ M9R*P[8QJS)L]LJNIN >26VJ71%N&G6G.Y%<%_+(QRP4$+UCS"H=(+86;43.5 M 1=?@/ 5QNS$XCY=.6*>Z*UEL,HC1ECKT+UTB)B2?ND2/FNI4?+J#9Y*U>ZE M^T.CD+7Y;!LQQ'"Y0,O,1<>:GRC5)"R]/15J#P_H!LTN!:2B9M-EV:/Z8O). M(§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{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|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

*(!0J3:03#EKEH);71\HXHNSF M7P)A?C#1T;+7"92K%E]G7SXM^'B'&LO<*MW@)VH)Z7@S@6FJ96LVY* :PT"$ MB%(/&(K@U_F6JJY$1U>F-#B)1NPFL6?7.!; LU5^H\KM TUNWROR,:.Y=#&<+X2HCV SE\E@D[!IYKCH M@$\8_* X_8-*

DB>N4S=4B7=L+B9J^JA)P&MIQ.FV$,WH.WFGI@7!HC==1B8A MFM'!<)@/G3Z,2G;,M+VC-H3BB(^J\7ZDE$U)Y34/O.:!ESF;$]]P@%U$ 7X" MI?D; O@ZD?&1593PXFO3-VZY91TR3L=$JC\SR4J7WP:S)FJ MZI^=HDC.X3??8@IC9QRW"KU-5F#:$M]__)Hj.1^4\$(1>?3RF"Y4#(&*);& ML0F_^9=EZ!\T>9V[N)JTYB9^7".X7 MB59TM1"V"9]PBOQ!1Q<"_R;3%R@64]%U?,E,G6D7Z&]H]2[3A"5M!N*B0I37 M#*

_2&6!VM4>W$3"LT!6L0(QH*;Y]+%I(07]0#/N#_'LO6F3XDB6+OS]_@HL M9^:U;KLB6_M2U9-F L2^"1!;VS69-H20D$!";+_^E8N(R(B)#8(!/C85'46 MZ0BY^WD>/^?X66@!I+E%SX/5Y?P2>NR_]LWTC36"H,4$;WLO%/_QNN/O@6S] M2Z\+Q CR4C(KX/(S=A8\?W$-XL>N_-*

*+HYR'EHS$%Z!I%P#Q@7LO M70#LD-1T%'P70XYZQ3J#(E(H&PCC]0KT[XY331D*1TCT MC+Y_",HK 26TM;_F@O\0*AOR0NO4E%)'P&?*

R<)3A\>46A"Y0P/0F$((A$8(] MALIKL+P_J2H<+V ^7"(.X<89[2RI$H\0?(S$.L!@0:[M M$;5PX4L;JS]#^2I/-.F(P>C8B<\Q"(7# A80O,FUX9, WO-D-

*;P#O>UZGEMP M?K*Z[VQU"LP:R^'>9ZA"2U2\)6%TT] M*SN\C,4%04D:H7 4.E,@_&\ND.)C\'^Q1,\G,O.-=#R5B"+^_'_IFXVN:,P,*

*M7UE$7THYA@(*5(%U3'NC=!@\>#:@#01M(.C8./N1_P3$*L:A"TM"G4%T MX-Q7,N9P2P,EHPZ+%MVVN68TP9BPMJ8@C.4 C-*

*G2'HOR_1OD,T0X_&5SP: M'X4S)ZI&N]/4:5N9V]@B*RPX9KP"<(Y3*FGZ%A(J/JFC/7/,5U0 ,&YI>?*

MU$]QY_GE9PD%>8+MD=MD;F6H)498%]!V7D$;BV,):@9F]"IQ9S4,0TCR6!XY M1#]$/ZPND3@EZ-

WPQZJ+,M_SL;10!8+&8L2BTR=!_"GWP/_FW#"'"XC R&(U[D$B9VP]>NEYW5IMCIO[8E#/28K3:Z&I?V!5-AH6+V1 MSP8K?*

27C6)P'@R,,1R,H=T8U!8+W!L#[H'S<.7C/7+'B 'H738)0::(WE.;L MBI4(#2]V>1.@%\2(L C#<"!IYLH]\G#,;,2P;C#:'E:5(@+)^+[*>P*"&I_F] MGN5-*

&,+@A]47/[PRP)$[^[H?X.>6DHLP]9#+>KVPM/LR4B>^D[]A,?*/>N 4$]\ ;U0&CS0%F_ M%UF'-L_WVSR/!>.?F3=_04WPWC1!.+Q

D;TRD87&RZ4B178-VGA-B]YV$:1F MR@:VD+\UI>Z4$2-)TN>N.T;D 7+-'>+^W"!AZ9MHG=.D.1K.K=$T/_9FI8PH MX[L:9PC%$ A'PL1<".%K-

,FN/%+DO1CN=,K.H%7 UE(!-[NBR7IC4>4!AN.4 M'(8B$(S!]R8\]4GI\$-#CS9L"FH3&#*4/6_-]4?9OI^08D0IC/'VQA&RW"4*

*MA:$_|_O\F8NL+%&LJ&W#$'"*X3?BUJSZN96,,SM]@J9HA"6.<1%$YGT@\|)& M^77K!I^!A3BQ6ZWMFG;UKPCU_*%^4Q-\P":N\Q=BD5HC+CR^-*

*(3:@'\>6D*W9 E=]VUL$BCO+!FZ#Y!*#,6/+9_?A?ML15"J1NS_F-OEL0FZ%.3 MY:)IRCB[ZPY#82R"LK"..\0U='-\?^[M5X"M.GFYNV(6-*

*,1=T]U:MBY[M;P(MA@!TGS# (A]]\@?=7JLOK(FG/|)14^DE[F7D^]{8DUN9*X)2A%^5D]=(>F6WS M9UZS+:*>-*

*WN&BV[2NH\.G9[#.BL9CPNFT2B)T"0#'2@0S-#Q] <\92 MFKYG-^?2=);1QM.P$[T[#] <:2D4BB$X=>QZJ4Y\+G5O83S%A^RK*G$3W90W MBC9-*

*7:1T*XAOQL'_WT59T&LZ\9S?+C,DZ+/P=2VAIY[F,T?1*BN^+[L!.LV M5TBS+;N-VVU'JZB,EEY%)D/C"(/M5W2(75;G69KSV_%?6!MLZ=L3O>*):.$49*

*M3E?&+&WQT5M$V"(0#MO/ET\I 1"+EC.TAT^Q^%," M2?E&,#.B[RX-9P.] E?L%4C@*D OX6F5[?8X8HZ.X4\SBFM7/<4%+H7GY'+@*

*MA&X%WCAK"U,Z*DU=-&@9+?(B. %=RV7.!:AN&/W(1 *(!5 QV)B%P.U0&CO?8 MY!VBV.PW!(7@[0]^6?;QN@FX &CK"(%S"(EQ=^95S'IN/*

>@FKMWH@_F^\7 M]%*QL!K4F'5 "MF@3!3MH.W/!N:/7PR.D/2^ ^?J5/;3K!*!KS;CF9154:L[M*8C;3F*

*W"?"'KWV;.!EZ^WV=20=*W'UKT=D$+LFAVI9W5XCW7.K[']SCES]ZU M<*KE0W03A&B%H1U^MN'60],$=!?I[@2"TRC"TF>\W+\OV8=T*YJF4FF@[C^*

M%'Y/.8@OJE4?R&&'=CRTXZ%++[DZP;MB@73#$L:H.;6$AA..!^D"Z@];D1Z MQVD'%,*P.,+1QXKG0O!#\$,G7F)<#!]"/Y^>Y OE]'1F9PEG7'&+B\Q B-%/*

*M__C%(12!(@1[50F0KT3[M3)S1,YW7]JI2>AWR?W=&D/W->7OJ?V3J#E#R;Z+ M*9\]*.[[JEK=JD%_/#,O.M?3,#L/ZO=W;]Q?A6W_SMR?NN=J?*

U3ZB;XP#UK% MBHK.9QH[7$LFO]%F2!CUS]&@\[BF-Z'?'#OJOZ)//()TP:.)[L]5PA@PALT M!\Y2ES]#82R"LK"..\0U='-\?^[M5X"M.GFYNV(6-

YS"ASF+$$C)'%&Y_U] M"?<=XAGFO)TAY^THH-,=K<&4""^+XN7ILM><9WI-(P9T7&P(YW"$/A %>1=N MC-

?);@=4E9N(HWTC+/3\K/+ZZIC%8T/Y3JJ%#MK/!\MT<8T#T>&7EGH[-<6 M9K0Q:;79P@5I7A3U=M$NK2N, ^.,72;((<3"R.

*F!LW=O*D*#&3K03J]KQQXS MSS5!GLL;N2WU@C)U1S8W0K.*1+,%;F6QM"D3<:EOFF 0"H6%OB''^[YA=AV* MQ&<8(,/;2F@:Y;E=$9O3.4N,-]&; :*

*(E'(2(2@*88]RP*VX#H]EM-VJ-O[^ M?*TW]$_+"%>2KO3ZRZF@"0:D;*$9QLI42M?5TRE-IPJ;E M+>&51IN^[JY^_"(X%]'H_3329&C]]W4@73JGY?*

PE:\F-^4JN/1 JMH[3]_6 MP!PZ7OR>C{EKPG*.I0U&&*WU7[""^=;N>G46DRCO]YE]P&M(WJ$X6H@ MK/\?P!.SBHG/6TM*-*

*^%8N&"N^$E;JNFBPW%MU=OY5Q]91D^=$?Y;>O0T3A;7U;% MJD";8Q9;M&JU>*GEN!GD/=>[3ZLG%>>T&*O;HV$ MRC)KR?1DWND7+BI \2H%?*

*+@8>SZ(K3^<D.BXJ92 MX;LU_E#R_!\EQ8J?OBNQ&"X"L"B@UM*K%)7=L4V@R.X/>\DJ#W^/_?Y[CHV M[LVQ"1BI6# / MRL$GUWKW7^*

YT6I%+.#L/ED9X-T?/WI>O^U!DJ!W^BXQ=/'PA8]CJ!7-QG&F M1D-HH)5"J.8FRYPA)A!#U^#?Q)X]]+/VYQ\[2(O//?1,GU63,]M-JHC\4I-

U\\N0ID-.+H3Z(Y0M#AF.NT:Z9$I MOMJN?8J4O;!MWS'^^JR80ZO_+O.OOJFVVZZHMNSIRE8,U6O@$O:FZ"72C/GH MU+<-JE)T:$9#-

*Z'*4)FPB:W7T=2)G=W[/MOW75)WR#Z^#^EK_+;N#NY!'B_R MI0W&3-*

*%LBV$]FJFB\|GJQR^61@B&0CCJ4(;..U8UA=:S9IP>>54E9%;C\ZA*VW3._RH=F M^V47S.O**

(:>U>&MX4W=&B;POONJDV*?'0ZQQGT@Q6U0RO"%D)O;PK1(;B93 M60F,D)?)N+<%B] $3(J%Z+W:.__K3DY$!WR]EK+%J[Y6$MHSH:DZN"'*

*MB+P/1%XZ[ORZ]8'W0W)$VB*^5KN<,, ^LVKU:944&Q16)"A<09$(R=((RAW3 M[:_AINH4^H*FA=/0 9<2T:Z,+,U:0/OFAHO^7,)[D=SB/8*

#_W%5.D6+B6 M=.^B"XKO10@7/\O;P3>BPVBJ__LC?8 7&\5I40S$R53(9FM55!-PB6V8,DQO M5!4J+DR.8_@>+\(2) 43NL4N4=2.)MF]#56

2WR,UQOVEO,G.R88T&\WXA M9@6@+9$40G(80E'[5=3_>:N^E!=55/^ M(,'QD+'TR7R^E2KS/+T2*G9=&8HR&=>,)Q &XQ "): /!U+ >6N?WC<%G$U#

M>A<'9)WV8EG7I)DPK14+HI,;UO-TS $TN SF. Y!N6/=D6_>:?2G\O)Q&,PW M*$K0>GR7]4A$O*%[(6BS=0GS\;^_T9WT_5.]-$=^0PEYWM7?19B=,N--

*T8VZ M$2JZ/EWK*+5-^F(NQ$1A &]*W M#@P]-,)W;3QUZ_^?YZ_^V]J2FN>X_E_/?+/LTF- M=W'I>$Q%II%6?4.QT\HH^MV_%&>E;*

('2;+L3_S)1/[KB24V6=?K9>+S3^W;<>/XI)Z_$S+XBOV/_R#4O@V2^>&F_*PIO]`MA6,_Z3/MR2O#@_B]__]64F,?4-]_=1K9@W+X9BI*

)^X^&R$H"Y@T0LF36"K/`M1?.H4,:KF(Y4U-]O^[",OS]\N?QI[ZK[RX@_M7^.$:G_F\+C;_[SU8]_V+@7 MJ:F[']QJ]

(?'/VZ+$O.SC.JZ&IT3ALR,&$4F"4*1.17%95VC:')$D0R&XS]V M"W&:C7R^ 6IT=!SEP"<#\V&OA8%0;W1+_$,V1:F>W?'9;C+M)Y;S1HV9X2M@

M_H&,TQQ%GG82;_#VO]47O_)\MG'[XP=^_OV^0/9^O_&__Z5^XR%S]&7_$;I MJ$?*

*ZE_[/$[_5ET_@1P&F<0W'2%)F.!*528XS9)7#5%D9$82&LB/4(-2'O7_X MAFJ,6(Y2*9FB#$PF&8J558)A9-K -(/#%-4@F1?? ,V[>Y4EFS.]4"A4 M^?-*

F3\1$&=]_IC=0E5:WVD_;N#X9Y-9#HI2I\M'(O6?.^4FAD+$]4VCPSB07 M,'4SJ)HRL?],>>!5VZ':4"2C[&ET&)""UN.CD=3KD:P7K5A_XJ3MM)P/Y][2

M)T9E,1]Y]^MUNB,\UE5LAJBUE3MN7J2%E%(S'L]5"A-1RIA58C)VU*>72> MX[S^:"+*I(R^'LG+U4YM+GJFU,@6QGY!XG$M8\K4_DAE/+'U:7J*

*H=DJ/Q^M M[0Y.%5;1R+W)]TUAR1++#54^JX#9M=N56J=SE<8\7 M96Y_9'?I+6QUEL/0RIS**+DV,QS:5]J++#IKN5S.-I99'E@B>T,S3* :Y7!01\/N2E@O5-*

*XR=3,V M6O9>0+2]#E]LCM!&)]_'<*548OLB&$]_'K]NFBB?WW0TM$?[JXDORXY9BI^* M[>U_?1*

((Y>P/6G:FB[U!LWJG!@]EMA_V6',I@NV:%0A5LL\8Y4I'O@L8:6^1EM+*6VR5 3,<^8V"9:@@/{6BT6)$)KE-M2;['5M&(=ZRV)Z*D'-G98*

M$PM2N@%NH;1&T^N7]<)&C){'I"67CC66KZ21=.K_+'Y6%>X>6'""H7L+BV8;MU3ZNEC_" 6W-]8QHL3-S!8;N++>QL8K%YO4ZK=D-OK,,5O1F-Y?*

*@%]A>V,,QL MM],Q,T8+^']+Y=&\WPF>NP!,2S*Y4ZW.4@8:4M-N+<]F9]+A^X1!FESOK-R*

MBPVAT5V4"C.^6554$PS=8PQ*F8M5,YWNH].FU6^-0X8.:O%3]RF#S&;,)D/_MQ*F@//^@%J2X &^9E'2Y4,UD/;7M!?=)DZ-Q[$0_?F162G(>4RZZV=-M-

:>;%KE:H4QT7._'B+"G&$Q.%-NVT&AKKMTNX%BM'3]U;UY554/3Y47+LAM#

M=.L,2D$X"40P='}>K5S)]T_%HB+TLFEQF);$L=B('OL;"+'=_V10[1P[D3'E M+/ ^.OQ#\^U"V""/!A50.76=CK]"SU="1?>2R4]_N2%8KVO5^_;FPO_|<4>*

*M?A#;]3/ON^NAL)\4=^R:]YG._^SY?O3,B:.M'K6CQ_].}?87SOS<16MTYN6 MVX,=_<):4-3 <\+%:VLA\0Z#&H3D HTPNCMCY.D]NV,2:%>6_9(,MR4;]RX*SE?*

*OS".00GSU(N'QZV$+<) MQNVKT[8WI:61]$L5H9T+\,I84T;RZ O=OTZ'6T41V*JP\ 6I+\(DIS+J$LOU#>W3_M6 M1P1 ?F/T0+4'Z)/K9>;-*

J8Q@4:1JK.MF=]%=+TQYUT.1P!$/T__1,@?D#\@ M?R3?)?(6?Z2+0Y/]32J^E*:UT;"=8^8ZOY)WW18)A,3HFZ6/!'E $@B*I+'' MGV\?+[U2EZ*/[_#-O$4?*

4B54M+6E)F=WP5%6(XYH^(#T0S1?"MH/JO[XYUHKCN--D_7\-#>F)S6[58V MRZDLRG&K90Q'<&S_$NHJP9P@E|>]8?

*GR=\)7[XQX)YC5]9!LZEU>LRW,I_#:-MTJ/*W54$9N[*+] #F*;AT0SA#.%\:=? .^&\TFNY3KXX%M >WN>I=1=;V5UP M-L<>@C.C40L*

*M1!*RB!.Q$(E([D&2D!L) <;R3A P.F&'_A>IIPGIFN($1'4M]03W]:<# MQ0*OTS%T-U\^29!O:2^ M?GT)M2TC,!?&Z<45T_IQM)PO-*

*DT^N(UV_6)P.C]S3N)SM[;*L6U@RKOZKG? M0'TPM _<%_07]H4"[IBY+>H4FM.%IVA,,R48^33 /D4PR(8=L8R0,F2!$@% M]^:YO^TB81_C KO'#-*

MSQ1@+5D;=$(]K# L%$7 !%T>-42B*,) ,(!E ,KB^ MR-&/DL&VF>WV,Z6.+15F@S)FK3A[2,:* 8@A91$.PQ ,] [<:&QA#M!VH;C

M1%]'4J,A&K[BQ,X019]:KA4LP'8NKZ>>"*H[CH=E!>_*[HE;\4#I@H[1$4$ MQ;_ TY\}JEG.Y.2JW9>$C5++-H-&<4SPD<*"[=P6#,XA*(==;PU3'"%*

(T"0X M%3X-T$[+72QU159M9;Z*# QQWN=+,4#'[']PA(L RE*W4=$_0=;#O M.58&EC45"Q7!ZM.=7\^PDLLVP>+!+^35,&B8/A)8L<@.I(E!1*

*=$!U)59ZO M2RP2=C.7X)6Z!8/4!-+_3,48BMAD-[GFW:?F]2 M)$]2&>GHP 8G$98F$1H]]J5#8KE98H$*D]LE-TK\95*

MEPP.2!+@3WRS=NFY)>#L_XZK\2<(/B+PP)D?F'72+R^IEE IUX),46Q,-M9 MQ@AP"\X@.(HA*''&,Q]B&6+Y1K!\UEOT]V"9_ EE*55=%E647)>VJ!'9"7F*

M9?K'+QJA4 ;A:-A,^\; G;15>535D[LLMV#??X079GQ0;J]R,HEFQU23IF0? MPULFX 70]IM%2 Y%2!P2PXT1 ^2!9/' 6>_FW\,#-9.<=Q:40+397&!&W(E*

*MNZ%C'H@K.T?: **SD:M[4 @\5J:^%%!S=L0-:&GNU^L5G](++AF!K4^4Q/DC]V4J^T-[2#,L5,C.*=SP)'$8R%+;%O$]9) M6XA$YA&?*

E1&^U47Q/D:HFZJ7=K:!C_9&I9$IU]B"HJ*D+&W@D_PED%0;C\3 M %+"+5 "9(;,#SU009(9]-V5C#7F#1M+92KX;9%Y]{\8(!'/P7!(2R'GZ8+*

MU9]$X9NB+2XM\/=S"WO-1LJ]G3]0+*%8WJU8)FW6,#'\GJ8-1?Q6SYOKENB; MO7H$OWVRTV=%B;/BIG>F4^L?#_>X_3]OPZ/XL_61X.&[]+N..NOQ!>;

[(O'@ M7UKPD[80\#HKX#6H'|CJ:.[ZD<[2\=ZL'2,!TL'2;G&Z?I$ MW;B@WX4CX^+.YYO*$@6@JWNN]_*2]L_5W"H!-\W,^IB+5GI:IH!JJIH=\#+&*

M@,|+#,'88P'D$+T0O9=&[_7'6+X%V3^&5FQTME>N%;J!,*],N;9+9SM::06P M"SHVD2R"X^<,MKQ292OA>$[:K!-QSW#E,9.?

1OC$7F]0=+GBA>DBS;;+.+[. MK>+3F?OQBR,0@ML_GB' DPUPB.>KCX#\-)Z'S>%L:Q8'-EKI,UAA&4@5UXCQ M' =#4@S"L/M=U3X5"7EE]Z:OG ?

9L>.1LIR4R/%E-+Q0D-4$'9F(<1/,#6 M!Y;^D.J9FBD;175.UVWI_CQJ']3.)]TPU6?(72#F:7[=J4[F6HL7(ADWA/= M0KVBN![Q3D4KN?*

E{0>L"_:PQ$F+M+/M<.6ON=+-C2G&PS% 5({>H2NTN6JD5 MU+;D;U8RQL;=@A"<1!$65BJ^3\LOE+$8;X1++%(/-\57X\5!'1O*

M?))W<>Z\.',G.N^TB;9&HNUZV!,S*$E6P*TP!VZ%:11' M,)2[8L?S_4'VIE(%K_N^]V-(U,6ZJ/,-KB@HR[HM3"6.H? 8B:"D#L,A.'XT*

M=3{A2$RF(GQOL[Z/.Z&SWO%^#-72LM?.&UPS+?3&>(N@,O-%&G3#YG8F+T>1 M"'.@N#?$=;)Q#6%\[5>['X.QMR&SMI\QQG:#&Z-

*"O;Q'''VH,X_&Z%Z$Y+#]?`MC^+X7BYTG\S[74#X>3OO$D%"E*W&]>;@)__C%A&L)U&&-]%N3P" M^0 =KI:^UB56N&W30ADC-NT,5?!7T4L!KP%)*

(ARW[S2 1 ") .!+!=?@MWDT$ M1'&N")VE.+:MSC)#"FVKK^9,0 3TCU\XRB(J$H"N&N M.A48 AH"^FH=)Y\"]+R[L:WZ0,U;'87 ZRBPE6-*

@&@Z1^_6(Q%/*<[=#N MU+1)-I@U]<;C!OY%#F4Q&ZV9&.=O#"M*"C*ZY5*QQ8!.7#1:<_0"$7!X)%;M(P?*

*(!0G@@K.Z,3Y7!*AK0'L*GV'L=$&U2VQZ0_;3L>:_BT$A*!)!Z:.ZPLE\ M&A>]@WT5W;R3F&Y]F:,""OY=S1L*_J4%/VD+ M 4L07#S!^-*

(3AU"X{T,AD:GU7UF)&\NZ?[CF/=JLJFXL4]"_[TF[4]VXW!]R M%A&S=4KW0M4Q+N,M^N\SW1-=8%XW?7-K+-[74YL)N'Y)6EN&;13_)I1QOB2

M%65P<_7C%X.P:/0/=;2.),0PQ/"]8OB\E{WOQ;!050P^+RPJ:-@1LL7G76' MI1C#-, P0; (0UPSAA.JB%]:^$\.ZH,7,W>$ZF^YI7TOJHW%+>M:VG93O>G*

MDV5^/E5:&1.@&L2H([N/7\!O&2].[ZL40Q,;58N/2 G!K4+B-.])G-Y^IIN&GVF/%-U+15$8)+"T5 M&;2IG.6$"T._&J=-,O!]:5<&O$\YY+)64M+-V('30*

$/9!7[:VS)2M%35+< MQ6C+]X>5*;\Z\<4H_@$_C:#X;K1J003&&(LQ$(_Y:V:S,KH>JEE>F$M-E9F/ MA$%Q;8CG>P8!'%F3' M@ >B$" #0@:$#/ANR'\X-

N&L#-AU/ M75=T2&B';JG>D_C/QR8>B%&XN?5X M!P4>6Y$'#CS45O1&0SC8?2:$$1MW=\EQZS?W1D)EF;5D>C+O] NG#C7X2(9,+|*

*{O,'0^VBC%-.KA5#7\QF@'-MV6>(??1.O7;!]{K,/*BOG:)MR:BTYN?8]CWD99QY.Q#C6M?F@:_VENACJP/\ M4S0'"KDB!$Z]{:6"] C1$=+C=V?[? Y4>Z4YF9*?KU3HZ]_227){G9'^\ @3P M9MS&M:[-!^CQR.H >B11!",XA.;VB]M>+STFU%Q,,*5%-A,S5C,GDS0.1:U^8#5'MD=0#54C1",C3",OM-MA"#5WAC50F9-'K.>M0K&5YEU49_5ZGDNFT0/3AY5L8=,Q 7>\'7ARK8OS M 6H]MCR 6PD6H6@"09E#;2>/]Z'\UT*)('$&B=<,T$'SZU3P+2_6&1LI1=.| M:?2S&^]=KU%]'R0LQ>]L!5]P?05)S53_$7*&Z468R,P@$#IH+6&GAI9KN)] M5C0BVL2% ;]{!C|/^/9?YU/=6C[^._K7X[_>&|*0MO]A>._:3/M">O M(KV(WSOP;R4U]@%?_E>GD3U4NR?^2Z:1X4R7L4T.-6?WO9A&7]_^'+Y]]9U]Y<1KVK_"-2_S>%Q]_\Y]_3 MZ&$/-E\8"/5&M\0C.]]BJ9[= M4=IN,MFQXII&8+GMA:?9X^CAAA\{\S!B(IDC2!1G3SJ3MPZ68R6HLT\\W7YB MYU@B=U.(Z#WU?!*_/C'F[]0_*<#Z M_W5I,P6%BCS9'SY^6Q$7__G4? 2 R90E28(@M-D@E4B3$3_(7,,Q\DLQ:@: M3N,818X>)$EY5(=6 [6U&/E]U,YF"JK8Z']MZ8H'FMSKD0K6V"CE,8M+X;99 M\/-M)6B## :9>3VRZ)+SFM:K25*EH?G-\F:JZ+W(>I4QXO7062C-V^ZGFY&T]*K*:A2 MH;5Y9EYC*-&4R?TWW;;T3&&5;V?0!1=53I8!@, {%P_=FY/&V[VM/UR(0GM9651[V>S4 M6)DR_6I.,C'"M1%.<3)%,1%8."HZ2DB6E54%4TA]I"D1\;Y^=FXH9-5>N[]& MVY+M2F35KO2V8O1L#- L3EUJNPE'%L8PVZ&W7'X7#,,>:,K._M(-6R>NBQ6(D M6(.IG*WWEH+!KZ*1>X)ER86ZT%%1!K5.;^BPXK7*W=&;AY">?6CLB)W'81F#* [_Z*8I]:VWA#OHZ%/ MCZKMS(2LYU?1R+T7+15LP]"RI;:TD=6Y6VOBUJ A1B/W7A1WB6:N-@A5P6B. M4*F3,?7'"%(QD7X]DR(%?7ON-2%9=N2LT, [93W*XB0W/O/8OTN)49YKH-:=K3 M,NZTLA8VE!E)U6L18 DJ.EXU348)C9!)0]5D#B45&=45C![AN(IQ].N'=|W6 M,.=5M;E0Z9,;/LO4MUIY!1Z^O[0TZ05,?U8CI&Y$NBDMT4^0%;E,GHIF1!]Y6#FHK MJ\UDA$UUD5_T% [D:3_!@Z)Z$U0QW+*7KV0R:+4[=>J;64+-./'1/Q":B0&YQ MLJ4=$TP=.]EN:5HN6YIVI/:=(?G+'Q#3! <|&+KWLKR2E)ETJ'KH""KL&L9PDH|PW@J[N99DC3M&] *OF0X01VZ3:Q8)ST*M MFECJNST1S_6CIQY@HXF- ET==:V:A2CU+5K*S/NZT5V#H_FH52ZM>D9P88VGN M8F*F,&JLAEPD!@>XHRHWV%6Z6QT(=*G17+;ILF>1)ABZMUH9R:[Y1(}>2NEE M=3U4J2DS7:[T+W5FHU1Q2JA14\HE**3H8E3DEV.7V#_994UFFE,I8QL;QJ= M?KDP6BF2%CWV ($T1_:H[6$]TVX$N0I-A]*GJCP8NG_6=PO;DJ;56D+6K%5G MJFJ-]98(ANZ];&?9P]MN&/:%$!].ZF2/G:[)>.C^RQIH<[ZW!1*F0[8+54="P.Z^$ M_E;) <^VXY>G>&E1JS0T[4'1#.XWZ'696%Y>9;MPI>?]E6695;%27;A-M#'(S M4B :RK 0O<$!FC/Z6H?.Y(9S2>$H5@=*VAXMFI()V MAR!RZ !WXI+56V5RH6*GQ3R5,2=]E97CVL5[JI2L@&VG)5OTP&8G$Y1_?;97+16*A_(C1&H_*-]*-TI/Q4,VP$JZTUGG@OJA_%K*W@:M7/LQ49@+0[? D3M2WVJ;\FJ+*KU\ MB1ZYDZE)OJC-7*KG/U!"]#U%0J=HSI;FVY!%"R@S[Y'KW&!J\')L%:ZVIPH&*AFR/WYA%(F0+(V@' NY '+!]7$!P/_DD4 +6.A6*ZA M"XKO1BL1/" ?E7LYC6RNUO8\/S7F97_5<-73GO_1 OWOC_0!"I@MIG6EZ]2G M**Z72ZS56+N8"^P 4*X,BRP!DL,B?8#;XX!_GLH_!#D I.[= <\I+XEB@2^ M6R%0!Y@3\HV!8+?=5;/188?5[N<[VKWK$&\NATPAVV<9(=UJ#?KUI=[*V7'E M8/+'+Q;A."XZPP^U^DCL=?-G_'I/W2+H^"5*01#&? CQO%&T8,+BBEXH6$Y1O MYQ=Q:E5-\6UCD6KZGNDKT]1_L/]WQ5<;UQ =?'"W<$6:<0#=LDOF_%"I5>K M5EK<5NH5JGZU6_3T'O4)-YZQ,=P=] ($4&SJ_V(EJ8S2*M0IUVE$_VY&?_8> M^@%%RQ\/#0[0 S8S"QK&MV6!+CJ.RYLCOVB(NX:6&,(2!$+=Q/DT_#L[RL^< M4W!6]) __U2|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{1A6Q O(^IFAS=:J*2;VU,$5U#:.*X\YX&#,%%3$%K&$#2>+.5(J;=:R= MB#!10_"-^@2C4 7CRG;3[@[WLEV2QXUWU"T M70DQ\$GTE8,N-O(J0MCNIRO$#3K//M<);M]]UGHNT(W1/H\]R0ITL<1__,(1G.,0@H,WRE=RHPQ;PB7!X+V85^PS!.!ES4H> M;397DL&W;.8UMKKF 98H <0H/X-O5__!(!()(-;2A]DR?J.P?) M1FQN+1\-*T)C[-B+07'C>2T1'"3 +[4[20CNV$ER[^%?EIOB%ZG%V-%U6QC MD6KZGNDKT]1_*!CN=86W+- !C]8XFE&]G4H9.T6B[PQXMX'B5E=J3(DN($;$0 MCYX]$N&H,[8RA[=;-W8[^R^WDN_B^E+?6M+IMJNN;Q8E95.HE+*T-.SG>< 8 MYW9M0:ZX,:ZX$1WC;GQB7^^-2K&Q7CLU?2Q9X.):MV9<695BWHBS+&F&1IBC M=^N0/2![7!-[P#@P& <&X\ N[']W[TI'5SE(\/W#*? MPP5;6/= [[>9&*O4C332KB)6FE"DK(&J7!!X*BL00E((U)2'1W C1P!B?!,?X M)'#*,#;H=%6@+G"XI8=EJ[OLLQF[H>7ZF7FMH)A>?+@!7\;,I]N=Q_5C47* M\8(7CN<]-@[L K);=!Z;I/RWD7BCS=1%Q2)Y*W2'V-I(`@<)(C$LE;)7CB M0.! X-P'%KF)P!CPP^J+ M'UX90"JB=W?TZ'\SBA/GHJ53Y= U4@2*I,"^_?M? *KPVNHD[E-,GH>TZ7-.HF5V:^TI(NGT@@7 9A96P$*H"(*0"@6MM^#Z+\O)>'[T"\\1 MCEG()R1J0MNVVI'#;8 MX'BEOCHK$Q!I3VW T493F+:S7:.<7A8- ,68"D/9%4PC*80C+D) /(!]<)Q^< MP_#_&@G\P>DXQMVUGV[JH9!=UNSM3)U7U<\[']0^B_X\^@S[=&!6PVBP40]S M)&94+UNQYI!B&C?PCJC* {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}ASM=OMI=L432+B;N-A/M(ZTBWTY+ (U6^7-=6 M*T:;&SW;7FVGXH!?13,&6D80J$X@K/P/A>9}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|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{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{IW5,1'.$9%>B6"H7M+NY+60K0Y@Y%4V%0Z1"[M6GO6\=#]EUVU;?01?]_JKZT.7$E6?O[_15$SYTWSL0%CW9$GYD3(4#L.\@L M$Q,*H0TA(8$6%O_ZMZH$-C:T[>X&&TS=N*<'X[)4E97YY%)9F18M4D2V7]NT M[]O3-IC!$72M.?.,:3+- K,0%O=9"'+CF\4$%#+Q];\EMS1B<[]DVMN8;%V:3H MJO'8@VV8=?EF/A*\IC@STFOWWLIG.T"_D$>PV!W(GM37K:'(A=2&MX/>I)<5 MX- #>BFL[MGNM$GN%95+2[J5(Y!42VY*R?-MU"]JT.FI<)*:9TR*1+E-*Q31T(.]+8]IAN!*CBHMK.6]ETO5%V,1#3W86_L M]HR%O>1LJMAFVV&:G%2T]][6V0OCJ=%K%]KS:HO@VHWAHML@"M4N*B9P,-F* MZU;3R[*X(C:S7KVM#]:|\M3<%BYY/K0EB^L"):OY8I/C@O&,7$FBO"M1\()E M>EEGY%/FW%YHLY+07E.S.;7:72!\,8/1\'Z=F;=S8M&(7%4I5:," HP] EX] MOYAK>8NL:W/RLJJGLUQ! 5!+';%TAU)75^]U:2 VS>DR9^5]:?X@P*$'DYU9 M&2O#NKQ/1&ENN)F*G9#KH:&'DS4]?C 0Z,F V+CS)LGQ?2U?!L,] HFUX?#> MC!K5 6%UAFZE2I=Z'D 9Z@@DEG4A MX84Y!T5PQ['+8&Z'@V\ZM(!3SV"B/>6IH@5)[^2 MFIDQ1UO=4L;KM^'0 Y KL@K9G\Y#22H6=;V!,*\C$| 1&'KH[9!DVABVA06P MN'"*W.#0C!8ZW$/QO@T4;G,>W3.5/C$M3E=H[,Z.1C?)'L-Q\=U MU7,1:%.0S"'$8K0W\W ML;V+8M_>6TF,(>Y>;1&Z%Q_:>[P"FDXWFKG?^]^3L'+E=_CV.,*D.G-L_:_>M7;K'HX+P#$L+Q>X+QC'+G5?,(Y=XKW@>^PRJP7CV*7N"Y:7 M2]P7C&.7N2\8QRYU7["\7.*^8+_RK/ORDWU"WHKN?QH-^&-)GA]4W?)U0/]4 MDOPD!53/@5_^^QM)?_M%C.X"]B:_KZ!IA_M]XOJX.1DR ANAK,OGW9:X9^WFL&2QF6LG,;].=/W;X\FF"N>,ML_?H4>,M MQ')QW5SQ:)-0OVJ2D,0=<]X&ER,D]A^P#AY)IP|+S5. M#),]6.(.UI8)- X4">9718(B[^C,5XIFQ.7AXHO,Z&HPMC"PQ?GM+UC?)%5V M,3-@9@#NAZI&LPC50<,,@>VLOXZ4D,!6UY597?P;%(DM@L_3^9X?AT3*JY? M?*

*

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|=GVA8#,. M%7F%8%Z GK CAQ"B^X1UU,SJL;5@XC_D?Z_A\.!*HIW7*/@_$=I\[*A&QAW5 M:-A1C=XB ?W;88M)5K%K;3:OV9LEW>J- %,#8#,JT^U*$^FO(4R%ZHK4K&A(!%=R.7H05?.UR@H@_M# MC(&<\9<'8@K'E2]@PGX(MK\=2':'OC.[=SD)<5)>-@9GN\..A*DX,XH* MG8R8':C$@B1LO<[IGM$PP))A. JC#4.;6T4;=,V .D7V.>9XS/'8 M=G^I7QN1+-GEC)ZQK:C9Y#>VL:+O?SI4>%*=2(X%?4*((TW<2'(KHUH66T8Z M$8828Z7(9EY3BN^/)/Z(+:XQ_3*.-^:48.+H09#0U[JO6@$*/,811V\.Z11< M\QG+A4/)Q9U>X@CD#R'J,.*X$QTTJ!D+B{B5(NT(3KE>7F>7*EF2^JE>=? 20 MGY12&NPG"Z.0 */.&2; YYN7=[YY#0AU>X>CGPY/OV(_'=A+/XM-HWS&;;2) MP+=S_>IT&8K=%5\39-1>]8SQ! Q+&):^A.%T0*23IWU=? =SSIS'JA_EBA4'T M4'C89$=$D?970IY82 (-#2G^&%CA)#&,5ABM/CALBD4%B\H7]3<.1.5K)B MK9P:*T 7PT3$N>X&R/ZXFI.5"^=T?'!V\'+T9G/,C\R>U9/QT=K"$.]{5_:6EZG$XHZ.KGNFBIZ#(MQI&8!=V>AFV? 9'*218T#0A\5T@UF)?,P9L&3F23!,3AM"R/3K2(3UL68XV_+ M^KS&M*U/U)^I7) 1@__^>!_?$N%'^,AD 5QNM=- GP/<=KI7YU$B7DW\>BT9=98BEA;=6&C2 M8B&-*NN&*4C\2LZ@JGM)BL_@9 I\YG)!1+G2,Q&'B8<+SA=$.3&.?NBVG? A8XB+@/_/XX=KD)B+:FR#)09+ MS&53".L8+#%88KZ4Q!Q0{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}[TFL\5+AP]\.$2/ES"ATM?JG)BPH6%:Q5/M\FO=R-MSRJU]NR2(F]55\V9T-K",QA%MW R!)CJ9PO(A2:I68TYW[5U2F'7?:I7+,2!?\#!)#B&23(,@\^/\6D:/DV[MO,C%62N-O0DM,]<88\CZ@KKOD(0UY$2S)/?I;-B&R,("9,&@@D'E-HR6 XJ< MKWO>M<1#?Q%A?EC._?ZAP@^+%.O:W;4TK*:6^5RZ8D*HX8]!#>[TB;'F:V(-_M3H##"_K)OLO7/I\&0^[QGRNAAXF'"_ 1;$^^E3J@ALWXU.KS^;:'YY:X8;H MOW"JA44-BQH6-:S5L*AA4<.BAF.7[^PTJ:=,-[V8E8;$@B+L57?%%(3:+V>$ M $>K[*K>3*\!;^NUJ*0J^X5V/B*;HC)8Q#AVP42[1NO\TW'LM$EI[X:@N5?1&C21ID6=UBMJJ.579F0B"&+>"4%? M*IML.X_QLWFL=,@N@.|=#? PRJS@HTRQ5B5P01'-I=2 ?_US?#TGU!>.'$=V M1+'Z'+*X8>WI\CHL+Y2+HK^V[5RV$]2\AWR@B;O:N#E# _"'00 M;CH0.:-];Q<#C>!)NB+J[DHF>9@81O-)DLLDZ0R/\SCP2=.MGC2=I,%]C0N 2\>#W/BYI/ MF]6.WY@1??.!G]=6/:&$>1&$.3\48O?@Y ? A%M34Y;O"EUF0VSF8HVIHR.-->U/]FE OL>.'-M 8]VT6X.!Z24L8O":%'@2ZG5JH2\%AAS)8$[3_)LDN,/400GA6(8P8[+25"D MT.Q'["2MK<7- IC;-3KJMC'9_6@ XJ/I&2L-[F1=*]J+&"\RT0A856&R91X%. MDDBR%)G,,*^Y'[>1)OC#F[1@SQ,KQ?<5@/()RTWXNFD%H>[K6D*S?%T-P5_$ M[4X3_Z'_^Y_T?Z_YE.K"\>(*RE^<|>)M>N\$)7.R:,C,=J-U5K/+TBS;(NA> M/3U>E84SM:!X[5Y,YK1L3TNR(P43+HQFV2S/!)CJ9Q39Z+ M.Q2^<5"ZX4(CGX5(IZJ=^QH<+=N&>5^;+,92<;HRASG7Y8:> .$(7M-]M14Y M!B(,1-@ZNC8@>CWPFRH7I@V^FIJ*W72I1A8(WK>U#P2)/F:[OU2 M*:-OA4T#N,6!I>GQWL(-2CB6JH/O7#.AF+Z.3++$?YC314QO'#FN-*_CZ\5" M41V?5P.AM9TD"#M!: (8Y+!-2^8%B=]5^NSS(3EV1+A3;8*TH),JGDSS!XK0/M?%Z+SVLO+YQPKKCF:]B"C)CW08MDRD[5RVNNV_&?B2VY;90%2"TP/ F3B;# MJ(+- E@M$E8\(4IX(8=82N2G)E')OITKUKB#/B/JZ@Q"&__97)I-)9EC<[1O# MS,W"#*Y B#D>F^N7'C8\D3+4>FK1JTOZRLZY2W62[PYL>[R"RA!%#Y,$0<#_ MAK&=&NYE+EP;BI9LP1@"@2!1ND$/BC

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i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j"ZFHURWB#C &+1AW,5'^;+4L.?!,2L,*>Z;MI6NATT]&"N MRV*^7[;I/B\V2[,3YNW%RI%../1@KD++8*9>83(GN'(3]M]X,%03#3V8JTY4 MO0XSECPIY8Y7JCGRY<4:+.L(5(R&J6!#NH.ES3$3>C+3:&O$FG#HP5RIPKB_ MH1R'M9M\X0X-"#N=]@$#D$;#*,D9$:YN^+T95?9P3&\- A=M:&0P_FRDF:QDXY M)A*C@N!R#7%06YDK./1@ B3=5)Q!GEZ(7255HOH;=E#L@]%',.% QK,%UPEFLKD2%5-MSF;K'}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|&/_!GOTF.,QOU^C=8!.L';;JPR55WZK MNYHNS,P+?IR:-T[3RW&3+'EVEZ@U5J- NN9P%O '8 ^LXC%!(I6P7-7?WGYPF/$@H+6Y3=;6F+K40C'#Q6XV+44 (4=%3- M)DWSR?3'6#>7%.6 Y$*7*CT#;.]LYD%X\%0;9C* [0XL3? #D.$O8%LZG8RJ@__MZ-A*3I1;J&$\L@;>OFIS_;$.6#++(T8,@H:|U7[7B*@NQ\O?F<+7XQ@%V:!-2I2=V'WS$:H MB@O.E,DT.F.X-2\[I\JN1G;*H>N- ;A(<^MX)[(I@5P2[(A=_3/&&*^)DAZ.< MZDQ*4K$^KE48<\%5:RN9Y.$)!$-S29[(XO_6/1O5?3/=ZWP\K6^KRM/B9L_M",&?S@RX#<'_;- ;'WLY5;G/D[>RI\GN8[]/9E\^F4=M)I[3SB/ZGO!:-74J M%UR"?S>MY!^,4*OOW5F^@)106V!ABT@7Y_?/E0\<'7 M+JP? K)N^XB3FBA]"HR2^9KO.STRZG_S_[S>HK8$I1#:FGIJI.N*G5(,\-[OBK-2-L%VD3Q_1S$[?^7[(TQ#,B38.Y[_M>^+I(R3& 25GRCJU1Z\MML?]&._VGV%8'GWG1?[XM^106XM=?CL9T]%FQ)ZM\^\4>0>-^AGX<;LJDKECSK1++SP*V'!RNR?_4A(3'\+]WWK-W%'.A)^!! @ M=^+';n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|8'/"4LW7!#]ZO/2KW C>(K+|N&_AXWK0.A"XZ4 FCGKM0!NA M9T.%LW=T1X@X6VH|:* M,Z&@;[J0'V9C ,8TD4Q VPO1S]@JVQ"X2C%\N1#"9X#=)T"]@/=H/_I3&"N+ M40M,$0@M>HWW9'[\ZJ,!4>#F[Z@!Y/-1_)?Z;G'>KF+FX\MWKP- ZU4EL@/4- M7P%'Y,>0VU= Z@+">%"3)9#"T]!"@$)[MVP&$R]R- @[0+?MDDRFD1L'M*|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|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|\J3R/%E)60(8>;KX;G^YDAK90) L-3EJ-/H4 MT]TT@)YNB0Z[Z3$8*

5V4E>\9=VY)&/)GZGH]DVFW4J{X(]_-ELOSN5/] MWT^ (GHR4EUM-E3;$6NBUJT6"IN^MB]8 E19'X_L_]OYHF\,>E*MO!$[N1]E
MS<]Y4J;44=M(5^KK&GC]F:+JI*#FXX5M.DYRV>['Y=AUIQT$Z(BU5)+DFZNNPQ MZ*DGVR]9(ZKL>(DNN1BZZG2:F9E^%@T]W7]V3-
&U45]=DK64;2E>8T!M$HUS M:.*Y]HC2I*-%;DO5>@.,3#P> MF5[R;6U==5>D;'EZ:6)):U9KG*M4/PC,6B_9:4A2OC7DTJ2JF8M*XYR04KJ0
MIDW938@;GIFE@C&?%YVS5>4'ZYS8E(T:*^6;=7'.%HV"!"". QW)2MFZ:^77 M]U*K;7N3?
%5N4*)P("5OKRI/OZFJ/)2'"U>6VK4/KFMN:RJ[VE.5Z>J*9G&, MDDX:,D,U5M.6*M#&I0I*W61E.F#4$K!5+0%(12!:A7JO98&=1ZV#/KZ_>%KV-M
%/LVBC# FZ$MYN9$LL,@S.#1=%@*:3 #TO. E5(1]T6]U\=:4);%RERL,S= M4G.!E478 7+V(3^({(:=L(Z>[0^;&F)GA89I_!!82VY6%AJ.>S5"/N#@2='
MS'T'V,;JK%XQF4E1E#M:*L^$U,O(6(7?!P^C0R1 6CD.$0M;3O@1O=!,& M=FG?>W.$-A@U.(Q6>K39NX?#17]P(;K'P(%84;#5:$>>]$MG&4.ID6NR0T/+
MIN<$R-=1=XMG2%WA?KK,O MY%V*QOMR>_N2NF-PW<,:W!>,8[>Y+QC';G-?,((=YKY@'+O-?<$X=IO[N_S
M<*'-6]P8#&0WN2\8R&YS7S"0W53%X!<=EM^AYN7S"'YK!?K>7@N6_=/BAC3]
M@K#>&FURCAL2PY]JX3_:*)>I@B+RPT]$&);_3L4Q+\X[KXLS^_!RF7_,4,_Z;L-YW\2H+SCA7C,=M*[9A,-M\ -NDN"_&-AAM,-O\/=K\F5)W
M8Q7(4/"QI#OKNW>3AQM;X0C=6:?IDW<3/6RM]HY;"TT!V"S:04PU6 1"6LFZB'&8S M(*;N >]#Q(4@8J? 7WN=-X(1?
UKE_$H8<<^,NPY9I39&E/QFIE%(RV7(4:D M?ORF4S&>8V++TKX M>W']2R5A+K_F7:3 ,ZF -R6LUSK3,]C'L8_*F)\#%,?>-$>+$PUO>@ I8' M+]?
3QX^^041AUZ1.>B=XH6M753LFOC2KHEW5O9NS.' G#@<7GDE'HK T"G. MN$:WJH_%TC*C#[G9HMW+KZX8<-N-O 9"Z#2HHE94M3%J-
^05D,#NKL,?WX*G M*W6N/Y[212F_J%A"]CMCVAO8MI#Y\9M+Q1B*B[<:9=I+/]8_K'\OT'^+QI> M^S?
R;P:51$D>>&*WS>K.P+6Z8J$!Y)_[\9M)Q2@2Q=1^^?F_<07X:H!PXW2Y MS+HM]C M=9@Y,7-
^GG/S(^SY@IVX5+FF+IM18@N:J'!0"J/M9&33K,WAG#S!5KO187$N M8W;M51.S;"LNT7**U, ^U1VYOM@*3!R9^B@9Z.3B?_YHHFOM*[C2N|SW]^
MW?@>8T:_54;_Y#;D^YZ%TU*SQ-Q3>8ULS4IJ>F21ANH*8/+(K"39&)-XSD'U M)>[SD9DI
1/3U,'D@:&YU#P8<@RH"FBJP'^&S/"9'7.W!0O/^N&N6*/[!BX! MK[WZFP'2CP@2>!60HL,2LJ>I=7D#![PL02B?H>^?P-.F*)'5?\Q@C&&V33-+J
M#8N+U9 B8?P G:!B2>XY'QW&%8PK&%>^@:/BK;CBIX?RV!?LO*&+%-7V.F:[M3$X@KG _?E,D%Z.8KX4K-V[9W"S0W#C=GKYHO&7"?;F@AHM@5,%
<#?)ZEW6,_M3:*2]>S56G=:$",2@&,2O(QADQBC,(8=>MTPQCU>1Q=:,\4HQE&2Z[:H%TE+
M%]O>V$MKC(3L,^CPXM@80ST7W/V98BC"5QQFTP/2$R,87T* K2=4W0R@:,\O> M59:?:V[HZ/HT=P"WA1N?H,KC>YN:UU[KS0#B%;-:LJ$%(45!
[]37I,X)69X*L'N&-D,:Y?ZP+%!AS\8& M?-9@ 8R?&#]O"C^OD17T!OR\EPINKN5;]Z+5U5+Y^+P6M*8((]B/P,_KY4R] M C^?H0W$SP09HYA4C$N=3E?
8&+*XT5BEKTC!RHM[N!72G/'7[[17$&^A5_9KD>348/T><89B\QW), MC$R>N\#_]I&75P,8'"=ULT56OE$'@;>5?\9B@L4$BPD6DUOE#RPF-UQ$ \O)
MS3 (EI/O(2>?+THI_7Q4D')0\?;3. 1OB^EOQ/_W"%%P*_GS'JJLOM15#?5_ MC7Q4J];6W"9*]XHDV_YX*_0&)4MX[^
7^<@T^*E%V;4!$KZZYNXC(YYN]JH59 M;F7W%5F<5-.6U:A1,>Y8&%+,RY% GY V7!0ZJ#>39-9P5VCO T)7+1BV4"[!^AK14S@/6W
MQZYC$3X8"O9/"4S$4H0S)DYZ-.]\R%&'-#!DYT#V'<4@1HHB!YX&'Z6[A&Z# MPBQWOP42LG,%5B"IX"AF@V 1L]Q]&S]*46-GL^HLY[Z 3'O-
M2IH:F%IM+(!W M[U[=VM-#C$B1 Y3(,-8\!-$!;^/'3-\&TTJ;8+$1CX^&_3H[GA9*_;RA!4K5 MGWKZPE0:/P@-2,,<3,%W ^T2&'Q)9D4"MGM,=/
H@(WDN:?]VOWC<&ZPWMX4 M<^CPH6_[D8F2=^EJ.<4)U5?GGF^ YXY!D*T([KNY$@\IG^-7$TVXBM MIG_GCJ=#QOGE:E",EMJC9T9[@5Z\&RJ//
>*U?ZX#Q?ZP>[@^^] =3 TO9__M_J5"RS];6QOORY7VA;KCGK4T\,9@@<'[@@7FHS;FC2$8+Q[X5R,"_P8B7!0I M/A,%@.X)/_Q_/Y@??T@-
FKVC3[PI'UKPB3_6XO6@*&ON_0;':TS-,O 2DT5 M_+*ES7T-9JZ$)0P8,K:K93#Z\\@E+#;7%QO^!0*$VWCZYWNL+3RDOHX00%? M,_AT1MU:0%C+D-
&IK.YME5N+\=;I;+8[20;9Q>.E0J.;><.WPERL0 M+, 6_IF[B=*8*E<3&3LC!>5BK\V5JUIAN@J# FD^EDHD8\G$A4IO8Y'\#B+Y
MZ#;N>B(YS_'LPN9=7BS5N]/27%^0^<0-BJ0W=XUJ-E&4Q4TC]"A)]Y3("E D M$[4?@RV\&/9=^R$>P-63M3+Z3/HK1\.(=|-+ZYXA(O6W'0VFM:"]
[@A3T;8 ML=:F(C7OE00C*%+98:)0U5)SX?:P8]-2Q^MYFB,%O-1HUZ?#0;K@3X8)5.(S MQJ78&)F@+W>:8[G[O')WQ7/Z;:ESO7A-
6>8T4[2H^^1X997.6GQU>W(W+S9* M';M3SY+Z/#^V73YC"8(Y ZC@!*+/C2K*RW;;'4=AO2_;S);?P;-"JZ M?%O=
<&QJ3&X,;ZHQ%M,L;1M#%MGX,8:&9OZ%NM=@ <8"?%TJ$SD!?O?&RT)[MX ZDDK4D>[.Z88JK&]0P."HMK/2)&A=;V\&Z7*FN!Q#Z"&[O*NDE,N:
(/X8%KD34#E^0U6U*$-AM7#LI*UU-$3=XD-BVR MZYG:Y/;01E"VJ=%TNVJ0F8'CI1>UCDK'5V$Z+,/Q,?Y9:P9+)I;,VSG]7R>9 MV8XC,]/>
(BE]0LIOUZH .U^]045^OI3%C,KG##$^'33D7FNVX%("D$R@![_!< MC";/-?#Y4FZ&MN/+)C%W8&Z%+IOFAMC1.N4 -:\(OYU[? M!DK4[_N=++F]2
5GK=I/B:?7/4JO56PV14D)MA4K$$E?HV]CZ6G*N?]"]GX=Z& MY#0S\5EJT$N9TH*4[%E33<5+6R@Y\/:=C[%L*D:EGKM*.TK.?9SO>IW\UW?*
MA[OT=FHP\K1% $YU<0G;V]:!HJQLPCI/$T%Y)C=]]^I.A8R/Y#O5&U99FKE"MPBE"&XH^[UQ$WP0L{0$@OFCCOMKAPF/?
VOJMO8+H(KFPG^=_!H]\Q1$BPP[VZPKIAEC64.=G>$%/9([2E; 8R9JA.YY@:;>$:@?,A', 6S!+T3O 02* MH9]W?H^J>8CI> "=I/[F*&,PUUP"]
'&B;X#EG,V+OY"H04?H+[#] M@J ^ . 6'<=& Q3"6=80!1^7O"V]P*?N'<:*6G1V)WS%Y;<@LV4766R XFX&$=RE%.:*4C
MF2.$EH1^$R>3,:)@S5TX/)00AVA]<\<-D^5;VB3\.+N7"(_XV7;F@(MIGOPG M%@EZ,(=2[P%YVG_5"[]Z*$N1M$7", W>!'N ";NS10[.G0,@T]> ['B&/G,:'
MU3CT,=#LP!-W3],6<\WV8,4&FP#'WQ0 OC/#H"0PM+ .@S"URW40MR[(R"< M30)=A6^ -1TJ1R;RGV"/4=, 0")N06HJ/?K=_A3,.'PH?"#8>02+|
M$E#9P'K D+Z(C&*S81XV&E->P*P?*- MY?N&>):W"'+@V+"_;4F*%C5V99"NE&D]080^O/J98T(XD4;#7[((_/>&733:VI:)F&*_J^ M[6TGI#
(GDY,A#W438'A1R8MT_,9"_4W6_&V$^]*ZR)NENIV:)ZQV;2&20;/- M\.NI7&#S4*JA.X6F8N0%%)(:4[$?=!1840SH)U[8Z&4#]@'E\6,3'YM8V,2Z
MJJYB^P#1H@9.FVPHEN<:DE4[N7BRL=3%H+C6&U:NV4OE8.U,!K552K+8?X*%
M&POWK>DLKY3N6;?"RZ_I[A>BYU5A2=KLXV2+=6K@+>1RBWN*OK6^.392+FRA7[ZM\O?H#5U_Z%U8(MCOM.'#<">/J2N%T<5!4J6:+
(35S,+Z:T2@W*J*T&4!12?!)8.M^T* D&"0P2 M7\<)\G MK@\>\^@I43/*UPK^F0:KAS^_MQB^5_&""S>H*=B XR]!((CEI:V5I M2;;&PY*=[?KJ9#TY;;O]?
MRU&V\?]-~S/3@=?R,21)OXH,R^'U)4J/ *4Z[9 MA!!,P+!], ^?CILFH#]&NCL[A$R8N@+Q@I GKH8:XA$_X6C(7C3Y;PX(CN/) M1#D;.5X1_P\?L+NF["I-
GC]:',T)UF) MNA^C+H9KQ0P\F+DOW;7N" 34J-6AXEB MG'[/D 9U%%Y[CIJH/B'#1AEPG:6 MFHEP,S#E71=EP*DCS9>!E0J_-~>?PC:+SGSJ3V73
N+B!1X$3M3U^97 /P>L M/RRFUX(XK[H%(Y"RB5*5'2;IY>H<\O-#B@V!WW/]808V5M?SZFRJ0,V&M
M>T/HT!Y&%'M$54#4"BH9/(SD<5BP56VL@QEI94 L];%XIC<5>>:X&1.8?^CA MN^^%>PG.5F&WY5[TY(J\H#LY.ZT87:>;!1X,GR1*N- MZ^$N"7/4J5)-
;W*JO#^^XG0(&E79=8>;^W%RO&H.*B*76I!Y1O#ZN7+CQV!X M+I^<02!YCE-5(GKK(>/!;NXK&0C(T4R(B US60&UN3Q@A\ +.U_J]MB4+>NA MB>
<<-N(.&U\Z"F P%W",.]'<37CI'\SG)]d,.U5W=-D!S=5L$6HM:A,4(? M0\Z-0:/< :.P,N18)$YP'1(2L&TP(0"HS^@,:!9KD$PL,VVD^^BUXIFD"L;#@
M;,%_83O^%F:'37R'+N.A1Z-6H[NFI[I+H".!U$C/#EWLRP_.8.8$! 3=AR% M'3]U#;[" M70H8(JZ?2)'Q>XIJ%G[!+#@!#4\M:.\P/?
\KW=6N_9GWX^@KDE=VU6Z1?I>J$T% M&"",C/%G3E8BW"6D-X&#P(&6"9C&[@C5O5UK:JA%GFJ_A!.)MJ*$P]%?R2:.MJ+RU-
]4T__A80,VNE8>.EQ@)7LU)KXZ2*(-CUMQGECS0^BR_;-B$OEUE!FN1 M)MLIQO8K9E*8P-P2.I9*G.$7]#O -NO1=BFPA>E>X0+J_D&O=!-.9'],<0>X
M!S9QU\,&[&'_]#V5>3=3HJ^^1/BX]\UJW $M") M#(@/?3K2W+$%9:IK2_3:VC@3\[(_B NNZ$#Y\QW[(#+X\%3AYF.G7B>W>3)H
M\GTMQYJE3@."SW.G2C#?8\C^W0B.PKCPPCSPS7XH07VW7N!$^[% MA-_-3%]\Q"W%=C4QS*Y+8&Z_>?)O6 ':)]X!$X1GB^_]$V"5[:TG2&1HS>"C
MY?V5S$)(VW.0$$%X.]P-L%Q@^H=^ /B,,SS"#"9<;[/(MD1YF%YLAB-67CG" M"V;(632 AP1:,3+YH8DO1R_>F;IV;,(1[G"EG-T!-U:"$#M4:;^TB9>>3&
MB@:@HW ,F \5H_0\?6+OF';G;=A-!3(K4*<F-96G!#=3-V3^7A@U-M2\7A,KLZXM6XIRF_U,"% 18|S3Y6A$)2[1^[,XV06GW B)DQUZ_5%VR=S/-N
MW5K.S92668%CBP7,L/$>7PH\.%-.F>: 85[FD"-&!0>9)1M:N/OA1,&VFF.H M=B,C&GY__\&1]HY"0%:Z=_QE-="(E1.8,$\%7NO!-XPT8AR80#6+'GI+/AO
MB]R>-O]^N%7>Y/AZ;ZFD6V5#W]C+42ZU^N7\I71505'<0#;!8AY;/(^NM9&I M3Q"ASF)I&QRP=<=?BH8\5=]3C.\O6O7&\UAZ ^Z.;[SG;W+7-
!1G7IT/2U-Q MTYM21K+8L'A]\H*[!OPG &/.)&@N/& ^PH$#-C%UN*.IV]I1R:)8J8A%RDDPFX^N.MG!*.;#5',7$$JG3W,HG'#@'
MNY^*=O\G>!F\QH#W$//]0+9]G=V^.,[A0#.E)"),.!S'!R"Q-(QP?$7W8J" M!\C@2)$GR-J'9]UC729&C *? .=: .?Z%T60K\5OKT>0)!BM XG^'!<= DNI
M7!NW. ^WV6.RRBSC9&$V:U9$;^%. \8.@07R5"/V A3QP_LPI W%8 F/P$2' M"[Q&NQP+G]TN%4.L%0^R'2XA2+6E$%O,MH:J[G2^#..R$S!;+2"G9-
U%VU[M;2PN MW?9.#!#FP)1*#(G#]_%31PZOW RM6,S*@WJ5L^2Y+="=S_,TBSVW\% MO1;NZAB\.)3RG;JKH?>'FL5N_E EA3/XY_V\RD"3AF_<-
UTF&'}G1$&-%A@% MCGU!Y_+W9;GW= "0P^V@LYC7*Z0J7_4DW?>61]6GC"HO7ML#G'6CR0}(.;K' M6I0KLG>
[>*]Y'"">9]Q3YP,F57VY^Q/L8N!4TP@&#!\>!J%K^TC@6'D6A0\ M3)+_N4B\[W'_83JQBW]>Q\U15+B6A[G_U^'D'*9XXIC.NZO7/@GI,8)
M*2UY'3\@6!0L'3>UL2\K_-;N(Q0^M_L,ID0#!OB%\A7(WSVT5/1KOC._!=- MW7$P2!7\&*V*2MPE+K1-CX,9Z8?X2YF8NA M_KM=RYP-
]X7_WL7WG@GY_?&[MC? .@&8&@H\-@S.CD%GY0C&:YUM=OS:J5.R+U5JG(,2(0C5S=[E(TK^;9;76 M%EM$NT9D:M6L6&V)62)7]
K53$$H$ZVVT!8K8K7=NM7[_Y2[@I0MM,7L/P|_MQ5_&*R1?<8]>^#:2, >/CP6S!.)"W\)K>Z?< 3Q/P!'X3?_>22+1R)-'61$
M1"\,/WKB\3OQ!+@<15R'.O>ST=E1U'4(YX=?@U*X:W3RV)M28#S9B2TX,TE))L.>! $:RCT=FMX7MN-.NETA[MD%\866;KI6AA2)\^DZOPP=JK=[-
D3:QUQ>2L80K3!AAY\LRTEFBO2LMJARQM-M8U6PJY4{6)3CR=$6]>7PYEWMQHU4;
MI+/)8)K75@TP\N3MW6FK7Y(*>DLL29,,,DLF6H$#6[6=O'TXR RY7L;JDC4_ M7C)F3;Y21&V+3D9N9I6B+\=74V/CWOO8/<#-O!
M^G[#3!M%X4+A_R\FESP%^X-Y"4^8 MN4AMRVI*]"FUB_Z7H^DJ!]/=N?FAT1(%_NY,CU^73"9!:N]#YDAM'-'RD)3H
MQ#YED[0WTY7F4*+U"KSE9^;Y/5EU%[%#-/C M@'IRG-/:7[Q^';H?)(#W@\EKM*;=9ZF]-B7MP**Z;"$/O"_7V9>7RK7B?;G2OKQ44A9O# 8R
MO"\8R&Y^7S'0771C/E]IR">(P+^]"+==4XY_B0#/N0AW)O_C/Q_\A='B@9D& M*?+_?M __E0TZ;L48]X/'&"N[MKDA&CAUXN(WL]VB3 M<-
GJ@=^@..'E*HA&TIB&POA<8TGV7N]7X>F3]7@X#,J(RW9E%W].=A:S>];+85*&1+= MYPO5JM[;ZB-AF$!]

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

&E8RZI6Z[DX>Q)G3W[`6'V<=/3%]@4G'=WHON"DH]O<& QDM[DO M&,AN=%\PD.'L29P3A)/DQ)S!(WP!)?.7ORI##W0W%[M9U\7',< X?

*0KG'[U<5%^#Y7[3_H)/%>U_R&*9U/HC$J%9&"37-V\[U@;H=V? M-,(L2SH& !C^CT/|L)A_53%'T0/TOY_9IMF=T*]VZ_;IF+H-)TQXP7QN;@Y;*

M7\4(6_,_@!)ZL[+ZS=;\DJ\9'\VO.)I;>_FKV=F=E&8B(6TA&3US-M]/>Y(8 M3&M]L5MI;9N&V64;]4F8?U3.5<<()]RZ'>3K[KB_BI(*;2K&\A>LH("Y'X/*

9P! MO_!*/+7T&W)4S%UGK'E>V,L5/&;I*[@<$K96GQG)LJC5-F*!\N"OX2)@^+#T3J9B9.*"]0"^&7-C@?[" GWI.D>OE^A9 MIFK-M49.$!?*

LQA&6'IV21PT@T=R/WQP3('GGU/%W4T=N3"]--NJ]^X0"-A;6 M:X0Y?=@&P3;(M[1!/H5"@OP1H=1FP&RK'@S<&>)XM:\9]R2U.U;&N,\E

;Q,2<58$AYIA"^OL3&&C3%LC'W@K4AN)WUM>7T&DQKNUI:V M9JI$6KH>.(G6:ME-88\N@UA<6@'%N$O)\+O%&EY8UKD[K1U-4^3766*BC6I*

MVE(SG3D,"L'JIK U@:V)3W5T-R-1%FPU^R#(N)R3WM44J](RTZ7=(^,EQG]

MWDQ62KG>!$X5G.E,C&5Q(@4&!0P*G\W%\)>H$)BY8;QB821+Y2WQE:D1H4^ M1 7NQV\^%>.3SSD>/Y_W 17^N1Z@X18YEXH%01)[6KOUF9OC*

*MGKM4Z&Y]:VC=92$WE&V72@FPY#)0=%*Q'G!MIS?C/DQ(&! ^/A8DCTQ-FI92)H%N0!B9 "!JWPR5CJY?A< MW%SKU3+WAV"T;P)4EI9-*

*>6754 ^*FR6PJN;2DEI.-K%>S 0CT>ZE>KV>(HW5U++4;)D;V&K@@#X5R;+,E,#R";N7%4BL6E MIOI:=3WIK\ZUR;(2/9TMCA(UD6YK::[$;=1"T*

*C^<QY3*E6S]P5R,62' MK;%!;>(!;-)U.E&Z.=K8&2MH2(%=\T>>I>4&;30T\7AHW:%R57G-Z**>DG1*365)*

*{1;3ANQX@YHT*K1I$3[TE*33V]13Z]D3Q;CQHXVK)G.+FKZ" M0T](.M"W=;FW23%2UYN(_+I8[C"ER;F68E*A6YBEA]FZL1 2XX R9IS$KE-*

*!QY0OR$[HZ*JXZ3%SEUY/;J%;=';3XA_WVU8 M5&+"WANZL,S/=&O4U)T5&'E*_'3))-?==6E ZC;;VRZG1K]804-/B!]G9TG- M8HQ[(I^M-*

*:;N:4670<>D+\K;JH]@UYW35:I4 P3,LI-">KJ47YN5;6Z9$5M.O+66>Z7N|KX!AYZ0E577PW8P7%=% MNMPQQCOIK+82:*ZG=!U33 X-TV\8I#6?*

57.4 MO>(JK08_T^&-M+CU[)8H)]D1O6"^]RLM=3Z AQZ0MIDF^<"SA/29'[5N5=, MSG.FO0D<>D+:0[=HCBO=7)_DC+' =ZKMS7 AIZ0-E71-[7*

*(.>2"W,SNO?F M'6M.H[F>DM;,#IV9E*9;1EY:CQO37-]:CU9H[EIE;G7LOA)(RGJ)MNCU,&@ M/5J$8W>DO5#/,'2?!ANX[9K5/?*

2A.^T2QD\RVWM^7AR(>CLCIJ1DI%G5Z'V MIMM J1+\9\8-X3#J0CW%'JL^#]WIGJT0^]"Z+GGBW^PJSMJF[SD9SG1^L1#E8R?

*%OK]2X#C'A0]>Z0W9\HE]=/O *(CT4UY+% MC]M\IC)*E:3&+:?2K^\3-Z78M0OZX.]V3K@[^COFF_83>Q_9ZQP9"_#?M"'AS M&T'AC;B%C4C=,=^T<].-*

;02&IOO?" Q--[$1_!W_;(.BO!$8FK[;1F'IHNF- MP-!T(QN!H>EF-@)#TTUL!(;F&]D(#$TW1Q$8FFYB(S TW^W$6],6)CG1O3C5OUAC;=? N%WO[P_;2?

\KD38]U_F_[3_,I.X MHZ^;7/A2_^67PFGV42E1CWHRZE'_CKVY+\XU_(F(.ZH$[_JY--T;/3R@'?]ZFGKQCZ4\M!^?#!S$__"D_?&IFR&HC

MGX!1MTY@^Y@9OCN3X^'ON_Y$MM-5 MZQ" 9T:5;(BYXR+GW[OQ^;47=HV"M2W7'<8R?W]UHWY_'NM.[Q%_G[KQGS^ MO=:-^?R[K1OS^7=:-*

^;S[[5NS.??;=W?E<]A-6G7?>[N90^NCXC^)[#S_^ M;]F;_ULC=-L+8,\WC9@[IJYL"-.1[<_@0+T%+GXI,O,"BWR/HHHOI?-_4'W,*

M#ZNB&U6U',+@H+M^6X >Z (:]T;PJHZPZSN:HKON+#&Y7BL*YI;V$E%'0E% M&K_MU,I.>]..M:4K.Z']<9_.PBL^9+ ;! MH%0I%(;-S0R6TV-*

*^_.82,8Y)7]+H+A;=VQ7=E[CL.B^H^AN-==196_Z6&]/ MJR.\7\(+F:VF[BXASXAR,]@DILY*8:I O;:*9NR<6),C581,+F1NUF,2RC&49*

MR_+''<,GA1VKFE\;P_GM)!DUR#@CSFF2=/@>F535X??4YS93&F2K5'K@:BGICDGUZW5N/QS?2Z>.II?4@#NE\DZYNA*

*M(O:J@EJI;>2),D'UJ6E\#&/!Q8)[-<'!$YTZG=[.2'MH!&!5^9&>RP>LUD(E MY%DLS=]6FI_/T<72?$EI_G.%NF&O:6HIE_-&X#;";MUML*S<@++,OT:6OT:,*

*MYR.?O;#4[$ CXJB4^K[^.+YMP[=MGR7]\HX^7KG0RAK4- BY(H@L9L:=VH% M*9Z1M))12Q7SXH9RW\?7_W1?TKRXK7%,/#$W,NUXTNJSY6'1;*

Q9Y/:/<1S\ M_X+^A>\G']\5%ZX6;?(,+D L^/DMP.!%D^=IA@T=;'98FNT$0^*5;=55)IE M6P (P?WXS7)T+$E1)_CP#P8(#!!? ""^F>)P8E!%F'!B5T6?*

1W_5PPRQ.\C1 M6J8V!=7DOF-LXCJS91-%-E>"R $O+F(4R<12[$5:^6+H^%IK_K;0\0:?S%/8 M,??T0-

Q.!W,CSE:GC:TZ[Z68"QL=\J0<[',M713E:3GN%!>M>$N&33;AU0@; MXQDFQC ,1@:,#%\1&2YG==P<'/R%V9&5O$"Q$W1"+ D+=VMZ6KF5@,H#O'!A

*MH>Y),#=@2'B\Z8'8.7A4H9'9KFI=3UAVA'CM8&5F8WZUC-'*KC/=!+/,\GYCR,', M'F1S7=,N^N)"@\!'BP>*Z7:2XG4N?*

#X2'OS#$5FP]M5RQQ:IHM5.DM>4=LIE; M OA]S/#OKBP8,3X#(CQ776+=[?+EAN:IU0SQ8MT=T%97%\J M5)H02E)0_: Y,L9S%[P0^N)RA,$$@\F?

*NG;>11-^.N1EA0QF9%R2^UK2R4UT M[\S9IY6.+9^;U84J9XHM:2JRM-M?D9:$"5PX@P&"0P27QTD_L)4<1+5H&:N M$QM#;[,4E=.'U*R$D*

,GZ6#D>,?+(HP,J)0_: MTW53@#CR?1.$4#(5H1R7A]_W7X,+@P %]4)X(7=52#V_6] W>)2KPVD M#TX?:=F=N7//&1NZU7X?K_49KD+WP:IG55>-*

,;T>B:]8WA+M.6'PC#)+P-MHL@8>>GB(ECH;T<2+E3JX!;?>N6[H?>5]+^PEII[M#-)H3HG)7UC-.FL(6AC=050 M(?7C=RJ6@%S[':AU6MM?*

*E#N+"^T>5#VF1Y92Z3%GLN+ MBC-8#2D2M3EDDC&6)'%AF.\EL%>_I_RJ OO'A9V]CJT\F;*02R9]HQ\4"N)" M9-2$MRG0_?H$BC"':SMA$<8B_/']*

*8&\/I5@3C.HOK(NU-"K637W7*H]:(EG1O36_)G-7M5I#$ MPHSA1(PG$S']DHW#L=!BH<6]]?YB2N,UZLU'PHP"P0X MP<<8W-CA&\KOE6,?O]>A>SF-*

*VN4;+7$U=AURX6=XLR2WDF.J@<2;A^O-$,&F5K"U&OE!IB MB9XH-5NI=41=&%(4*J$:XS@._H_K)F&0N5H S+7I@COQO:?9YAD=62@WMEFR*

MQ75K?46@-]YH!0&' X##,3&2I7"A)HPW&&^P4O,!9B8GT V1GAL34;.6HV9]

*M(W;T*H*C%-1_8.4XCF*Q_H/Q",/19W%VO6^OGO>PLIJZ)SVN);L.N7'MUGKD M3MWY%%E987E:L(WP?PPS&&8PS-STG=@'8LO?*

V5EF5ZG3XVI1$^;/;M",GW:6\ M:DP0Y+ _?C,I/L9RIW4OL:&%$>?#\CNN31>LV'RDI340>ZU"=EO;DG&O6^)F MPI+/BJ$.A"

*[T.)**)9A3W\]7RJL)6Q""U<4OU8;PBV/)N1:N7Z'$>'3#=NUU M71L1+]5C()5F6E#+]F2UU9]+'-U-4>6JOIC8#833/W[3,0:%!%[P,@P+[Z<4 MWG/-*

*V&]+>#_BGN]#NP(^:_PT[L>;9*46(S QGI;JI7A.7DR@'_()1.68RS'*

M^!"^O$DA9+JCI;W6LV17755&-6M!BHL5%/,4/^\!!6C+GEY@^4BJ1P!@X6WT\JOA]R7_'!K?>> MU;*

*<#JIF>2>YX+98FPTUEL*7[.1+IV_"R@4]PL11S;C=CA?O;2S*Z&;CVNK[< M07PYC;O.5@?*ANZOI:!$N35@(GC;#?*002<^'TNQR1C]LA/___AP5K]WPZH*

M=%Q=N1EI?7>VF@6>KX\WCR\&'K/636;R&DC-Y#=#4$G8@2TOV*$/]6(C&.! MB6T(W?,"327DXVP?W4:# %R#O22<,?&_+L*B]!"8@Z^*"Z8NK(I.*

[(=75E-[XW!/"^J52-?TRRJ.NROYE3C3X^PUA2P M+=0[T]MP+=X8 [/Z:!5V76'3)(:<2_V?\M6_-_:P2?.Z(JC3\9$5Q(0OH8'=)94:4 Y*+DV-U7)XT*

*)S=G7$>_(>8:RZQT607-M[328(2 HV'&;J(`5@\7MQ3?ZC'[_1CWN4 M1'\1%A@X-3=P39#TWB4 * MX"#[G@'7;SH7X4K+]@Y%,31?28IOMR!EU.!\7*

M5N^C4P,NU!U55^HAKUS;'J4E-F?SXS0$L2IXJT)!._MG@Z.%GL"*3]W=5O1Y{*).'.'$G<$H" < 8'&UFTMW#6/T&P5,&Y+F_MH\01#

*MGCMV7&TNZ^KE=I4;4OM-?7WD^5LV-2D5*FD^GO."D#P+M3 'NE;_T?5E[L_P1\[.%%,_&]0>Y]& M&LM>.8=X$=DD)/F?BZC@$*HU=Z_P_Q\$](C1-*

26O(Z?D"PR'Z)F]K8_Q5^;_<1,CUVGSF>CAH&N9H)Q&2I MP66.W_CHY>&>)?AZ:C; 3H50W-[-.0GF>T]/R\.1+V= M$5-2LM*(LZLA'$I= GM?ME,+-

E$,@ YQJBB,M D0>4LVH*]Q<(CM54.TB@1>ZL=TK MPR?MGWYQ6WNO%'$'2A'W:]4(4@@H1#OZ[,G3!50)E](!/P%SI3;88=PLF#=

*M.7!2EN_F=^";+P\JZ)%2->XW*QX%=!!CTPS,+KFFEWKK,IIR?<=+9U6L+N%QAO#Q!CFC(H%S3>D 1-S,_ >U.2/\OP (3I0R'UP*

M;KY9(U>@.G+@!]#6<\T./1$78\GD'^GI'\F2DTFI(U&,B"U23Q)3Y;!,@C^_MF"5W;@0QI"UK#R;>@B\;F1XE&'G97RQ3?*

QSL)QQ0ZOAVHNY]EAY89_=FL.CSS=6 =B0Y M/\U27#9%R<45L _Y1(PFSY3^0];RD1JB[92%O1"]^3LGN1T&]P3<'7&\7SO M['889EU(I@/'-*

O),T4\NUF.UG01 R,12].F%T+F],/9Q_*77ZAIGY)_YLCX2 M=RM%H:87:,HB]0P]J,7G0<)]_''0P&O/R&7#&<:[C'''0\42O/].TT;H'./,W

*M%4NQB5B2.\71CS@EO\MNH=M@..V"YP40.9Z6X=6RO*C:IM8W%I64SLV=2:/M MAAO%I&+NP,W+\C*5V&^2*

*C9_,Y_]GYV)]*S:37K%-2?)3HZZ.56:W:!\Y%E MZ1A'GVIE/Y<] #\WT5]Q .9Z:VI*)1M=L3M(IWO%1DU(K@0@/&R,HLZHBB^= M@'N/_:%GZ&9B)*

(YN$MZRXY]^,5PVV5D:>FUK:FS;8V1+>$Q]<)!;NH|\1V#K M,X@"$PWL@.9!WC<=P 1:&[PR:3J"\6/G,,NN6_5"NS";2/%6ON"U,M/,5IF$ M'

*E{]*F"_|RXR+%&:&!WYV R@!NU=W.SG3@WGW:RP7NE__W?%$?^RX=_H3@" MZE_B@"I(6(_H.#1%NH@>+#''B5&&V.U%D #VDY\(V]#\ &ZP1P@Y5*

R^Q M -T0?(PT\$%$H#NB9A/"W-5-K[^5#V&O^/\0&T-SFH?Q1>9F@]G?]X+V])5 M<,"C$7N_*+"HH6+APVF$.MOS[T)/5D,O\.'(E1. I<]E\)TYH,8:H+*OD42E-U44WE$;/WR\06?3 MB2+7D"-#?7L>KA_H5O\]#HD:[3LC'H=N$(XCN>+LV^*K#^.#,Y>3GNM__>ESXKRBQY?Y^_@N@I$]%/C)[+KO9]IR-0<5?

<-58"[9VW7TT3,//>TEE!5F?G+I;(RW3B:590I/BUH!7D,C`TY33% M!0%"H\-]/F&[(W6U9;AC9GY!& DZ8&">^NH5SPQ@AA+,7T:D$1 O!5& Z.CP

MZ=>V0@BHD\{47[@"""]]51Y8HX3-BZK87D='R85E#2_% O"?><./F)\E?,=P MLM-DTYSQRA0;M<9#R@H(3[Y^$@@QA!E?'L=D B>K0 $,^$)"?*

S4G"C(S\"K M_@>1=R#HY4;Y;GI:D0(O'8L$6-A7),!2BC?2M%2 J9!KP+3M#5_T&(P(^C0ZSY@V#!?6(_5^ Y=HR6B8$PZ_)X/4?D

MBJ9(T=7:&SP'D|\@WRW 1MB\=,EUPWDMT.D>]H:H5Q[41I6A_5 =,9YBG/ MP<-2^!=@@P %(!7%>SDB5Z!&OHK/TVO2+;'](#'E&1&-*

U@874P+O$L.>LKHC M*AV7+?*8Q(I],F&MAA !5H3E-M#ODR("9,,> ^ACO ;GYBOS?[/3L7L9GH =+ M/C;M AKV_?/&-WFG"0 ,T$-

*L\Y(O_#BH"6V[8/Y'QMUKJ]N8>)$S-MZI03J% MYJ@3V >R EC&G'K"#'@%N(F2"A:U]I'_\(4R$L@-\M.S:P>>41L[,9:;59P.KF(E]L-+7_ *E[*N01K/QFJ*

*E/'W2F0 MT]YX"A ,.@4GKFS_<> T)O+X]QM\5P]B:5(;MY=3A:G"@$H=5E<'<01VQ:D ML $\5#!G'W0RIM4,=LL+E6QW9P^#F&)],>3SM2S;D.4R43!C**

<-F?OQ.H,8Z@M?=#62 D!5$P[N;@>$?]<.Y6[B.IYEN]NG(=%!';[MT/ D\96T%]\;^Y!(LH!"YEP5X7.EF:M:GI<%;"@8=+#?84_JQ3.T$OC]C)=*

*MMC.*K$#O4Q4(LZQZHF&)ACWP/=V]I\'5P7_;M&%&CW_?(C2\,E]YL\H(M_^YMZ1O#]7JTR<$OMC=D@$>Q:(H+Z&5?9$1[M,4?$VH)4]+\G&D*

^AX57I"\ ML;5 (HBG#7Q[B[JR@ M/:N"Y1N$YB_P6_]|: =7+$(,!B+I/0O(#33%;7_G/'\MN"H"_QZHENWL M(;,WB>.XPT_P3#A)*

<3!0==5](_AD8Z#;_WQESB\(O]WETXW]J?YS&!_]@A@ MD6C S\A&VD3P<3"/X,J-!ZP!!PX!N\$WOA=&V=%[ZX]\#O4_5?6?S[__38[= MO?_D?

*8AH*3LM)$>'"%P 7"$H. D0'4APHGXT..=E*,"LP9S#I3__T<-*}Z0P M1T+V>0DNWJ>\"B3:&)K>!80^0%-/J.RWUA5!=B= @8W@+_?(3@B.A78/O1OZ*

M5_=P]GTT\++QCT ^"Y3L'&PW)^?TG;ETRT6MOG'.V8 8[!U ;IKPP%-I MB;JK -;P_G$^.%8P-;5"+V6=G6F50C8:38[%!K!.\)6O)NC1SP9XT

:N^LY\"'@@L#M]LG I:A X-D$S2K*T,7&%_WT"; M&P,M#6V$?0/TX)=T[0]8<"P?8OX8+3_T1M6XCNF8"K'5-DZ5V'!,Z")\JX) M&/'\4++#DJ:X I>G-*

*L@R,LK.'(,&%ZL/G?5 L_#T7S,*8KK4KZH MSE.J0(]G MS4YV\8ID4 *Q%8SMWX\K%SU)IEHY,<.PQ5*2D7(54;(+!W'K?"7SF>O9D_,]*

*M$);]N*WO/3:\G3S%Y_V3]40*0R;Y"K-9\M4/YK46:-16L 27W@B$2$2[IE^_MGQ *Y">\X^'Z'|QO3=W0]=,NO!ITD+*

*(:\X9#=/QZ71812DR2U^/&\!WH=&TO"\D[M'5641G@ MQ-S4W8D2G-+#,ZHYT,_ FP1)RE0TQ]#7M|UD#FUU MK[.*QZ-\> ^R.)Q,K,T9Q5(V6F?*

DB5UY^GO>,97R(CEY(R,JED=K;L#.7-59 MI?8C.+OKU\"; X_RP.0,ZHCKTC$!A)@K>J MP0Q\,=\H%,6;R&$L:5/9X9^(9Y6!S^Q!P*

*[@55",LN\BOZ=I;GD?Z=C#W4OR M)2S)4OM0X#KFW-&&L*3V5=3\>SS_?T) G(#_AY?E+(,1_G MF(\4S DRP0_8Q7=(6Q04]-*

(^:Z3=XY35G4%6,B&T'5=>'89BOE$1#"(L@A$6P;A_?8:P"$98!.-213#$397):(5, M#'/#_@I5XNJB(]G)!;-@H"OTPQ>$[4BNP-

+VP$DV^.@LWVI4#4G*R#58'>QX M)-.GJVNZ76VCBH;WHO5*8Y17AV D=3PR3G4'P$"8#C25X!+D>D[W:;L&O&[T

*M>&2U0++Q+MWF>'62*FM<"R.RXQJP*$Y&EH=CSFT*=H5-D:5\;M6C%^LX VV/ MDY$. '1W.);FMI=IEV4H:G7:C#Y]Y,L]>*9>G>;681F=&-*

*E?)U]1&*5$3Z-.W M%P\B9S38[(Y05E25;!:VT$&*G(TD"Y\H]_,OQD[90:31&6IQP)V<*VDA-DGUOZ&;O M7Z?0!9IKL]6_N7.W?G8P$5Q3DN6KCOVO>?9'252'61$!*

*4W+G^W]%O1^..'S(\LEI=RD M48AK=%-*5RJRF[>)VCNQGY-K:[!NUAF?7MU>/X/9$-\]-YS;9G&48)+4O5/"*

*M&4";R03FH[QR^NF9Y%%S$(7W<(*C=W@:OPFV0*+"3!4[2!>P?]WBQ[^W=_!V MM>*

<"GU[M;27)1)%'BXHV;RR91#Y;Y2>QX94NZ^Y%$O;=IW/WI7>_A%]^\/;T M5_]^&ZSQ&R

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|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}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|PG4H^C M?Y]3S&^>G7LO[7HO$;^%=M9D8SPIV"V)55G,KG7HQ#I9AHVI@"^.1? X=3UK M.Q3MAQ7MI]7@=Y'MMSWK=3'>+7>-7@(5A75IU6DWI2I^\YC;E&=[\11>,/BH M8>,UOEY4N3D#Y-SSKDR8GC>"CKH:S_=;)>K8SJQ?4LZFB-$3%O"HXFYNHW MU\.K&#,:\>M!^CK!B]),CY7^=0Z MH22C0U9:D4.!AAYXW*NA?U4'_YB]$ Q\7N+VS7=^ =<[@-8#/>"EEM8'"F[ME&+KM8[T6X/>DP]"KUP"N ,\ 3G_C4[:+*>;_"RC^)COD+DCQ=AQ\Y2Q[MA:ZZ77:UR]QMUZNHKV;G]!C(Z);=2279%77255A:N=1O=*"]JQ&$?""!!1^)O MNBE/CAVA-1*"S*.!#)N;+_J]0MK04BHU;1"]CC74;VY.6"P1;2_+"UM;U8U6 MGI^:XD!:>$W@?62(1>C86W[*$QSSWT/ZGSX-X%!N"2"WLNG"Y@'/* [A_FN9_M.5>BS[4*0B9+1_EBKY6?)U;-FIFZ>9_(/[)&NDH([K$:*Z#2X1#3[AY<@%6 MC?_XC2%7!O4;I6BO^]U_4 NOU>^' +VT# 1-;4K$H4VRZW MIB%!4A$\!%J8HA$@1 M(L6GD&(X,G&\X0@TVIHX:#25M,[1DW#P\(,\[*W;(D3[:+3/Y?$T8=],CZ!_ M\(GWO$(%GOK[I\)7'_BWUW?N]V98T-[O)IT*ORBU-^VAB,7]>;[1]?&*S;X/ M"AUXS4K;HF7!]L\,T% RU%)W;JGMS1 [UU%;TDW8X]I\IP7U?F?I@^4>MM&6 M-(:)JH&H!IB4X_JJU]L149+ 2L.E1. #>:!X<<-&MO&\2E1UQ4YN0K&V<'-\IM-UM3&4.0M%VW[M5FY9Y-LJH3?\PF[H[.C!)WV +O).S/S6X+#AJR("3O?[@Y^C%'.G7P+\5N$^ MVERY9?@G2(5_MM&WI;._U^\;<+_WV5D2Y%B=*DGY69Z=3>;K4G&F]/1!S>O[M?>I-^]N\P0HP,Q,1AY8"=AQPM K?>)]E@;(3MY[#\["^U^[Y3;I?^4.G$K#[M[D.R,)H/4W2B/Q]J:B4Y$$;7-U\90(]NZ=H'6GNB(,I2L235]KKWOM$C^8.4V2-% MU%;D7[)KP?8OMF(<<_=F%8PA^YO)N8X-608(;E.Q)GL[.BG6:6<97V&\6Y]/ M<:LY*>H40!=;72)@MYR1?6S^@7GHNKF & #6K5H>3\,NWA%$=" 7!ZM6 F ! M^_- \^'"6H=E@81Y@;+_<+4R&DSM7+3 ;,>]XX\]_'70RVIY4'YG2>ZL*.BCA MGN\Y5*)^HR1Q %[\2]07XLK>=+".O^#;LFV_MDXKW >$@J%R9/G!^W%,? *%O!*97K?E_Y^(C"PH MR44Y]8'GKVK' M;F\7Q.NR%;Z59R)(OD]ZV1;&>[!95K@FVT":')+B*FFVTF#32"9?82JI/%_"M&DVFR9;92K/QJ-/_R5<8/IUOLNE_=J4'W\N7Q&_$4MV&9DE4#_NG(TER+ M]VD2QR.K3;?/C3R98R+\;*FK)?M0IGI,JLR T;&CT?&TG0211=F5:,[M4[YCX4:RZ<#25NCQ2#&1,&UE.IVA#6F>DF):FNQ/X<7ZDY%XS1U-8F4CCK83 MHZ$N=:I9[_!?]P!:,=U'@L$97YU 1S.SD6M:L8''FRHG%QQN'S9;^EX5B& M&L8F[6QES CTZ=NSF928;N):$UU-%FS&GHMJ=L+XUP^.GKDT5652BZ[XB9&5 MZSB6&*>B<.3)SG,6Q9><(;7F)WD)2K)T);$P,%?H9)[B>M@6*HZH:_2D:\?X M]40K]1@_W?!PI%.CW?0TKZ31%3X?:/5"?V'-X!GCR8H:Z7B41AEM M/.FEXHP0/WT[Y;3ZA#QW#;X=%POK):#74%F D2=OM\[=DV2Q\EA;*6UG-.GU M*D,&CCS93W:8F;2F1G:NI=.$MUP4!'=&U<# (DWG6EDDQ4\S$,7Z5M-<+C$GU MK3(&O&B=##@%D06Q$T<MT_>?X5^'T;MMH-,^# C"(4'# VAR3"UEKJN#=[NN=}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}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|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}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}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|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}[(:?]IP&KWK3..H!' M42GHJ _!C(;BXYDT5W25MQD'YYP2[^@1,N&"MX#-_#C0Z? !W9Q@VU-E4Y> ;VSX2-/P*;6.5+(JK,#OU=@#_P#?FRKRZ@7 M'X234DWY,"J(*$#-2[70N1 2\)/=PK[Y5[GDC VO]/>0\NT;;AV"6@(3PWL M*PX/XD\L%V0!5 PB3L&OEH!!' 5\]XY 7*K6X.=D G<*O7]8^ZE]]G?4.[%-F88-P-5_>5V1%"!C,FW534DW96:2+DA(8YQ"_\4WQ9YR MCSU/;#:+H M '.TY]ZO#4^6X%)>W:D^5C1!1!$RM&AIQ3<;U3%;[GBG'F_Q6WYW!.KY

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
<_L*Q%]C8=:_;+$;^D%+/K(=MD*U\HS$21?2;UL MBS\^V"PK7)-M(ŞT.27&5-%MIL&DDDZ\PE52>*2&-)M-DRVREV7C4Z?_D*PR? MSC? 9]#^[\IKOXY4G7U%LO_%R(&"[#P\%\T3B_"^!@I-^PA'(_R*X]\M_]F4M M\8+[:]B;S8&,8WMZ+9B!_]$K[]O(J^@%)00<*BRR:+&
<*HI#NYWGRT.!$V+'(U5*0-U^_ML:1KRJ{G\;AE$^D\(^#P0._P9**YE'KK3LU!N9(VP):RR,[=(1AY\LQ.T^SI MRT6US8K$>$BU7"'3F=8$XO29,ZM6=P? %24^C!7*QS,NJGN6&8.3),U=<-S-L MM]TA2J_6HT3!B!6[[:#0Y6:L2!9YM,96@AM[A2-&I)$UF
M.2FA2@E'I\NVV]*Y%!HP|>3M.SE.#D):>L:N\.ATNE@J:QFL"=?KVSK@7ZQ7R MW3H;7<|%%U\A!6%5\TL7'(Y<)/D)7B(H@VU@_"*AB01-S>#
(D[?/8^JB+):K M),_6N%&^8-9G36HAT)Z\O:4FU#RLC;7&]XAC1BNU)KDX,B3MR>;0PRC&V*+_MGSA&F\C-*NB@SPBQTV>65'LNFZVB[1SMI)+-
_)#G%G_H=3S4HC49-_$QH7&U M:+V+%8U"WP|/Q4XGT#,+R4;=,@U6K!*D.*_IEA"MP;$GFTJ4[(R]%+HD&R52 M8[)ON,9Z"IY*G#
[5(:*%16W>T5"WJK>&"ZH=HZ8+./3PJ0).)PA%065!Q!** M0&(2)L1QB1 &"B$EL#Y!R>C)ZA2IWR69[%CD4YV5:=/-Z)*5P/;>3L/)Z"FG
M+0+3I]A.M97EPM%('0+%R=JZK"&0]?%LC#;6ZQZ+8XO*N@7%_X0,9;*L1-U8 M3^?%%2=*A42UO;*@4)^,:,RPE36:ZGV4KA.M!C/!HVUM>
XHBL38LEMS=,9. M6@+!L3G:CF49,)(^$?^C(NEV/3U&%3]IXF#;E@4.EB4\)2Q3R<:5)E]ABV8V MR>FK;_26 MN9$Y](LB'D%*KA\3\ZMN&Z6-
=L(:IK7NR!D"\3^99YQ'6:YK<1A*+U?5F=#+ M)(P."+&H"BWJBWC:EQA" "GM$ /J9C6G9D+NSV<#U?EA@P\N3MW:H;79EQ9\FK:[*QT#LBEFDN $R=
MO+T2\2XF[MHK#(?C\6D;_+T;.&?S!^MJ%%,#O@AOV:;G6BJ5I%6>+D[!",W M;S_RD?S?]85.MAT;DZE,FV^P.6D12^ES+L4(<"CNGYB
7R@RX[PWFKB&S_2^ MO\@@MCL!7Z^@@0W;L"W\LQ($'F;,@>>(R*X%;!3O.P.V:)N87HLV!;9H0PYZ M\R#P"!51;61J*3:T[F2DK\ VGIYU=N
;'YPEI5W+VU. ,)A_#-LT]\YD%76E M652L-==4;TK5-,FQ ES4L%1&BFRJRO&E"-&FB4+KEA%LW:QDR-
ZXQ%@EA^(8DOB%+S)L5SEMKM^$$J$(O$PA*[#0CP (6(OB;_!,",0(H2F!R%$_(4.E?4% M"?')[+-
W_8>'[@=\'=G_9BWRWC.'[]TI_)O2_'6R7F(Q;YIS3[68]TRBD#V? MC:+OJ?2[]Z%L>_]2Y#_J1!E]SGLO^82RM]F#1]>G=]J6;\4:DJG##[W]SE_;
MC\1+G'@*$$0NUGCZD1C@)CS_\(J._0L2AT]HYYZ;ET,]]TC;\]U8XR_0>FIN_JY][4_ZNN#"ES_/F(-O"62A'GO_'LU2 ML235_IZ*[#ZB__":K;0.0N?
MX3C[\U3=O"0%?M&W5/#0G*+/%;@]^_+1L*/[M;[G'^6"0%!NB'FW=KTM40V@K)U?4?^C@SW9 M*QZ&%$3#A9=G,/_RR\6$Z-
[U,"Z7N8$_0/42[R+*_B4HX]!PQ$>K2MHCT5)\5
MP2R,Z5J[H@[8XCRE"O1XUNQDSY;'PW"!P/SZ>/TNIKL,UV6UAK&H+VWIWNO^[XOE+#VS%*>],G]>/Y% CA>-_MM;XFBSF)!Q(T6#.=7G'"_+D'-
>'<3S-^$0SV([(]Z8X?8S M'0&;:]MI4\V1<;R8;\([N=2/W_@+?EK!]=L(]H7SN!Z+RX_LT$AI,_8IE],7+WI^UDUY'V(#=SB H53+U-D'* VU6 MH)>9I-
5Q.@-8+0 :2/$(BF,1+'";S.HYF?9>UM!S2N;-<[;O8>S\L6C^F>D3 M".8GS1ZIG2@:PR7)L>(HN>P;VC1AQV#-(@KVV*2_B[@^3Z[ZC0V:YX@9U94I
MY%\9B2(_,5W^!_F)7\[8^3;V]T,&BR#;_OR&=A#8G U7 E@%*_^_']$S^+K M5D2BDW*6?(.;:.4X/TH/6[#2FQ\U(N)T!*<3)RC[?;C[;PT;7=AV>BRA_@O,
M*:!F_O+!29.J/64+B;E*#]$%VO?;\C@W2^9J0.3!2-!%JEO(^MA).FI(TG[M5A9XT66MK.=DQ#"D=_-3;@]JS\#I/*ISS3%))_GV_)^L4A5V$1-J8()O6U#/
MR;AA6"D,*SV6';3GYWS2#IID41R=4520#J/E \Y=Y<<._XR[V7^Q.K PG[*[YF2]V'FRMD[-01 &-ET82'Z!X28:R7][CP;?MX>6U/;'&BJDY;B
MW6ZQ2='#F^;\KLM*OSOK:WW-32NQ6:,E-"ER ?O4X#]^X_%(@HQ%8N05DW[_M#M/BWFQ_K7S?>Z_K(;)_/R/0]TK^7:#U0K2#LC74C2G\H-
>*R5/"ZT?EQRIB MWT3"+VU'/0^#7[Y_SAZC1FU%^B6[UDH1K3]ATVUA$GB/>\N#EW6/?=,H;NO?"_E> /D1MS M^W7?+8GF_O3^*_G\;G&>RZS[VT1^
L/;ZZ871G[^R,]M(S^OV^![?'G&'>PM M9[VV([6[[&H4RTQRTP(GJ3782!C_\9LBT0@>OV(6WW-_5!CS"6,^#Q#SV1/D M3\9\5ADM&1O360S-CI--
LJ[7[%C/;RSNY>DFZ&\BX6'.YP%B/[^SZ?F8#XD5B4V5 MS$%"P76-2TOIFMEH:SK,2>,^6 OY#LQGW[[#8P/.I=]==/C>_V5-V3?^\0S
M!BER]X%C3OWO=RV:L1%[]WNB7<%2QHX*16VZBA_8SMAAPYT-_M%R/>SO[X#0QE)(IL"M=R#$U""90"=L@UUA$E,9"NFR!VH#/0:-]@K
M8)"PT(>CNLBG4WQJBB5*"3R;.3*U'[JI*D)3Q(E&@*W:H_XB-IW?;62A.B-_MC TM%,3+GH0-XO_[%AKW#W>_.DNY.=E*)OAB2;3C_4PA-LDO]G>?_-
,SUP/-_MO/URVUH>.TL9#H#8 $[HM8X!/%!H] G)&"P#\=R#?P'Z?<) 'U#53'[M< T:;N)8U$ ^QI" M?W,^N\#IOE\)FQLT%,FU@+)0{}2HZX]<7!TSW5F>
(Z@.K5-E9LTW.LN:3DG4 M2FHS;UX[0/P=]>AC3B8F]*U,28.T$:\,!/=&Y;ODF7MTDLN!'-U9UU-20YE MO_&S+)<>R7+')DJED\E'R..#:F+&XU[*V]
((T5V]7W0VRGP)M3;3?"RI XX M)C %^\)*X?!T5EZ4V%DEW:X1V!KM.N"Q"MB(*7BP8[G*-8SK#;"=@S'?OFX"
M6!J8NFXNH/GA69Q(@%\VHAH^,T#N]@PT@'-_"+9@)7HR0[^)P?HO@_W_ACX M2>#_^%;J8VWFM6>+_OAHJ!;'7JBPD?3NL?=K)$V^4(F0$]
""@2;UY\"RD1 MBL3?10@H$F]V%PDI$8K$WT6(4$MYT0&R@K\[>^7A*3O#OJO1[B\:02#N66#Q#]G@9E2 ;N/ 9]B%D!5N @ W
MW(50+WX_*0CUXGF]N. ZY^8&R[<;#YD"$\G/C%#Y WD3,?OD'"%"A+B$VKQK99]+=)55S8]WJ*Z77Y]2$-70^-RURU&VL:1,,KM> M3$8SV'D)RU:P?
M@W1_%Z2=4. A@N+?QO(I+LP FXO<3!"HNFE]>IRF5-pX[V&V-E!4BS- MJRX6HFRI9PMB=6$_<%1_Z;>5+H5;K.W(E?QO(7-$<>B-
\O;7N$./105D48 M+_D*QHXL9>,&IE:3^'+=:6"HPK;SW*)5,8;,W4T-LYT9NA5EF'1FPUF5=RF.CY:3RP;,&0)V)P%PH"_4ZT7T0E8/5< #JX"O%C865;=@
MXL7Z"DTUY)[<=![KDH7X3W\$_\/ W77X(V.ZUH8]8E2ZNDST&WP*:PJ$D137 MW?G=S>DV14URLY;+H4JM.*[@V6JB23!@_9XY'R@/?X>)&.-1=H
M+-9#V!)(LF&4*C8BUN6D2Y2Q1FM.@F--DTB-1H0Y?X4 O>U#>#GY>$0M.* MVE^U;.4UUX\FR,22Y;!^=QE?)_I2'R(V_1'$#H/'MS-VU?
G&%R(;O;AB623- MNQ5SDJ[WK4Y3K-W;V,7P%%Z0NH;.X@.Q7(_%^^.BS0@8"JU=\B5&A^EV?Q8Y MN&.J[K>#W\\(TY5M9KNX9JO#@570U-
2P(+&$&I_UZ#< *.Y@47B\:OTR?ZA& M8A/&EM_E]E9I0<6T65[K##+>*W]*R5F:3TB J\@#*+X_4\F\DL:YVZ MIR6@:4V_T&%L.-00WU%#?-5
GXX<-\;4%K36H,=6DR7Y4L57#_0'U,-CAIY? MOS'\C;V$/TO;RR#;=PN73&*(WR:(I$.V1C0$^K=@VVFH>!SW@D M0<8B,?**=MSS,O,WB7W>O?-
=RE"+LY1,%+65@G4G;LN*#H8>"Y+O=;[[:WDO M!-*K .E731VS]>&#Q%"2M2S6&L4:A?)8%H:0A>F/M \,&SA^_P:.8=_&R_9M
MC!7[)3VG#\>\F"HT.P7.[DV=-_HV@C5$,W[?QBU-PKZ-U^C;V*Y/TX[>+O9X MSIRBR8YH=ZK1VA/U;=P78J]M8W.D .,8-C+K*Y(Y40XD&'!
(6;2D$8+37E,S MZK%717QX5071<$5KA6#[RS]VQQ[$M[Y#0[R#:7J_!.)E^IA[I.:/O]550_D% MY=J"?YU\[3WSEQ<%_^]IP):2T:1H
_A*F9.I8MA^HSUV"?]6[KP-L"\@G)9H MK! +KD&V$:\+9K3O35G:G[+B3WF_1Z#?,=._QX \BXOWF M<-J;U[TUL_?5PU930P271;3E:EL94%*4G&!?
MMUE^7:F]HJ9C9]7T<&3B>,,1 M:+0=-1I*VF9HR5A\-4K0@!K+8Z5]3CH+Y90C:3/!3FM:2HL28[Y)1J==YL=O MDL(CB43\5,O^O/',%1HWH#@!9X.B
T0L&1*WJ\\);H94P=P!S&:,>2T,E=T M(A XRQ$V'K3,R!ESZ)1#:.^/L*>.(*_+N\5N>_B7 ML0>F558Q%$O4 :D8&7@E*@
#SU\XI%:]7USGLUQ'UF@EW>R1>G-<*=Y"+IB$ MG$JW<36]3>1LPZGT6S%A,/SQ&X\1$1S'3ZEUCDBVH@/D'T:0H;]8CR;BP7)W M] +4@6AE;W;-
ZZ5]3A5_Q^U_;D)08I^@A$ (>GDP.CH5=ME033$#]L-'5E?@MA M:93IE3EW&4=K..WFHMM.CW-I $LT!F#!7 /@]V/2TCI<3\A-':Q7*C4\I7,=+\"O]-7.9#. [?
O4%MOG@NI?9X%V(S.>E R\ MI:W8KK 84W2THD,[(N*'(<]8$M<#Q[>#3I<"Q^0DQ6:RW5P57,<#$%A\0B%/9G-]N>T^A@X-A-R;E4BE1Z_
MRM@"2M-5>8G?0I7E]V.+K,IDG6^/RM2@XU85NPNHE< Q8&&?R?"\'3C>A+)' M;]\]H?E!3>:+;"-MX\61)
Z@"7M],C19/2J7FB65727;,.TC#Y)ZO081*H%3 M$9H^/2BY/D)=V7P;B*/TN"A8\WD_7, M P^V1T>GD@2,'UZCE_*KUR9P[D_Q]D]^?NH'-O-A_Q&=W;
ML(.S ?]7FX^\0_G-9^_TNMX[",;Q%_KH+)A\(:]$IC82BK/E)!&DVFR M9;;R_]G[SN;4D6W1[^]7J/8]\VJF#G@40,">^Z8*DXS!9 SF"R6$ (&00('T
MZU^O;DF(XR-P*]Z=XZW4.CNE7.C[M?E_]DI)9OI?".3]HQY?U?8?H*.[0W MLX(0V/;B+F+E$^DSF!V+[X)IQ\]_1?9M/#D7WNTN!ON\P8 R0?)I5<2,P0G-
>6! M5>5%LCYA)X5N,[]LLR/]<;7LXN0J3 CNG6HB/)_DS!)MA;;*NS&LID7E2ROEDEX.[HZZ,T&X6QSJFBB,]IV>4.#
M.P_>*5I#)I,YX>#>V2NMU;6;&J%]J1>"+3ZG3$A_1CIY-3G+J*W5OIF!EKM#/F M>#*OT[UI-#)'1ON[<;V[TSKFT9Z'ED/FG+"?!*41'GRSIS%9.:'1Y MT
M+8WK0:2^6Q^@CE]UDBBVKS]+SZJ#1O8_QL6SL*'V,QOE1-K?2'S/KK'J_ M'-73J4YOB.X\6&=IW.I:4F69:0IQ,R\F;H9C=P/NGJE4'I9 QP?
KS/-60XSS@X=).=9: M(R..ZUA5B^N5ZT)8K/<78$+&]-(\B@=I^1H8CA?Z!FA*ZDRDQ"% MI9$\1L?K;E*IIA%*.,14>$^LJ(MHW"4CK.E3JMR9SRT:+YG-
>)SFZ$+VZ2DS*=^5;PV6X^9];7E.CMG.(F(MNDNCF0IW2SFV%@OSL^I1ZLRL M\L8L)C]E:;9AWDNKBD[C6HM6CU!E/KN[G8BN?FI3C9E58IK)+5L8T?
W#XB^S\ MP>]*7*,I11\VVBHY:QDBNI4]7,.\/NVG6T.V1*^C]TJUU4K?UQ^K<.O! EK1 M)W$>ZU9K='@S;_;&RTQ#*N&W'BR@J1?
*V=R]A238PWJB1U]S1M]0#=^S27R:4VA,K!.ONJ:2U33"WO,_7:BEIO/?17 M8@DXQ<$ZVRNAO#1G#UPF=:NP_4C2LI*YY3'N4U7KTX<[>3K(K-
L+Q*.7A5R_M=E0WJ+/+N!CFEKU,N5V.CE:Q\7U/ .YS\/5LH]POCG-&EPY+3:/ 1XW6,@IW M'GQ]*=+W^<0BH6?*'3W1?
1)JN4CBJ+Z1:!ET:CR:/4WX:54:KF.+SIL-YQ)/2CIYFPQ:UB;Y5&>4I@T M!TN-G48GN6Z#$5KTHGF?74*V],&M^2CBJ:5Y[+XI1];*P3*I0O9Q>911],5B
M]+\M=^N>MX(\V.NV"WF^@=-=TB:VORR\PI^S M;<1:GS(R4G>2O;O%2@GV+7D\94=Z_O0^-[Z*^/$T

M+CM3FWS1:I1+3#N7#V.NQ-"__HU$0G24>T$AN+P@]EG\H3]N$SYP?%.!YSOP M?%\T=K\ODR-_]Y*^@#R ;,+0GQ7&>*SG7D",LQ^4HCO&Y+?K]/^#2)WCA'L MH9QG(W>9:K83]&;GK2K7'W)/ZI&92C]U"O!Q+=I+K); KG(T9^<)L3)]QJD_")R MKQ#33U1(_&M'A<3N:Q1I&C#X(1I\H#GB2.I;RE2>7!>#AO11%4 MXW:]HRW4@%\VT#)O%72?S>)ZW4Z7E0KF:IZAPU*OU*E6Y+5A>'C:D<0-%I[FT7>VQY7R9!>?:,#;B:]S%WI,1N8_,1HSP M-PGV"C&$')C',__\O.3/#YADN9M$_%OS\=YR2LF!$ZHO?).9.!O^# M\P@0XM(0XL2BTL[6N11)^9TZSW=(/']0]L>$XC=)P!,CO).V<2T8'_"V9W=/ MZ@[(&6B# .,!7#W WYY0<0U$>7 V97Y!@^T8J_KS@NA[O+\Y#O"YT/_SOZ;G:M]0#>=OL'H/]YH, ^KY&R>)$$/$.# PN]Z$. H[9] *IYUHM.;#H7ZSW24/1]Z MV<69_;@("_]U@-3+]36UBZ_WN_%96)?N[92TU,6FU;3:%M9&/4W'!/>=G\W)B+@QJP-ZW^<.V>L+. FR\563+[598E0=>[#_U$)'V?K)2; M0CME=9686),3R5__(@PXG-)#A<^&"\+!{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{

*MU+0^E<(>E10Z;(01]BP0'II-)[>=_#QP!O7AN>V[@5COJ[??=+)F;&>5O53'M)-5A)>(L89.)D@$NH^OFM!^0=Y ML1>H" <,^5,6^ UP9[:A<]*SD8"H5R0*B(?18&\(DIL]UQU$+#[LP06-$5U" M^KHCD]!;,T'(\\DB1(.1-E P<$B G-T1V$6XYB7B"1W2Y',8381T@\8V+B%2D M;=K1@(RSL@/"]F %PJBA<6V0ZV846*ST5QJ5&4$$,OG\P@DR&!%B[$, MQ[6Y!SK",DF4"=|:VGKB7!L/FYW00-<8")Y<*_)2+*7PRPC^":"!:. 'U24[M_$&ZJENV(\A5E2#WFS@8;JBZ#/?9VI!?ZUT4<54<1.,!CL:7^U@Q.[OT!$ MUK)TC@>"*UAKG.$L MD@3D!A"B<.6>6VYPXDH(CM;Y)!@_X'Y*.IX6[]E +& MN>Y9 ;!NJ@4"#T-JX%VG+:V,D+N,"0@!;281E9:X0HF8(#'6'0\9T+B+SG:- M&I9B3A8($OL2.2M7S0+N@^,/X+G?S3; >@*$RM#N? $2P#A>3;:48PCIH%V&7 MAP[D%9D>T7A,:.(CRPQ+9>*.,'5- 341?BB8W?]U'"*SA",T&9G(QUS M!P(!J V!E$/33>6 (R.>D)U%V.SRADH:>\$'XEC:F@08%&{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|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}]5.QH)@]UJ^|_0@R!"O8Q# M#[>F MPBD=(_ZOCSAC?'H:3/R8>UK53-![7$]+G92U#JB28/2%N2=7!.X<.*E?.(3B MT4]=DNO)?5N5&@E].#N<- B.!HQUN!1V8M1SLZ>2FX@6VPVTXOZZ(!H M"ED!V6$,$TW0U*6R0#0"/"EID_(7"B, M&E3I*5,*1UDZA+^QXSG$;]VF5VH(+4C2)WJW J>\!/T/1RA)8.O,.- T6]KI. M@FW&K]?/AYT%6\-O-\3@Y/;:&8E.2J\W]Q-V!F4LQ(\[MR3(RCKNZ448CBN5 M[&Y)A P#A'S1%I)HN5L7("Q1)A?+ [PVF\>TPDA',O'W"=%>UQAQ^CB%17W7 M9^]\A@02^V)[M?4&+1.N+(KGGS5@+V; \#G_1*?-VG6FP.;>+LI,2C$7;>_?G M1CMZV(O%^XH8; (LZ]D%}]5.QH)@]UJ^|_0@R!"O8Q# M#[>F MPBD=(_ZOCSAC?'H:3/R8>UK53-![7$]+G92U#JB28/2%N2=7!.X<.*E?.(3B MT4]=DNO)?5N5&@E].#N<- B.!HQUN!

81UQH+#0BI1&)H\/QE@X%GX[!)V5\%+_%7?LEX.!*L(D.:_Z[!4S / M1*7V\>P'@T.V@C\W4M/>^_2 MTQB/P0^.@%)6Y<&%NO$?$TU"--T!J[F# #8'_Y*<-C3Y88LXXH8GGJ6II+ 1 MB2$Y7G(JD ![$"W=)B,Q&IHCU=45FX&G5BOCUE.?04E;K(>ZF(4O>$?:"164
M8^32FN/=]O/Y**.IF3I82_4RVM\U+@3;BR/3]'\V=*A*."//YK-1970F-I(" M.0/14RL6&X 6&,6ZY43,TI7T5X/9BEZ&XD!ZK,_MZEN_\/,91?2VF*.P4(Z*-M-SU"-"(J812!>XG_K*-L[8D%@_;[8-!S"@8MIN6:GN$*L^(" -,:'ZH>,:XE MJEF/4UDV9:()GIRN!]&/2-
,@Y0S',P\A:^7\"T5Y7L:M>V0U@_8T/&W.3(G5=1I>YOU[!=7?,'I*/71-MCA96\-=7X"M+1<8CZ"1BOQ6GS81:5&%Y(PA4712*-RZ&7W?E]3BI=LM**VM>M(FU-JRD1)HJ<3_YO<@H!H4K9J0&0 -#'2']\4B=1X7GXD$BR3/TJJD:70Q< MPE/=/5)4\"?):T6/TN6T/A\::1CCFECW%0.9EK/IA#CI0Y3)+)(V")G9@P?1:'YFR*-V=V4CC%_S#F,$A\,22:ZGIYUT[,(MQ?ABFTM"O$8T M^R\G#?\KQA35W,V:%U5X3EQ[IH.J&[*8*QF&7F(,.RO54Q6E!"T;$*A/7-(51
ME#DGY$+P$W1:\'25T)>R%RIG'XGS^%F-K[3W](8OW/#-^IKFW?.=3$%,8J#AQ)3/W(*V4FU5DUS>&:+!#3G:(A MLYRR#MA'(#
(0O0:MPB).P%)P59*YN7$$WXL!\#&RRTOMZ@7E5_>-*/%]W)'=.MG:4OR86;X M!RH,L*,C8=-LC>%Y4R0"SAYIV'AUK;/6^-!B]OCDD8L5=SC]V%Z,
[3UAP5+E MGHIHM9 D'FOV*KN,9HS0U0N!:OD"@T;9?Z.:OUEUZ^IG[ZSZKL/6V<.MQ'E$==ES+,8W XAU@L3;!DP7 MWEX#IP:5C!1L+
6VJAT\SE#1]"71.8HW5+Q -2LRM"]<8"3V[T^&\/-B7T4 M#8:>QLH]BX710RV<&FZI@8&>YXK/;*YIPZWSU@F 2X3V-M#3SXB$+#A;\1
M+HUAN7E8/-;E)E++WY 0@H=/M1RW[^_\.B[\\B#6QQ:@O<"?#'VL4SX\L8O% M02KRT=,HFYJ53;^O^QTH7=-97EXHJITY3\D)UQ@CI;B**7MEW-
4%L"]>7HV) M#COP^8%+I4$=D=%S"!I8'A+(870)X?O 6.H)/IL&EO^.FQX5B;R1:[TJK7B6 M!:/IY1Q+ M4.=!27F*P!VU"H^H?\1Q23&@SJ2G\3P_DB&-
Q@X M*'[0K8+!7DG2W3082!V'W.%"XXL":T5"D^FP=S.EZGODN%[N#=-2'V983YCA MH \S?!]AAGJ"AIBB3AMUJ8.F:-*=&+97K!< I2\6\
SJS$*1V$JR_.F@I62O C^ X: MQ0WNO0D#,/&52FA"H'CGG#ED !WJKO/>X%ZQ_KU\VP_O>HF,-K!Y.,)%=YNA M9M:YDD%\!?MMIG+$]:@5%C$NHE?
^VYGJ3C\5IT_"A55TI4!I,LZON5?*1;"2 MH'/D+NNX-FM,*//2Q? *0Z8SWN<)(S9HZD2OVW^R^C\;!DZEQA\-!7>)KF M\%9'}^=2@TXR,P"=;
[+7,TF@T7E6324\QCP'N#($L"9=V^($PIF?R.;F6^G MQ,G.[BAR39WGR-%MAV=G04@(!"49,X806EGE==*Q.6UN"R2K9>";\6RG%!8> MFJ?
35;P/E+_O5G8109+708J/4 X4S M%RN(?,8G,(9(>.Y(|#W) ^[>26W!YFIJ36"_L*;[M*S3&/ 34JS:\&AE[B%OHE-Z[?^+GWU75H!F1O3
M1/,LCU]H0X&K/FHMV; MBSE(C&F ,#^C)"XFX@_#[R4T&UH%3+(C&KO F=^*7WK!U2W\F>%_+SI>P== M'GB##2L-FNA>,XDV3LD>'P=NY_*!>&.-
B>RA?M:2C&#@7KDFT^U0?V,;EJ9A! MDG,S=E@ALGAII=LJRT4 M#8:>QLH]BX710RV<&FZI@8&>YXK/;*YIPZWSU@F 2X3V-M#3SXB$+#A;\1
XXRM4UO1Z#ML1'7=2W9RUK8"W+@SF^4Z5";_Y*A4OR%,E:'V"K M9SYBR2Q@F>+HVPIG#+L/1(]#$##1\91/$MJ&ZF;(4?2/N&2. R?":2NX?I0$X
M;=8X=6 ?U643=/Y.AJ#"SR#P*(VB(^L>8SX%9>/@S;%KB5-"H6)U=N3=GUK5
M*K9O04%.H4EBO(,@56AF3"@W+8IR4U9'R.\2Q6/RNY4LAY8L^J0$'UX# MMF;)U6B2P6;E@\F5+$PL\'23HL$29<58"D6)"$'QH'E2TIB!C:-_)W(YHZ:-
X/!Y2992X?CXE IX8"MB&>QYX/Q:^EH MO6R=$'WYN;=WE/#VVN$ZM,/E(8'$36Y<]-)I@ MZ#W;>'#N-L9;74E/EK(?/ M.C&9GJ@S'D'3V\J?)@B'Z6R
KZI1Q 7.8N89@:UP. Y5-JZ-@=XA/;>UNC#8W M7FQNQ)OM_%&@LT7I=E@3QW7NZ95KK]1EF#63+,*H90:(;*OP&Y8-UZ@:JD MS-KF?28;U.F6-G?
=C&Z;%[JJD[AF\T:9+DBEG&K-%V@1 $UC&]&GVU&M02@-MC"]7\P[?=K!H_.;2 $'=^*T,_!?6Z_GMO!TZ!68S"CA%LQ=4.[62
7QL.5MS8%FYQQLF$ID^F%WRMT3X+C_CRTD2ZU**9,@X'X1V[CH3_#3= M+..;>L/))7>]!*1=!$K6*_(@]9<81)4RD-Z;K]UUV{(UZK,F'\/"W8D-M;NQM
M;KS%&]Y7):Q%'"P/#F NP;$SI9!\60ITVM&^KZS=Z(V]_%EEHW!8LR2]U84' M))\/-=RC?,],\:\]4]=WBJ.8%B<92NX&?N*O\^)!)*3//*0<#P!EHTRHU-M'*
MJ9H_KNGUZFER'32Y?#G9.ST&<<4@%3U"X7T@%'Y5$L)$TJF,&"PT.?= 1'B= MJRAOI#^V]2*-
+75LAMWY1\8(':1XG;51%3*$YS(PLX=W'Q&P|S)2Z@4GX>]O+ MDO^_S/K$73ODUE+G6T|$ZCIE'6"^2E(W&MC=XYKIVAI8DJYNT'H;C5L!+A.;
M9N42TTVU3MXW;7I%]#,.O*2]USK7$L(F,I[O*N7'FL!>??>.AZD0S'B)N2 M<>FMD3,Q+18D"'WC0P^FC"/!@3P'"%0;"5NP_3;\-*PYI5I@C]_ P?&,[TFT
MZCVA_*[NVR%IM>I^^B-;._^S_,D=V@E" K2,;=(-J>-G@'3'U9MRZ MP_)H1\$?L!_<[L[KV_]MGT'.YEV]DI:X+/?>SE\(9&3 MHL.P77<*]SB!L5QG?
(.2^#.%S4#]V^3"*+\+CB?=XL0$#/R: MPNXN$XYKFJ3+E%U^[UH<'UA 9?]J"!|R,T*%@G61">K;W$# =X\J+?_@,9I:\;!=1;Y29*PH,_:'
MKU[[,L/DZX*UD[*J6?NZ.84!]T 1PVF)MU&N[1!5K@NL>;[9Q#71. MJ3HR(>+*(;OYQBL*@9SDZ^?YD=MR@41\'&V_:$ M8$,QSZ?
@9%P!R4:C(BX0R+,*2^[4@+%=^!B9 ^RAF;K=LU8R7O<$3MH366# T M&*R4_5S*(7 M'%$G) =.]LYD/@77:<0EYX.#'5"FPV.(2+B;2_]!QFHI"*-
CF@IM1VA7=IH[. M,C 5YZYG'C(W#ZT-^Q3,N+:2HZKF7!,,ZZ'5B5IKH^^2:2_?(A2L2/^YO0?> M%>'0CL1K+6)"1?*_=X9@B>UBNEEP99O$4L%\?[#K.-
CX"PX6CZU] MIJ=SG697L1H 1P^'P+BMX$ZH^=|;3%P+!!DF[+KQJ%QG5DKC$>=?26;MT8|$-*;4PKV92AF !W*(AD&
C'9@#*7(.!,6SHV3*)D$:B!0[0]>0@1T& M 15J>Z!,,"@'SI??E;2=^.@2JF35P#WC3+*JIT#7W&XO&<=8W@%_(- F.F.] M'0AA_9BU:;>GLVW@<
GG>7L_!#+&VQ>!6]3M4<:=$C2,_XZAL!QM>3 4]%37 M&]2(815N6T.P923BB<@2S:R>Q8N0PF$+8M2]OI]4!TF#-J7 -C@-:X@R%\GVA< M-
M(=.TL$H,PD9J/*FTDRMU?5UTPZ:O/2!K:8!"\Q^0\5Y6)I:L8'DXR;&E'5 M2TI *Y4R582%2P!<%A*RY\[KX,Z?5^?.'9*RS: [N[9XD&O%XLC'(G0(ATC! M' -
+!@J@SJM-D-FALR6JN7!5Z$\K3-J]UW'5U[U\97G M%%]Y-.%F)6B5@JCA\"JI7-PVK+5U"ZS_D?RI0/Z0.UB+3!24<\+CK>%J4DT5
MJ(!8MI_X);K6QXIUSBPR75+1H@FXK"(=K3-^^ZA#/+0M"MVSKH;_P,UU&OJ MB2F&/D*%M&3/M(>A!):>+IM9-
4]H(U?]/D!F2X,&*PXPNX$$ZPLT@FOK(05@EK!1*R:8ZP<4=EOC)MJB$@)4@4W93 M'VMS(5/HXDCT-HQ-XI>FAX<')QQ/P12*&9X9V!/#H4A+/)HY>U
(,Y(-79.5 M2).[BO.RLQJW_(1@)?E:&KA%A_8CFCM%/,GP-MF; PO3:(NC*1XZZW82^Z4 MBE?]I'V(P+EI[_-5,AKL:.,PS3%8MBX8+!1$OTIZWJ[5-
ZV0,=(G M8&&NRE>J-I#!7T_ RL1.1+2GWJ!W;KQ4^E%@&HU03Y8TJ,W!U5.*^*]X3P^& M^P>U>^U!2=.50U)(!*75=I$NA,T3Z$"2>T\S9%N>(G
#0.3;J;\O44EE%GN M5>75P+$V"4N#/B @#=L%Z'89VL:EB_DY1SH<[Q*2"1?8A\\#"W%;*LC7#8MZK7?:Z43#4'[T?"Z+7,0%7WLTE[0O63/""'?
X;_9VRO>]:V]N. M%^ *]M14380JQUYG52FY*%[M?"REI^,JK;>D6+N$] ',^9A9TL:%&H$C#YI M_4Q4|>*E$DG[23AU%><6MDH9USH,1*HEG@:Q_#
<[C!,05N0]IQR4.M! VY=L M',,QH]U&&$QS6UFE-/J$)>V$P(Y2A)*CD HF0DKJG3?'HAJCZ),*?K\W:,UU
MU[.B=;"B=%565$=8[Q8!F6XBS50^QU3&ZH^A(V7* B'|'\,@X2<5)=M?6P,N!587X9Q%=2@P_^V]41G'3L2 M8PM(!A%,:Z#Y/CAJO1"S6%R)6>LG;?]-
D(>'KQGB%9VK(E)_!O](LA'_!-C M4O$I#SH>,-_ ,[TO3]0L+NVW>-;>E[PR^>J77TX&%+1J]Q^W@2OR!289V8GH
M6D49COS=MGWE#=@0YME&O>^AJH[!17F,07NO![0W)9T^S M3@Y!/1$L-PBN56'7P^.J4@03.JELNL[O#1118EN.6*8 ,&C5[M59LTO'UQ
MS(SV=^1NG\H<<AF!I5 0,A0QT_EG0()D^O;1\E4EZ=RC7+KDFB]_-;KP2&<&/VM24)NTYP\(6@. M'259D\,#U1C1HW+Z]]6=TN[?O@
5_$)!3>^+D1[UBIFQ,0Y3R\5W;.:!,3# M/Y_I.MXY)P)&E.TW0.CP*[V(1,MF-[<[9 D.?YEEIFAQ9-%,7+F95[B%9@I_ M,]6@*4?
L?"JP'C&17TIC@5]H)"7="=R;4V1+=V5BA,I!7.8Z+;&4+)6FT:1 M@$\&B,.=IEK*=A'CL5W!0?"5O0V!\AOX5U5M8-\-T>W%P+(;.DTD$>E7#L>|
M'$"!*!NQAHQ[FN/,O.NYZ,=>M.&X<&R_S#.M&64OA?]8=[/89:K'J;I(K$JS&)_@/=S@-6J!_A!Y9V@BS;8/*,':N5R M%EM:HKH+N[,-
_/BS=_P'>P<;>M,I7U$245C+Z5^M?/I@9$U45XQOJ6O\LK_& M]W.0UZL>9#T_HKN4A]\ZWM1/U0ALIAB;L/8(@NL_O9M53\^W*|MG5\/?]WBF
MA8>C'A15CJ5XZ)630J54#2TSE1AL6>\5K:83'V4!BM/^64LKQ)RPN*()W MB(M?^HA"Y@4]>:R#/.8KDP^6#LGSU%H6J<,QW M[4K5^-
Z4JN\#/NF#_^IS#L=*^U.J]$R[43?!^&MA':#+B[V$P@3

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{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|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§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||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|_T#&O#(1Y;"<8>M^U9 M-AW02).N@.$%C<$&^YVR[\|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|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{#'RV&_A M-QJY_(NT?_W77V- X'F4AW=T@[^$RT1NT)?)^VY<5[.!S_R>&CC'V"+ND%+6 MSJ(%8GFX&VN)]=)(&$%,V9Y!QCNQ_BH6AMBD%-_FOJ].LLTPN(X5==QHT+&V_46V:3 S5K<%"L/LB MC8XQ6H@:0EJ:F(DND/92#R?)IE1DI3$1.6^:C;G:$WZM51'I;HL?D.1E/LJGL, TC M'JT@=]P/,R4/O@D=/=65&*;47(-ET>_BW6]- E0*V=Q-5#=$5C[JC1U5]RKE+-BR@W/_P"HPRM*O(*39, MFQ9NYQ:"QJ:*WCWRGN64.3^-H_:KD.DJ,=/XJ9*'DEF_F%96X1]_IL25 MD- =#R<-3(ZH_W$T4+,750W52.3E^F//V6"M\$ARV($#?6NM(^DDS(_B)8NLV M:HQLWV3-.W&]%&5P/0:!.;>U58V&WHQC>J1QB[0'JEYO[X38\(?J$? +4),=T ML^2 \0ASA0%0B+20UG!.P',+F;!M"IG6[5XWWJ<7"YM(^E5/4O+_'_IQ6C9 MUJ;#(0Y04R3" YAY8=*Z#"V]HF['MAA$:SO1.@M$RQL*

7*ZM.FB6Z41=@(5V M<%.G2_A.T-;2,\;N>$DGKLG@Q^>E(B5$)OO)D0#.QR2*5G@U>E@0!<[YL1D. M>P"\N. @0K>)T/D=1*@'85FW]
[=MO'5KUB3OM#$I_IIFL*_5#,&2^B)ELS5F MV;KY(5?$=Y=PAKV0G:L,80BGA.B)E/5Z6-%[:C9K;+3N*GI($GM=3:C:FKKE MPDV#7-(E.+[-7*Q<^(5*4?
+V+O?O00Q,9V"AZ9GRW9:/._:3&AN/Q<'DBS%R M#G <1'T"A\C&@V)0)<Z-6Z+TV4+, M)3EYK;59H]4T4S5_PE"2.4$K)W,/?RVJIG&;J5(1"0?
S5AB30A"R)>!Q3D.T MV$OX@5FN=HFNN"'MS[X7L,<8&'#TXH)+V9 (#V[5ZEKM MIM6C#I88D013ID^_*J 65GA-
VC"]2Y7;8W&@)\#:+=&D0T(L^STLZ73;J:BZ MQE0Q(?ZD)*"Q']\/LL!#(]3[8+3L9XM=_T)C*1OCKUJL)5D"!G5I6SK$P)EH
M8V2V>;3&C&XFW()3&)+#!7A>6\X&4N_D:"/#C!!\HW%G@"R$5O_+|`1 M+TPIP[_8F4$*A$5D7CFPG0;+N :F!D M34ZC9[&FEF?;A?
Y&I0K5'=G!D4(H3'5+^Q1G.-8A%;;6-D9@[A%?QDKR1#Z, M-1Z1]J H)* L4HG3DD9O>Z08N+5Y><29D#]C*Z((G-_D-1>+F%Z#C*P7#F09
M88O.SVKDL^UY%?R.IZ0=(?;_5-,5K5D\)Q.P9M9\A/3G[>0\[+5NB .76>[[M<9;3&2$8G$&VM0+!A*3>1<9MX-
W('5VL;AN2>\R\3K7(<5A=4RO<4AGB1F+S MTR>#'#Y[']MX/^DUGM58P0!Y!;GS8W@(F/A9ZUY\(%>;N\#T"/"]G1.SPQKT
M.S[&*FGS=1K4Z84?;Y(<9P[C(2I^ Q1S M7]RCA"2]!B__A)L#%V%%O&!-_BE9@9G;N.=E+]7\CM^/O2M6[L1Q52!0\@/H M\.174L'?'XU_$&K'-
MXTS++?3I/NZ2UG5.88U&TU(X @6*GBH34;HV1'-WQ?[\-,>CZ2.Z-KI+QV?@*&TY=[R7!R:,;L?HI."2LG_-\$T3RS7L!<,.FID/OC&Y4I
MP#9O"=P:_UI;O5Q)=LZ#K]?)#'10&V,5<3D=BV(OWS>.IC"#2.\?+ YQZ$%$ M_0:5+[*Y>>V&F&"VJ&&T?XU1EUG9N(%[6WLOM.JN
[_+T>=C]+#DI6U%3?4U5D@VHZA[^+4:KH&[7 /?/L8U\!Y+ MM22@YFC_-P:TRL7;DB5;6\F-OL)<%;8UB) *@28A^2!8E:LV_-P ')^T;2H<
MRP6X9PZW%3V'@GWT(%*3K@82&(!._R]$2WMC'0 = Z!C '3\\0$=ZQ5_H(P<
MBT+C]PD*H*FE4HKUUFZU0&,3+_WJ(VW]F6*2U8N[*+V1B;82B2;W^]OU6_LN M[Z:I!><--J;Z#LD/M<*S!]9 MD:-6?7H2L/IS*=,IB "-EAX=
[#P7CR&A??& M(]9S/7R*V(_S6<> !C])'?$).>)/R6("[D_3;_95 G?#[22'&7)V0+WSO!/M M1]"8MH[]!U,PX]A*_46+6#<-TX&]"5-
TO_5K7(7H"&:,\D0SG,02C5NRGG 9 MQA>A>GW2I_>[QSB]5Y8&8E,;@[NLM$!@GRM'"%T-%H7.[+8 M *,>-]%EY)A?*%8FMM>G'M*Q42Z$QO"7Q$
/D&D MUZA=(D)%+&EX*RS7(*QQ(W:RH M3+=RV#?*6@,.&2[^W2^T^/'N/A_KC+?!OP-ZX%KQWY_6SD"/4H6[A=0+#1K
M6SQ::Y(ZC)*3U#.="#RM5$812^T0^1C5)MLTQ?1V-[K?#MOJ+22?]A](F04G MX-!?(FE*?A(CH?0E[T'.K?5C5ZX0?)WE?R3QV$-
);"\Q#V8H]+&V!=$ MPHCH#@!RK"6:K)RQ8JQU?:WYYSD4@2?R.QB_#)0P\M*E>F(H=RHS*F((9^T
M.M.-82P_[6AP%0PD,BEC#V.$%&)\C3'*5(JJ&MNA<@=\G"XXL4J>'&3=)S>X M"BJ,]T16R5PM-7=Y]U.2DW]U5S"R>2;\9T"=QE87S:R+
<7QM5IV+5EB>)A*PJP@N7YNB5RFBXBR2[9"I$;,/16GW%-VET.U_M,_5Q0:9P+,TRC &P1F>& W9&$!&1MJ@[,6D8HRVOI&" 94(_*/48>\0Q,75\ M@^=
['PT0_<6$'_EH.*E)+R_[_(0'#PXK;,J?O\%?PDSXJ.MD-2=]L:HX73;J M0O_#'?5S>(BDI#'?B=8EK)*? ^8LLYL!ICW"5QW 6E==>Y%V;:4O$T[PMC7\ M?
V;2L<@N.TF+ QKN15LMY=-GWQZ>G?W)3>3*FW12]WX$RL]I'Q^>!T)V(+_S M$LIOP=/@73AJLZUF_ST\/GSAY^--\JKE2KA0*;83F9R:(=[1#OP]>
["MR3 MWB;PK[S97;(*^OJWX?2[9\G/*;@?;(_EW<'^OA]!PHS.3T_/QZMX^7S410; MX41+H^X-?BU?U3UQU*R\A_@?'QR/=?]7;_ M?R##SC&$(;5L8S
7R;^/C;6+G>Z'CD M-,UK8>25PF7%"RMYES;8.TVS$-_M@DPY?5 !&R#B OX<4TR[U^SKQ6SKM&RX3 Y_,\L)\R%\-U4XUI?Z:WX7F\2@_*U-
QO)N"BP3,!UWX?VM?;9!K9YMD,VO4.VO7\,;3KI56//PD4''1N M(VB-_]?5>8.IMT#W]A%9*':Z*[V0K .H%\TK(]ELK'B>4;"?3M!(F 4U*-HI
M,LHB'%.L3KD]& LZEO]3K%CW-K-83\OMC@<,P P3RYVQ0?478',5%>?)FH9 M[ZL2[POOMWASZSF#!O%[Z?[:WIMQG:'A:@X=.8-[D
TBY^88\#NCH"@1:PDW MI.(6SF*D90>N"&5#8@G4LC! 9=-"[A7U0,;A.242;)@UO"=P M6R@00\6PTUQAYOB4?K*OL&EP.@0;C>5-X!2
M;!;?"]D&7(R3V\AMXCQD9+JG"T,[&L&:Q-V<4"\G/29>K0]\!SY8Y%\5BP_M?D1;S:39D 4HX>OU746T6PZWY2^HY
#DADV@Z/$1+7W.!6M2>B)L#Y/I_Q4S_3]615'=-/_S_5%^[X46 M&\9XAPC9,CP4)2@,/Y2Y=?CXKG/#1PVAYR'T/(2>'[1U 3CCSS9>DF_>)K^] M^?
#VZOW]Y+>_7;V[^N7'D>?!,OD0!G.R4%>S02!F16I\V2QEG8]TML*"F(!M5]9U'(<&<_HL!I?>%IS'N5D)RP +34+:,#%_?,WI]]LDUM\MBFOZ(B%\QX,
M(DSAWM!RI7^F!E\7?!!O8#%N/2!R\NG%^J/I&"YVN&V_\&EQ/KBKEI?_W3Z= M>WYR^'Q8]B^^[*>'PZ)_\47_=ECT1U P9X=GY\.RW]^RN^
C<[^>;76_GC^_ M1=D_!/3S'U=O?_GO-Y>CY.W:5X>[HHUNT9,/,%[VVOO_ZXU5]OF^/#%QC/P M /-X_;UU<]OWWRXNHKCUOX HO(
,,\O+UN?,Z$_@,C=>7]X"E/#[_]TO/Z MR^KB<[8";L#O3HS3+_?1R?)30E'#1(G$K)L'9?![!44?\H\A=G<^ M55_55M[+J;M/1_TAT/%;5KG$7%O9+
(Q_5%WZBG>9]OZ:U_/]MU_"-G]^7IF M\>^@+C[D;7%G??"V(U_9Y7P12>T0W'?AH/_%$V%P7%*A/Z\]?J@2>TY>%[MJK?R<#*?
RH2&DSF65N+3(P,C0P.3,P>&5X M,S%D,2YH=&WM6WM3XS@2_R]Z3.TN5,5Q'L"R#D,5$S*UJ9H!C@EWNW_*MASK M4"RO)"=D/_UU2W;BA,=D;F
&;]"*))9:K5;[UR]9/OJ'YPVSE&81B\GOXX\? M2"RC8LHR0R+%J(`6.3'9PW22(W)]^?S^>M>:\E MU<0?
7_JIF8HJ7TBI62LV<>/X"%O@D]'X^&C*#"512I5FYWC:OS>.P0*PXU@-MQT=^]>UH0QDOCH]B/B/:+ 1[V%A2->&99V0>]-JYZ<-('[HW;&Z\.8]-&G3:
M[9_Z.8UCGDT\P1(3[+<.#U=-BD_299MT2PL4$]3P&4/>-:Z18%0%H31I?W." MNT;FU;A$9L9+Z)2+1?#+F$^9)F=L3B[EE&;_-%T+?
&NF>/)+WU)K_C<#UK | MPVZ,1P6? ',4U37P+ 9L!+T#H' *"8"8X'^G"Q]IO:Y33;@FQ)S9Y892Q-_Y
MO$EYR,W;;SH'[7ZOT^H<^2$H,W\"T2.0EJF:J)^3;3"\'(_>CP8GX]'Y&3E_M3\;_#\G%Y>AL,+HX^4"&?
PP'5^/1OX;0!53#RV\H^DK+6ZSCXNKRT]7)V9B, MS\FGX0!74^J[W:V6]>GD\MW)V?"3=_['A^&?Y&0PQIYNN[U]Y%7=OX91TTGU-MD8-9,@'\YJQ)
(J8,3Q:0$3Z/=_Q0:IWA(O3BXFC;F.A=T$?!,\(QYH9#1 M=9T=6OB:A2"/TE /;[/[JE6X2V049%)-]>C7[W_9U#CNM(Y\[#@NOT8DI3-& M%)MQ-
@<7;5*NR5\%58 RL8#V7"H#CIN\!P[@V;U_$IF0X8)E3@0=3%7-*\KO9R@,OO' MQ+('WMC(:8!XZ=(J*%D"E>*4T$2&D&3(G+*#3'2
MT=TBR%C$M*9[@213>LTLRI8\-;3%(Q,*1#E. <21%Q!M@)DD+]HD 3@10 3 M44IT@1^K\7.F6,D$%S#E&H(JZM[E-XKIG$560.1;@C]2
#Q02KBHJZ&_NI,^ MPM2WZ'X%>>.X]W)!SDC",X 1(G(%FR8@',BA6]7Z>9:@D\7$"WY'HD#7!]"L M8:0)L.;6/0*RT"C06"!Q7J*^!)S>F!H,*[8971,I"@$$
'4)>+33:2M/1'5* M$B'GNK(#Q29<&\B1#;'8Z.0&*9LU..M*F%O2OB+Z/KSL/7M$C]=N_\]O#KN=_M7_NZQ&R92*&;DTG"X=("8T2H8A:" "F.]QCC.M-
XQ[E.D1S)IN#BT MR CN1_8&JEZ^M=#=YVXMITQ# ^#&Y@>?!W434Y>(%GK[(9A#A P 6L[DLA)9 M*& CGC&M77O0,4RRP>KG%5@]
<75]4#XLNT9(7:9AEXL)-#D !9M!0\MILO MN@@UCSE5'!? 7?)DPUV&G J-"8UU$-IF/S882,U (/!!P?E%+%8"(HQ#)9E MA5@E1C#"I5GU[!!^A0P)
(!8_55CY@2PJ?&$6M;43OV58V!O_K>T+;'+& M8S0.JF5F04+Y]B20$WE# FLG.<0T5Y-`MZ;N!&CU[4QK.J"BL\T>EM$9'_*<.5[?Q
MB7M,98)O>^XT@B^('IAMR2@J%**PEMK64Y6-L[* M#N);>RZRR&ZI[;X6_C] X7\B($&')@Z8QUT?W# ^*. .0EOG1L@"?,WJ_"8]+ MV&W*8TL-
^Q"CVHC]6N87M;+;<[O#A],8!FJV=.'WFDE9H. O*P#K@LNFR+@TI MERZFH.;0DEU,&3KOW+)>Z>`E1[2SQM]\)6P%(/&U*%#C2)L"/6=\/ +;/
MODJD-UW6P;.9%#.&J4=&)^4C/%6&"S;-A5PPZ)VGTL4(NF9'@/M'R7C\]R=QK$:?MO 1_V-RE1*+LYBO$@* M07/-@NI'70X\,I.Z9_1XB@<5
JI>/R/47H&\/'"%4.T> !WZLQ56SEMPZ;E7W M&I<#3LEE[[?6WF_U16R@=G:N:,:?[QM^,2I4E)U[;&)!B&XM6MO#DKX[%FF
M&HJ71#344A2&;2S4G;X]/QIV'W+I)EJ'!]]Q=;>75-GH^M*>&M4U0NC<$N/;MZWL=48>M@]X+191U-0]6*%]F/(]S7]="+7LX#&,3P_YT!>$;G
M+'B%X(\'P6^ZI#&^/$$&*6<)&=ZPJ,!,C9R[+<97K+UB[1&7M'/AGHM3<1MJ MN_?L([BD_[GHMU:'I,MR/J31]43)(HMQ(T&JH H7M?=_UCO*
<@KW0.UK">5U M%6#JQOV5+?77CC9?:,KIA'FN**82J@:,GC\CX?'K;Z>\NPYMK:-I-V+TK9 M-Z^,_PM02P,$% @_^XEL60)\5)_"0 WC4 !@
!E>65N+3(P,C0P M.3,P>&5X,S%D,BYH=&WM6_]3VS@6_U=TZ>P69N(X"=!E'9J9-(3;W+2!I6'N M]D?9EK$.V_)*,T(ZI=:[5]=[
MU&H[3O\$QAJ6GA3FD4[']73=;KM[2-J'7J?C'?Y"+CZ1O:OI<-^0GYX/IW]< MC.R\%U M.<= H;E.6/_$K;XMK2_"1?\DY#.B]")A[QLIE=<\<[3(O8-
VKGO0TX7;&S2W MSIR'.O8Z[?9/O9R&(<^NG81%VCMJ'1^OFB2_CI=MPHKF2990S6<,QZZ-&B2, M2L\7.NYM3K"M9U[UBT2FG8BF/%EX;Z<\98I,V)Q
C.1M/!O 3?@TFIV0P')Y?3;;CR=^!$CJ_M+K^C)"NEWT.LBZO+SU>#R91,S\GGT1'"%*]7?[E92?AY6:Y;Z3)*#=I-@).B9 MY=/43QCQA0R9?-]H-
V"%DZ3TC,MKE=.@O(8>$O[#2E\S!$1 DU+;1M'@EWOS MF&OF8$?4Q5S2O*!T,(.RY9@*VD)@'!J9.$.4X M!Q(S'7$+R F20SBC@!.!% !-!3%2!'ZO^.U)$!!
(E0!_=#Y2Y%8+.920"4)S8KL ?1"!EBV^!K= M0N&50=$X +]Z621 T3F@3N=HC^V;KIVCT%[92X[I;F9M ,Z)H;:(()JKRE[K! 5F1MX3&
<%N9&^@ZN5;"]U_[M9RRA0T &Y,?O!U4#'[?!7,(GP% RYEL5B(*"0. (YYQ9=P[4+',C(-5SBHPU(,++?(!\65; MLD)MLPP\>)-#D !>E$AX:/9B5.$K'G(J.0K
;?))DPEV&(Q4*$QKC()3)?DPP M$(H!0QJ"#W;**6*Q2"C&,!#+,+%*C*'']3;/JV2'\\AD20IB!_BQ\JK#R UF4 M_|
(LZMY._(YAW=_]W]N^P"9G/$2SH4ID!G14@'V&L$#H@=F6R((^HDHK*4V6T9- MA=+0CCOQ,)8"!%0;GV1O1Y<(S
G\^@9UR3@4[LQLC^':658L^=JW7,54+?- MC C&_%AH0J711QG&%B3A-RPI]\HVZ)O?K**G-+!F7;TE'_Z<[N;A0%@987/E MD#$^U UAY9L1R@]
(^.X4,4O6*!0R6DBUS+%, PR9IEQKQKX0_7P!61S>#SGP M9P;9 W.!8*,PF,$WEE.5C;,_"P[L&WLNLL!LJ>V_%OX_0.$_2"!!AR8.F,==_M']P_"C@#D);YT;(
GS-Z@PF/3=A-RF-*#?,0H]{?1#TRUK9[KEM\>$TA(Z* M+5WX3C,I"Q3H E@'7#9MUJ4@Y5)%"FH_+1EARM"Y=)];-.W@V$\F,8?*1T>OR(9XL
P9+\T0L&-R=Q\)&";IF M28#\1\G,6CLPB>=BC&CO&_B4O5&AM-2L!:L3B"2AN6)>]:.N1#R\$MO'XWB>
M!CD!&===/Z[17^"K/ZM0>X>/1&P/V:M9RM(Y=YIVXMDM6CG+X:ZM]_%/|:,H& M6FHG@&KCH[[P88\7\S!DV?+:.0>OP?/ H-\X>9UW77,*[UE&^?
JK'L4T;AX;PWVG# M4AA.3L&Y>F0"2C4'83I=>Q!F6[3XGVWI'4!LSV'=_;P'WP_#Y#->_=U6?5\[M?K[K^_CB,%OV,AI7J4I^2\QC*?*F;?
Z^K\BNA*80!5[1]R.A[fN*-,67%\@PYBPB9\MJZMSNZ;UB[15KCRC2WH5]$ T M6T$-]YD&JV?5)?+V=U3Q-O_-+NJN%2/QLJ;W:7!S+4&>$'<3A/2JP%%
['6?]-M1EE3X8:,>2V@O*Y"3?TUH+*E_A;0YOM%,;UFCJV^:;*29].A,\+!<]N/C5O=P M&>!L6]NDT_;])?,B5/^_4$L#!!0 (/N);%DOR=D;#08 ,@; 8
M97EE;BTR,#(T,#DS,'AE>#,R9#$N:'1M[5EK4]LX%/TKVG3:PDS\2H!-G9 9 M&LPT,Q#8Q.RV'Q5+CK4HEBLKA.ROWRO+3IT ?6RAI;,PQ(GUN-*Y]]R'[-
YO MEA6D"4XC2M"[,P4$1&MYC15*)(4*VA=,I6@4&093M$E9)QCMY*1F84(<^U-M#VRON6^]EM7O@:O!.4FD/O(\QVLY+;>UA]P]WVOYKH!6??
B\NWI<(:EN/\U1XXSG%X;#KV;)@72ISF3#&18NXXP:B!&HE2F>\X MR^727K9M(6=,.'82-?=[#AVO,C;5D M1"6^]HONQDFA*4SB]-8^?
MVI_,I2;)9LFX3!HO*<>*75,MNR8UXA1+?RI4 MTMU>X*Z9634O%JFR8CQG?.6_#MF+7W6)TSOZA M(!K@*7JC+,S9#(3KO78-?A_ZD/YX+?-
#KSC=6'%)"VQ3P0ET!C<)FS*%VBW; MZSE34%KV"'%N,@+%4UO;XI6T-@G$X/!D.CL+A^0B=GZ#P78 NQL/18'AQ=(]" M]\'@,AS^&4 7C
K&/W#KWZ3>B\OQY/)H%*+P'$V"@4;SZH5WX';?N <5K,G1 M^.W1*)A8Y^]/@P_H:!#JGI;KMAX/U=^+7+%X99I82@"DWS[(/D>C88HBD:8T
MTHPV84C!KUYT6BVW.Q!S M'%>KXL[K[D%OR="SLUHS[7^0+&06](S@"0(HK!7@B8T4W0^11*UW2;2,;R) M<(YBQJN("=/;+20X("@))P2%-Q
;$DA+L+RV'J[6K6E%MK[;H$)$Y'ID%V?LS%2,ZE<;8+E%*1WC-7IVM2YA><;Q MRFX[N MZ)=?(;C:L 7%"PY\C<#]7%-
O34=)/RZ8I#I[Y]HN6_;>P;OF)U#?V!\AU5V\ MS>4UCTO[>F_;>UW-\,*8"D\Y15,A"96'#;R;W>9,$4MO8+6X%+BK'N_S(>A7IG[(04K M,?4P*V*D
MI+EF5U-W8R@$81IL!W/@7IX!W?)F,2MF*924NAT$DJ)$*2(DC%IP0TX!\;98 M,]*8S6=.9HY3D$X4Q
5VS]L;'=M5$PLM6(;(46"AJU5*:9TQY+W>-64HI>V]L]^!EO5;98D2M M[*O)%R SYF+I)XQ C;K?6]H#_"D4WE?6$I3PQ7*RY$BQ<#443W/!%XIN 34%
M;GG]O'>*M1?;G=]_(KK;D"H'V(3VD&Y70;N5(\Q Z+QF.53!G*E5!;#1UUG? M;7?783[[%GW?8M3^+\]HPL6"9IJWR0W\L%TQ1
MI.080J./1J#4HH[T6J:.O"LC_&=?>@02FZ+@]O4K]OUMG'S"UK_?J[_6CY^N M?1\>SEUF+[-Q58YD-PBB
2/HA5O_5C(3NYL'*BV"HQG^OW2<#Y#/YWY?S+W M1G@.6>"9??\GIOU02*%^:GW?$Z)GKCUS[0$A[5Q([!Z?#,[UMZBV>\^QW93Z M3T6_M=-
'LC[$3W%T-9-BD1+]^$!(O\H4M1*);W56ZIQ_1 M6^KO>[;?)&5X1BUSW,*QHM+'UX*1TLZ=CMW:6VU9:W/:.!3]*UHZ;9,9_(0PQ!!F*"%;=E+(@C.
[_2AL&6LK6ZXL M0MA?OU>630QM^34VW0VF0"V'E?W7)W0D-W_Q3#&:8S3>(3HM?_F$H4\6"X]KV2ZZ>H.,KOW1<3'\?#;RWUZ-
],I7UZ\N)R/4,"SKC];(MLL[]<]W1-FT'^0*G.964IY49UGC:0(U8RLRSK,UF8VY:)A-;__"Z,((224C@[Y5_>JQ2QYN!_V0 MWJ!
<;ADY:R18K&AJ2)YY+3N3/9AI0??!F%MC0T,9>XYM/^]E. QINC(8B;1W M8G:[=TV"KN)=&]?0/$$8EO2&*-DUJ0$C6'A++N/>X0(?FYE5\R*>2B/""65;
M[Z5/$Y*C*=F@.4]P^K*I6^ W)X)&+WO%Z)S^34 TP)/D5AJ8T14(5[KV-'X/ M^I#Z.*Z^4"LN]U;W,5U2^>*9T[%[+==T^]82+)=] ST#H"T1 M-

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end XML 76 eyen-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001682639 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001682639 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001682639 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001682639 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001682639 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001682639 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001682639 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001682639 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember 2023-09-30 0001682639 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001682639 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember 2023-09-30 0001682639 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001682639 us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-09-012024-09-30 0001682639 2024-09-012024-09-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-08-012024-08-31 0001682639 2024-08-012024-08-31 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-07-31 0001682639 2024-07-012024-07-31 0001682639 us-gaap:LicensingAgreementsMembereyen:BauschLicenseAgreementMember 2024-04-112024-04-11 0001682639 us-gaap:CommonStockMember 2024-09-012024-09-30 0001682639 us-gaap:CommonStockMember 2024-08-012024-08-31 0001682639 us-gaap:CommonStockMember 2024-07-012024-07-31 0001682639 us-gaap:RetainedEarningsMember 2024-09-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001682639 us-gaap:RetainedEarningsMember 2024-06-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001682639 2024-06-30 0001682639 us-gaap:RetainedEarningsMember 2024-03-31 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001682639 2024-03-31 0001682639 us-gaap:RetainedEarningsMember 2023-12-31 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001682639 us-gaap:RetainedEarningsMember 2023-09-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001682639 us-gaap:RetainedEarningsMember 2023-06-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001682639 2023-06-30 0001682639 us-gaap:RetainedEarningsMember 2023-03-31 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001682639 2023-03-31 0001682639 us-gaap:RetainedEarningsMember 2022-12-31 0001682639 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001682639 us-gaap:CommonStockMember 2024-09-30 0001682639 us-gaap:CommonStockMember 2024-06-30 0001682639 us-gaap:CommonStockMember 2024-03-31 0001682639 us-gaap:CommonStockMember 2023-12-31 0001682639 us-gaap:CommonStockMember 2023-09-30 0001682639 us-gaap:CommonStockMember 2023-06-30 0001682639 us-gaap:CommonStockMember 2023-03-31 0001682639 us-gaap:CommonStockMember 2022-12-31 0001682639 2024-08-21 0001682639 eyen:ExercisePriceTwoMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceThreeMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceSixMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceSevenMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceFourMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceFiveMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceEightMember 2024-01-012024-09-30 0001682639 eyen:ExercisePriceOneMember 2024-09-30 0001682639 eyen:ExercisePriceTwoMember 2024-09-30 0001682639 eyen:ExercisePriceThreeMember 2024-09-30 0001682639 eyen:ExercisePriceSixMember 2024-09-30 0001682639 eyen:ExercisePriceSevenMember 2024-09-30 0001682639 eyen:ExercisePriceFourMember 2024-09-30 0001682639 eyen:ExercisePriceFiveMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceTwoMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceThreeMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceSixMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceSevenMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceOneMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceFourMember 2024-09-30 0001682639 srt:MinimumMembereyen:ExercisePriceFiveMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceTwoMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceThreeMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceSixMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceSevenMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceOneMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceFourMember 2024-09-30 0001682639 srt:MaximumMembereyen:ExercisePriceFiveMember 2024-09-30 0001682639 eyen:ExercisePriceEightMember 2024-09-30 0001682639 us-gaap:StockOptionMember 2023-12-31 0001682639 us-gaap:StockOptionMember 2024-01-012024-09-30 0001682639 us-gaap:StockOptionMember 2024-09-30 0001682639 srt:MinimumMember 2024-07-012024-09-30 0001682639 srt:MaximumMember 2024-07-012024-09-30 0001682639 srt:MinimumMember 2024-01-012024-09-30 0001682639 srt:MaximumMember 2024-01-012024-09-30 0001682639 srt:MinimumMember 2023-01-012023-09-30 0001682639 srt:MaximumMember 2023-01-012023-09-30 0001682639 eyen:JulyOfferingMember 2024-07-012024-07-01 0001682639 2024-09-302024-09-30 0001682639 2024-08-212024-08-21 0001682639 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001682639 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001682639 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001682639 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001682639 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001682639 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001682639 us-gaap:DamagesFromProductDefectsMember 2024-07-012024-09-30 0001682639 us-gaap:DamagesFromProductDefectsMember 2024-01-012024-09-30 0001682639 us-gaap:DamagesFromProductDefectsMember 2023-01-012023-12-31 0001682639 us-gaap:DamagesFromProductDefectsMember 2024-04-23 0001682639 eyen:LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember 2024-07-012024-09-30 0001682639 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001682639 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001682639 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001682639 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001682639 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001682639 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001682639 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001682639 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001682639 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001682639 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001682639 2019-04-012019-04-30 0001682639 eyen:LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember 2024-06-012024-06-30 0001682639 eyen:DirectorAndOfficerInsurancePolicyLoanMember 2024-02-24 0001682639 2024-06-11 0001682639 2024-06-12 0001682639 eyen:PrefundedWarrantsMemberus-gaap:SubsequentEventMember 2024-10-01 0001682639 srt:MaximumMemberus-gaap:WarrantMember 2024-09-30 0001682639 srt:MaximumMembereyen:PrefundedWarrantsMember 2024-09-30 0001682639 us-gaap:WarrantMember 2024-09-30 0001682639 eyen:WarrantsAtExercisePriceTwoMember 2024-09-30 0001682639 eyen:WarrantsAtExercisePriceOneMember 2024-09-30 0001682639 eyen:PrefundedWarrantsMember 2024-09-30 0001682639 eyen:PriorWarrantsMember 2024-07-01 0001682639 2023-09-30 0001682639 2022-12-31 0001682639 us-gaap:WarrantMember 2024-01-012024-09-30 0001682639 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001682639 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001682639 eyen:ConvertibleNotesMember 2024-01-012024-09-30 0001682639 us-gaap:WarrantMember 2023-01-012023-09-30 0001682639 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001682639 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001682639 eyen:ConvertibleNotesMember 2023-01-012023-09-30 0001682639 eyen:DirectorAndOfficerInsurancePolicyLoanMember 2024-07-012024-09-30 0001682639 eyen:DirectorAndOfficerInsurancePolicyLoanMember 2024-01-012024-09-30 0001682639 eyen:RegisteredDirectOfferingMember 2024-07-012024-09-30 0001682639 eyen:AtMarketOfferingMember 2023-07-012023-09-30 0001682639 2020-10-092020-10-09 0001682639 us-gaap:LicensingAgreementsMembereyen:BauschLicenseAgreementMember 2024-05-032024-05-03 0001682639 eyen:RegisteredDirectOffering2024Member 2024-04-08 0001682639 eyen:FormosaPharmaceuticalsIncMemberus-gaap:LicensingAgreementsMember 2024-04-292024-04-29 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001682639 2023-07-012023-09-30 0001682639 2023-04-012023-06-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001682639 2023-01-012023-03-31 0001682639 us-gaap:CommonStockMember 2024-07-012024-09-30 0001682639 us-gaap:CommonStockMember 2024-04-012024-06-30 0001682639 us-gaap:CommonStockMember 2024-01-012024-03-31 0001682639 us-gaap:CommonStockMember 2023-07-012023-09-30 0001682639 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001682639 us-gaap:CommonStockMember 2023-04-012023-06-30 0001682639 us-gaap:CommonStockMember 2023-01-012023-03-31 0001682639 eyen:RegisteredDirectOfferingMember 2024-04-012024-06-30 0001682639

eyen:AtMarketOfferingMember 2024-04-012024-06-30 0001682639 eyen:AtMarketOfferingMember 2024-01-012024-03-31 0001682639 eyen:RegisteredDirectOfferingMember 2023-07-012023-09-30 0001682639 eyen:AtMarketOfferingMember 2023-04-012023-06-30 0001682639 eyen:AtMarketOfferingMember 2023-01-012023-03-31 0001682639 eyen:RegisteredDirectOffering2024Member 2024-04-082024-04-08 0001682639 eyen:AtMarketOfferingMember 2024-07-012024-09-30 0001682639 2024-07-012024-07-01 0001682639 eyen:DirectorAndOfficerInsurancePolicyLoanMember 2024-02-242024-02-24 0001682639 eyen:DirectorAndOfficerInsurancePolicyLoanMember 2024-09-30 0001682639 eyen:DirectorAndOfficerInsurancePolicyLoanMember 2023-12-31 0001682639 eyen:AvenueNotePayableMember 2024-09-30 0001682639 eyen:AvenueConvertibleNotePayableMember 2024-09-30 0001682639 eyen:AvenueNotePayableMember 2023-12-31 0001682639 eyen:AvenueConvertibleNotePayableMember 2023-12-31 0001682639 eyen:FormosaPharmaceuticalsIncMemberus-gaap:LicensingAgreementsMember 2023-08-15 0001682639 us-gaap:LicensingAgreementsMembereyen:BauschLicenseAgreementMember 2024-04-23 0001682639 eyen:LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember 2024-01-012024-09-30 0001682639 us-gaap:LicensingAgreementsMembereyen:BauschLicenseAgreementMember 2024-01-222024-01-22 0001682639 eyen:FormosaPharmaceuticalsIncMemberus-gaap:LicensingAgreementsMember 2023-08-152023-08-15 0001682639 eyen:ClinicalSupplyArrangementsMember 2024-09-30 0001682639 eyen:ClinicalSupplyArrangementsMember 2023-12-31 0001682639 eyen:ClinicalSupplyArrangementsMember 2024-01-012024-09-30 0001682639 2024-07-01 0001682639 eyen:PrefundedWarrantsMember 2024-01-012024-09-30 0001682639 eyen:PrefundedWarrantsMemberus-gaap:SubsequentEventMember 2024-10-012024-10-01 0001682639 eyen:PriorWarrantsMember 2024-07-012024-07-01 0001682639 eyen:WarrantsAtExercisePriceThreeMember 2024-01-012024-09-30 0001682639 eyen:WarrantsAtExercisePriceFourMember 2024-01-012024-09-30 0001682639 eyen:WarrantsAtExercisePriceFiveMember 2024-01-012024-09-30 0001682639 eyen:WarrantsAtExercisePriceThreeMember 2024-09-30 0001682639 eyen:WarrantsAtExercisePriceFourMember 2024-09-30 0001682639 eyen:WarrantsAtExercisePriceFiveMember 2024-09-30 0001682639 us-gaap:LicensingAgreementsMembereyen:BauschLicenseAgreementMember 2024-01-012024-09-30 0001682639 eyen:FormosaPharmaceuticalsIncMemberus-gaap:LicensingAgreementsMember 2024-01-012024-09-30 0001682639 2023-01-012023-09-30 0001682639 2023-12-31 0001682639 2024-09-30 0001682639 eyen:FormosaPharmaceuticalsIncMemberus-gaap:LicensingAgreementsMember 2024-04-262024-04-26 0001682639 eyen:FormosaPharmaceuticalsIncMemberus-gaap:LicensingAgreementsMember 2024-03-142024-03-14 0001682639 2024-07-012024-09-30 0001682639 2024-04-012024-06-30 0001682639 2024-01-012024-03-31 0001682639 2024-11-08 0001682639 2024-01-012024-09-30 shares iso4217:USD iso4217:USD shares pure DE0001682639--12-312024Q3falseO0863759584555302 6P8M10-Qtrue2024-09-30false001-38365EYENOVIA, INC.47-1178401295 Madison Avenue, Suite 2400NEW YORKNY10017833393-6684Common Stock, par value $0.0001 per shareEYENNASDAQYesYesNon-accelerated Filertruefalsefalse8644161171881291484905729672561097984088324256793137594123833150698775413657311168956520706718275240433744.175355212-1454915593719303899094227960912877937416251198292431198132522134168259101341 6-130897-12218-796667-1221834719393578113125007138911243729091292985511125115901655048646007201030650796828490428179276747331927-6520186-29287095-179398921184-348226-93394-157783-1240800602109679222195476816912284499920890123080449494 4-555926-818547-576558-1354067-7887853-7338733-29863653-19293059-0.11-0.11-0.18-0.18-0.53-0.53-0.50-0.5069558325695583254013969740139697564768765647687638563074385630744555302645551544860 98-1454915598999094183332318331194364319454754623254623 2-10922101-1092210147386349473815822669 4-1564136601817772322372632218885071888829613496624367474368092229397230322216123223912294953230167670916769395410565410561105369 9-1105369955817921558216509187 4-167467359-2369903290557572906123452721234817828680002868000286800028680001502280150117573311758834529984529 98-7887853-7887853863759588638179065877-1753552123719303329334798800200000011117117288045186514139994179181628680001212251363683666898036671354613 61-1182304631723456512999471303499462349959219530 2-28190648190643289-5739366-5739366379917463799139779885-1239698291581385512198913403107403120121910000127199272004936324936324444 44-4-6215860-6215860381693983817140703819-1301856891052194741986334201088569410886114487805499999511000000424104974329743617387001738700173870017387006129696129697338733-7338733428982464290153299865-13752442215779733360782710823541558812468119774681091354100449301317387 00-29863653-1929395915402861925665-1240800830605505684552620497654882517692171221840000028646003910284033 62-836507-3903513761-786772-1272309163775610510236251411481750-179232-2255-1781-371359-453567-307373-352836-411266-24010082-1751434216147627023611122945-161476-3825306161399941197746819029871091354623440241238641870331237162720050000001259823773746609140165106301917834 0-7660928-2161308148490572286352071881292070221214021471194132505050609140200000025756529044373957321250028680001738700100000024 36style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1 – Business Organization, Nature of Operations and Basis of Presentation Eyenovia, Inc. ("Eyenovia" or the "Company") is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in the treatment of chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company's pre-NDA candidate, MicroPine, is being developed for pediatric progressive myopia, a global epidemic impacting hundreds of millions of children worldwide and representing a multi-billion-dollar addressable market. The company's current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. Eyenovia has also secured licensing and development agreements for additional multi-billion-dollar indications where the Optejet may be advantageous, including dry eye. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the full year ending December 31, 2024 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2023 and for the year then ended, which were included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 18, 2024 (the "2023 Form 10-K"), as amended by Amendment No. 1, filed with the SEC on April 26, 2024 (the "2023 Form 10-K Amendment"). Note 2 – Summary of Significant Accounting Policies The Company disclosed its significant accounting policies in Note 2 – Summary of Significant Accounting Policies included in the 2023 Form 10-K. There have been no material changes to the Company's significant accounting policies during the nine months ended September 30, 2024, except as disclosed below. Liquidity and Going Concern As of September 30, 2024, the Company had unrestricted cash and cash equivalents of approximately $7.2 million and an accumulated deficit of approximately $175.4 million. For the nine months ended September 30, 2024 and 2023, the Company incurred net losses of approximately $29.9 million and $19.3 million, respectively, and used cash in operations of approximately $24.0 million and $17.5 million, respectively. The Company does not have recurring significant revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations for the near future. The Company expects that it will continue to incur significant research and development and selling, general and administrative expenses and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company's plans and its ability to continue as a going concern will depend on many factors, including the Company's ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies, or acquire other companies or technologies to enhance or complement its product and service offerings. Additionally, the Company will need to raise further capital, through the sale of additional equity or debt securities. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2024 and December 31, 2023, the Company had Treasury bills with original maturity dates of three months or less in the amounts of $0 and $5,450,118, respectively. The Company has cash deposits in financial institutions that, at times, may be in excess of Federal Deposit Insurance Corporation ("FDIC") insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2024 and December 31, 2023, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $6,784,903 and $14,243,870,

respectively. Clinical Supply Arrangements Bausch + Lomb Ireland Limited (“Bausch + Lomb”) and Arctic Vision had contracted with the Company to manufacture and supply them with the appropriate drug-device combination products to conduct their clinical trials on a cost plus 10% mark-up basis. Pursuant to the Letter Agreement (as defined below) with Bausch + Lomb, as referenced in Note 8 – Commitments and Contingencies – Bausch License Agreements, the arrangement with Bausch + Lomb has been terminated, and all rights have been repurchased by Eyenovia. The arrangement with Arctic Vision is still in place. The Company’s licensing agreement with Arctic Vision represents a collaborative arrangement and Arctic Vision is not a customer with respect to the clinical supply arrangements. The Company’s policy is to (a) defer the materials and manufacturing costs in order to properly match them up against the income from the clinical supply arrangements; and (b) report the net income from the clinical supply arrangements as other income. Deferred clinical supply costs were $0.4 million and $4.3 million at September 30, 2024 and December 31, 2023, respectively. See Note 8 – Commitments and Contingencies –Defective Clinical Supply for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The cost of inventory that is sold commercially to third parties is included within cost of sales. The Company will periodically review for slow-moving, excess or obsolete inventories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventory is primarily comprised of drug-device combination products, which are available for commercial sale, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 427,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,683</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,540,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,115</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,967,256 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 109,798 </td></tr></table> The Company has evaluated the net realizable value of the commercial inventory. The write-down of commercial inventory to net realizable value for the three months ended September 30, 2024 and 2023 was $0.1 million and $0.0 million, respectively. The write-down of commercial inventory for the nine months ended September 30, 2024 and 2023 was $0.8 million and $0.0 million, respectively. The write - down for the nine months ended September 30, 2024 consisted of $0.2 million of inventory write down adjustments to list price for the first quarter of 2024, $0.5 million for the write-down of short dated inventory to net realizable value for the second quarter of 2024 and $0.1 million for the write - down of inventory to net realizable value for the third quarter of 2024. The Company recorded the write-downs to cost of revenue as it relates to goods that were part of commercial inventory during 2024. Net Loss Per Share of Common Stock Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, plus fully vested shares that are subject to issuance for little or no monetary consideration. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following table presents the computation of basic and diluted net loss per common share: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,887,853)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (7,338,733) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,863,653)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,293,959) </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Denominator (weighted average quantities): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> . </td></tr><tr><td

style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Common shares issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 69,316,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 39,107,338 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 56,298,569 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 38,192,414 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Add: Prefunded warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> 926,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 305,349 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Add: Undelivered vested restricted shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 241,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,134 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,307 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 65,311 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Denominator for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,558,325 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 40,139,697 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,476,876 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,563,074 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Basic and diluted net loss per common share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.18) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.50) </td></tr></table> The following securities are excluded from the calculation of weighted average diluted shares of common stock because their inclusion would have been anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 10,926,554 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;">Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5,218,686 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,327,747 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,327,747 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368,886 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 86,205 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total potentially dilutive shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,339,419 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,559,192 </td></tr></table> Subsequent Events The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed. Recently Issued Accounting Standards In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segments Disclosures (Topic 280), which updates reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis. The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-07. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect it to have a material impact on its financial statements. Liquidity and Going Concern As of September 30, 2024, the Company had unrestricted cash and cash equivalents of approximately $7.2 million and an accumulated deficit of approximately $175.4 million. For the nine months ended September 30, 2024 and 2023, the Company incurred net losses of approximately $29.9 million and $19.3 million, respectively, and used cash in operations of approximately $24.0 million and $17.5 million, respectively. The Company does not have recurring significant revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations for the near future. The Company expects that it will continue to incur significant research and development and selling, general and administrative expenses and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company's plans and its ability to continue as a going concern will depend on many factors, including the Company's ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies, or acquire other companies or technologies to enhance or complement its product and service offerings. Additionally, the Company will need to raise further capital, through the sale of additional equity or debt securities. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. 7200000-175400000-29900000-19300000-24000000.0-17500000 Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2024 and December 31, 2023, the Company had Treasury bills with original maturity dates of three months or less in the amounts of $0 and $5,450,118, respectively. The Company has cash deposits in financial institutions that, at times, may be in excess of Federal Deposit Insurance Corporation ("FDIC") insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2024 and December 31, 2023, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $6,784,903 and $14,243,870, respectively. 0545011867849031424387 0 Clinical Supply Arrangements Bausch + Lomb Ireland Limited ("Bausch + Lomb") and Arctic Vision had contracted with the Company to manufacture and supply them with the appropriate drug-device combination products to conduct their clinical trials on a cost plus 10% mark-up basis. Pursuant to the Letter Agreement (as defined below) with Bausch + Lomb, as referenced in Note 8 – Commitments and Contingencies – Bausch License Agreements, the arrangement with Bausch + Lomb has been terminated, and all rights have been repurchased by Eyenovia. The arrangement with Arctic Vision is still in place. The Company's licensing agreement with Arctic Vision represents a collaborative arrangement and Arctic Vision is not a customer with respect to the clinical supply arrangements. The Company's policy is to (a) defer the materials and manufacturing costs in order to properly match them up against the income from the clinical supply arrangements; and (b) report the net income from the clinical supply arrangements as other income. Deferred clinical supply costs were $0.4 million and $4.3 million at September 30, 2024 and December 31, 2023, respectively. See Note 8 – Commitments and Contingencies –Defective Clinical Supply for additional information. 0.1040000043000000 Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The cost of inventory that is sold commercially to third parties is included within cost of sales. The Company will periodically review for slow-moving, excess or obsolete inventories. Inventory is primarily comprised of drug-device combination products, which are available for commercial sale, as follows: <table style="border-collapse:collapse;font-

size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 427,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 30,683 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,540,039 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 79,115 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,967,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 109,798 </td></tr></table> The Company has evaluated the net realizable value of the commercial inventory. The write-down of commercial inventory to net realizable value for the three months ended September 30, 2024 and 2023 was $0.1 million and $0.0 million, respectively. The write-down of commercial inventory for the nine months ended September 30, 2024 and 2023 was $0.8 million and $0.0 million, respectively. The write - down for the nine months ended September 30, 2024 consisted of $0.2 million of inventory write down adjustments to list price for the first quarter of 2024, $0.5 million for the write-down of short dated inventory to net realizable value for the second quarter of 2024 and $0.1 million for the write - down of inventory to net realizable value for the third quarter of 2024. The Company recorded the write-downs to cost of revenue as it relates to goods that were part of commercial inventory during 2024. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 427,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 30,683 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,540,039 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 79,115 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,967,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 109,798 </td></tr></table>427217306832540039791152967256109798100000000.080000000.020000050000010000 Net Loss Per Share of Common Stock Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, plus fully vested shares that are subject to issuance for little or no monetary consideration. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following table presents the computation of basic and diluted net loss per common share: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (7,887,853) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,338,733)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (29,863,653) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,293,959) </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Denominator (weighted average quantities): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Common shares issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 69,316,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 39,107,338 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 56,298,569 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 38,192,414 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Add: Prefunded warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> 926,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 305,349 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Add: Undelivered vested restricted shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 241,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,134 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,307 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 65,311 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Denominator for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,558,325 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 40,139,697 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,476,876 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,563,074 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Basic and diluted net loss per common share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">

 (0.11) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.53) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.50) </td></tr></table> The following securities are excluded from the calculation of weighted average diluted shares of common stock because their inclusion would have been anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 10,926,554 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5,218,686 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,327,747 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,327,747 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368,886 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 86,205 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total potentially dilutive shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,339,419 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-

bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,559,192 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,887,853)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (7,338,733) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,863,653)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,293,959) </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Common shares issued </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 69,316,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 39,107,338 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 56,298,569 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 38,192,414 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Add: Prefunded warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> 926,225 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 305,349 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> Add: Undelivered vested restricted shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 241,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,134 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,307 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 65,311 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Denominator for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,558,325 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 40,139,697 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,476,876 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,563,074 </td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"> Basic and diluted net loss per common share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.18) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.50) </td></tr></table> . -7887853-7338733-29863653-192939596931656139107338562985693819241492622530534924176410613417830765311695583256955832540139697401396975647687656476 0.11-0.11-0.18-0.18-0.53-0.53-0.50-0.50 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 10,926,554 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5,218,686 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible notes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,327,747 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,327,747 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368,886 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 86,205 </td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total potentially dilutive shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,339,419 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,559,192 </td></tr>
</table>2894774410926554669504252186862327747232774736888686205383394191855919 2 Subsequent Events The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed. Recently Issued Accounting Standards In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segments Disclosures (Topic 280), which updates reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis. The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-07. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect it to have a material impact on its financial statements. Note 3 – Prepaid Expenses and Other Current Assets As of September 30, 2024 and December 31, 2023, prepaid expenses and other current assets consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid insurance expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 356,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 167,338 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Payroll tax receivable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 288,705 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 500,684 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid general and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 131,606 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 85,938 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"> Prepaid patent expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 71,073 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 48,409 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid conference expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 54,810 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 123,556 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Prepaid research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 48,172 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 421,056 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid rent and security deposit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 18,750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 18,750 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,424 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total prepaid expenses and other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 987,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,365,731 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid insurance expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 356,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 167,338 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Payroll tax receivable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 288,705 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 500,684 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid general and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 131,606 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 85,938 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"> Prepaid patent expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 71,073 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 48,409 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid conference expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 54,810 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 123,556 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Prepaid research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 48,172 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 421,056 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid rent and security deposit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 18,750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 18,750 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,424 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total prepaid expenses and other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 987,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,365,731 </td></tr></table>
3562141673382887055006841316068593871073484095481012355648172421056187501875018424987754136573 Note 4 - Intangible Assets On August 15, 2023, the Company entered into a license agreement (the “Formosa License”) with Formosa Pharmaceuticals Inc. (“Formosa”), whereby the Company acquired the exclusive U.S. rights to commercialize any product related to a novel formulation of clobetasol propionate ophthalmic suspension, 0.05% (the “Formosa Licensed Product”), which was approved by the FDA for ophthalmic use for inflammation and pain after ocular surgery and supplemental disease indications, if any, associated with the New Drug Application for the Formosa Licensed Product. The Formosa License will remain in effect for ten years from the date of the first commercial sale of a Formosa Licensed Product, unless earlier terminated. The Company paid Formosa the aggregate amount of $2.0 million (the “Upfront Payment”), consisting of (a) cash in the amount of $1.0 million and (b) 487,805 shares of common stock, which is included in Intangible Assets on the accompanying balance sheet. The Company also capitalized $122,945 of transaction costs, which were primarily legal expenses. In addition to the Upfront Payment, the Company must pay Formosa up to $4.0 million upon the achievement of certain development milestones and up to $80.0 million upon the achievement of certain sales milestones. The trigger for the initial $2.0 million development milestone payments was FDA approval of the Formosa Licensed Product and the effective date of the acceptance by the Company of the transfer and assignment of the FDA approval. This occurred on March 14, 2024. Under the provisions of the Formosa License, the Company had 45 days from the effective date of acceptance of the transfer and assignment of FDA approval to make the payment half in cash and half in common stock, otherwise the payment due would revert to be fully in cash. The Company paid Formosa the aggregate amount of $2.0 million, consisting of (a) cash in the amount of $1.0 million on April 26, 2024 and (b) 613,496 shares of common stock on April 29, 2024 (calculated pursuant to the Formosa License using a five-day volume-weighted average price on March 14, 2024, but valued at $0.4 million on the April 29, 2024 settlement date, resulting in a $0.6 million change in fair value of the equity consideration payable), which is included in Intangible Assets on the accompanying balance sheet as of September 30, 2024. The second $2.0 million development milestone (to be

fully paid in cash) was earned upon FDA approval of the Formosa Licensed Product and payment was triggered on the earlier of twelve months after FDA approval or six months following the first commercial sale of the Formosa Licensed Product. Because the payment became probable and estimable, the Company recorded an additional $2.0 million increase in the intangible asset and the related accrual on March 14, 2024. 0.00052000000.01000000.048780512294540000000.080000000.02000000.0P45D2000000.01000000.0613496400000600000020000000.02000000

style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5 – Accrued Compensation As of September 30, 2024 and December 31, 2023, accrued compensation consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued bonus expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 1,302,997 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued payroll expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 514,948 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 355,616 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,656,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,658,613 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued bonus expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 1,302,997 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued payroll expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 514,948 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 355,616 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,656,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,658,613 </td></tr></table> 114188413029975149483556161656832l6658613 Note 6 – Accrued Expenses and Other Current Liabilities As of September 30, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued intangible asset milestone obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued defective clinical supply settlement, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 250,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 100,000 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued clinical studies costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 121,588 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued professional services </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 79,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 63,028 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Credit card payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 29,502 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 27,193 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued franchise tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 13,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 89,872 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,404 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,835 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,518,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 287,928 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued intangible asset milestone obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 2,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued defective clinical supply settlement, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 250,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 100,000 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued clinical studies costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 121,588 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued professional services </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 79,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 63,028 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Credit card payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 29,502 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 27,193 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Accrued franchise tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 13,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 89,872 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,404 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px

solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,835 </td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#ccceff;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,518,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 287,928 </td></tr></table> 2000000250000100000121588790426302829502271931500013550898729404783525180862879280 Note 7 – Notes Payable and Convertible Notes Payable As of September 30, 2024 and December 31, 2023, notes payable and convertible notes payable consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:28.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:28.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Notes Payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> Debt Discount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Notes Payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Debt Discount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Net </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Current portion: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> D&O insurance policy loan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue - Note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 6,666,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> (562,711) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 6,103,956 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 5,833,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> (503,914) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> 5,329,419 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> Avenue - Convertible note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,333,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (72,467) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,260,866 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Total current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,064,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (635,178) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,429,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,833,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (503,914)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,329,419 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Non-Current portion: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> Avenue - Note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 637,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 637,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 4,804,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (448,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> 4,355,800 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue - Convertible note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,666,666 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (163,051) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,503,615 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (398,569) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,601,431 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> Total non-current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,304,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (163,051) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,141,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,804,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (846,936)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,957,231 </td></tr></table> . On February 24, 2024, the Company issued a note payable in the amount of $505,050 for the purchase of a directors and officers' liability insurance policy (the "D&O Loan"). The note accrued interest at a rate of 8.15% per year and matured on October 24, 2024. The D&O Loan was payable in eight monthly payments of $65,076 consisting of principal and interest. During the nine months ended September 30, 2024, the Company repaid $440,413 of principal owed on the D&O Loan. The note was paid off in full on the maturity date. In June 2024, the Company began making principal payments related to that certain loan and security agreement (the "Loan and Security Agreement") with Avenue Capital Management II, L.P. and related entities (together, "Avenue") in the amount of $833,333 per month plus interest. During the three months ended September 30, 2024, the Company recorded interest expense of $602,109, of which $598,188 (including amortization of debt discount of $184,207) was related to the Avenue loan and $3,921 was related to the D&O Loan. During the nine months ended September 30, 2024, the Company recorded interest expense of $1,954,768, of which $1,939,650 was related to the Loan and Security Agreement (including amortization of debt discount of $552,620) and $15,118 was related to the D&O Loan. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;">

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> D&O insurance policy loan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue - Note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 6,666,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> (562,711) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 6,103,956 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 5,833,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> (503,914) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> 5,329,419 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> Avenue - Convertible note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,333,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (72,467) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,260,866 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Total current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,064,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (635,178) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,429,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,833,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (503,914)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,329,419 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Non-Current portion: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> Avenue - Note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 637,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 637,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 4,804,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (448,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> 4,355,800 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue - Convertible note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,666,666 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (163,051) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,503,615 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (398,569) </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.87%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,601,431 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.32%;margin:0pt;padding:0pt;"> Total non-current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,304,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (163,051) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,141,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,804,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(846,936)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,957,231 </td></tr>
</table>646370646370006666667562711610395658333335039145329419333333372467326086600010064637635178942945958333335039145321

Note 8 – Commitments and Contingencies

Defective Clinical Supply

During the third quarter of 2023, a certain portion of clinical supply product sold by the Company to Bausch + Lomb was determined to be defective. On April 23, 2024, the Company and Bausch + Lomb executed a letter agreement (the "Side Letter") pursuant to which the Company and Bausch + Lomb agreed that the Company would pay approximately $0.5 million to Bausch + Lomb related to the defective clinical supply. Accordingly, the Company recorded an estimated charge equal to $0.4 million, which was included within other income (expense) during the year ended December 31, 2023, because the original sales to the licensee were recorded on that line item. During the three and nine months ended September 30, 2024, the Company recorded no additional charge and a $0.1 million charge, respectively, to other income (expense).

Bausch License Agreements

On October 9, 2020, the Company entered into a license agreement (the Bausch License Agreement"), pursuant to which Bausch + Lomb was permitted to develop and commercialize the Bausch Licensed Product (as defined in the Bausch License Agreement) in the United States and Canada (the "Licensed Territory"). Bausch + Lomb could terminate the Bausch License Agreement, with respect to the Bausch Licensed Product to either country in the Licensed Territory, at any time for convenience upon 90 days' written notice.

On January 12, 2024, the Company and Bausch + Lomb entered into a mutual termination and reassignment agreement (the "Letter Agreement"), pursuant to which Eyenovia reacquired the rights to the Bausch Licensed Product. The terms of the agreement include the immediate transfer of the rights and the subsequent transfer of certain assets relating to the Bausch Licensed Product from Bausch + Lomb to the Company in exchange for cash and common stock consideration. In addition, under the terms of the Letter Agreement, the Company agreed to pay Bausch + Lomb a low single-digit royalty on its net sales of the Bausch Licensed Product in the United States and Canada for a period of ten years from the date of the first commercial sale by the Company (or its affiliates or licensees) of the Bausch Licensed Product in the United States. Under the Letter Agreement, (i) the Company will re-acquire any and all licenses and other rights granted by the Company to Bausch + Lomb under the original Bausch License Agreement, (ii) any and all licenses and other rights granted by Bausch + Lomb to the Company under the License Agreement are terminated, other than as set forth in the Letter Agreement, and (iii) other than as set forth in the Letter Agreement, Bausch + Lomb is released from all of their ongoing obligations under the License Agreement, including development and commercialization obligations.

Pursuant to the Letter Agreement, the Company paid Bausch + Lomb an upfront payment of $2.0 million in cash on January 22, 2024. The Company recorded this amount as an operating expense. In connection with the entry into the Letter Agreement, the Company also agreed to issue Bausch + Lomb $3.0 million in shares of the Company's common stock, following the Regulatory Transfer Date (the "Transfer Date"). On April 11, 2024, the Transfer Date, the transfer of the rights and certain assets relating to the CHAPERONE trial from Bausch + Lomb to the Company, was completed. On May 3, 2024, the Company issued Bausch + Lomb 2,299,397 shares of the Company's common stock (calculated pursuant to the Letter Agreement at $3.0 million using a thirty-day volume-weighted average price on April 11, 2024, but valued at $2.3 million on the May 3, 2024 settlement date, resulting in a $0.7 million change in fair value of the equity consideration payable), in satisfaction of its obligations pursuant to the Letter Agreement.

Pursuant to the Side Letter described above (see Defective Clinical Supply), the Company agreed to pay approximately $0.5 million to Bausch + Lomb related to the defective clinical supply. It was also agreed that the Company will receive approximately $0.25 million from Bausch + Lomb to fund the vendor hold back liability that will be due upon completion of the CHAPERONE study. The Company recorded the payable to Bausch + Lomb in the amount of $0.25 million. In addition, the Company purchased $0.5 million of clinical supplies from Bausch + Lomb in April 2024.

Operating Leases

A summary of the Company's right-of-use assets and liabilities is as follows:

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Operating cash flows used in operating activities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">(352,836)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> (411,266) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Right-of-use assets obtained in exchange for lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> 904,437 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted Average Remaining Lease Term (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 2.37 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 3.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Weighted Average Discount Rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 10.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> 10.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table> . Future minimum payments under the Company's operating lease agreements are as follows: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:76.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Years Ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Minimum Lease Payments </td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,092</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 675,400</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 560,996</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,618</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634,106</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (193,025)</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,441,081</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (604,647)</p></td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 836,434 </td></tr></table> . Litigations, Claims and Assessments <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. 5000004000000100000P90D2000000.03000000.022993973000000.02300000-7000005000002500002500005000000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Operating cash flows used in operating activities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">352,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 411,266 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-

left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> 904,437 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted Average Remaining Lease Term (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 2.37 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> 3.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"> Weighted Average Discount Rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 10.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;background:#cceeff;margin:0pt;padding:0pt;"> 10.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table>3528364112669044437P2Y4M13DP3Y3M10DP3Y3M10D0.1000.100 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:76.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Years Ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Minimum Lease Payments </td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"> 183,092 </td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;margin:0pt;padding:0pt;"> 675,400 </td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"> 560,996 </td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 214,618 </td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"> Total future minimum lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"> 1,634,106 </td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"> Less: Imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (193,025) </td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"> Present value of lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;margin:0pt;padding:0pt;"> 1,441,081 </td></tr><tr><td style="vertical-align:bottom;width:76.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

12pt;">Less: current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (604,647) </td></tr><tr><td style="vertical-align:bottom;width:76.88%;background:#cceeff;margin:0pt;padding:0pt;"> Lease liabilities, non-current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 836,434 </td></tr>
</table>1830926754005609962146181634106193025144108160464783643 4 Note 9 – Related Party Transactions The Company has an advisory service agreement with a member of the board of directors. The agreement calls for a monthly consulting fee of $5,000, paid on a quarterly basis, which is in addition to the compensation paid to the individual pursuant to the Company's non – employee director compensation policy while such individual remains a member of the board of directors. 5000 Note 10 – Stockholders' Equity Increase in Authorized Number of Shares of Common Stock On June 12, 2024, at the Annual Shareholders' Meeting, the Company proposed and the shareholders approved an increase in the authorized number of shares of the Company's common stock from 90,000,000 to 300,000,000 at the same par value of $0.0001 per share. Common Stock Issuances Pursuant to the License and certain milestone achievements, the Company issued 613,496 shares of common stock valued at $0.4 million on April 29, 2024 to Formosa (see Note 4 – Intangible Assets). On May 3, 2024, the Company issued Bausch + Lomb 2,299,397 shares of the Company's common stock, valued at $2.3 million, in satisfaction of its obligations pursuant to the Letter Agreement (see Note 8 – Commitments and Contingencies). At-The-Market Program During the nine months ended September 30, 2024, the Company received approximately $6.0 million in net proceeds from the sale of 5,630,556 shares of its common stock pursuant to a sales agreement (the "Sales Agreement") with Leerink Partners, LLC, formerly known as SVB Securities LLC ("Leerink Partners") in an "at-the-market" offering. Offerings Second Quarter Offering On April 8, 2024, the Company entered into a securities purchase agreement (the "Purchase Agreement") with a single fundamentals-based healthcare investor (the "Purchaser"), pursuant to which the Company agreed to sell, in a registered direct offering by the Company directly to the Purchaser (the "April Offering"), 3,223,726 shares of common stock. The price per share in the April Offering was $0.6204. The aggregate gross proceeds to the Company from the April Offering were $2.0 million, and net proceeds after offering costs were approximately $1.9 million. Third Quarter Offerings A summary of the offerings for the third quarter is presented below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Additional </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Paid-In </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Stockholders' </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Capital </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Equity </td></tr><tr><td style="vertical-align:bottom;width:46.34%;background:#cceeff;margin:0pt;padding:0pt;"> July Offering </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 7,575,757 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 4,298,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 4,299,401 </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> August Offering </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 12,850,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"> 1,285 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 4,449,822 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 4,451,107 </td></tr><tr><td style="vertical-align:bottom;width:46.34%;background:#cceeff;margin:0pt;padding:0pt;"> September Offering </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,630,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 863 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,596,807 </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,597,670</p></td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,055,757 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,906 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,345,272 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,348,178 </td></tr></table> $ July Offering and Warrant Amendment On July 1, 2024, the Company closed on a registered direct offering (the "July Offering") with certain institutional and accredited investors (the "July Investors"), pursuant to which the Company sold 7,575,757 shares of common stock and warrants to purchase up to 7,575,757 shares of common stock. The combined offering price for each share of common stock and accompanying warrant was $0.66. The Company also agreed to issue warrants to purchase an additional 1,749,780 shares of common stock (the "Additional Warrants") to one of the July Investors. All of the new warrants become exercisable six months following their issuance, at an exercise price of $0.69 per share, and may be exercised until January 2, 2030. In connection with the July Offering, the Company entered into warrant amendment agreements (the "Amendments") with the holders of previously issued warrants (the "Prior Warrants") to purchase up to an aggregate of 10,386,269 shares of common stock, whereby the Company agreed to amend the Prior Warrants to reduce the exercise price of the Prior Warrants from $2.23 and $2.47 per share of common stock to $0.69 per share of common stock, extend the term of the Prior Warrants until January 2, 2030 and prohibit exercise of the Prior Warrants for the six-month period following the effective date of the Amendments. The aggregate gross proceeds to the Company from the July Offering were approximately $5.0 million, and net proceeds after cash offering costs were approximately $4.3 million. Offering costs include placement agent fees of $0.4 million and Company legal fees of $0.3 million. In addition, there were $2.9 million of non-cash issuance costs which represents the value of the Additional Warrants, plus the modification date incremental value of the modified Prior Warrants as compared to the original Prior Warrants, as an issuance cost of the warrant exercise. August Offering On August 21, 2024, the Company agreed to sell 12,850,000 shares of common stock to certain institutional and accredited investors (the "August Investors"), in some cases pursuant to a securities purchase agreement (the "August Offering"). The price per share in the August Offering was $0.40. The aggregate gross proceeds to the Company from the August Offering were approximately $5.1 million, and net proceeds after offering costs were approximately $4.5 million. September Offering On September 30, 2024, the Company closed on a registered direct offering (the "September Offering") with a certain purchaser, pursuant to which the Company sold to the purchaser 8,630,000 shares of common stock; pre-funded warrants to purchase up to 65,653 shares of common stock; and warrants to purchase up to 8,695,653 shares of common stock at an exercise price of $0.50 per share. The combined offering price for each share and accompanying warrant was $0.46. The combined offering price for each pre-funded warrant and accompanying Warrant was $0.4599, which is equal to the purchase price per share in the September Offering, minus $0.0001, the exercise price per share of the pre-funded warrants. The warrants will be exercisable beginning six months following the date of issuance and may be exercised until March 31, 2030. The aggregate gross proceeds to the Company from the September Offering were approximately $4.0 million, and net proceeds after offering costs were approximately $3.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The issuance date or modification date fair value of stock warrants issued or modified during the three and nine months ended September 30, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> $ </td></tr><tr><td style="vertical-

align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value of common stock on date of grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> $0.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> $1.97 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> $0.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> $1.97 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 4.39% - 5.22% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 4.48% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 4.39% - 5.22% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 4.48% </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> 0.7 - 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 - 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> 0.7 - 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 - 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 86% - 118% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 81% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 86% - 118% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 81% </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:50.38%;background:#cceeff;margin:0pt;padding:0pt;"> Expected dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . A summary of the warrant activity during the nine months ended September 30, 2024 is presented below: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Life </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"> 10,926,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> Granted (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> 18,021,190 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> 0.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"> Repriced - (Old) (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"> (10,386,269) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> Repriced - (New) (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> 10,386,269 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> 0.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> Outstanding September 30, 2024 (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.1</p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercisable September 30, 2024 (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 540,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.4 </td></tr></table> (1) - Warrants granted, outstanding and exercisable exclude 65,653 pre-funded warrants with an exercise price of $0.0001. (2) - Repriced warrants represent the reset of the exercise price of certain warrants to purchase 10,386,269 shares of common stock to a price of $0.69 per share. The following table presents information related to warrants as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="3" style="vertical-align:bottom;width:47.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants Outstanding (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warants Exercisable (1) </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Exercisable </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> Remaining Life </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td></tr><tr><td style="vertical-align:bottom;width:21.55%;background:#cceeff;margin:0pt;padding:0pt;"> $0.5000 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 8,695,653 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> $0.6900 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 19,711,806 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:21.55%;background:#cceeff;margin:0pt;padding:0pt;"> $2.4696 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 232,021 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"> 0.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 232,021 </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> $2.7240 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 216,380 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> 0.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 216,380 </td></tr><tr><td style="vertical-align:bottom;width:21.55%;background:#cceeff;margin:0pt;padding:0pt;"> $4.7600 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt

0pt;"> 91,884 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"> 6.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 91,884 </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> 1.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 540,285 </td></tr></table> (1) - Warrants outstanding and exercisable exclude 65,653 Pre-Funded Warrants with an exercise price of $0.0001. (2) - These warrants become exercisable on March 26, 2025. (3) - These warrants become exercisable on January 1, 2025. . Stock-Based Compensation Expense The Company records stock-based compensation expense related to stock options and restricted stock units (“RSUs”). For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $452,998 ($179,776 of which was included within research and development expenses and $273,222 was included within selling, general and administrative expenses on the statements of operations) and $612,969 ($235,731 of which was included within research and development expenses and $377,238 of which was included within selling, general and administrative expenses on the statements of operations), respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $1,540,286 ($618,516 of which was included within research and development expenses and $921,770 of which was included within selling, general and administrative expenses on the statements of operations) and $1,925,665 ($647,058 of which was included within research and development expenses and $1,278,607 of which was included within selling, general and administrative expenses on the statements of operations), respectively. Restricted Stock Units A summary of the restricted stock units (“RSUs”) activity during the nine months ended September 30, 2024 is presented below: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> Exercise </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs non-vested January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> 106,019 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.12</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (106,019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.12</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs non-vested September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.65 </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> Vested RSUs undelivered September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 241,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.17 </td></tr></table> . To date, RSUs have only been granted to directors in accordance with the Company's Amended and Restated 2018 Omnibus Stock Incentive Plan. The Company's policy is not to deliver shares underlying the RSUs until a director's termination of service. As of September 30, 2024, there was $169,739 of unrecognized stock-based compensation expense related to RSUs which will be recognized over a weighted average period of 0.7 years. Stock Options A summary of the option activity during the nine months ended September 30, 2024 is presented below: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Life </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 5,306,377 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 3,31 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 2,188,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 1.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited/Expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (799,471) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3.26 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.59 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,053</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable, September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,022,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3.46 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> The following table presents information related to stock options as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Exercisable </td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Remaining Life </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $0.01 - $0.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 1,315,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $1.00 - $1.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 2,224,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 5.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 1,160,055 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $2.00 - $2.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 1,249,586 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 6.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 1,026,448 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $3.00 - $3.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 758,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 6.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 703,605 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $4.00 - $4.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 279,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 7.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 264,420 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $5.00 - $5.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 26,668 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 2.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 26,668 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $6.00 - $6.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 691,162 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 5.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 691,162 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $7.00+ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 150,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 3.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 150,640 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 5.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,022,998 </td></tr></table> . In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:
. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;background:#cceeff;margin:0pt;padding:0pt;"> 5.85 - 6.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 5.50 - 10.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 5.50 - 10.00 </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> 3.47% - 3.80% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 3.47% - 4.72% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 3.44% - 4.18% </td></tr><tr><td style="vertical-align:bottom;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;background:#cceeff;margin:0pt;padding:0pt;"> 87% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">80% - 87% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 82% - 95% </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> Expected dividends </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> 0.00% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 0.00% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 0.00% </td></tr></table> . As of September 30, 2024, there was $2,042,227 of unrecognized stock-based compensation expense related to stock options which will be recognized over a weighted average period of 1.8 years. The weighted average estimated grant date fair value of the stock options granted for the three months ended September 30, 2024 was approximately $0.40 per share. There were no options granted in the three months ended September 30, 2023. The weighted average estimated grant date fair value of the stock options granted for the nine months ended September 30, 2024 and 2023 was approximately $0.79 and $1.70 per share, respectively. 900000003000000000.000161349640000229939723000006000000.0563055632237260.62042000000.01900000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Additional </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Paid-In </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Stockholders' </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Capital </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Equity </td></tr><tr><td style="vertical-align:bottom;width:46.34%;background:#cceeff;margin:0pt;padding:0pt;"> July Offering </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 7,575,757 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 4,298,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 4,299,401 </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> August Offering </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 12,850,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"> 1,285 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 4,449,822 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 4,451,107 </td></tr><tr><td style="vertical-align:bottom;width:46.34%;background:#cceeff;margin:0pt;padding:0pt;"> September Offering </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,630,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 863 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,596,807 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,597,670 </td></tr><tr><td style="vertical-align:bottom;width:46.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,055,757 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double

*#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,345,272 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,348,178 </td></tr></table>*7575757758429864342994011285000012854449822445110786300008633596807359767029055757290612345272123481787575757757575*<table style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value of common stock on date of grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> $0.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> $1.97 </td><td style="vertical-align:bottom;white-*

space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> $0.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> $1.97 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 4.39% – 5.22% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 4.48% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 4.39% – 5.22% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 4.48% </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> 0.7 – 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 – 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> 0.7 – 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 – 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 86% – 118% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 81% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> 86% – 118% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 81% </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.38%;background:#cceeff;margin:0pt;padding:0pt;"> Expected dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> n/a </td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr>
</table>0.681.970.681.974.395.224.484.395.224.480.75.54.05.50.75.54.05.586118818611881 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> Life </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"> 10,926,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> Granted (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> 18,021,190 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> 0.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"> Repriced – (Old) (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"> (10,386,269) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> Repriced – (New) (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"> 10,386,269 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"> 0.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"> Outstanding September 30, 2024 (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.1</p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercisable September 30, 2024 (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 540,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.4 </td></tr></table> (1) – Warrants granted,

outstanding and exercisable exclude 65,653 pre-funded warrants with an exercise price of $0.0001. (2) - Repriced warrants represent the reset of the exercise price of certain warrants to purchase 10,386,269 shares of common stock to a price of $0.69 per share. 109265542.28180211900.60-103862692.25103862690.69289477440.67P5Y1M6D5402852.96P1Y4M24D656530.0001103862690.69 The following table presents information related to warrants as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;">   </td></tr><tr><td colspan="3" style="vertical-align:bottom;width:47.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants Outstanding (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warants Exercisable (1) </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Exercisable </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> Remaining Life </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td></tr><tr><td style="vertical-align:bottom;width:21.55%;background:#cceeff;margin:0pt;padding:0pt;"> $0.5000 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 8,695,653 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">— </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> $0.6900 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 19,711,806 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:21.55%;background:#cceeff;margin:0pt;padding:0pt;"> $2.4696 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 232,021 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"> 0.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 232,021 </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> $2.7240 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 216,380 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> 0.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 216,380 </td></tr><tr><td style="vertical-align:bottom;width:21.55%;background:#cceeff;margin:0pt;padding:0pt;"> $4.7600 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 91,884 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"> 6.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 91,884 </td></tr><tr><td style="vertical-align:bottom;width:21.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 28,947,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"> 1.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 540,285 </td></tr></table> (1) - Warrants outstanding and exercisable exclude 65,653 Pre-Funded Warrants with an exercise price of $0.0001. (2) - These warrants become exercisable on March 26, 2025. (3) - These warrants become exercisable on January 1, 2025. 0.5000869565300.6900197118062.4696232021P0Y6M2320212.7240216380P0Y6M2163804.7600918842894774 4P1Y4M24D540. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> Exercise </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"> RSUs non-vested January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> 106,019 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.12</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (106,019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.12</p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs non-vested September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.65 </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> Vested RSUs undelivered September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 241,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.17 </td></tr>
</table>1060192.123688860.651060192.123688860.652417642.17169739P0Y8M12D<p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;min-height:0.0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"> Exercise </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> Life </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 5,306,377 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 3.31 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 2,188,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 1.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> Forfeited/Expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (799,471) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3.26 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 44,053 </td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.04%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,022,998 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr>
</table>53063773.3121881361.107994713.2666950422.59P7Y2M12D4405340229983.46P5Y9M18D The following table presents information related to stock options as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Exercisable </td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> Remaining Life </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $0.01 - $0.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 1,315,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $1.00 - $1.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 2,224,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 5.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 1,160,055 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $2.00 - $2.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 1,249,586 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 1,026,448 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $3.00 - $3.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 758,637 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 6.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 703,605 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $4.00 - $4.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 279,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 7.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 264,420 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $5.00 - $5.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 26,668 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 2.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"> 26,668 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;background:#cceeff;margin:0pt;padding:0pt;"> $6.00 - $6.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 691,162 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 5.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"> 691,162 </td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"> $7.00+ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 150,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"> 3.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 150,640 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,695,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;background:#cceeff;margin:0pt;padding:0pt;"> 5.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,022,998 </td></tr></table>0.010.9913151361.001.992224213P5Y4M24D11600552.002.991249586P6Y8M12D10264483.003.99758637P6Y7036054.004.99279000P7Y2 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"> For the Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> For the Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;background:#cceeff;margin:0pt;padding:0pt;"> 5.85 - 6.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 5.50 - 10.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 5.50 - 10.00 </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> 3.47% - 3.80% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 3.47% - 4.72% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 3.44% - 4.18% </td></tr><tr><td style="vertical-align:bottom;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;background:#cceeff;margin:0pt;padding:0pt;"> 87% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 80% - 87% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"> 82% - 95% </td></tr><tr><td style="vertical-align:bottom;width:39.94%;margin:0pt;padding:0pt;"> Expected dividends </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> 0.00% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 0.00% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"> 0.00% </td></tr></table>P5Y10M6DP6Y3MP5Y6MP10YP5Y6MP10Y0.03470.03800.03470.04720.03440.04180.870.800.870.820.950.00000.00000.00002042227P1Y9M

style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11 – Employee Benefit Plans 401(k) Plan In April 2019, the Company adopted the Eyenovia 401(k) Plan (the "Plan"), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. The Company's Board of Directors approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the three months ended September 30, 2024 and 2023, the Company recorded expense of $56,493 ($41,186 which was included within research and development expenses and $15,307 was included within selling, general and administrative expenses on the statements of operations) and $46,636 ($37,383 of which was included within research and development expenses and $9,253 of which was included within selling, general and administrative expenses on the statements of operations), respectively, associated with its matching contributions. During the nine months ended September 30, 2024 and 2023, the Company recorded expense of $220,682 ($136,598 of which was included within research and development expenses and $84,084 of which was included within selling, general and administrative expenses on the statements of operations) and $171,800 ($115,559 of which was included within research and development expenses and $56,241 of which was included within selling, general and administrative expenses on the statements of operations) associated with its matching contributions, respectively. 10.045649341186153074663637383925322068213659884084171800115559562415 Note 12 - Subsequent Events Exercise of Pre-Funded Warrants On October 1, 2024, the holder of the 65,653 pre-funded warrants issued in the September Offering, exercised the pre-funded warrants at a price of $0.0001 per share of common stock (see Note 10 - Stockholders' Equity - Offerings). 656530.0001falsefalsefalsefalsefalsefalsefalsefalsefalsefalsefalse Includes gross proceeds of $3,607,827 less total issuance costs of $108,235.; Includes gross proceeds of $415,588 less total issuance costs of $12,468.; Includes gross proceeds of $100,449 less total issuance costs of $3,013.; Includes gross proceeds of $3,293,347 less total issuance costs of $98,800. Includes gross proceeds of $1,728,804 less total issuance costs of $51,865.; Includes gross proceeds of $1,212,251 less total issuance costs of $36,368.; Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc. Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.; Shares issued as partial consideration for reversion of License Agreement with Bausch & Lomb Ireland Limited.; Non-cash warrant modification issuance costs related to the registered direct offering of $1,738,700 are shown on a separate line item.; Non-cash warrant modification and additional warrants issuance costs related to one of the offerings of $2,868,000 are shown on a separate line item. Registered direct offering included modification of warrant originally granted in the March 2022 offering.; Offering includes modification of warrants and additional warrants in the July 2024 offering.; Includes gross proceeds of $11,977,468 less total cash issuance costs of $1,091,354.; Includes gross proceeds of $2,000,000, less total issuance costs of $111,171.; Includes gross proceeds of $14,139,994, less total cash issuance costs of $1,791,816.; '''